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Abstract
The presence of up to 30-40% more sialic acid (or hypersialylation) on the tumour cell surface
compared to normal cells, along with a marked up-regulation of sialyltransferase (ST) activity
is a well-established hallmark of cancer. Due to the critical role of these glycan-building
enzymes in tumour growth and progression, ST inhibition has emerged as a potential new
antimetastatic strategy for a range of cancers including pancreatic and ovarian cancer. Human
STs are divided into four subfamilies or groups based on their linkages (ST3Gal, ST6Gal,
ST6GalNAc and ST8Sia) with each subtype controlling the synthesis of specific sialylated
structures each with a unique biological role. This has important implications for inhibitor
development, as STs also play significant roles in immune responses, inflammation, viral
infection and neurological disorders. Thus, to advance to the clinic it is essential to develop
subtype selective ST inhibitors.
A wide range of ST inhibitors have been reported including inhibitors from design, from
Nature and from high-throughput screening. In the absence of crystal structures of the human
STs, the early inhibitors were designed and their activity optimised by using empirical
observations for almost two decades. However, the recent publication of crystal structures of
mammalian forms of the major enzyme subtypes ST3Gal, ST6Gal and ST8Sia, has furthered
our understanding of the differences between the subfamilies and provided the opportunity to
use computational tools for the design and optimisation of inhibitors.
All ST subtypes use CMP-Neu5Ac as the natural donor, and the most potent ST inhibitors todate are all transition-state analogue inhibitors that essentially mimic the donor structure. As
part of our study we published a major review focussing on cytidine-based inhibitors
comprised of three key fragments: a nucleoside component and a sialic acid mimic linked by a
phosphate group. Despite the nanomolar potency of the reported phosphate-linked inhibitors,
II

little is known about their selectivity towards the different ST subtypes or in vivo activity.
Furthermore, their synthesis is often challenging and utilises expensive and low yielding
methods. To facilitate an in-depth biological study of ST inhibitors, the design of novel
compounds must be directed by the newly emerging structure activity relationships to create
libraries of inhibitors via highly efficient and inexpensive synthetic routes.
Therefore, the current project was aimed at the convergent synthesis of triazole-linked
inhibitors, which would allow the versatile ligation of nucleoside derivatives with a variety of
functionalised sialic acid mimics. The choice of the building blocks for this strategy was guided
by computational methods using the recently released ST crystal structures. A series of 19 αhydroxyphosphonae esters were synthesised for the preparation of carbamate-based inhibitors
and also examined for their own inherent anti-inflammatory activity. A series of 10 nucleoside
derivatives and 15 alkynes fragments were also prepared, leading to 27 novel triazolonucleoside
products. The preliminary testing of our library of triazole-based derivatives towards ST8Sia-II
showed promising inhibition up to 98% when tested at a concentration of 100 μM. The
incorporation of a fluorine atom on the nucleoside or the sialic acid mimic as well as
heterocyclic structures provided the greatest inhibitory activity. Finally, the absence of toxicity
of our candidates at concentrations of up to 300 µM allows for further cell-based evaluation of
the effects of our compounds on tumour cell adhesion, migration and invasiveness.
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ST
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glycosyltransferase
protein kinase A
sialyltransferase
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sialyltransferase catalysing an α-2,8-linkage onto a sialic acid residue
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Chapter 1: Sialyltransferases
1.1. Sialic acids
1.1.1. Background
Sialic acid is considered to be the second most important sugar in the human body, next to
glucose.1-3 It belongs to a family of sugars containing more than 50 derivatives,4-5 that are
found in all vertebrates and are also present in bacteria, plants and animals. Sialic acids all
share a nine carbon backbone bearing a carboxy group at the 1-position and a hydroxy group
at the 2-position (fig. 1.1).6-7 One subfamily of sialic acids is N-acetylated to form Nacetylneuraminic acid 1 (Neu5Ac, NANA, Sia), which is the most ubiquitous member. Sialic
acids are typically found on the extremity of non-reducing glycan chains on the surface of
cells, where they are linked to the 3- or 6-hydroxyl groups of galactose (Gal) moieties, or to
the 6-hydroxyl group of N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc,
fig. 1.1). They can also form polysialic chains by linking at the 8-hydroxyl group.8

Figure 1.1. Strucutre of sialic acid derivatives and O-sialosides on the cell surface.9
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1.1.2. Cell surface glycans
Sialylated oligosaccharides have long been predicted to be information–containing molecules
and critical determinants in cell-cell recognition processes, cell-matrix interactions and in the
maintenance of serum glycoproteins in the circulation as a result of their terminal position on
oligosaccharide chains.10-12 The cell surface sialic acid residues, which are negatively charged
at physiological pH, have been known to act as receptors for the influenza virus.13 They often
function in the “antirecognition” or masking of the carbohydrate groups they terminate.11 The
highest concentration of sialic acid (as N-acetylneuraminic acid) in the human body occurs in
the brain where it is an integral part of ganglioside structure.14 Consistent with this finding,
human milk was also found to contain a high concentration of sialic acid, associated with an
increase of gangliosides in the brain and improved learning ability.15 Conversely, sialoside
reduction is correlated to erythrocyte destruction.16
Glycan structures of cell surface glycoconjugates have pivotal functions in various cellular
recognition systems involving cell differentiation, development,17-18 inflammation,19-20
immune response,21 tumour metastasis, bacterial and viral infections, and many other
intercellular communication and signal processes.22-24 However, glycan expression and its
microheterogeneity in common glycoproteins cannot be predicted because protein
glycosylation is not template-driven and is subject to multiple sequential and competitive
enzymatic pathways.25-27 The biosynthesis of complex glycans is carried out by a variety of
glycosyltransferases (GTs) sharing several sugar nucleotides as substrates in collaboration
with many glycoside hydrolases (GHs) to define further synthetic pathways.28-29 In other
words, it is extremely difficult to identify every enzyme responsible for synthesizing
biologically relevant glycoforms. In the future, large-scale glycomics may help to reveal
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whole human glycoforms and profile their structural alterations during cellular differentiation,
proliferation, carcinogenesis, malignant alteration, and metastasis.30-33
Specific and potent inhibitors of GTs would be useful tools for the investigation of structurefunction relationships of the human glycome and the regulation mechanism of glycan
biosynthesis as well as leading to the discovery of new classes of therapeutic agents. Extensive
efforts have been invested to develop such inhibitors for biologically important GTs.34-36

1.2. Sialyltransferases
1.2.1. Classification and occurrence
Sialyltansferases (STs) are a subset of GTs involved in the biosynthesis of sialylated glycolipids
and/or glycoproteins. Depending on the glycosidic linkage formed and their monosaccharide
acceptor, vertebrate STs are arranged in four families of proteins (ST3Gal, ST6Gal, ST6GalNAc
and ST8Sia, table 1.1).37 ST families are further subdivided into 20 sub-families in mammals and
more than 25 sub-families in lower vertebrates, each of them being characterised by conserved
amino acid residues. All of them use CMP-Neu5Ac 2 as the activated sugar donor to catalyse the
transfer of sialic acid residues to terminal non-reducing positions of oligosaccharide chains of
glycoproteins and glycolipids (fig. 1.2).8,38 However, these enzymes differ in their substrate
specificity, tissue distribution and various biochemical parameters. Enzymatic analysis conducted in
vitro with recombinant enzymes have revealed that one linkage can be synthesised by multiple
enzymes.39 Moreover, even though eukaryotic STs share the same sugar donors, i.e. CMP-Neu5Ac
2, and recognise identical acceptor substrates, they do not exhibit similar protein structure except for
the three short and conserved consensus sequences present in the catalytic domain.40-41
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Table 1.1. Nomenclature of the 20 human sialyltransferases (STs) described to-date.42
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These enzymes have been shown to be topologically restricted to the cisternae and the Golgi
network of the Golgi apparatus, although catalytically active soluble forms can be generated
in vivo by proteolytic cleavage at the stem region, e.g. serum soluble ST6Gal-I produced by
proteolytic cleavage at the stem domain.43 ST3Gal-III has also been identified in post-Golgi
locations in rat kidney tissue.44

1.2.2. Sialyltransferase mechanism of action
The mechanism for the sialylation reaction was first proposed by Horenstein (fig. 1.2).45-49
The reaction undergoes mechanistic pathways similar to other GTs50 and uses the sugarnucleoside conjugate CMP-Neu5Ac 2, with the CMP fragment of the donor behaving as a
leaving group (fig. 1.2).51-55 The catalytic residues are usually histidine or tyrosine, however
arginine residues have also been observed in some cases. These residues play a key role in the
deprotonation of the hydroxyl group of the acceptor sugar and in activating the phosphate
group. Most of the other residues in the active site help in positioning both the donor and the
acceptor in their respective binding pockets.56 The transition-state proposed seems to be
applicable for all ST subtypes. During the sialyl transfer, the acceptor approaches the
anomeric centre of the sialic acid fragment by the side opposite to the CMP residue. At this
stage, a planar carboxenium intermediate is formed in a SN2 fashion. The final products are
CMP 3 and the sialylated sugar (fig. 1.2). This proposed mechanism was recently revisited
and assessed by Schmölzer et al.57
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Figure 1.2. Mechanism of the sialylation reaction and expected products by sialyltransferase subtypes.

1.2.3. Sialyltransferases in Cancer
More than 90% of cancer deaths are caused by cancer metastasis, despite recent advances in
cancer chemotherapy and the advent of tumour-targeted agents.58 Currently, treatment and
chemotherapy are focusing on primary tumours rather than metastatic processes and
antimetastatic drugs are often used in combination therapy. The metastatic process itself is
highly complex, depending both on the tumour and its microenvironment.59-60 Therapeutic
benefits in late-stage or elderly cancer patients are especially poor. The development of
antimetastatic drugs emerging from current drug-screening pathways is thus urgently needed. In
order to improve this approach, efforts on understanding and reversing the metastatic processes
might have a great outcome on the effectiveness of chemotherapy. Human cancer metastasis is a
long-evolving, multi-step process that can only be treated or controlled by drugs or immunomodulators to date. Research in the field has suggested that future antimetastatic therapies could
7
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be strategically optimised according to the characteristics of metastatic processes in order to
address these unmet therapeutic benefits.61-63
Elevated plasma levels of STs have been observed in cancer patients since the 70's, and
hypersialylation of cell surface proteins is now a well-established hallmark of cancer that
forms the basis of several diagnostic cancer markers.64-68 One such example is the
carbohydrate antigen CA19-9 for pancreatic cancer, which results from overexpression of
ST3Gal-III, IV and VI leading to the production of large amounts of sialyl Lewis a. This is
typical of the involvement of the ‘incomplete synthesis’ mechanism in the enhanced
expression of sialyl Lewis X (SLex) and sialyl Lewis A (SLea) in cancers.67,56 Sialylated
glycans have long been predicted as cell-type specific markers and critical determinants in
various cellular recognition processes (cell–cell recognition, adhesion, protein targeting,
blood coagulation, fertilization, and other biological events).69 They also play significant roles
in immune responses,70 inflammatory diseases, viral infection71-72 and tumour proliferation,73
migration, and metastasis.74-76
STs have also been described as “engines of self-fuelling loops in cancer progression”.77-79
Hypersialylated integrins are believed to facilitate cell migration in many different cancer
types,80 such as colon,81-82 lung

83-84

and ovarian cancer.85 Aberrant sialylation at the non-

reducing end of glycoproteins or glycolipids has been shown to promote events involving
abnormal stimuli in the interaction of neoplastic cells with extracellular matrices.33 The
biosynthesis of sialylated glycoprotein, mediated by ST6Gal-IV, was also reported on various
kidney cancer cell lines.86 As well as considering membrane sialylated glycoproteins as a
target for treating cancer, these molecular patterns are also useful in the prognosis of cancer8788

and other diseases.89 Tumour cell migration and invasion are regulated by sialylated

glycoforms of integrins. Specifically, β1 in colon adrenocarcinomas81-82 and lung,83-84 where
ST expression, in particular ST6Gal-I,90 ST3Gal-I,91-92 ST3Gal-III,74-90 ST3Gal-IV,74-93
8
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ST6GalNAc-I94 and ST6GalNAc-V95 are strongly correlated with tumour invasiveness. This
is also the case in numerous other cancers including, bladder,92 breast,96 pancreatic,97
ovarian,85 gastro-intestinal98 cancers and leukemia.99 The level of gene alteration observed for
the 20 ST subtypes is summarised in fig. 1.3 for melanoma, lung, ovarian, prostatic, breast
and pancreatic cancers.

Figure 1.3. Gene alteration frequency of sialyltransferase subtypes in various cancers. 100

Lung Cancer: Sialyl Lewis x (SLex) is a well-known tumour-associated antigen that is found in
elevated levels in lung cancer. It facilitates cell adhesion to the endothelium, initiating the
process of extravasation and metastasis. ST3Gal-III, IV and VI enzymes play a key role in the
synthesis of SLex. In lung cancer, expression levels of both SLex and ST3Gal-III are inversely
correlated with patient survival.101 Hypersialylation and increased expression of SLex is also
observed in the mucins of cystic fibrosis patients,102 while over-sialylation of several other
proteins including integrins has also been shown to enhance cell invasion in ovarian, colon and
lung cancer. ST3Gal-I is not detected in normal human bronchial epithelial cells, but is overexpressed in highly metastatic lung cancer cells such as A549 and CL1-5.84 Thus, inhibition of
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STs, in particular the ST3Gal subfamily, has emerged as a new target for the treatment of early
lung cancer, and to aid in understanding the progression to more aggressive phenotypes.
Ovarian Cancer: Increased serum glycoprotein sialylation in a murine ovarian carcinoma
model has been found to correlate with inflammation and tumour progression, with increased
expression of ST3Gal-I and ST6Gal-I.103 The latter also regulates ovarian tumour cell survival
mechanisms104 and confers cisplatin resistance.105-106 CA125, the clinically used ovarian
cancer marker is a heavily glycosylated mucin (MUC16).62 Levels of sialyl-Tn antigen,
expressed on MUC16 in patients, is found to differ between endometriosis and ovarian cancer
raising the potential for its use in diagnosis, and evaluating the clinical stage, cytological
grade, and histological type of ovarian cancer.107
Breast Cancer: STs have been found to play a key role in breast cancer progression,
aggressiveness, metastasis and drug resistance. Recent studies in triple-negative breast cancer
patient-derived xenograft models treated with standard chemotherapy identified high levels of
the sialyl-glycolipid stage-specific embryonic antigen 4 (SSEA4). This treatment-resistant
breast cancer subpopulation also exhibited high expression of ST3Gal-II, which is required
for the biosynthesis of SSEA4. This could be used as a predictive biomarker of poor clinical
outcomes in both breast and ovarian cancer patients treated with standard-care genotoxic
chemotherapy.108 Gene expression analysis coupled with functional analysis of clinical
samples has also identified ST6GalNAc-V as a key mediator of breast cancer metastasis to the
brain. Atypical expression of this brain ST in breast cancer cells is thought to facilitate their
passage through the blood-brain barrier.109 A strong correlation between the expression of the
transmembrane tumour-associated glycoprotein Mucin 1 MUC1 and T antigen has been found
in breast cancer tumours and breast cancer cell lines, along with the down-regulation of
expression of ST3Gal-I.110-111 Expression analysis of 74 primary breast cancers showed a
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significant correlation between ST3Gal-I and COX-2, indicating that malignant characteristics
of the cyclooxygenase-2 expression may be related to tumour cell surface sialylation.112
Multiple Myeloma: High expression of ST3Gal-VI has been identified in patients with
multiple myeloma and correlated to poor patient prognosis. Knockdown of ST3Gal-VI in
myeloma cell lines MM1S and RPMI-8226 significantly reduced α-2,3-linked sialic acids on
the cell surface and reduced adhesion to bone marrow stromal cells and fibronectin. It further
inhibited transendothelial migration in vitro and reduced homing and engraftment, decreased
tumour burden and increased survival in vivo in a xenograft (SCID-Bg) mouse model.113
Leukemia and Glioma: Elevated mRNA levels of ST expression have been found to positively
correlate with a high risk of numerous cancers including paediatric leukemia, where it has been
suggested as a potential biomarker.114 In particular, cell surface sialylation is emerging as an
important feature of cancer cell multidrug resistance (MDR). Recently, the α-2,8sialyltransferases ST8Sia-IV and ST8Sia-VI were found to positively correlate with the
multidrug resistant phenotype in chronic myeloid leukemia cells, with ST8Sia-IV appearing to
regulate the activity of PI3K/Akt signalling and P-gp expression.115-116 Overexpression of
ST6GalNAc-V, a ganglioside-specific α2,6-sialyltransferase, inhibits glioma growth in vivo.117
Metastasis and MDR: Also of important consideration is metastasis, a major challenge in the
treatment of cancer and is largely responsible for the high rate of cancer mortality. It is
emerging that molecules conferring drug resistance may also promote metastatic invasion.
This gives rise to the situation where metastatic disease is often more resistant to treatment.118
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The biological functions of sialic acids are well known and the literature provides a strong
body of evidence for the role of sialylation in various medical conditions and in particular
cancer. This growing knowledge on STs is illustrated in comprehensive reviews published by
many experts in the field, including Schauer,119 Varki,9,120 Crocker,121-122 including reviews by
Dall’Olio et al.,79,123-124 Schultz et al.,77 Harduin-Lepers et al.,8,37,39 and Boons et al.125 Over
the last decade, the therapeutic potential of targeting STs has also appeared in reviews
focusing on GTs and altered glycosylation in cancer from Brooks et al.,126-127 Brown et al.,128
Compain & Partin,129 Gloster & Vocadlo,130 Hinou & Nishimura,131 Izumi et al.,132 Kajimoto
& Node,133 Roychoudhury & Pohl,134 Schnaar et al.135 and Zhou et al.136
In summary, sialylated cell-surface carbohydrates are crucial in the course of cell
development and differentiation.137 Anomalies in their expression is indisputably associated
with cancer progression76,138 and metastasis75-76 as well as directing carbohydrate-mediated
adhesion processes in angiogenesis124,139 and drug resistance. Therefore the development of
antimetastatic drugs targeting aberrant sialylation has recently emerged as a new therapeutic
avenue in cancer treatment.68,140

1.2.4. Biological assays
A key challenge in the ST inhibitors field is the choice of biological assay employed to
evaluate the effectiveness of newly developed inhibitors. There are no commercially available
ST inhibitor screening assays at the time of writing and very few commercial sources of
mammalian ST enzymes, those being rST3Gal-I (EC 2.4.99.4) from Merck (#566227) and
hST6Gal-I (EC 2.4.99.1) from Merck (#566223) and Roche (#07-012-250-103). For this
reason, most research groups clone, express and/or isolate their own ST enzymes, which are
used in either crude, partially purified or purified form.39,141-149 As with all enzyme work,
there are a wide range of enzymes used (e.g. predominantly human, rat, and bacterial STs)
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and a variety of assays employed (colorimetric, fluorescent, radioactive, mass spectrometry
and HPLC-based) to evaluate inhibitory activity, and this should be considered when
comparing biological results.
HPLC-based Assays: Earlier studies into STs used asialofetuin or lacto-N-tetraose as the
acceptor moiety and

14

C or 3H-labelled CMP-Neu5Ac150 as the donor and the radioactive

products were isolated by chromatography or precipitation.150-152 In 1998, R. R. Schmidt and
co-workers introduced a HPLC-based assay using the p-nitrophenyl glycoside of Nacetyllactosamine as a UV labelled acceptor, and this continues to be one of the most widely
used ST inhibition assays today.153 Recent extensions of this method, include a continuous allin-one HPLC-based assay that enables the quantification of productive turnover, error
hydrolysis and site selectivity of sialyltransfer and donor substrate hydrolysis, with the
potential for high-throughput screening.154 Further HPLC-based assays include those reported
by Kijahara et al. and involve a combination of HPLC analysis with a fluorescent analytical
technique based on reacting sialic acid with 1,2-diamino-4,5-methylenedioxybenzene,155 or
using 2-[(2-pyridyl)aminoethyl-β-D-lactosamidine as a ST acceptor for potential use in
fluorescent assays.156
Fluorescence-based Assays: Rillahan et al. designed a fluorescence polarisation

assay

enabling high-throughput screening of sialyl- and fucosyltransferases.157 The method employs
a CMP-Neu5Ac derivative bearing a fluorescein isothiocyanate (FITC) tag at the 9-position158
and asialofetuin as the acceptor. This technique has the advantage of being suitable for
various enzyme subtypes by using a versatile acceptor, however, it does require the non-trivial
preparation of the FITC-labelled CMP-Neu5Ac donor 4 (fig. 1.4). Kumagai et al. have
reported a multi-enzyme system allowing the screening of potential inhibitors against a wide
variety of GTs including glucosyl-, galactosyl-, glucuronyl-, xylosyl-, fucosyl- and
sialyltransferases.159 Three kinase enzymes are used in order to provide glucose-6-phosphate
13
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(G6P) starting from the nucleoside monophosphate resulting from the glycosylation reaction.
G6P dehydrogenase converts then resazurin, in a dose-dependant manner, to resorufin and the
fluorescence of the solution is measured. This method has the advantage of allowing HTS of
compound libraries. More recently, Preidl et al. designed a binding affinity assay in which the
dissociation constant was determined by comparing the anisotropy changes in fluorescence
polarisation.160

Figure 1.4. Reagent 9”-FITC-CMP-Neu5Ac 4 used in sialyltransferase inhibition assays.

MS-based Assays: Hosoguchi et al. designed a MS-based protocol suitable for HTS of
potential GT inhibitors. The authors monitored the inhibition rate by determining the
amount of glycosylated acceptor using MALDI-TOFMS.161 An alternative technique
consists of immobilising the acceptor sugar on a plate or a cellulose membrane. This
method was described using N-acetyllactosamine 162 or trisialyl lactoside (GT3) by clickchemistry.163

Other

assays

using

multi-enzyme

systems

combined

with

spectrophotometry81,164 or colorimetry165 have also been reported.

1.2.5. Structure of sialyltransferases
On the basis of sequence similarities, STs are grouped into five different GT families within
the carbohydrate-active enzymes (CAZy) database.166 All eukaryotic STs, along with the viral
enzymes, are found in a single CAZy family, GT29. Mammalian STs share a predicted Nterminal membrane-anchoring region and four conserved sequence motifs denoted as
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L (large), S (small), VS (very small) and motif 3.167-171 Although these ‘sialyl motifs’ have
been instrumental in the identification and cloning of new STs over the last three decades,
their structural context has remained unknown, with the only insights being those obtained by
kinetic analysis of mutants.167,169
Due to the tremendous therapeutic potential associated with STs, extensive efforts have been
made to identity and understand the structural differences between the different ST subtypes.
The ST crystal structures so far reported were usually obtained with an additive cocrystallised with the enzyme, such as CMP 3, CDP 5, CTP 6, the inhibitors CMP-3FNeu5Ac172 7 and simplified aromatic inhibitor 8, later described in section 1.3.4,
selenomethionine and several sugars, including oligosaccharides as well as the modified
acceptors such as 2-nitrophenylLacNAc 9 and the sialylated keratin sulfate 10 (α-Neu5Ac2,3-β-Gal-1,4-(6S)-β-GlcNAc, fig. 1.5). The presence of these compounds provides some
information about the location of the active site.

Figure 1.5. Additives found co-crystalised with sialyltransferases.

15

Chapter 1

1.2.5.1. Bacterial Sialyltransferases
Bacteria have been found to be a good source for STs. For example, from Campylobacter jejuni,
Cst-I173 and Cst-II174 were isolated and promote specific or multifunctional sialyl patterns.
PM0188, an α-2,6-ST from Pasteurella multosida, has been reported175-176 along with Δ24PmST1
was also examined and shows α-2,3-ST, α-2,6-ST, sialidase and trans-sialidase acitivity.177-178
Some mutant versions of PmST1 were described,179 including D141N and M144D,180 which
showed significantly decreased sialidase activity. In a similar approach, the crystal structure of the
mutant bifunctional α-2,3-ST and α-2,6-ST Δ29NST was obtained from Neisseria meningitides.
Δ16psp26ST is a truncated form of JT-ISH-224, mono-functional β-galactoside α-2,6-ST, cloned
from Photobacterium phosphoreum.181 ΔNpp23ST, also a truncated form of JT-ISH-224, was
later crystalised.182 Finally, the structures of Δ15Pd2,6ST(N) and Δ112Pd2,6ST(N) where
reported, also α-2,6-ST from Photobacterium damselae.52

1.2.5.2. Mammalian Sialyltransferases
The first mammalian ST crystal structure was reported by Rao et al. in 2009183 The crystalised
enzyme is a porcine ST3Gal-I variant, which shows 85% identity with human ST3Gal-I. In
addition, kinetic studies of pST3Gal-I samples revealed similar profiles, i.e. KM values on the
micromolar scale, in comparison with STs obtained via eukaryotic expression systems and
different animal species.171,184-186 From these data, the authors later proposed a mode of binding
for the donor CMP-Neu5Ac 2 and the acceptor 2-nitrophenyl-Gal-β-1,3-GalNAc 9.187 More
recently, both rat188 and human189 ST6Gal-I crystal structures were also reported, along with
human crystal structure for ST8Sia-III.190 The superimposed ST crystal structures are represented
in fig. 1.6, aligned to the nucleoside fragment (CMP 3) that was co-crystalised with them.
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Figure 1.6. Superimposed ST crystal structures aligned to CMP 3 (in white sticks). The porcine ST3Gal-I
(PDB: 2WNB, in green), the human ST6Gal-I (PDB: 4SJ2, in grey) and the human ST8Sia-III (PDB: 5BO6, in
orange and PDB: 5CXY in dark orange).

The crystallographic data provided insight on the mode of action of STs and allowed the use
of computational tools to assist structure-based design of inhibitors. The reported mammalian
ST crystal structures are summarised in table 1.2. All reported PDB files are available on the
RCSB Protein Data Bank website (www.rcsb.org).
Table 1.2. Reported crystallographic data for mammalian sialyltransferase substypes and their
corresponding PDB file entries.
Enzyme

Organism

PDB file

Reference

ST3Gal I

Sus scrofa (pig)

2WML, 2WNB, 2WNF

Rao, 2009183

ST6Gal I

Rattus norvegicus (rat)

4MPS

Meng, 2013188

ST6Gal I

Homo sapiens (human)

4JS1, 4JS2

Kuhn, 2013189

ST8Sia III

Homo sapiens (human)

5BO6, 5BO7, 5BO8, 5BO9

Volkers, 2015190

ST8Sia III

Homo sapiens (human)

5CXY

Volkers, 2016
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Collectively this data confirms the mechanism for the reaction proposed by Horenstein
(fig. 1.4).45-49 The conserved sialyl motifs frame the catalytic site, and a disulfide bond
stabilises the two sialyl motifs (large, L, and small, S), a feature conserved throughout the ST
family.191 A flexible loop missing from the electron density is proposed to form a ‘lid domain’
that participates in the binding of the donor substrate. The acceptor binding sites of different
mammalian STs must vary in structure in order for them to accommodate different
carbohydrate moieties such as galactose in ST3Gal and ST6Gal, N-acetylgalactosamine in
ST6GalNAc or sialic acid in ST8Sia. Likewise different regiochemical outcomes must be
encoded; thus, ST3Gal and ST6Gal need to bind the galactosyl moiety in different
orientations relative to CMP-Neu5Ac 2 in order to make α-2,3 and α-2,6 linkages,
respectively. Previous mutagenesis studies revealed several conserved peptide sequences
within each subfamily group, located between the L and S sialylmotifs, that were postulated
to contribute to the different linkages and acceptor specificity.192 Two such submotifs are
observed in the case of pST3Gal-I.187
Several structural features of the mammalian ST family have previously been deducted from
their primary sequences.191 All were known to have N-terminal signal anchor sequences that
tether them to the Golgi membrane, and a flexible ‘stem’ region that is not required for
catalytic activity. Various homologous regions have been identified in the catalytic domain,
also called sialyl motifs, and were postulated to be involved in binding substrates and
catalyzing the transfer of the sialic acid to the acceptor glycan.171,193-196

1.2.5.3. Computational studies
The recent characterisation of mammalian ST crystal structures have further enabled
visualisation of the substrate-enzyme interactions. As predicted, the donor binding site which
is highly conserved between the different subtypes, remains consistent while the major
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variations occur in the acceptor site (fig. 1.7-A and B). Insight from crystal structures, such as
rat and human ST6Gal-I show many similarities and inhibition of the rat-derived enzymes is
thus likely to be translatable to the human form of the enzyme.

Figure 1.7. The sialyl donor CMP-Neu5Ac 2 (green sticks) docked into the human ST6Gal-I (A, PDB: 4JS2)
and the porcine ST3Gal-I (B, PDB: 2WNB) with their respective acceptors LacNAc 11 and 2-nitrophenylGal-β-1,3-GalNAc 9 (orange sticks).

Using recent crystallographic data, research groups have started developing new inhibitors by
structure-based design. Kumar et al. designed non-charged inhibitors and docked them into
the bacterial Cst-I enzyme (PDB: 2P2V). Chen et al.197 evaluated the binding site of potent
fluorescent probes by docking into the bacterial PmST1 (PDB: 2IHZ) and pST3Gal-I
(2WNB).160 Sujatha et al. established an homology model for the six human ST3Gal I-VI by
aligning their sequence with the bacterial enzyme Cst-II.198 Grewal et al. later created
homology models for the human ST6GalNAc-I, ST3Gal-III and ST8Sia-I using the crystal
structure of the porcine ST3Gal-I as a template and evaluated potential binding sites for the
natural products curcumin and resveratrol.199
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1.3. Sialyltransferase inhibitors
1.3.1. Reviews
The design and development of potent small molecules inhibiting ST enzymes was pioneered
by Schmidt and co-workers, almost two decades ago.153,200-202 The synthesis and biological
evaluation of ST inhibitors described at that time have been reviewed previously and focussed
on α-2,3-ST and α-2,6-ST subtypes.203-205 In the intervening years since the first development
of ST inhibitors, a rising number of biological and medical-related articles have appeared.
This has expanded our understanding of the role of glycosylation in various disorders, as well
as the role of altered sialylation in diseases, in particular metastatic cancers.206 In recent years,
along with the mounting evidence of the critical role of sialylation in cancer and growing
structural information on STs, several new potent ST inhibitors have been described.207-209
These have been derived from various scaffolds and thus increasing the molecular diversity of
ST inhibitors in the literature. The biological data provided for the known inhibitors relies on
a large array of assays (Cf. section 1.2.4), which provides intuitive trends for the compounds’
potency rather than enabling consistent comparison. A comprehensive review aiming at
bridging the gaps between the chemical and biological aspects of ST inhibition was published
by our group in 2016. The article also presents emerging techniques in the STs field such as
computational modelling, recently made possible by the publication of the first crystal
structures of mammalian STs (Cf section 1.2.5), and towards diagnostic tools using imaging
and glycoengineering. Herein a brief history of the published review is presented.42

1.3.2. Inhibitors from Nature
Screening natural products for their activity towards STs has provided a few new potent
inhibitors. Three spirocyclic drimanes isolated from the fungus Stachybotrys cylindrospora
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have been reported as ST inhibitors. The activity of these terpenoids was evaluated towards
ST3Gal-I,

ST3Gal-III,

ST6Gal-I

as

well

as

some

fucosyltransferases

and

galactosyltransferases.210 Mer-NF5003F or stachybotrydial 12, inhibited these enzymes in the
low micromolar range (fig. 1.8). The Taiwanese cyanobacteria Lyngbya Majuscula was found
to produce fatty amides, including isomalyngamide A-1 13 (fig. 1.8), which inhibits ST3Gal-I
with an IC50 value of 65.7 µM.211 The natural product 13 also significantly decreased the
proliferation and migration of the metastatic human breast cancer cells MCF-7 and MDA-MB231. Several flavonoids have been recently reported by Hidari et al.212 and moderately inhibited
rat ST3Gal-I and both rat and human ST6Gal-I. Epigallocatechin gallate 14, a flavonoid present
in green tea, was previously shown to inhibit rat brain ST3Gal-I with an IC50 value of
2.7 μM.213 The compound 14 also inhibits fucosyltransferases in a similar order of potency.
The steroidal derivative soyasaponin I 15, extracted from soy beans, inhibits ST3Gal-I with a
Ki value of 2.3 µM214 and reduced the migration of breat cancer cells MCF-7215 and
melanoma cells B16F10.216 The bile acid lithocholic acid 16 exhibits ST3Gal-I inhibition in
the low micromolar range (IC50 = 21 µM).217 The synthetic derivatives Lith-O-Asp 1783 and
AL-10 1884 show improved activity (IC50 = 21 µM and 0.88 µM respectively, fig. 1.8) and
further biological evaluation revealed that their antimetastatic effects are mediated by
inhibiting the sialylation of integrin-β1 in several cancer cell lines.
Most of these compounds are built on classical naturally occurring scaffolds and were found
to exhibit activity towards various biological targets which could also be responsible for
unwanted off target effects.
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Figure 1.8. Examples of sialyltransferase inhibitors from nature.

1.3.3. Inhibitors from high-throughput screening
High-throughput screening of synthetic combinatorial libraries is widely used for identifying hits
in medicinal chemistry. In the context of ST inhibition, this method was used to screen libraries of
synthetic peptides showing moderate activity for the hexapeptide GNWWWW 19 towards
ST3Gal-I, with a Ki value of 8.8 µM (fig. 1.9).218 The Paulson’s group evaluated a library of
molecules against porcine ST3Gal-I, rat ST3Gal-III and human ST6Gal-I as well as the human
fucosyltransferases FUT-6 and FUT-7.157 The compound JFD00458 20 was identified as a broad-
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spectrum inhibitor and the compound 21 showed specificity for ST3Gal-III (IC50 = 1.7 µM),
while being competitive with the natural donor substrate site (fig. 1.9). The authors also stated that
despite the possible existing similarities at the active site of the various enzyme subtypes,
significant variations may allow differentiation for the design of selective inhibitors.

Figure 1.9. Examples of sialyltransferase inhibitors from high-throuput screening

1.3.4. Inhibitors by Design
Several approaches have been explored for designing ST inhibitors, based on the enzyme
substrate structures. In the early days, the design was driven by empirical observation
given the lack of crystal structures for the mammalian enzymes.
Acceptor-analogues: Since the early modified disaccharides reported by Hashimoto’s
group219-220 a few different types of acceptor-analogue have been designed.204 As the enzyme
subtypes are classified by their respective acceptor, using this as a template for designing ST
inhibitors presents the advantage of targeting the different subtypes selectively. However, to
date this has onlygiven inhibitors of weak to moderate potency. Of these, inhibitors created
from the structure of lactose, modified on the 6-position of the galactose unit, the 2-position of
the glucose fragment or in the form of dimers, gave compound 22 as the best example, with
some significant selectivity towards ST3Gal-I, with a Ki value of 185 µM compared to 533 µM
against ST6Gal-I (fig. 1.10).
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Bisubstrate inhibitors: The bisubstrate analogue 23 prepared by Izumi’s group for a SAR
study only showed weak inhibitory activity against recombinant rat ST3Gal-I
(IC50 = 1.3 mM) and ST6Gal-I (IC50 = 2.4 mM).221 The compound structure consists of a
CMP-Neu5Ac analogue in which the carboxylic acid group was reduced to an alcohol and
linked to a glucose molecule via a phosphodiester moiety as shown in fig. 1.10.

Figure 1.10. Examples of acceptor-analogues and bisubstrate inhibitors.

In addition, their preparation involves challenging carbohydrate synthetic methods, resulting
in long multistep sequences and leading to a low overall yield.
Cytidine-based inhibitors: Over the last decade, several research groups focused on the design
of donor analogue inhibitors. Prevention of the glycosyl transfer is mediated by binding in the
active site of the enzyme in competition with the natural glycosyl donor CMP-Neu5Ac 2. Most
of the active compounds resulting for this approach are CMP-Neu5Ac derivatives which have
been modified on the sugar fragment. Various scaffolds showed promising activity aligning
with the expertise of the research groups where these inhibitors were synthesised. For example,
the Horenstein’s group investigated some bicyclo[3.1.0]hexane derivatives to mimic sialic
acid.222 The structure was obtained using the Meinwald rearrangement of norbornadiene
promoted by a peracid. This scaffold offers an elegant way to imitate the elongated distance
between the anomeric position of the sugar and the phosphate linker upon leaving. The prepared
compound 24 displayed some inhibition in the low micromolar range towards ST3Gal and
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ST6Gal (fig. 1.11). This work was continued by Niwayama et al. using a different synthetic
pathway in milder conditions but the biological activity was not communicated.223

Figure 1.11. Bicyclic sialic acidmimic 24 as sialyltransferase inhibitors.

Transition-state analogues: Designing an inhibitor by taking inspiration from the transitionstate of the enzyme often provides potent compounds.224-225 This concept was implemented in
the Schmidt’s group, based on the SN2-like mechanism,45-49 whereupon many transition-state
analogues were designed and evaluated. This transition-state is believed to occur through an
oxocarbenium ion-like structure on a distorted half-chair conformation ring. Using this
strategy, a double bond was introduced at the anomeric position of the sialic acid fragment in
order to replicate the planar geometry of the oxocarbenium intermediate. An extra carbon
atom was added to the structure to mimic the elongated distance between the reactive center
and the phosphate group while the CMP moiety started to leave. As a result, molecules
derived from unsaturated sialic acid analogues or simplified polyhydroxylated cyclohexenes
emerged (fig. 1.12), including compound 25 which reached submicromolar levels of
potency.153,200 To our knowledge, these inhibitors exhibited the most potent activity towards
ST6Gal-I but very little is known about their activity against other ST subtypes.
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Figure 1.12. Rational design of the first transition-state analogue 25.

Replacing the native carboxylic acid group of the sialic acid fragment with the phosphonate
congener resulted in an increase in the ST inhibitory activity of up to 100-fold.202 Various
aromatic groups were evaluated to replace the carbohydrate moiety, starting from phenyl 26
and furyl goups 27,202 substituted benzenic rings 28,226,207 heterocycles 29227 and substituted
phenyl goups bearing a fluorescent dye 30 (fig. 1.13).160 The fluorescent probe 30 was
efficiently taken up into cells and translocated to compartments surrounding the cell nucleus
without the need for transfection agents.

Figure 1.13. Examples of ST inhibitors bearing an α-hydroxyphosphonate moiety.

This strategy offers the advantages of providing potent inhibitors, ranging in the low
nanomolar range, while considerably alleviating the synthesis of the sialic mimic. The
substitution of the aromatic ring is important and the 3-phenoxy pattern (drawn in orange in
fig. 1.14) gave the most potent inhibitor 31 of the series, with Ki values of 0.07-0.3 nM
against rat ST6Gal-I and 19 nM against human ST6Gal-I. The compound 31’s structure is
reminiscent of the sugar-based compound 32 reported by Schwörer (fig. 1.14).228 The
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synthesis of the phosphate-based transition-state analogues used the phosphoramidite route
activated with 1H-tetrazole. Compound 31 is the lead structure for the present study.

Figure 1.14. Optimisation of the transition-state analogues from 25 to the lead compound 31 and their
activity against rat ST6Gal-I.

More recently, Li et al. reported potent cyclopentane-based CMP-Neu5Ac analogues. These
transition-state inhibitors also bear a CMP fragment and an α-hydroxyphosphonate moiety
and the sialic acid fragment was replaced by a five membered ring (fig. 1.15). The design of
more elaborate sugar mimic fragments was inspired by the structurally related sialidase
inhibitor peramivir 33, which provided the most potent examples (36, Ki = 28 nM) towards
human ST6Gal-I.208

Figure 1.15. The neuramidinase inhibitor Peramivir 33 and examples of functionalised cyclopentane
derivatives as sialic acid mimics.

As with neuramidinase inhibitors, sialic acid mimics can range from highly functionalised chiral
compounds229,230 to much simpler aromatic moieties.231 This was illustrated in Kumar’s work
with a series of benzamide derivatives linked to cytidine with a sulfamate group.197 The
compounds were tested against the bacterial α-2,3-ST Cst-06 and ranged from 9 to 79 %
inhibition at 500 µM. The two best inhibitors 37 and 38 (Ki = 87 µM) are shown in fig. 1.16-A
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with their possible binding mode docked as a part of this study in the active site of the bacterial
enzyme Cst-I (PDB: 2P2V, fig. 1.16-B).

A

B

Figure 1.16. Structure of benzamide derivatives 37 and 38 and their inhibition at 500 µM against Cst-06
(A)197 and the possible binding mode of 38 in Cst-I (B, PDB: 2P2V) docked as part of this study.

A number of studies explored various isosteric replacements for the native phosphodiester
linker. Historically, the exploration started with deleting the linker, with some of the earliest
ST inhibitors bearing no linker and the sugar mimic was tethered directly to the cytidine
fragment. Amongst these, the activity of the inhibitor KI-8110 39 (fig. 1.17)232 was evaluated
against colon cancer (NL-17,233 SW 837, H-29 and MIP-101 cells)234 and in animal models.
When the cells were exposed to KI-8110, they showed significant reduction of cell surface
sialylation along with tumour regression and a decrease in metastasis. After further
evaluation, other experiments showed that the activity of 39 was not directly related to ST
inhibition but rather to blockage of the CMP-Neu5Ac transporter into the Golgi.235
Of note, most GTs use sugar-nucleotides that contain diphosphates and this makes CMPNeu5Ac unique donor, in which cytidine is linked to sialic acid via a monophosphate. The
phosphodiester linker is the moiety present in the CMP-Neu5Ac 2 and utilised in the design of
a large number of compounds which exhibit moderate to highly potent ST inhibition.42,236 A
comparative study of ST inhibitors reported in literature showed that the CMP moiety, which
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includes the phosphate group, provides the most potent compounds against rat liver ST6Gal-I.
As a result, the incorporation of the phosphodiester group played a major role in the
development of ST inhibitors.237
In an early study, Amann et al. prepared CMP-Neu5Ac derivatives bearing a phosphonate
group instead of the native phosphate linker (40, fig. 1.17). The design strategy was to prevent
the cleavage between the nucleoside fragment and the sugar mimic by using a non-labile
linker. The concept of using a phosphonate group was later used by Izumi et al. to produce the
compound 41 which displays comparable affinity for ST3Gal-I to the parent compound 2,
with a IC50 value of 47 µM.221
Another phosphorous-based isosteric replacement for the phosphodiester group was evaluated
by Skropeta et al. by tethering cytidine to an α-aminophosphonate via a phosphoramidate
linker.226 The sugar mimic were prepared by using a stereoselective hydroxylation method
leading to the compounds 42-43 (fig. 1.17). Both diastereoisomers of the nucleoside conjugate
bearing a phenyl group were tested against rat liver ST6Gal-I and showed considerably lower
activity than the phosphate counterparts, with the R isomer being the most potent
diastereoisomer. Interestingly, no examples of the phosphoramidate linking a 5’aminonucleoside to an α-phosphonate fragment were reported in the literature to our
knowledge, and so at least for ST inhibition purpose. A phosphoramidate linker was also
explored to attach the cytidine fragment to amino-acids.238
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Figure 1.17. Examples of sialyltransferase inhibitors bearing a modified linker.

Further examples of moieties used to replace the phosphate linker include the 1,2,3-triazole
ring. Lee et al. prepared a series of 5’-triazolonucleosides to evaluate their activity on rat liver
ST3Gal.239 Among the cytidine based triazole molecules, only compound 44 showed
significant activity (IC50 = 37.5 μM, fig. 1.18). Interestingly, the presence of a phenyl group
seems to be a determinant factor, presenting a 2-fold improvement over the analogues
cyclopentyl compound 45 (44 % inhibition at 300 μM). Finally, Kumar et al. also investigated
different types of linkers involving complex functional arrangements.197 These include mostly
combinations of triazole and amide, and amino acids (fig. 1.18). These functional groups were
selected to increase the hydrophobicity of the inhibitors by bearing non-charged linkers.
Further

modifications

on

the

sialyl

moiety

also

included

2-deoxy-2,3-dehydro-

acetylneuraminic acid derivatives or aromatic rings. The inhibitory activity of these
compounds was evaluated against the bacteria C. jejuni Cst 06, using a HPLC-based
technique,153 and relatively low inhibition was observed (11-80 % at 500 μM). The 5’-triazole
nucleoside analogues obtained by click chemistry appeared to be competitive inhibitors. On
the other hand, two of the most active compounds (46-47) showed non-competitive inhibition,
suggesting the nitro group could play a role in the binding with the active site of the enzyme.
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Figure 1.18. Sialyltransfrase inhibitors bearing a triazole linker.

In summary, a variety of functional groups have been evaluated to replace the native
phosphodiester linker. The lack of consistency in regard to structures makes any comparison
difficult for establishing the SAR. The phosphate moiety remains optimal in terms of potency
but it can not contribute to selective activity towards the different ST subtypes because it
belongs to the natural sialyl donor 2, which is used by all ST enzymes. In addition, comparing
the functional groups and their influence on the activity of the corresponding inhibitors
indicates that the size of the linker matters and a three atom chain is optimal. In Kumar’s
compounds,197 the nucleoside and the sialic acid mimic are spaced by up to five atoms, which
keeps the fragment too far from each other and reduces the affinity of the inhibitor with the
active site of the enzyme.

1.3.5. Global metabolic inhibitors
A global metabolic inhibitor was investigated in Paulson’s group based on glycoengineering
techniques. By feeding the peracetylated 3-fluorosialic acid P-3Fax-Neu5Ac 48 into cells as
a biogenic precursor, the authors observed successive incorporation of the modified sugar
inside the cells, deprotection of the hydroxyl groups and conversion into the inhibitor CMP31
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3F-Neu5Ac 7 both in vitro240 and in vivo conditions (fig. 1.20).241 CMP-3F-Neu5Ac was first
discovered by Burkart et al. in 1999.172 A fluoro group was added at the 3-position of sialic
acid leading to the inhibitor 7 (Ki (ST6Gal-I) = 5.7 µM, fig. 1.5). The presence of a fluorine
atom at the 3-position of the sialic acid prevents turnover by inductively destabilizing the
oxocarbenium ion-like transition-state of the catalytic process.242 Although highly effective in
vitro, subsequent in vivo studies by Paulson involving systemic blockade of sialyation in mice
revealed the limitations of using global sialylation inhibitors such as P-3Fax-Neu5Ac in vivo
due to renal failure. Given the crucial role of sialylation in such a myriad of biological
processes and in particular the high level of expression in liver and kidney tissue, this is not
unexpected. However, as stated by the authors, these results highlight the importance of
developing selective, small-molecule ST inhibitors for therapeutic purposes, while metabolic
inhibitors will still have a crucial role to play as biological tools in uncovering more about the
role of sialylation in disease progression.241
In a different study, the metabolic inhibitor was also illustrated by Horstkorte et al. by
exploring the activity of 5-N-acyl-modified sialic acids on polysialyltransferases.243 The
CHO-mutant 2A10 cells expressing either ST8Sia-II or ST8Sia-IV were fed with 5-N-acyl-Dmannosamines and the artificial sialic acid precursors bearing longer chains, i.e. propanoyl
(49), butanoyl (50) and pentanoyl (51), at the 5-position were found to considerably reduce
the occurrence of cell surface α-2,8-sialylation (fig. 1.19). Real time RT-PCR demonstrated
that these compounds also affected gene expression. Unnatural sialic residues were also found
to be incorporated into sialoglycoconjugates. These results indicate the formation of the
corresponding CMP-Neu5Ac derivatives (52-54) takes place inside the cells. These nonnatural sialic acid derivatives were also prepared and tested in a different study with
consistent findings (fig. 2.2-C).244 The authors suggest that the inhibition may be indirect as
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the polymerisation of α-2,8-sialic acids stops after the first incorporation of these 5’-modified
analogues as the unnatural conjugates are no longer suitable substrates for the enzyme.

Figure 1.19. Possible mode of action of metabolic inhibitors peracetylated 3F-Neu5Ac 48, and 49-51.53240-243-244
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1.4. Aims of the project
The scalable synthesis of selective sialyltransferase inhibitors remains as an unmet need. The
literature in the field largely highlights the therapeutic potential of ST inhibitors with isolated
studies showing tumour regression both in vivo and in vitro. Amongst the wide molecular
diversity of known ST inhibitors, the compounds mimicking the sialyl donor CMP-Neu5Ac
and, more precisely the transition-state of the sialylation reaction represent the most promising
group because of the large data set available and the high potency of its members. This
knowledge allowed the elaboration of a SAR model, which could be simplified to 3 key
fragments: the nucleoside fragment, the sialic acid mimic and the phosphate linker. This model
was the framework leading to the rational design of novel ST inhibitors central to this project.
Therefore, in order to address these issues, the specific aims of this research project were:
o Synthesis: To create a concise and cost effective synthetic route in order to further
explore the SAR of ST inhibitors and enable a more complete biological assessment of
their activity. This requires a versatile strategy to facilitate pharmacomodulation and
allow the structural modification of the fragments separately. The most appropriate
synthetic strategy for the preparation of donor-analogue ST inhibitors is a convergent
approach which allows the coupling of the sugar mimic with the nucleoside fragment
via a linker. The type of linker chosen defines the synthetic route because the key
fragments must bear the required functional groups suitable for the coupling step.

o Computational methods: To utilise the recently released crystal structures of STs in
order to gain insight into the different binding modes between subtypes. Molecular
docking will support the design of the building blocks.
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o Biological testing: The ST inhibitory activity of the final target compounds will be
evaluated in both enzyme and cell-based assays, along with screening the building
blocks for their own inherent activity in other bioassays including anti-inflammatory
and antibacterial assays. Cytotoxicity will be evaluated for all building blocks and
final compounds, however, the cell toxicity of the ST inhibitors is expected to be low,
as inhibiting cell surface sialylation affects cell migration not viability. This low cell
toxicity is beneficial and will enable us to better examine the anti-metastatic effects of
ST inhibition on cell adhesion and migration.

Figure 1.20. The 3 fragments framework used as a guide for the design of new potent sialyltransferase
inhibitors.
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Chapter 2 – Sialic acid mimics
The vast majority of reported sialyltransferase (ST) inhibitors are built around the three key
components of the natural ST donor CMP-Neu5Ac: the sialic acid moiety, the phosphate
linker and the cytidine nucleoside. This gives rise to structures bearing a combination of sialic
acid and cytidine mimics coupled together through an array of linkers including
sulphonamides and triazole. A review of known inhibitors has revealed that each fragment
plays a significant role independently.42 A convergent synthetic route is preferable for the
preparation of such structures and ensures the flexibility of the method. Consequently, the
choice of the linker is a central theme in this study for several reasons. First, modifying the
linker is expected to contribute to major changes in the biological activity as the native
phosphate linker is often described as critical for the enzyme activity. Second, the charged
molecules are known to impart poor cellular permeability, by reducing the affinity for the
lipidic nature of cell membranes.197 Finally, the type of linker selected directs the synthetic
strategy by imposing the connectivity with the two other fragments.

Figure 2.1. Design of triazole and carbamate-based sialyltransferase inhibitors.
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2.1. Design of new building blocks
2.1.1. Carbamate derivatives
As a part of the study dedicated to the modification of the linker between the nucleoside
fragment and the sialic acid mimic of ST inhibitors, the carbamate moiety was selected as a
potential candidate. The carbamate moiety meets the criteria for the isosteric replacement of
the phosphate linker because of its similarities with the phosphate group. Structurally, the
functional group is a linear assembly with a length of three atoms and the central planar sp2
carbon at the basis of the carbonyl group provides some rigidity. In medicinal chemistry, the
carbamate group has typically been used to replace ester groups, to prevent cleavage of the
natural parent scaffold and improve the metabolic stability.245 This was illustrated in the
chemistry of fatty acid amide hydrolyase inhibitors246 and acetylcholinesterase inhibitors,247
both of which have various libraries of carbamate-based ligands.
In the context of ST inhibitors, the carbamate linker offers a non-cleavable alternative to the
native phosphate group. In addition, carbamate-linked ST inhibitors have not previously been
evaluated to the best of our knowledge.
Retrosynthetic scheme: Carbamate derivatives can be prepared from an alcohol, an amine and
a coupling reagent responsible for the carbonylation such as phosgene248 or less hazardous
reagents such as carbonyldiimidazole,249 isocyanates and others.250,251 The synthetic strategy
proposed in fig. 2.2 utilises an intermediate shared with the preparation of the triazole derivatives
(discussed later), that being the 5’-aminonucleoside fragment attained by simple reduction of the
azido counterpart.252 The investigation of a series of α-hydroxyphosphonate derivatives required
as precursors to the carbamate-linked ST inhibitors is presented in this chapter along with their
biological evaluation.
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Figure 2.2. Retrosynthetic scheme for the preparation of carbamate-linked sialyltransferase inhibitors
(PG: protecting group).

2.1.2. Triazoles
The triazole ring is readily attained using the the 1,3-dipolar cycloaddition reaction between
acetylenes and azides, pioneered by Huisgen in the 1960’s,253-255 and brought back into focus
by Sharpless and others.256-262 The concept, nicknamed “click chemistry”, gives rise to
reactions that are high yielding, modular, wide in scope, stereospecific, and environmentally
friendly.263 The reaction between an alkyne and an azido derivative was initially performed
using a thermal cycloaddition. However, Medal, and then Sharpless264-265 later discovered that
copper (I) salts could efficiently catalyse the reaction, allowing the use of milder conditions,
such as room temperature and shorter reaction times. Catalysis also brought more control over
the regioselectivity in the reaction, favouring the 1,4-regioisomer when copper is used and
1,5-regioisomers with ruthenium. Because of its numerous advantages, the Cu alkyne-azide
cycloaddition, also called CuAAC, became extremely popular and it has become almost
synonymous with “click chemistry” itself (fig. 2.3). Compared to other metal-catalyzed
reactions, the use of a copper catalyst presents the major advantages of being inexpensive and
easy to handle. The active catalytic entity is Cu I, which is often generated in situ by reacting a
stable source of CuII, such as copper sulfate or acetate, with a gentle reducing agent.266-267
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Within a short time frame, click chemistry has proven a remarkable utility and broad scope,
not only in organic synthesis, but also in chemical biology and drug discovery.256,268

Figure 2.3. Mechanism of the copper catalysed alkyne/azide cyclocondensation.

Herein, the triazole ring shows promise as an isosteric replacement for the phosphodiester
linker,269 as demonstrated by Lee et al.239 (Cf section 1.3.4). Incorporating an unnatural
linkage into ST inhibitors provides several benefits, which include retaining geometric and
spacial characteristics of the native glycoforms,31,51,270-271 yet inhibiting the targeted enzyme.
Changing the phosphate group into a triazole ring provides an increase in chemical and
enzymatic stability.272 In CMP-Neu5Ac 2, the phosphate linker is instrumental in the sialic
acid transfer because of it being a leaving group. Consequently, the triazole ring offers here a
non-labile alternative.
In terms of geometry, the triazole ring appears as a rigid structure opposed to the flexible
phosphodiester moiety. The 1,4-disubstituted triazole is a planar and aromatic heterocycle and
the orientation of the substituents attached to the 1- and 4-positions is fixed and defined by the
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dihedral angle that separates them. Conversely, the phosphate linker tethers the sialic mimic
and the nucleoside fragment via 4 rotatable bonds. This difference between the triazole and
the phosphate moieties provides a geometrical constraint, which can influence the activity of
the proposed inhibitors as the conformational properties of the acceptor substrates have
proven to play a role in the specificities of ST reactions.273 Two of the nitrogen atoms that are
part of the triazole ring bear lone pairs of electrons, which do not participate in the
aromaticity. As a result, they are two hydrogen-bond acceptor sites.
Retrosynthetic scheme: The preparation of triazole-based ST inhibitors using the CuAAC
reaction requires two key building blocks: an azidonucleoside fragment and an alkyne
derivative (fig. 2.2). Incorporation of an azido group on the nucleoside fragment allows access
to various possible linkers presented in chapter 3.252 As the presence of the phosphonate group
was previously found to contribute to the potency of inhibitors, the retrosynthetic scheme
proposed in fig. 2.4 includes the proposed preparation of 1-arylpropargylphosphonate esters
as described in this chapter.

Figure 2.4. Retrosynthetic scheme for the preparation of triazole-based sialyltransferase inhibitors
(PG: protecting group).
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2.2. Synthetic strategy
2.2.1. α-Hydroxyphosphonate esters as building blocks for the
preparation of carbamate-based ST inhibitors
2.2.1.1. Aspects of the phosphonate group in the lead compound
Originally, the α-phosphonate group was introduced into the early ST inhibitors to replicate
the CDP 5 moiety (fig. 2.4),200 which itself is a moderate ST inhibitor, Ki (ST6GalI) = 10 µM. At physiological pH, CDP bears two charges. The methylenephosphonate
analogue 55, for which the activity was not communicated, was an intermediate in the design
of the transition-state analogue 26, which was 50-fold more potent than CDP (Ki (ST6GalI) = 200 nM).

Figure 2.5. CDP and other compounds used in the rational design of transition-state inhibitors by the
Schmidt group.

In the ST8Sia-III crystal structure, co-crystallised with CDP 5 (PDB: 5BO6), the second
phosphate unit binds to the threonine residue Thr301. Furthermore, docking CMP-Neu5Ac 2
into the three subtypes, co-crystallised with CMP, the porcine ST3Gal-I, the human ST6Gal-I
and the human ST8Sia-III, reveals similar interactions between the carboxylic acid group and
the protein. In all cases, the phosphonate functional group forms a hydrogen bond with a
serine or a threonine residue, Thr272 in ST3Gal-I, Ser323 in ST6Gal-I and Thr301 in ST8SiaIII (fig. 2.5). This indicates that the diphosphate unit in CDP mimics the interaction with the
carboxylic group in CMP-Neu5Ac. In addition, according to the reported crystal structures,
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the environment in the active site is very similar for the three subtypes, therefore this region
might not be the most favorable spot to achieve selectivity. The carboxylate group binds to
the protein via a hydrogen bond, not an ionic interaction. These last observations suggest that
the carboxylate group could be replaced, in theory, with neutral isosteric groups.

Figure 2.6. CMP-Neu5Ac 2 docked in ST3Gal-I (A), ST6Gal-I (B) and ST8Sia-III (C) crystal structures using
Autodock Vina. The residue interacting with the carboxylate group is highlighted in green and the cocrystallised CMP 3 in A and B is represented in orange sticks.

In order to gain further insight on the binding mode of the linker itself in the active site, the lead
compound 31 bearing a 3-phenoxy group was also docked into the human ST6Gal-I crystal
structure (fig. 2.7). Amongst the various possible conformations proposed by AutoDock Vina,
only the results that best aligned with the co-crystallised CMP 3 molecule were selected for
comparison. Analysing the models presented in fig. 2.7 reveals that the phosphonate group
binds to the Ser323 which validates the hypothesis that the phosphonate mimics the native
carboxylic group of the natural sialyl donor 2. The docking experiment shown in fig. 2.7 was
performed by using both the R and S isomers for the position bearing the phosphonate group.
Both diastereomers displayed comparable calculated affinity (-10.6 and -10.1 kCal/mol
respectively) as determined by AutoDock Vina. This counter-intuitive result indicates that the
configuration of the stereogenic center at the benzylic position of the α-hydroxyphosphonate
fragment has little importance because both diastereoisomers give superimposable
conformations in their binding pose. This result is supported by the biological activity of the
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compound 31.207 The docking of 31 in the human ST6Gal-I also shows significant interactions
with the neighbouring residues Asn212, Asn2333 and the catalytic residue His370.

A

B

Figure 2.7. Docking pose of the R (A) and S (B) isomers of the lead compound bearing a 3-phenoxy group 31
in the human ST6Gal-I (PDB: 4SJ2, CMP 3 is represented in green sticks).

2.2.1.2. General procedure for α-hydroxyphosphonate esters
α-Hydroxyphosphonate esters and their analogous phosphonic acids exhibit a wide range of
biological activities such as anti-osteoporosis,274 anticancer,275 antibacterial,276 antibiotic,277
antimalarial,278 and inhibition of several types of phosphatases.274-275,279 Many procedures
have been reported for the preparation of α-hydroxyphosphonate derivatives, including the
reaction of aldehydes with dialkyl phosphite. This procedure is the most commonly used and
can be promoted by the use of additives such as acids or bases.280
Most α-hydroxyphosphonate derivatives used herein were prepared from readily available
benzaldehyde. The choice of the starting material was directed by the SAR model proposed
and focussed on aromatic rings bearing hydrophobic groups at the 3-position. Inspired by
previous aromatic sialic acid mimics, a range of benzaldehyde derivatives were chosen to
prepare the requisite α-hydroxyphosphonate esters. These aldehydes bear electron donating
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(4-methyl, 4-ethyl, 3-hydroxy, 3-methoxy) or withdrawing groups (3-nitro, 3-bromo, 2-,3and 4-fluoro). Methoxy groups were used to mimic the typical polyhydroxylated sixmembered ring moiety found in hexoses (2,5-, 3,4- and 3,5-dimethoxy).
Other starting materials were prepared to increase the molecular diversity of the library.
Hydrophobic groups were chosen in order to balance the overall polarity of the coupled compounds,
mainy because of the high hydrophilicity of the nucleoside fragment. 3-Hydroxybenzaldehyde 56
was alkylated using 1-iodopropane in the presence of potassium carbonate (fig. 2.8) to give 3propoxybenzaldehyde 57 as described by Nishikawa et al.281 A similar procedure was applied to 5bromosalicylaldehyde 58 and 2-hydroxy-α-naphthaldehyde 59 to prepare the known intermediates
60 and 61 respectively, with spectral data matching those reported.

Figure 2.8. Synthesis of the known intermediates 57, 60 and 61 by alkylation of the phenolic aldehydes.

Another two derivatives were synthesised from vanillin 62, following reported procedures, by
acetylating the 4-hydroxyl group to give 63282 (96 % yield) or by successive bromination283
and acetylation284 to give 64 (82 %, fig. 2.9). This sequence was also applied to 4-
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hydroxybenzaldehyde 66 and yielded successively the brominated derivative 67 (83 % yield)
and 68 after acetylation (89 % yield).

Figure 2.9. Preparation of benzaldehyde 65 and 68 as precursors of α-hydroxyphosphonate esters.

In the context of this study, the straight forward and reliable methodology reported by Wong et
al. for the synthesis of α-hydroxyphosphonate esters was preferred because of its practicality
and low cost.285 Benzaldehyde derivatives were treated with 1.1 equiv. of diethyl phosphite and
2.2 equiv. of triethylamine at room temperature until disappearance of the starting material as
judged by TLC, with addition of CH2Cl2 if required. Unless solubility issues were encountered,
the reaction was set up with no solvent. This method did not provide any noticeable side
product and as a result, the expected α-hydroxyphosphonate esters were isolated in excellent
yields after a simple extraction (table 2.1).
In total, 19 diethyl α-hydrophosphonate esters were prepared in this manner as coupling
partners for the preparation of carbamate-based ST inhibitors. At this time in the project,
however, a change in focus to the triazole-based inhibitors meant that a second PhD student
pursued the development of the carbamate-based inhibitors taking off from this point, while I
pursued the triazole counterparts.286 To round off the investigation of the α-hydrophosphonate
esters, a selected set of compounds were subjected to biological evaluation.

47

Chapter 2
Table 2.1. Summary of the α-hydroxyphosphonate esters prepared from aldehyde derivatives.

Yield
(%)

Compound

cLog P

1.79

78

79

2.15

91

70

2.31

95

80

2.46

86

71

0.62

92

81*

2.38

56

72

1.21

93

82

0.95

86

73

2.26

93

83

1.29

84

74

3.38

90

84*

1.29

95

75

1.03

94

85*

0.37

66

76*

1.43

92

86*

1.08

94

77

1.43

95

87*

2.21

68

78

1.43

95

Compound

cLog P

69

Ar

* Novel compound.
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2.2.1.3. Biological evaluation of α-hydroxyphosphonate esters
The series of 19 α-hydroxyphosphonate esters produced in this study underwent various
biological assays, including cytotoxicity, anti-inflammatory and antibacterial activity assays.
Cytotoxicity: The MTS cell proliferation assay is widely accepted as a reliable measurement
of cell viability.287 This assay was performed by using the MTS CellTiter 96®, which consists
of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
salt 88 with an electron coupling reagent (phenazine ethosulfate, PES).288 In contact with viable
cells, the MTS reagent gets reduced to red formazan 89 and the number of remaining viable cell
can be determined through colourimetry (fig. 2.10). The reduction is carried out by
mitochondrial dehydrogenase enzymes along with the production of NADH or NADPH. The
amount of formazan produced is proportionally related to the number of living cells which
justifies the accuracy of the assay as the MTS reagent can only be converted into formazan by
metabolically active cells. After seeding overnight in 96 wells plates, the cell cultures were
treated with the α-hydroxyphosphonate esters and incubated for 24 to 48 h. The MTS reagent
was added to the media and incubated for 3 h before reading the absorbance at 492 nm. DMSO
and media in the absence of compound were used as positive and negative controls, respectively.

Figure 2.10. Reduction of the yellow MTS tetrazolium salt 88 to purple formazan 89 by viable cells.
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The 19 diethyl α-hydroxyphosphonate derivatives 69-87 were evaluated for their cytotoxicity
against two different cell lines, Mia-PaCa-2 (human pancreatic cancer) and RAW264.7 (murine
macrophages). The cell viability was evaluated in exposure to these samples at 100 µM. At this
concentration, the cells exposed showed more than 100 % survival with all compounds tested,
and are thus considered non-toxic to these cells at concentrations of up to 100 µM.
Anti-inflammatory activity: Nitric oxide (NO) is a signalling molecule involved in many
physiological and pathophysiological processes in the human body, including cardiovascular,
immune, inflammatory and neuronal.289 NO has thus been the object of intensive research for
drug development, appearing as a target for a wide range of pathologies such as cardiogenic
shock,290

cancer,291-292

anxiety

disorders,293

neurodegenerative

diseases294

and

inflammation.295-297 The production of NO and other mediators by macrophages has been
determined in many inflammatory tissues following exposure to immune stimulants including
bacterial endotoxin lipopolysaccharide (LPS).296 Amongst the number of synthetic
compounds that inhibit NO production295,298-299 endogenous molecules also contribute to
modulate this inflammatory signalling pathway such as melatonin, a tryptamine derivative
synthesised in the pineal gland, which regulates circadian rhythms.294
In accordance with some recent examples of α-hydroxyphosphonate derivatives showing
inhibition of NO production reported by Abdou et al,300 the activity of our series of diethyl αhydroxyphosphonate derivatives was also evaluated using the Griess reagent assay.301
For these studies, the murine macrophages RAW264.7 were used. The cells were cultured in the
appropriate media such as DMEM or RPMI supplemented with fetal bovine serum (FBS) and
optional antibiotics to avoid contamination (commonly streptomycin-penicillin). The cells were
treated with the samples and incubated for 24 h before adding LPS, at a concentration of
-1

1 μg.mL

in order to induce the inflammatory cascade. After 30 min, an aliquot of the cell
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supernatants was collected and to it was added the Griess reagent (1 % sulphanilamide 90 and
1 % N-(1-naphthyl)ethylenediamine dihydrochloride 91 solution), which initiated a colour
change. At this stage, the NO produced reacts with the sulphanilamide in a Sandmeyer reaction
fashion and the resulting diazonium salt reacts with the N-(1-naphthyl)ethylenediamine (fig.
2.11). The absorbance of the diazo product 92 was measured at 540 nm and the nitrite
concentration was determined from a sodium nitrate standard curve.302

Figure 2.11. Mechanism of action of the Griess reagent.301

Using the Griess reagent assay, 14 diethyl α-hydroxyphosphonate derivative were evaluated
for their ability to inhibit the production of NO in LPS-activated RAW264.7 cells at a final
concentration of 10 µM (table 2.2). A few compounds were not tested, such as 73, 74 and 79,
because of their low solubility in aqueous media, leading to precipitation during the assay.
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Table 2.2. Inhibition of NO production in LPS-stimulated RAW264.7 cells by selected diethyl α–hydroxyphosphonate esters, tested at a final concentration of 10 µM and listed by order of potency.

Compound

Formula

% Inhibition

Compound

Formula

% Inhibition

78

7.7

69

36.5

84

21.1

75

46.0

76

21.5

70

47.5

71

24.6

80

54.6

83

25.7

81

80.0

82

28.1

87

76.8

77

29.0

86

101.2

Amongst the 14 diethyl α-hydroxyphosphonate derivatives tested, a few compounds exhibited
promising activity, showing over 80 % inhibition of NO production at 10 µM. The presence
of hydrogen bond acceptors is probably not a major requirement given that compounds 80 and
81 are more potent than their methoxylated analogues 69, 82 and 84. The electronic effects of
the functional groups present on the aromatic ring do not follow any particular trend. For
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example, the 3-nitro (73) and the 4-ethyl (70) derivatives display similar potency (46 % and
47.5 % inhibition respectively). The orientation of the substituents on the ring may not play a
critical role in the activity but a bulky hydrophobic group at the 3-position is preferred
(compounds 87 and 86). In conclusion, the influence of the substituents attached to the
aromatic ring is more steric than electronic.
In previous studies evaluating α-hydroxyphosphonate derivatives,300 Abdou et al. identified
tetrazoloquinoline-based compounds as anti-inflammatory agents. The NO inhibition was not
measured by the compounds successfully reduced paw edema in rat. The study reports
tricyclic derivatives bearing a hydrophobic moiety at the 3-position of the central benzenic
ring. This structural similarity with our most potent α-hydroxyphosphonate derivatives
suggests a possible related mode of action eventhough, the biological evaluation is not
comparable for both studies.
Antibacterial activity: Various recent studies on the activity of α-hydroxyphosphonate esters
highlighted the benefits of these derivatives for antibacterial purposes.303-306 The 19 diethyl αhydroxyphosphonate derivatives 69-87 were tested against five Gram negative bacteria
Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa
and Staphylococcus aureus. The assay was performed by WADI (Worldwide Antibiotic
Discovery Initiative), now CoADD (Community for Open Antimicrobioal Drug Discovery). At
concentrations up to 32 µg/mL, the α-hydroxyphosphonate esters tested had no effect on the
viability of the five bacteria listed above.
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2.2.2. Propargylphosphonate esters for triazole ST studies
Alkynes are important in organic and medicinal chemistry as extremely versatile
intermediates307 or functional groups of natural products and molecules of a pharmacological
interest.308-310 There has been a renewed interest in alkynes since the advances in Sonogashira
reactions,311-313 metathesis,314 click chemistry315-316 and the recent development of other novel
synthetic methods.317 Attention has also been paid to transition-metal-catalyzed propargylic
substitution reactions of alcohol derivatives with nucleophiles, showing that an acetylenic
carbon-carbon triple bond has a high potential for a wide variety of transformations.318-320
In order to obtain ST inhibitors bearing a phosphonate group on the benzylic position (fig.
2.2), an original synthetic pathway using the corresponding propargyl alcohol was explored.
Catalytic propargylic substitution is relatively common and a wide range of nucleophiles have
been introduced from propargylic alcohols or esters with the help of metal-based catalysts.
Historically, the Nicholas reaction was a pioneering example for propargylic nucleophilic
substitutions. The procedure consists of forming a dicobalt hexacarbonyl complex with the
propargylic substrate.321 The complex stabilises the carbocation and thus facilitates SN1 type
reactions with nucleophiles. This methodology also improves thermodynamic control of the
reaction. To an extent, the dicobalt complex can be considered as a protecting group for
alkynes. Despite the relatively versatile applications for the Nicholas reaction,322 no records of
this method leading to phosphonate derivatives are available to our knowledge. More
recently, a large number of research groups investigated the activation of propargylic alcohol
of esters promoted by Lewis acids. These studies described propargylic substitutions using a
wide variety of catalyst such as InCl3,323 Rh(PPh3)3Cl,324 TiCl4,325 SnCl2,326 FeCl3,327-328
Au(OTf)3,329 BiCl3,330 Bi(OTf)3,331 ionic liquids,332 and para-toluenesulfonic acid.333-334
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Copper-catalysed amination of propargyl acetate has been inspirational for the development
of a new synthetic strategy leading to propargylphosphonate esters. Catalytic propargylic
amination emerged about 20 years ago335 and has attracted renewed interest including the
exploration of various catalysts,336,324-325 enantioselective versions337-342 and applications to
synthesis of natural products.321-322,343-345 These methods were also found to be particularly
attractive here as the use of a chiral ligand in addition to the catalyst would allow us to obtain
the desired product as a single enantiomer.
In order to prepare the propargylphosphate derivatives required for this study, a starting
material was chosen to screen conditions for the copper-catalysed propargylic substitution
reaction. The addition of ethynylmagnesium bromide to p-tolualdehyde 93 to give the α–
arylpropyn-1-ol 94, which was not isolated and directly acetylated as reported by Ghosh et
al.to give 95 (fig. 2.12).346 The 4-methyl group was chosen for the optimisation process to
simplify the spectral data and facilitate the identification of the reaction products. In the
1

H NMR spectrum, two doublets are expected in the aromatic area (6-8 ppm) and a singlet,

downfield in the spectrum is expected to be characteristic for the 4-methyl group.

Figure 2.12. Synthesis of the alkynyl intermediate 95 used for the propargylic substitution trials.

Despite the number of different catalysts reported for this transformation, it was decided to
focus on copper because of it being relatively inexpensive. Moreover, using a catalyst suitable
for the next step would enable the development of a one-pot strategy within the optimisation
of the sequence. To our knowledge, no procedure to prepare propargylphosphonate esters has
been reported to date. Given the previous work using copper catalysts to prepare
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propargylamine derivatives, as well as ether and thioethers, screening similar conditions
involving diethyl phosphite as a nucleophile was our priority. The first attempts consisted in
screening catalysts, with copper catalysts considered a priority as a previous study reported
the synthesis of allene derivatives by using a palladium-based catalyst.347 The initial
conditions that were evaluated for the preparation of the α-arylpropargylphosphonate 96 are
summarised in table 2.3.
Table 2.3. Screening catalysts and conditions for the propargylic substitution.

Entry

Catalyst

Base

Solvent

Reaction time (h)

Yield of 97 (%)

1

Pd(OAc)2

Et3N

CH2Cl2

1.5

61

2

Cu(OAc)2

Et3N

MeOH

6

72

3

CuI

Et3N

MeOH

1.5

78

4

CuI

(iPr)2NEt

THF

1.5

79

5

CuCl

Et3N

MeOH

1.5

76

6

Cu(PPh3)3Cl

Et3N

CH2Cl2

24

47

7

CuO

Et3N

CH2Cl2

24

N.D.*

8

CuO

Et3N

MeOH

24

N.D.*

9

CuCl

None

CH2Cl2

6

N.D.*

10

CuCl

MeONa

MeOH

6

N.D.*

11

CuCl

NaH

THF

6

N.D.*

* Not detected.

Various conditions were screened with the aim of synthesising the proparylphosphonate ester
96. First of all, palladium acetate was used (table 2.3, entry 1) as a reference for the catalyst
screening study, in accordance with a method previously reported by Kalek et al.347,348 The
authors described the synthesis of allenylphosphonate esters by using activated propargylic
substrates and dialkyl phosphites in a reaction catalysed with a palladium complex.
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The following entries 2-6 in table 2.3, show the results of the propargylic substitution when a
copper catalyst was used. The major product that was isolated is the same for all these trials,
as monitored by TLC and ESI mass spectroscopy giving a m/z = 266 [M+H]+, which matches
the mass of the expected product 96. These first results were particularly encouraging because
the spot on the TLC plate was moving faster than the product from the reference reaction
using palladium acetate (table 2.3, entry 1). The 1H NMR experiment confirmed the presence
of the skeleton, with the para-substituted aromatic motif appearing as two doublet (around
7.10-7.17 ppm) and the diethyl ester moiety as two triplets (at 1.28 and 1.3 ppm for the
terminal methyl groups) and a multiplet in the 4.07-4.14 ppm area and integrating for 4 H (the
two methylene groups). Conversely, the terminal alkyne signal is not clear and instead, a
doublet at 5.77 ppm and a doublet of doublet at 6.42 ppm suggesting the formation of an
allenic derivative 97. Further investigation on the trial catalysed with palladium (table 2.3,
entry 1) revealed that the reaction mixture contained a major product with a mass of m/z =
405, which suggested the addition of two equivalents of the phosphite as previously described
by Milton et al.349
One trial using triphenylphosphine as a ligand (table 2.3, entry 6) also provided the
allenylphosphonate. Surprisingly, the kinetic of the reaction was slower in this case than the
trials using no ligands. The phosphines seem to stabilise an intermediate, not isolated, as shown
by the appearance of a faster moving spot TLC, which was not observed in the other trials. No
reaction was observed when using copper oxide, which seems to have limited solubility in the
solvents evaluated (CH2Cl2 and MeOH, table 2.3, entries 2 and 3). To our surprise, CuI and CuII
gave similar products. In trials using CuCl, CuI or Cu(OAc)2, only the allene derivative 97 was
isolated in good yields (72-79 %). From this set of trials, the base used plays an important role
and tertiary amines are preferred. It appears that the use of sodium salts (table 2.3, entries 10
and 11) promoted the precipitation of the phosphite or, at least, reduced its solubility in the
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media leading to decrease its reactivity. No reaction occurred when no base was used, indicating
that the phosphite may react in the deprotonated form.
Our results were consistent with those reported by Shen et al. at the time of our study, although
with noticeable differences.350 In their 2016 study, the authors also described the isolation of the
allene product in excellent yields. As a part of the optimisation, they first screened catalysts and
additives, mostly ligands for the copper catalyst. They found that the CuI/TMEDA system was
optimal and report considerably lower yields when using other ligands such as 2,2’-bipyridine,
1,10-phenanthroline or dppe (1,2-bis(diphenylphosphaneyl)ethane). In the present study, a
slight excess of Et3N (1.2 equiv.) was used for all trials. The base was added to deprotonate the
phosphite and to optimise its nucleophilicity but the amount present in the reaction mixture was
not enough to coordinate with the metal. It is reasonable to conclude that a ligand is not required
for the reaction. Shen performed most of the reactions at 0 °C but only a trace amount, if any, of
the side product was observed when the reaction was set up at room temperature. Other
comparable results to ours were observed by Trost et al. using C-centered nucleophiles and
propargyl bromides.351 In a more recent study, the allenylphosphoryl derivatives were isolated
from the reaction of propargylic alchols and catalysed with Cu(OTf)2.352
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Figure 2.13. Proposed mechanism of the formation of the allene product 97.350

The formation of the propargylphosphonate is not excluded and could possibly occur before
rearranging in the allene product. This type of reactivity has been observed with other alkynyl
compounds such as propargylsulfinamides.353
Some examples in the literature suggest the possibility to attain propargylphosphonate
derivatives, in particular a study reported by the Uemura group showing the preparation of a
propargylphosphine oxide using a ruthenium catalyst.354 Despite leading to versatile
propargylic substitution, this catalyst is not readily available and involves synthesis from
expensive starting materials. Therefore, this method does not fulfil the requirements of the
present study. Other metals, such as iron,327-328 bismuth330,331 or indium,323 will be considered
for further exploration in future work.
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2.2.3. Arylpropargyl ester derivatives for triazole ST studies
Encouraged by the succesful synthesis of the propargyl acetate derivative 95, a series of 1arylpropargylic esters were considered for click purposes. This fragment, which aims at
mimicking the sialic acid residue in the three key fragment model presented in the
introduction, offers an interesting opportunity for exploring SARs. Following the example of
95, which was prepared by addition of ethynylmagnesium bromide on the carbonyl group of
tolualdehyde and then acetylated, various benzaldehyde derivatives were prepared and
screened as a source of molecular diversity.

2.2.3.1. Benzenic derivatives
In accordance with the retrosynthetic schemes presented in section 2.1.2 of this chapter, the
preparation of the sugar-mimic fragment requires aldehyde derivatives as a starting material.
Following the SAR model described in chapter 1, the 3-position of the aromatic ring appears
to be a privileged scaffold for making a library of analogues. Hence a series of benzaldehyde
derivatives was selected for this study, including some of the starting material introduced for
the synthesis of the α-hydroxyphosphonate esters (Section 2.3.1).
Further derivatives were prepared in order to mimic the side chain of sialic acid. Amongst the
transition-state analogues, the use of arylethers was found to greatly improve the inhibitory
activity of the sialyl donor analogue.228 The resulting inhibitor 31 displays inhibition in the
low nanomolar range (Ki (ST6Gal-I) = 19 nM) and 32 (Ki (ST6Gal-I) = 29 nM, fig. 1.14).
N-Arylation from aryl halides and amines (the so-called Büchwald-Hartwig reaction) 355,356 or
O-arylation resulting from the coupling of an aryl halide and a phenol (the Ullmann
reaction)357 are well-known and suitable pathways. However, since all these reactions usually
require an expensive catalyst (albeit in extremely low amount in some cases),358 the cost of
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the metal catalyst may become an issue for their wide spread application. Interesting results
have been obtained with nickel catalysts,359 but in the last few years copper catalysts have
undoubtedly taken the lead.360 A few attempts for the synthesis of diarylethers were
performed using the Ullmann reaction. The trials involved 3-bromobenzaldehyde and 4chlorophenol under various conditions and using tertiaryamines or NaH as a base. In the best
case, only the starting material was recovered. Suspecting that the reactivity of the aldehyde
group might compete, the acetal was prepared and led to similar results.
Independently reported by the groups of Chan,361 Evans362 and Lam363 in 1998, this new
simple procedure allows for the formation of C(aryl)-N and C(aryl)-O bonds in mild
conditions. The aryl fragment is provided by an arylboronic acid in combination with a
tertiary amine base (triethylamine or pyridine in most cases) and the coupling is catalysed by
copper acetate. Anhydrous conditions are preferred to restrain the amount of side-products
formed, molecular sieves are thus often added to the reaction mixture. The reaction is
performed at room temperature in air, as exposure to oxygen was found to be advantageous.
The solvent used for this reaction does not seem to be of importance. CH2Cl2 is the most
commonly used solvent, however successful couplings have also been reported using many
other solvents such as acetonitrile, dimethylformamide and dioxane. Since the extensive
development of the Suzuki reaction, a large number of highly functionalized boronic acids are
now readily available. The Evans-Chan-Lam reaction offers a simple and mild alternative to
the Ullmann reaction, which usually requires high temperatures.357
This elegant method using arylboronic acids and catalysed with copper was applied to the
arylation of isovanillin 98 (fig. 2.14). The reaction was performed by using 98,
1.2 equivalents of phenylboronic acid in the presence of copper acetate and triethylamine and
led to the 4-methoxy,3-phenoxybenzaldehyde 99 in 79 %.
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Figure 2.14. Synthesis of the intermediate 99 by arylation of phenolic benzaldehyde derivatives.

The preparation of further functionalised building blocks was attempted by using the unique
physicochemical properties of fluorine. 4-Fluoro-3-phenoxybenzaldehyde is commercially
available and was used as recieved. The Chan-Lam-Evans cross coupling reaction was
suitable for the introduction of a fluorine atom on the second aromatic ring, i.e. the phenoxy
group (fig. 2.15). Encouraged by the successful results attained when using isovanillin,
similar conditions were used for the coupling reaction. 3-Hydroxybenzaldehyde 57 was
treated with 2- or 4-fluorophenylboronic acid 100 and 101 in the presence of copper acetate
and triethylamine in CH2Cl2 at room temperature (fig. 2.14).

Figure 2.15. Synthesis of the intermediate 103 by arylation of the phenolic benzaldehyde derivative 57.

According to the SAR model (fig. 1.20), the substituent attached to the 3-position of the
aromatic ring aims at mimicking the sialic acid fragment of the natural donor CMP-Neu5Ac
2. The structure of the side chain present in the parent compound 2 is a glyceryl residue and
can be described as polar and flexible. Despite giving the best biological results, the
physicochemical properties of the phenoxy group present in the lead compound 51, planar
aromatic and hydrophobic, and those of a glyceryl residue are not alike. This observation
motivated the preparation of derivatives bearing various substituents at the 3-position such as
cyclopentoxy and propoxy, which are hydrophobic, but more flexible than the phenoxy
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counterpart. For this purpose, the corresponding benzaldehyde derivatives were synthesised
by alkylation of 3-hydroxybenzaldehyde 56 (fig. 2.16). The 3-propoxy derivative was used as
reported in section 2.2.1.2.

Figure 2.16. Synthesis of the intermediates 104 and 105 by alkylation of phenolic benzaldehyde
derivatives.

The requisite alkyne fragments were prepared from the starting material (57, 94, 99 and 103105) by using the method described by Ghosh et al.346 that showed positive results for the
synthesis of 57. The synthesis proceeds in two step starting with addition of the
ethynylmagnesium bromide to the suitable benzaldehyde derivative and followed by
acetylation. The acetylation step helps diminishing the polarity of the intermediate, which
alleviates the purification of the intermediate. Consequently, the propargyl acetates were
isolated by a simple extraction, and the organic layers were washed with sodium bicarbonate
to provide the expected alkyne derivative in excellent yields (89-97 %) and the product was
used without further purification (table 2.4). In addition, decreasing the polarity of the alkyne
fragment results in increasing the difference of polarity with the nucleoside building block,
hence promoting a very efficient separation for the purification of the coupling step.
The 1-arylpropargyl alcohol intermediate was usually obtained in acceptable purity (>90 %) as
judged by NMR and used in the following step without any further purification. The alkyne
derivatives obtained from benzaldehydes presented consistent patterns in the 1H and 13C NMR
spectra allowing their characterisation. The C-H on the benzylic position (doublet at 6.6-6.9 ppm
and 61-65 ppm respectively) and the terminal alkyne position (doublet at ~2.6 ppm and ~75 ppm
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respectively). A series of 1-arylpropargyl acetates were prepared by using the substituted
benzaldehyde derivatives (57, 99 and 103-105) described above. This method perfectly matches
the project objectives by providing a series of clickable building blocks in excellent yields.
Table 2.4. Preparation of the alkyne-based building block from aldehyde and ketone derivatives.

Entry

Compound

R1

R2

R3

Yield (%)

1

106

MeO

H

H

93

2

107*

MeO

H

MeO

89

3

108*

PrO

H

H

92

4

109*

cyPentO

H

H

89

5

110*

cyPentO

MeO

H

91

6

111

PhO

H

H

97

7

112*

PhO

MeO

H

83

8

113*

PhO

F

H

94

9

114*

4-F-PhO

F

H

92

* Novel compounds.

2.2.3.2. Extension to heterocyclic derivatives.
In order to further extend our library of inhibitors, bicyclic and heterocyclic derivatives were
considered as promising targets.227 Docking the compound 29 (fig. 1.13) bearing a
benzothiazole ring into the human ST6Gal-I crystal structure (PDB: 4SJ2, fig. 2.17) provided
possible binding modes similar to results attained with the 3-phenoxy counterpart 31
(Cf section 2.3.2.1). In addition, in this case the configuration of the pseudobenzylic position
seemed to have little importance as the α-phosphonate group could bind to both catalytic
residues, either Tyr354 or His370, as already observed with the lead compound 51.
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Figure 2.17. Docking of the benzothiazole 29 in the human ST6Gal-I crystal structure (PDB: 4SJ2). CMP is
present (grey sticks) along with the R (green sticks) and S (orange sticks) isomers of 29.

The first heterocyclic derivative was prepared from 2-benzothiophenecarboxaldehyde 115
(fig. 2.18). Following the sequence used for the initial series in section 2.2.3.1, the 2benzothienyl 116 derivative was isolated in 86 % yield.

Figure 2.18. Preparation of the benzothienyl derivative 116.

When 2-quinolinecarboxaldehyde 117 was used to prepare the corresponding alkyne
derivative, a complex mixture was recovered (fig. 2.19). The crude material did not display
any evidence of desired alkyne derivative 118, either by NMR or mass spectrometry. The
absence of reactivity of the aldehyde group could be explained by a possible chelation of
magnesium by the quinoline nitrogen atom decreasing its reactivity.

Figure 2.19. Attempted preparation of the quinoline derivative 118.
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Examples of ST inhibitors bearing an indolic moiety motivated us to explore this scaffold.238
Amongst these examples, Whalen et al. synthesised the CMP-Neu5Ac analogues 119-124 by
linking cytidine to amino acids via a phosphoramidate group (fig. 2.20).238 The rationale
rested on mimicking the carboxylic acid function present in the native sugar. The series
exhibited inhibitiom in the low millimolar range and the tryptophan analogue 124, bearing the
indole ring was the most active (Ki (ST3Gal-I) = 0.3 mM and Ki (ST6Gal-I) = 0.73 mM).

Figure 2.20. Phosphoramidate amino-acid derivatives 119-124 as sialyltransferase inhibitors.238

The commercially available indole-3-carboxaldehyde 125 was a suitable starting material in
order to keep our synthetic methods consistent. Direct reaction of the ethynylmagnesium
bromide on indole-3-carboxaldehyde required protection of the N1-position because of the acidity
of the proton attached to the nitrogen atom.364 Tert-butoxycarbonyl represented an attractive
option for the entire protecting system to maintain consistency, i.e. with the acetonide group on
the nucleoside fragment. Indole-3-carboxaldehyde was thus treated with Boc2O in the presence of
a catalytic amount of DMAP to give 126 in 76 % yield (fig. 2.21).

Figure 2.21. Preparation of indolic aldehyde derivative 126.
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The substituent at this position mimics the native carboxylic acid group at the anomeric position
of sialic acid. The carboxylate binds to a serine or threonine residue depending on the ST
subtype (Cf section 2.3.2.1). Even if modifications at this position may not contribute to the
selectivity of the inhibitor toward the different ST subtypes, they might be informative about the
importance of interactions taking place with specific residues. As a result, a derivative bearing
an additional ester group was also prepared. Following reported procedures, the reaction of
indole 127 with oxalyl chloride was quenched with a solution of triethylamine in methanol to
give 128 (fig 2.22). The indole N1-position was then protected with a tert-butoxycarbonyl group
for the same reason mentioned for the aldehyde counterpart 125.

Figure 2.22. Synthesis of indole derivative 129 bearing an ester group.

In the case of these indolic derivatives, the addition of the Grignard reagent required
protection of the N1-position of the heterocycle. The proton attached to this position is
relatively acidic and propably reacts with the carbanion, which loses its nucleophilicity. The
Boc protected compounds 126 and 129 were suitable for the general sequence and provided
the corresponding alkyne building block in 73 % and 59 % respectively (fig. 2.23).
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Figure 2.23. Preparation of indole derivatives 128 and 129.

Isatin is another heterocycle of interest in drug design for the development of compounds with a
wide range of activity including cancer.365,366 As discussed for the preparation of the indolic
alkyne derivative 130, using isatin 132 as a starting material would lead to an alkyne derivative
bearing a hydrogen bond acceptor at the pseudobenzylic position. In addition, as the carbonyl
group is a part of the oxolactam ring, the expected product 133 is attractive because of the
geometrical constrain promoted by its cyclic structure. The geometry of this fragment results in
restricted conformations for the aromatic ring by preventing its free rotation. Examples of
cytidine-based ST inhibitors, such as 134, bearing a lactam moiety reported by Schaub et al.
(fig. 2.24)153 Ethynylmagnesium bromide successfully reacted with isatin to give the alkyne
derivative 133 in 58 % (fig. 2.24). In this case, the starting material did not require any
protection and the spectral data was consistent with those reported by Ghosh et al.367

Figure 2.24. Preparation of 3-ethynyl-3-hydroxyindoline 131 and example of cytidine-based
sialyltransferase inhibitor bearing a lactam moiety 132.
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Finally, the trifluoromethyl group was investigated as a substituent at the benzylic position.
For this purpose, the method using ethynylmagnesium bromide was applied to 1,1,1trifluoroacetophenone 135 and, after acetylation, the alkyne derivative 136 was isolated in
89 % yield, as reported by Kourist et al.368 (fig. 2.24).

Figure 2.25. Preparation of 1,1,1-trifluoroacetophenone derivative 136.

The entire series of alkyne derivatives synthesised in this chapter is summarised in table 2.5.
These 15 α-arylpropargylic derivatives will serve as building blocks for the preparation of
novel ST inhibitors as described in section 2.1.2. Given the hydrophobicity of the alkyne and
their lack of solubility in aqueous media, no biological evaluation was conducted on this
series. In addition, no reported biological activity was relevant to this project.
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Table 2.5. Summary of 1-arylpropagyl esters from aldehyde derivatives.

Yield
(%)b

Compound

R

H

90

113a

H

94

106

H

93

114a

H

92

107a

H

89

116a

H

86

108a

H

92

130

H

73

109a

H

89

131a

CO2CH3

51c

110a

H

91

133

CO-NH-

58c

111

H

92

135

CF3

89

112a

H

83

Compound

R

93

a.
b.
c.

Ar

Novel compounds.
Overall yields for the two steps.
The alcohol derivative was isolated and characterised without acetylation.
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This chapter describes the synthesis of building blocks suitable for mimicking the sialic acid
fragment in the natural ST donor CMP-Neu5Ac. Different synthetic approaches were
explored depending on the type of connectivity required for the linker.
First, a series of 19 diethyl α-hydroxyphosphonate esters was prepared from benzaldehyde
derivatives in good to excellent yields (56-96 %), including 5 novel compounds. The αhydroxyphosphonate derivatives were subject to biological testing and were found to exhibit
no toxicity and some anti-inflammatory activity, via the inhibition of nitric oxide production
in murine macrophages. Secondly, attempts to prepare propargylphosphonate esters using a
copper-catalysed coupling reaction led to the corresponding allenic derivatives. Finally, a
series of 15 α-arylpropargyl acetates was achieved in good to excellent yields. These alkyne
derivatives are suitable for the preparation of the target triazole-based ST inhibitors as will be
discussed in chapter 4
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Chapter 3 – The nucleoside fragment
Nucleosides are a large family of molecules, well represented in the pharmaceutical field.
There are currently fifteen nucleoside-based drugs approved as anticancer agents369 and
twenty-five as antiviral agents by the FDA.370 Nucleosides represent a scaffold of choice for
the design of donor-analogue ST inhibitors because of cytidine 137 (fig. 3.1) being a
component of the natural sialyl donor CMP-Neu5Ac 2. Using a nucleoside fragment as a part
of the pharmacophore presents a number of advantages. First, incorporating components of
the natural donor guarantees to conserve a certain integrity in the mode of binding of the
proposed inhibitors. In addition, the most potent inhibitors reported to date contain a cytidine
moiety. Finally, as nucleosides constitute key elements of living systems, specific transporters
are present on the cell membranes to ensure their uptake and the fulfilment of their function
through the body,371-372 the blood brain barrier,373 as well as cancer cells.374 Retaining the
nucleoside fragment will also aid the drug’s bioavailability.375-378 The cytidine fragment was
identified as essential for the activity of inhibitors towards ST6Gal-I from rat liver but little is
known about the SAR for this fragment and its activity towards other ST subtypes. It should
be noted however that metabolic weakness may be an issue when using cytidine-based drugs
as the pharmacological evaluation of FDA approved compounds have highlighted the
possibility of rapid deamination at the 4-position.379

3.1. Background
3.1.1. Overview of small cytidine-based inhibitors
Small cytidine derivatives have been the object of extensive studies in the context of anticancer drug development including analogues such as gemcitabine 138, cytarabine 139,
decitabine 140 and capecitabine 141 (fig. 3.1). However, many of these are rapidly converted
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to their uridine counterpart by action of cytidine deaminase which results, in most cases, in
inactive metabolites.379,380 In this study, we are planning to use both cytidine and uridine
derivatives and comparing their relative activity in enzyme and cell-based assays would be a
good indicator of their metabolic stability.

Figure 3.1. Examples of cytidine 137 and FDA approved nucleoside derivatives 138-141.

Small cytidine derivatives and cytidine 137 itself display some inhibitory activity against STs.
These include the product of the sialylation reaction itself, cytidine monophosphate CMP 3
(Ki (ST3Gal-I) = 64 µM,235 Ki (rST6Gal-I) = 50 µM,235 and Ki (ST8Sia-I) = 10 µM381). CDP 5
and CTP 6 also are ST inhibitors and are both more potent than CMP (e.g. CDP, Ki (ST3GalI) = 5 µM,

Ki (rST6Gal-I) = 19 µM

and

CTP,

Ki (ST3Gal-I) = 64 µM,235

Ki (rST6Gal-

I) = 16 µM, respectively). These cytidine derivatives were shown to act as competitive
inhibitors.382,383

3.1.1.1. Variations on the cytosine ring
A number of natural nucleosides have been evaluated as potential ST inhibitors, mostly uridine
and adenosine derivatives. Interestingly, despite being closely related to cytidine in terms of
structure, simple uridine-based nucleotides promoted weak but non-competitive inhibition
towards ST6Gal-I,382 with UTP 142 being the most active inhibitor (Ki = 350 µM), followed by
UDP 143 (Ki = 2.0 mM), and UMP 144 (Ki = 5.67 mM, fig. 3.2). In ST6Gal-I-catalysed
reactions UMP-Neu5Ac 145 (fig. 3.2) showed about 10 % of the activity observed for CMP-
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Neu5Ac 2.49,237 The sugar-nucleoside conjugate was also found to be a poor substrate for
ST3Gal-II, ST3Gal-III and ST6Gal-I.384 In comparison to uridine derivatives, adenosine-based
nucleotides showed weak, non-competitive inhibition profiles. Of these, the triphosphate
derivative is also the most potent, ATP 146, Ki = 200 µM, and the monophosphate analogue
(not shown) the weakest, AMP 147, Ki = 7.0 mM (fig. 3.2).382 Other adenosine derivatives
bearing a functionalised triazole ring at the 5’-position were evaluated, however they exhibited
lower potency than their cytidine-based counterparts.239 The CMP derivative bearing a methyl
group at the 5-position, 5-MeCMP 148, was tested against a wide range of ST subtypes and
showed some activity with a marked preference for the ST8Sia subfamily (fig. 3.2).385 In the
context of ST inhibition, only a few non-nucleoside replacements for cytidine have been
reported. For example, the cytosine ring was replaced with a resorcinol moiety (not shown),
however the resulting CMP-Neu5Ac analogue showed reduced affinity for ST6Gal-I.237
To a larger extent, 5-Aza-dC, also called azacytidine 149, was found to promote the induction
of ST3Gal-VI (fig. 3.2).386-387 However, the activity of this modified nucleoside on STs via
direct interaction has not been evaluated in ST inhibition assays to our knowledge.

Figure 3.2. Structures of small nucleoside derivatives including UMP-Neu5Ac 145, 5-MeCMP 148 and
azacytidine 149.
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3.1.1.2. Variation on the ribose fragment
There are a limited number of examples of cytidine-based ST inhibitors in the literature bearing
a modified ribose fragment. Most studies involved small nucleoside derivatives.
Variations at the 2’-position: 2’-Deoxycytidine 150 was evaluated against human serum ST
activity and showed very mild inhibition, ranging from 5.9 % inhibition at 100 µM to 32.5 %
at 1 mM (fig. 3.3).382 The phosphorylated analogues of 2’-deoxycytidine were tested later by
Kleineidam et al. and exhibited stronger activity, despite being less potent than the CTP
parent compound 151 (72 % and 84 % inhibition at 250 mM towards ST3Gal-I and ST6Gal-I
respectively, fig. 3.3).235 According to the same study, the 5-methyl analogue thymidine 152
remains significantly less potent than cytidine.235 Amongst nucleoside derivatives modified at
the 2’-position, arabinonucleosides represent an important family. Both ara-CMP 153 and araCTP 154 exhibited weak competitive inhibition against ST6Gal-II with Ki values of 1.10 mM
and 0.50 mM respectively (fig. 3.3).382
Modifications of the functional group at the 2’-position have also been explored in terms of
ST inhibition. Phosphorylation of cytidine at the 2’-position results in a weak inhibitor, 2’-CMP
155 (fig. 3.3), displaying 40 % inhibition at 250 mM against ST6Gal-I. 2’-Deoxy-2’fluorocytidine 156 inhibits ST6Gal-I with less potency than cytidine (74 % inhibition at
250 mM, fig. 3.3) and had no effect on ST3Gal-I.235 The 2’-methylated derivative 2’-OMeCMP 157385 displayed 84 % inhibition at 250 µM against ST3Gal-III but was not active
against ST6Gal-I (CMP exhibited 67 % and 49 % inhibition respectively at the same
concentration, fig. 3.3). This result suggests that the environment in the active site neighbouring
the 2’-hydroxyl group’s binding site is significantly different from one enzyme subtype to
another. In addition, this confirms that this pocket provides an avenue for creating selective
ligands as observed in the X-ray crystal structures.
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Figure 3.3. Examples of cytidine derivatives modified at the 2’-position and thymidine.

To our knowledge, modifications at the 3’-position of the ribose fragment are absent in the
literature, with the exception of 3’-CMP which is cytidine-3’-monophosphate.235 The activity
of 3’-CMP against ST6Gal-I is weak (39 % inhibition at 250 mM, not shown).
Variation of the ring: Ribodialdehyde-CMP 158 prepared by Klohs et al. was about 20 times
less potent than CMP against ST6Gal-II, ranging from 13 % inhibition at 250 µM to 50 % at
1 mM.382 1,3-Dioxolane was also evaluated as a ribose replacement to give compound 159
and 160 but this led to dramatically decreased activity compared to that of the parent cytidine
derivative (5 % and 16 % inhibition against ST3Gal-I at 100 µM, fig. 3.4).239

Figure 3.4. Examples of variations on the ribose ring.
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In a different approach, Tanaka et al. explored the replacement of the entire ribose moiety by a
peptide scaffold,388 however, the resulting compound 161 exhibited low activity, IC50 (ST6GalI) = 1 mM (fig. 3.5). A few years later, the same research group published the 5-FU analogue
162 for which the inhibitory activity towards ST6Gal-I doubled, albeit still weak.389

Figure 3.5. Examples and activity of ST inhibitors bearing a 5-FU moiety.

In summary, various nucleoside derivatives have been evaluated for the inhibition of STs.
Despite showing more structural integrity than the sialic acid fragment, the nucleoside derivatives
with ST inhibitory activity reported in the literature do not lead to an effective SAR model.
Comparing inhibitors that bear two or more different parameters is not accurate but provides an
intuitive starting point for the design. A selection of representative examples of small nucleoside
derivatives and their activity towards the main ST subtypes is summarised in table 3.1.
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Table 3.1: Summary of activity of simple nucleoside derivatives against ST3Gal-I, ST6Gal-I and ST8Sia-II
displayed as Ki, expressed in µM, or as percent inhibition.235-381-382-385

Compound

ST3Gal
Ki (µM)
64

%
-

CDP

-

50

85a

19

-

-

CTP

-

60

90a

16

-

-

AraCMP

-

-

-

1100

-

-

AraCTP

-

-

-

500

-

-

2’-O-Methyl-CMP

84b

-

0a

-

-

5-Methyl-CMP

31b

-

16b

-

UMP

14a

-

24a

5670

66-81a
24-55c
32-53a
15-48c
-

UTP

-

-

-

350

-

-

Cytidine

30d

-

70a

-

-

-

2’-Deoxycytidine

-

-

32e

-

-

-

-

-

-

-

-

-

Thymidine

-

-

2’-Fluoro-2’-deoxycytidine

0a

-

74a

%
-

ST8Sia
Ki (µM)
10

CMP

16a

a.

ST6Gal
Ki (µM)
50

%
-

-

Percentage inhibition at 250 mM. b. 250 µM. c. 50 µM. d. 0.65 mM. d. 1.0 mM.

3.1.2. Sequence comparison of ST subtypes
Prior to the release of crystallographic data for STs, various studies were performed to analyse
and compare the sequences of the ST subtypes, which enabled the identification of the
residues involved in the enzyme’s activity.171 Mutation studies highlighted the importance of
motif L and motif S in the recognition and affinity of the enzyme with the donor CMPNeu5Ac 2.167-168 Comparing the sequence of the motif L shows a high homology between the
different subtypes (table 3.2). The sequence of motif S is highly conserved (47-62 %) within
the ST8Sia subfamily but presents significant variations in the ST3Gal and ST6Gal
subgroups. The motif S contributes to the recognition of the ribose fragment, in particular the
2’- and 3’-hydroxyl groups, which interact with the beginning of the sequence as well as the
binding of the nucleobase, mostly through a hydrogen bond with the 2-position (located at the
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end of the sequence). The amino acids located between these two keys sections of the motif S
are mostly hydrophobic residues such as leucine, isoleucine, valine and alanine. The sequence
and conformation of this region in ST3Gal-I allows the formation of an hydrophobic pocket,
which explains the selective activity of 2’-MeCMP 157.385

Table 3.2. Sequence alignment of motif L, motif S and of the 4-amino group binding region of the human
sialyltransferase subtypes ST3Gal-I, ST3Gal-III, ST3Gal-IV, ST6Gal-I, ST8Sia-II, ST8Sia-III and ST8Sia-IV.
Major hydrogen bond interactions between the protein and the donor CMP-Neu5Ac are highlighted in green.
Motif L, CLUSTAL W (1.83) multiple sequence alignment
hST3Gal-I
hST3Gal-III
hST3Gal-IV
hST6Gal-I
hST8Sia-II
hST8Sia-III
hST8Sia-IV

RRCAVVGNSGNLRESSYGPEIDSHDFVLRMNKAPTAGFEADVGTKTT
RRCIIVGNGGVLANKSLGSRIDDYDIVVRLNSAPVKGFEKDVGSKTT
RRCVVVGNGHRLRNSSLGDAINKYDVVIRLNNAPVAGYEGDVGSKTT
GRCAVVSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTT
GTCAIVGNSGVLLNSGCGQEIDAHSFVIRCNLAPVQEYARDVGLKTD
NICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTN
KTCAVVGNSGILLDSECGKEIDSHNFVIRCNLAPVVEFAADVGTKSD
* :*... * . * *: . *.* * **. : *** *:
↑ interaction with O-1’ (ribose)
↑ interaction with phosphate group

Motif S, CLUSTAL W (1.83) multiple sequence alignment
hST3Gal-I
hST3Gal-III
hST3Gal-IV
hST6Gal-I
hST8Sia-II
hST8Sia-III
hST8Sia-IV

PSTGILSVIFSMHVCDEVDLYGFGA
PTLGSVAVTMALHGCDEVAVAGFGY
PTTGLLAITLALHLCDLVHIAGFGY
PSSGMLGIIIMMTLCDQVDIYEFLP
PTTGLLMYTLATRFCKQIYLYGFWP
LSTGILMYTLASAICEEIHLYGFWP
PSTGLLMYTLATRFCDEIHLYGFWP
: * :
:
*. : : *
↑ interaction with O-2’ (ribose)
↑ interaction with carboxylate (Neu5Ac)
↑ interaction with O-3’ (ribose)
↑ interaction with C=O-2

NH2 binding region, CLUSTAL W (1.83) multiple sequence alignment
hST3Gal-I
hST3Gal-III
hST3Gal-IV
hST6Gal-I
hST8Sia-II
hST8Sia-III
hST8Sia-IV

-DS-KGNWHHYWENNP
MST-PNAPLHYYETVR
AYN-KKQTIHYYEQIT
-SKRKTDVCYYYQKFF
QNQ-NPVKYHYYDSLK
PNTREDLPYHYYDKKG
LNG-KAVKYHYYDDLK
:*::
↑ interaction with N-4 (cytosine)
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3.1.3. Insights on STs from X-ray crystal structures
Based on the range of derivatives described in the literature and their accompanying
biological activity, the essential component of the nucleoside structure as expected appears as
made of two key components: the ribose fragment and the pyrimidine base. In addition, the
binding mode of the phosphate moiety will also be discussed in this section. In all ST
subtypes, the cytidine binding pocket is decorated with a number of polar residues, such as
serine, threonine and asparagine, which explains the affinity of the ribose and cytosine rings
through a network of hydrogen bonding.
The ST crystal structures all show similar binding interactions between the ribose fragment of
the donor and the active site of the enzyme for all three subtypes. The endocyclic oxygen
atom on the tetrahydrofuran ring forms a hydrogen bond with the protein backbone via the NH donor of the residue Asn150 in ST3Gal-I, Ser169 in ST6Gal-I and Asn167 in ST8Sia-III
(fig. 3.6). The hydroxyl group at the 3’-position of the ribose fragment forms the same type of
hydrogen bond with Gly273 in ST3Gal-I, Gly324 in ST6Gal-I and Gly302 in ST8Sia-III, in
which the secondary alcohol is an acceptor. Slight differences are observed in the interaction
between the hydroxyl group at the 2’-position of the ribose ring and the different ST subtypes.
In ST6Gal-I, a hydrogen bond occurs directly between the substituent, this time behaving like
a donor, and the OH side chain of the residue Ser322. In contrast, in ST3Gal-I and ST8Sia-III,
the secondary alcohol interacts with a water molecule, which creates a bridge between the
ligand and the protein.
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Figure 3.6. CMP 3 in the active site of ST3Gal-I (A, PDB: 2WNB), ST6Gal-I (B, PDB: 4JS2) and ST8Sia-III (C,
PDB: 5BO6). The motif L and S are shown in orange and purple respectively.

In the case of the cytosine ring, more significant differences between the ST subtypes are
apparent. First, the carbonyl group at the 2-position of the cytosine moiety forms a hydrogen
bond with the N-H of the Lys376 side chain in ST6Gal-I. In ST3Gal-I, this carbonyl oxygen
atom binds to the N-H donor of the residue Gly293. In the case of ST8Sia-III, the crystal
structure does not show clear evidence of an interaction taking place between the nucleobase
and the protein despite the proximity of the hydrogen bond donor part of the residue Trp322.
All the interactions between CMP and the protein are summarised in table 3.3.
Table 3.3. Summary of the interactions between CMP and the crystal structures of sialyltransferase
subtypes ST3Gal-I, ST6Gal-I and ST8Sia-III.
Fragment
Cytidine

pST3Gal-I (PDB: 2WNB)

hST6Gal-I (PDB: 4SJ2)

hST8Sia-III (PDB: 5BO6)

Gly293 (via N-H)

Lys376 (via NH3+)

Trp322 (via N-H)*

His301 (via C=O)*

Cys353 (via C=O)

His337 (via C=O)

Gly293 (via C=O)*

Thr365 (via OH)

Trp322 (via C=O)

Asn150 (via N-H)

Ser189 (via N-H)

Asn167 (via N-H)

2’-OH

H2O-Ser271 (via OH)

Ser322 (via OH)

H2O-Ser300 (via OH)

3’-OH

Gly273 (via N-H)

Gly324 (via N-H)

Gly302 (via N-H)

2-C=O
4-NH2

Ribose

1’-O

Asn150 (via NH2)
Phosphate

O-

Asn212 (via NH2)

Asn212 (via NH2)

Tyr354 (via OH)

His302 (via NH+)

Asn167 (via NH2)
Asn190 (via NH2)
His337 (via NH+)

* The interaction mentioned is not clearly observed in the crystal structure but considered possible because
of the proximity of the residue with a hydrogen bond acceptor/donor.
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Kuhn et al. suggested the possibility for key differences in the binding mode of cytidine-based
and uridine-based donor mimics: “Of note, the exocyclic amino group of cytosine does not
engage in specific contacts with the protein, raising the possibility that porcine ST3Gal-I
could also accept the non-natural donor substrate UMP-Neu5Ac, which is impossible for
human ST6Gal-I.”189 Some of these hypotheses were confirmed by biological experiments,
for example UMP-Neu5Ac was found to be a poor donor for ST3Gal-II, ST3Gal-III and
ST6Gal-I.384 The same study demonstrated the ability of UMP to inhibit ST3Gal-II and to
participate in reverse sialylation reactions. This experimental evidence suggests that CMP and
UMP may act as substrates for the enzyme to perform the reverse reaction rather than
inhibiting the active site by binding.
The change from the imidine moiety present on the cytosine ring to a lactam in the uracil
counterpart may promote a considerable shift in the possible binding mode of the ligand. The
hypothetical interactions between the enzyme and the uridine moiety were evaluated herein
by docking experiments (fig. 3.6). The major changes appearing consistently related to the
hydrogen bonds, which are summarised in table 3.4. As expected, the unchanged carbonyl
group at the 2-position of the pyrimidine base retains the same type of bonds. The nitrogen
atom at the 3-position of uridine, which did not participate in any obvious interaction with the
protein in the case of cytidine, is protonated in the uracil ring. In the case of the imide moiety
of uridine, the N-H group is now a hydrogen bond donor and the docking experiments suggest
it binds with the carbonyl group of the residue Gly293 of ST3Gal-I. No binding seemed to
take place with ST6Gal-I and ST8Sia-III at this position. Finally, the major change in
replacing cytidine by uridine happens at the 4-position, where an exocyclic carbonyl group
takes the place of an amino group. In ST3Gal-I, the crystal structure does not clearly show
significant interactions between the cytidine amino group and the protein, even though some
hydrogen bonds could take place with the carbonyl group of neighbouring residues (Gly293
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and His301). In ST6Gal-I, the hydrogen bond between the amine and the carbonyl group of
Cys353 is lost, while a possible interaction of this group with the residue Thr365 seems to be
possible. Finally, our docking of UMP into ST8Sia-III did not provide any significant
interaction between the pyrimidine base and the ST protein. Although, the proximity of
hydrogen bond donors or acceptors in the backbone of the enzyme suggests potential binding.
In summary, both from the literature data and our docking experiments, the exchange of the
nucleobase from cytidine to uridine could favour the selectivity of the potential inhibitor
towards the ST3Gal subfamily.
Table 3.4. Summary of the differences in ST binding interactions when replacing CMP with UMP.
Fragment

pST3Gal-I (PDB: 2WNB)

hST6Gal-I (PDB: 4SJ2)

hST8Sia-III (PDB: 5BO6)

His301 (via C=O)*

Cys353 (via C=O)

His337 (via C=O)

Gly293 (via C=O)

Thr365 (via OH)

Trp322 (via C=O)

Cytidine

4-NH2

Uridine

3-NH

Gly293 (via C=O)

Cys364 (via C=O)*

Trp322 (via C=O)*

4-C=O

Ser151 (via OH)*

Thr365 (via OH)

Ser168 (via OH)*

* The interaction mentioned is not clearly observed in the crystal structure but considered possible because
of the proximity of the residue with a hydrogen bond acceptor/donor.

The binding mode of the uracil ring that was observed in the docking experiments of UMP into
ST3Gal-I is similar to those reported in other GTs using a uridine-based donor. For example,
the fucosylgalactoside 3-alpha-galactosyltransferase (EC 2.4.1.37), involved in the biosynthesis
of the blood group ABO, exhibits this particular type of interaction with a co-crystallised
uridine-based inhibitor (PDB: 4Y62, fig. 3.7D). This provides further support for our proposal
that uridine-based ST inhibitors may have selectivity towards the ST3Gal subfamily.
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Figure 3.7. UMP 144 docked into the porcine ST3Gal-I (A, PDB: 2WNB), the human ST6Gal-I (B, PDB: 4JS2) and
the human ST8Sia-III (C, PDB: 5BO6). Crystal structure of EC 2.4.1.37 co-crystallised with a uridine-based
inhibitor (D, PDB: 4Y62).

Of note, the crystal structures of STs, as with many other proteins in the PDB server, are
reported with a large number of water molecules present in the crystallographic network. In
some cases, the water molecules create a bridge between the ligand and the protein via
hydrogen bonds. Some studies on different ligand-protein complexes demonstrated the
implication of the water molecules in the affinity,390 but this has not been clearly elucidated
for STs. It is important to remember that the crystal structure represents the complex in the
unique and static conformation, which helps to understand the binding mode of the substrates
but does not illustrate the protein in a dynamic environment such as an aqueous solution.
Molecular dynamics provide hypothetical conformational changes, which simulate the
possible behaviour of the enzyme in solution. These more in-depth calculations have been
carried out in our group on the human ST6Gal-I subtype by my fellow co-worker Andrew
Montgomery as part of a separate project.286
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3.1.4. Fragments of Interest
The first azidonucleoside (5’-azido-5’-deoxyuridine) was prepared by Horwitz et al. in 1962
by azidonation reaction of 5’-tosylnucleoside and lithium azide.391 In general, azido analogues
have been used mostly as intermediates in the preparation of aminonucleosides. In order to
investigate the practicality of protecting systems, different strategies for the synthesis of the
ST inhibitors were evaluated. The chemistry of nucleosides is well known, as a result, a range
of methods of preparation and strategies are available in the literature. Numerous nucleoside
derivatives are also commercially available.
Nucleoside-sugars belong to a group of compounds responsible for critical biological
functions. Amongst them, different combinations of nucleoside and small carbohydrates are
typical donors for GTs, a large family of enzymes widely distributed in mammalian tissues.
Nine sugar-nucleotides have been identified in mammals and are UDP-Glc, UDP-Gal, UDPGlcNAc, UDP-GalNAc, UDP-Xylose, UDP-Glucuronic acid, GDP-Mannose, GDP-Fucose
and CMP-Neu5Ac.392 The structural similarity between CMP-Neu5Ac itself, the present
series of inhibitors and the natural donors for other GTs could represent a challenge in the
development of potent and selective ST inhibitors due to potential off-target activity.

3.2. Cytidine derivatives
A common synthetic route to nucleosides functionalised at the 5’-position involves a multistep
sequence starting with selective protection of this position using TBMSCl or TrtCl followed by
acetylation (fig. 3.8). Despite the efficiency of this method in achieving regioselective protections
the entire synthetic pathway involves a large number of steps, which can affect the overall yield.
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Herein, cytidine 137 was first treated with TBDMSCl in the presence of triethylamine and
DMAP to give the selectively protected intermediate 163 in 67 % yield. The silylated
compound 163 was acetylated in excellent yields by using acetic anhydride in pyridine and
the resulting intermediate 164 was treated TBAF to provide the primary alcohol derivative
165 in 77 %. Of note, the resulting 2’,3’,4-triacetylcytidine 165 has relatively low solubility in
organic media, including CH2Cl2 and acetonitrile. Consequently, the use of this building block
in organic solvents was considerably diminished and led to lower yields and longer reaction
times, often associated with the formation of side products which affected the accessibility of
the desired coupling products by purification. As a result, the preparation of the tosylate 166
was achieved in dry pyridine. After reaction of the tosylate 166 with sodium azide in DMF,
the clickable building block 167 was attained in an overall yield of 36 % over five steps.

Figure 3.8. Preparation of protected 5’-azido-5’-deoxycytidine 167.

A different approach was also used in order to improve the overall yield and to evaluate the
influence of the protecting system on the reactivity of the building block (fig. 3.9). The protected
5’-azidocytidine 167 was prepared according to a procedure reported by Kumar et al.197 First, N4acetylcytidine 169 was treated with sulfuric acid in acetone at room temperature to install the
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acetonide group on the ribose fragment. This was confirmed by 1H NMR spectroscopy with the
appearance of two peaks at 1.29 and 1.49 ppm. This first intermediate 170 was then reacted with
methanesulfonyl chloride and triethylamine to generate the 5’-mesyl derivative 171 in 82 %.
Finally,

the

reaction

of

mesylate

171

with

sodium

azide in the presence

of

benzyltriethylammonium chloride (as a phase transfer catalyst) in DMF provided the ‘clickable’
azido derivative 172 in 71 % yield. In order to protect the cytidine fragment with a consistent
protecting system, the N-acetyl group was interchanged with a N-Boc protection. The acetamide
group was first cleaved with concentrated ammonia in methanol at room temperature to give the
free amino derivative 173 which was not isolated. The amide cleavage was followed by reaction
with Boc2O in THF in the presence of a catalytic amount of DMAP. Evidence for the Boc group
was provided by the appearance of a singlet at 1.52 ppm in the 1H NMR, integrating for 9 protons.
These two additional steps led to the key protected azido compound 174 with an overall yield of
72.5 %, and provided the advantage of simultaneous cleavage of all protections on this fragment
at once, i.e. the Boc and the acetonide groups, by using acidic conditions.

Figure 3.9. Preparation of the protected 5’-azido-5’-deoxyuridine derivatives 172 and 174.
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3.3. Modification of the base
3.3.1. Uridine
The preparation of cytidine-based building blocks requires several steps in order to achieve
regioselective functionalisation, while protecting the uracil ring is often not required, making
uridine a more convenient building block than cytidine. The azidonation of uridine has
already been reported and in the context of this study, the synthetic route was adapted from a
three-step sequence, starting with the protection of the ribose diol using an acetonide group.393
First, uridine 175 was suspended in dry acetone and treated with concentrated sulfuric acid at
room temperature to give the acetonide derivative 176 in 86 % yield. The primary alcohol at
the 5’-position was converted into a leaving group by treating 176 with mesyl chloride and
triethylamine in 91 % yield. The reaction of the resulting mesylate 177 with sodium azide
provided the expected clickable building block 178 in 82 % (fig. 3.10) with the spectral data
matching those reported.

Figure 3.10. Preparation of the protected 5’-azido-5’-deoxyuridine 178.
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Following the approach described with cytidine (Cf section 3.2), the azidouridine derivative
178 was deprotected to provide the versatile synthon 5’-azido-5’-deoxyuridine 179 (fig. 3.11).
The acetonide protection was cleaved using a method reported by Golden et al,394 using
In(OTf)3 at room temperature. The reaction took place under reflux conditions in a mixture of
acetonitrile and water and was completed within 6 h to give the intermediate 179 in 95 %
yield. Alternatively, the azido group could be installed in one step with high regioselectivity
and high yield (86 %) using the Appel395-397 or the Mitsunobu reaction.398 This was followed
by the acetylation of the ribose fragment, using the classical procedure with acetic anhydride
in pyridine, and the desired clickable uridine derivative 180 was obtained in 97 % yield.

Figure 3.11. Preparation of acetyl-protected the 5’-azido-5’-deoxyuridine 180.

3.3.2. 5-Fluorouridine
5-Fluorouracil has been widely used in the treatment of various cancers over the last 30 years.
It is the phosphorylated form of the drug, 5-fluoroUMP, generated via metabolic pathways,
which promotes the activity by causing DNA and RNA damage.399
In the context of ST inhibition, some promising 5-FU derivatives were reported by Nakahara
et al., showing that the 5-fluorouracil derivative displaced cytosine.389 Furthermore, the
introduction of a fluoro group at the 5-position of the nucleoside in ST inhibitors may not
raise major sterical issues, as the fluorine atom is slightly larger than hydrogen but smaller
than a methyl group.400
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The azidonation of 5-fluorouridine 181 was similar to the uridine counterpart (fig. 3.12). The
protection of the ribose moiety was previously reported by Ajmera et al.401 In the case of 5fluorouridine 181, the reaction was completed in 1 h, about 20 times faster than the reaction with
uridine, and the protected intermediate 182 isolated in 80 % yield. Next, reaction with mesyl
chloride in the presence of triethylamine gave the resulting O-mesyl intermediate 183, which was
treated with sodium azide in DMF to give the clickable building bock 184 in 94 % yield. The phase
transfer catalyst benzyltriethylammonium chloride was also used in order to improve the azide salt’s
reactivity. The spectral data for the 5-FU derivative 184 matched those reported by Ajmera.401
The acetonide protection was cleaved from the ribose fragment by using a catalytic amount of
indium triflate (5 mol%) and the reaction was carried out in a mixture of acetonitrile and water
[9:1], as described earlier.394 5’-Azido-5-fluorouridine 185 was isolated in 96 % yield. As
described for the preparation of the azidouridine derivative, the solubility of the intermediate
185 in organic media is significantly lower than the protected counterpart. For this reason, the
hydroxyl groups present on the ribose fragment were acetylated in order to decrease their
polarity and aid their solubility. 5’-Azido-5-fluorouridine 185 was dissolved in pyridine and
treated with acetic anhydride to give the clickable building block 186 in 92 % yield.
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Figure 3.12. Preparation the 5’-azido-5-fluorouridine building blocks 184 and 186.

3.4. Modification at the 2’-position of the ribose fragment
2’-Deoxyuridine 187 is a naturally occurring nucleoside, differing to uridine by bearing only
one hydroxyl group on the tetrahydrofuran ring of the ribose moiety, at the 3’-position. In the
porcine ST3Gal-I crystal structure, the 2’-hydroxyl group of the ribose moiety engages in a
hydrogen bond with a water molecule, not the protein (fig. 3.6). This is not the case in human
and both rat ST6Gal-I and the human ST8Sia-III in which, this alcohol binds to a serine residue
(Ser322, Ser319 and Ser300 respectively).188-190 Thus, the absence of the 2’-hydroxyl group in
187 offers the possibility to decrease the affinity of the inhibitor for the ST6Gal sub-family,
while having less impact on the affinity towards both the ST3Gal and ST8Sia subtypes.
Similarly, thymidine 150 lacks a hydroxyl group at the 2’-position but bears an additional
methyl group at the 5-position. As no thymidine-based ST inhibitor has been reported to our
knowledge, it was interesting to explore the influence of these two features. 5-Methyl-CMP
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146 has been shown to weakly inhibit both ST3Gal-III and ST6Gal-I (31 % and 16 % at
250 µM respectively) as well as ST8Sia-IV (30-40% at 500 µM).385 This nucleoside analogue
150 might trigger an active transport through the cancer cell membranes.402 Thymidine 150 on
its own remains significantly less potent than cytidine against ST6Gal-I (16 % inhibition at 250
mM) according to the inhibition study reported by Kleineidam et al.235
Other moieties worth investigating are 2’-deoxy-2’-fluorocytidine derivatives, which have
mostly been evaluated for potential antiviral activity,403 against the cytomegalovirus, the herpes
simplex virus404 and the hepatitis C virus405-406 as well as against various cancer cell lines.407
Fluoro groups are highly represented in medicinal chemistry. In addition to providing
metabolic stability the fluorine atom rarely engages in hydrogen bonds and allows modulating
the hydrophilicity of the compound. The structurally related 2’-deoxy-2’-fluorocytidine 154
was found to exhibit some inhibition (74 %) against ST6Gal-I at 250 µM, while having no
activity on ST3Gal-I at the same concentration.235 For this reason, 2’-fluorinated nucleoside
derivatives constitutes an interesting scaffold in the context of this study.
In addition to fluoro groups, other compounds bearing a slightly bulkier group at the 2’position, such as a methoxy group, were synthesised. The methyl ether moiety presents the
advantage to accept hydrogen bonds, while promoting significant changes in the hydrophilicity
of the substrate. Interestingly, ST3Gal-IV and ST8Sia-III activity were inhibited by 2′-O-methyl
CMP 155, which had no effect on ST6Gal-I.385 For this reason, 2’-O-methyl derivatives
constituted an interesting avenue in the aim of achieving selectivity between ST3Gal-I and
ST6Gal-I.
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3.4.1. 2’-Deoxyuridine, Thymidine and 2’-Deoxy-2’-fluorouridine
The preparation of 5’-azido-2’,5’-dideoxynucleoside derivatives has been reported and the
literature provides numerous examples of the regioselective activation of the 5’-position by
using sulfonyl chlorides.391,408
Thymidine 150 is the most common building block utilised and the synthesis of its azido
derivativative is usually carried out via a short sequence409 starting with a regioselective tosylation
(undertaken at low temperature),410 followed by the acetylation of the 3’-hydroxyl group to give
the intermediate 188 (fig. 3.13). The tosylate 188 is then treated with sodium azide to afford the
building block 189, which is ready for the CuAAC reaction. In our experience, the regioselective
first step produced the expected product 188 in 59 % yield along with regioisomers. On the other
hand, the azidonation provided the clickable material 189 in 93 %.

Figure 3.13. Preparation of the 3’-acetyl-5’-azido-5’-deoxythymidine building block 189.

Given that the structures of thymidine 150 and 2’-deoxyuridine 187 is closely related and only
differ by the presence of the unreactive methyl group at the 5-position, similar procedures
were applied (fig. 3.14). The novel tosylated intermediate 190 was isolated in 62 % yield. By
using the present sequence, the building block 191 was achieved in an overall yield of 58 %
over three steps. The 3’-acetyl-5’-azido-2’,5’-dideoxyuridine 191 had aready been reported by
using a different synthetic approach.411
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This successful procedure was then applied to the 2’-fluoro analogue 192. After tosylation and
acetylation preformed in one pot, the intermediate 193 was treated with sodium azide in DMF to
give the clickable nucleoside 194 in 89 % yield. The spectral data for these two compounds was
very similar to the non-fluorinated analogues (189 and 191), with the exception of the 13C spectra.
The C-2’ position appears as a doublet with a large coupling constant (90.4 ppm, J = 126.6 Hz)
due to the presence of the fluorine atom, as well as the C-3’ albeit displaying a smaller coupling
value (70.2 ppm, J = 15.3 Hz). Surprisingly, the C-1’ appeared on the 13C spectrum as a singlet
(91.5 ppm) with no obvious coupling with the neighbouring fluorinated carbon atom.

Figure 3.14. Preparation of the building blocks 191 and 194.

3.4.2. 2’-O-Methyluridine
The synthetic scheme used for the preparation of other nucleosides modified at the 2’-position was
attempted (Cf section 3.4.1). 2’-Methyluridine 195 was thus treated with tosyl chloride and acetic
anhydride in pyridine at 0 °C. After work up, a product came out of the column as a single spot with
LRMS analysis showing a mass matching the expected product 196, m/z = 477 [M+Na]+. However,
1

H NMR experiments showed the presence of a mixture of diastereoisomers.
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Figure 3.15. Reaction of 2’-methyluridine 190 using one-pot tosylation/acetylation method.

The longer route that successfully gave the azidocytidine derivative 165 by starting with the
selective protection of the primary alcohol at the 5’-position, was evaluated for 2’methyluridine. The TBDMS protected intermediate 197 was prepared according to Rozner’s
procedure,412 and was acetylated to give 198 in 74 % yield. The 1H NMR spectrum clearly
displays the tert-butyl (singlet integrating for 9 H at 0.92 ppm) group and the dimethylsilyl
moiety (singlet integrating for 6 H at 0.10 ppm). The LRMS experiment gave the expected
sodiated molecular ion peak of m/z = 437 [M+Na]+. The silylated protection was cleaved
using a TBAF solution in THF in the presence of acetic acid in order to avoid the migration of
the 3’-acetyl group and the known compound 199 was isolated in 76 % yield. The azido group
was installed following the method used for uridine and cytidine, by successive reaction with
methanesulfonyl chloride and sodium azide, which provided the mseylate 200 in 72 % yield
and the building block 201 in 91 % yield. In summary the azide derivative 201 was achieved
in 37 % over five steps.
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Figure 3.16. Preparation of the azidonated building block 201.

The present chapter discussed the various aspects of the nucleoside fragment of ST transition-state
analogue inhibitors, highlighting the importance of cytidine as a component of the natural sialylation
machinery. Different nucleoside derivatives have been tested against a number of ST subtypes along
with crystallographic and computational data, which suggests that functionalising this fragment
constitutes an avenue for achieving the preparation of selective ST inhibitors. Seven commercially
available nucleosides were selected as starting materials for the preparation of new potential ST
inhibitors. Cytidine and uridine were considered as key elements of this study. 2’-Deoxyuridine and
thymidine as well as synthetic analogues such as 2’-methyluridine, 5-fluorouridine and 2’-deoxy-2’fluorouridine were also chosen because of their structural modification at the 2’- or 5-position of the
nucleoside scaffold. Several synthetic routes were optimised for the synthesis of the required
clickable 5’-azidonucleoside derivatives. In total, this chapter reported the synthesis of eleven azido
nucleoside derivatives usable for the key coupling step to generate the target ST inhibitors, as
presented in the next chapter. In addition to the types of activity pursued in this project, the small
azido-nucleoside building blocks presented in this chapter may also find utility in the development
of other types of enzyme inhibitors, in particular for antiviral activity.
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Chapter 4 – Triazole-based sialyltransferase inhibitors
In Chapter 2, the design and preparation of sialic acid mimics was presented, along with the
synthesis of the nucleoside building blocks in Chapter 3. The current chapter describes the
coupling of the building blocks leading to the final target inhibitors. After cleavage of the
protecting groups, the library of newly developed compounds was submitted for biological
evaluation, and the experimental biological data compared to the earlier calculated enzyme
affinities.

4.1. Copper-catalysed azide/alkyne cycloaddition
4.1.1. Optimisation
Once both the sugar mimic and nucleoside fragments were successfully obtained, conditions
for the coupling step using the ‘click chemistry’ strategy were screened (table 4.1). The 3phenoxyalkyne derivative 111 was used for all the preliminary trials and the synthetic
approach to the triazoles 202-206 is shown in table 4.1. The synthesis of 1,4-disubstituted
triazoles involves the in situ generation of the Cu(I) catalyst from Cu(OAc)2 and sodium
ascorbate as a reducing agent to facilitate the CuAAC reaction. The reaction can be carried
out in various solvents, at different temperatures and also using additives in some cases.413
The first trials were performed using the azidocytidine derivative 172 and catalysed with
10 mol% copper acetate and 20 mol% sodium ascorbate in aqueous t-butanol as reported by
Lee et al. (table 4.1).239 The formation of the triazole ring was monitored by TLC showing the
appearance of a slower moving spot, while the starting material was disappearing and the
expected coupled product 202 was isolated in 49 % yield (table 4.1, entry 1). Replacing t-
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butanol with acetonitrile increased the reaction yield from 49 % to 57 % (table 4.1, entry 2).
The miscibility of acetonitrile and water is probably responsible for this improvement by
facilitating the formation of the complex intermediate. Interestingly, the protecting system
proved to have a great influence on the reactivity, in particular for the cytidine-based starting
material. While the reaction of 172, bearing a N-acetyl group, takes over 20 h to complete, the
N-Boc counterpart 174 required only 90 min for completion under otherwise identical
conditions (table 4.1, entry 4). When only acetyl groups were used to pretect the azidocytidine
fragment 167, the reaction completed in 2 h and the product 204 was attained in 91 % yield
(table 4.1, entry 5). The reaction of the azidouridine derivatives 178 and 180 proceeded in the
same conditions as above, which led to the expected triazoles 205 and 206 in 88 % and 90 %
yields respectively (table 4.1, entry 6 and 7).
Table 4.1. Preparation and optimisation of triazole-based inhibitors using click chemistry.

Entry

R1

R2

R3

1

NHAc

-C(Me)2-

2

NHAc

3

Equiv.
of
alkyne

Equiv. of catalyst
Cu(OAc)2

Ascorbate

1.0

0.1

0.2

-C(Me)2-

1.0

0.25

0.5

NHAc

-C(Me)2-

1.2

0.25

0.5

4

NHBoc

-C(Me)2-

1.2

0.25

0.5

5

NHAc

Ac

Ac

1.2

0.25

0.5

6

OH

-C(Me)2-

1.2

0.25

0.5

7

OH

Ac

1.2

0.25

0.5

Ac
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Solvent
tBuOH/H2O
[1:1]
MeCN/H2O
[4:1]
MeCN/H2O
[4:1]
MeCN/H2O
[4:1]
MeCN/H2O
[4:1]
MeCN/H2O
[4:1]
MeCN/H2O
[4:1]

Reaction
time

Yield
(%)

24 h

49

24 h

57

24 h

64

1h

86

2h

91

1.5 h

88

1.5 h
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In summary, the CuAAC reaction led to the expected results, which makes it an appropriate
synthetic tool for the preparation of novel ST inhibitors. The azidocytidine building block
showed to be susceptible to solubility issue and those were managed by adapting the
protecting system. In comparison the uridine analogues proved to be excellent substrates for
this reaction. The conditions involving 1.2 equiv. of alkyne, 0.25 mol% of copper acetate and
50 mol% of sodium ascorbate in a mixture of acetonitrile and water [4:1] consistently led to
the expected triazole derivative in excellent yields (> 90%) and were used as ‘optimised
conditions’ for the rest of this study.
The triazole derivatives isolated during the optimisation process were fully characterised
using mass spectrometry and NMR. Given the number of aromatic protons, the appearance of
the CH at the 5”-position was confirmed by 2D NMR experiments. Both carbon atoms at 4”and 5”-positions were identified in the 147 ppm and 123 ppm areas respectively. The gHSQC
correlation between the C-5 carbon resonance signal and that of the triazole H-5 resonance
signal is also consistent with the 1,4-regioselectivity assignment. The NMR spectral data for
205 were summarised in table 4.2 with focus on the nucleoside and triazole fragments.
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Table 4.2. Summary of the main correlations observed for the HSQC, COSY and HMBC NMR spectra of 205
with focus on the nucleoside and triazole fragments.

Position

13C

(ppm)

5’

51.2

1’’’
3’
2’
4’
1’
5
5”
6
4”
2
4

67.5
70.6
72.1
81.8
88.5
102.2
123.0
140.9
146.3
150.7
163.1

1H

(ppm)
4.59-4.64
4.66-4.71
5.81-5.82
3.97-4.00
4.03-4.06
4.14-4.16
5.75-5.76
5.58-5.61
7.85
7.43-7.44/7.48-7.50
-

COSY

HMBC

H-4’

H-3’

H-2’, H-4’
H-1’, H-3’
H-3’, H-5’
H-2’
H-6
H-5
-

ArH
H-1’, H-5’
H-4’
H-2’
H-3’, H-6
H-3
H-5”, H-1’’’
H-1’
H-1’’’, H-5’
H-5, H-6
H-6

4.1.2. Scope of the coupling step
This section describes the application of the optimised method for the preparation of 5’triazolonucleosides by using the alkyne derivative series previously obtained in chapter 2. The
coupling step was performed under the optimised conditions achieved in section 4.1, using
1.2 equivalents of alkyne with copper acetate (0.25 equiv.) and sodium ascorbate (0.5 equiv.)
in a mixture of water and acetonitrile [1:4] at room temperature. The azide derivative 178 was
used as a common starting material for the synthesis of the first series, hence providing the
acetonide-protected uridine fragment, which was reacted with the six propargyl acetates 106109, 111 and 131 as summarised in table 4.3. The yields for the coupling were consistently
high (207-211, 88-93 %) with the highly functionalised indole derivative 211 isolated in
81 %. The reaction also proceeds rapidly as the reaction times did not exceed 2.5 h.
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Table 4.3. Preparation of the acetonide protected triazole derivatives 207-211.

Compound

Ar

Yield (%)

Coumpound

Ar

Yield (%)

207

93

205

90

208

88

210

91

209

90

211

81

In order to compare the efficiency of the coupling involving the starting materials 178 and
180, and thus the influence of the protecting system of the reaction, the key step was repeated
using the azide 180 and the alkynes derivatives 106, 108-114 and 116 (table 4.4). By using the
optimised conditions for the CuAAC (table 4.1, entry 6-7), the triazole derivatives 212-218
were attained in excellent yields (84-95 %). The yields were similar to those observed for the
reactions with the azide derivative 178.
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Table 4.4. Preparation of the acetyl protected triazole derivatives 212-218.

Compound

Ar

Yield (%)

Coumpound

Ar

Yield (%)

216

87

89

217

95

214

84

218

92

215

89

212

90

213

The heterocyclic derivative 218 was isolated in 92 %, which shows a consistent reactivity
with the benzenic derivatives 106-114. The indolic alkyne derivatives 130 and 131 were used
next in the same conditions as above and the resulting triazoles 219 and 220 were isolated in
90 % and 81 % yield respectively (fig. 4.1). The compounds 211 and 220 only differ by the
protecting groups attached to the uridine and were both attained in the same yield (81 %),
which shows that the functional group chosen as a protection for the nucleoside fragment has
little influence on the coupling step.

Figure 4.1. Preparation of the indole-based derivatives 219 and 220.
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The reaction of the 5’-azidouridine derivative 180 with 3-ethynyl-3-hydroxyindolinone 133
gave the triazole-linked compound 221 in a slightly lower yield (84 %), which can be
attributed to the solubility of the alkyne derivative 133 in the solvent system CH3CN/H2O
(fig. 4.2).

Figure 4.2. Preparation of isatin derivative 221.

Finally, the trifluoromethyl derivative 136 was employed for the CuAAC reaction with the
uridine building block 180 and provided the protected inhibitor 222 in 97 % yield (fig. 4.3).

Figure 4.3. Preparation of triazolouridine 222 bearing a trifluoromethyl group at the benzylic position.

In summary, the CuAAC reaction between the azidouridine derivatives 178 and 180 and the
series of alkynes 106-114 as well as the heterocyclic derivatives 116, 130, 131 and 133 led to
a series of protected ST inhibitors in consistently excellent yields. At this stage, the protecting
system present on the azidonucleoside fragment, acetyl esters or acetonide, showed little
influence on the reactivity with the alkyne derivatives, if any.
The nucleoside fragment is a key component of our triazole-based ST inhibitors. As mentioned in
the previous chapter, cytidine has been largely explored in the field. Not only because the natural
donor CMP-Neu5Ac and natural inhibitors such as CMP and CDP are cytidine derivatives but
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also because, the large majority of studies focused on the activity of nucleoside-based ST
inhibitors. Once the relevant 5’-azidonucleoside derivatives were prepared as described in chapter
3, the coupling step was performed using the optimised conditions (fig. 4.4).

Figure 4.4. Huisgen coupling using the alkyne 111 and the 5’-azidonucleosides modified at the 2’ and 5’positions.

When using the acetonide protected 5-FU derivative 184 and the 3-phenoxy alkyne derivative
111, the CuAAC provided the triazole derivative 228 in 91 % yield. As described at the time
of the azidonation reaction described in section 3.3, uridine and its 5-fluoro counterpart have
similar properties.

Figure 4.5. Preparation of the acetonide protected 5-FU derivative 228.
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4.2. Deprotection
4.2.1. Cleavage of the acetonide protection
Once the coupling step has been optimised and validated within the scope of azidonucleoside
and alkyne derivatives, the various deprotection methods were evaluated. The deprotection of
the 5’-triazolonucleoside derivatives described earlier was attempted in various conditions.
The acetonide protection on nucleosides is commonly cleaved by using concentrated aqueous
trifluoroacetic acid (TFA) solutions. In our experience, this method led to unreliable results.
The success of this procedure seems to depend on the substrate and moreover the reaction
time. For example, the reaction of the 3-phenoxy derivative 206 in 90 % TFA for 4 h led to
the expected product 228 in moderate yield (48 %, fig. 4.6). A variable amount of degradation
products were observed depending on the conditions used and the starting material and, as a
result, the crude material attained would require a case to case purification on top of
discordant yields. The outcome of using TFA to cleave the acetonide protection on the ribose
was unreliable hence did not fulfil the requirement of this project, which focus on developing
straight-forward and cost effective synthetic access to new ST inhibitors. As a result, several
other acidic conditions were evaluated such as dilute sulfuric acid (1 M to 6 M concentrations
in water or methanol), and acetic acid.

Figure 4.6. Deprotection of the acetonide-protected derivative 206 using TFA.
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Encouraged by the successful cleavage of the acetonide protection on the building block 178
using indium triflate, to generate the deprotected triazole-based inhibitors prepared using the
CuAAC reaction. The coupled compound 210, bearing the isopropylidene protection on the ribose
fragment and a cyclopentoxy group at the 3’’’-position, was dissolved in acetonitrile and treated
with water and In(OTf)3. The mixture was stirred at room temperature, according to the procedure
described by Golden et al.394 After 24 h, no reaction had happened and the mixture was brought to
reflux. Increasing the temperature resulted in the appearance of a slower moving spot on the TLC
suggesting the presence of the expected product. After work up, the crude material was purified
by flash chromatography column and two products were isolated. The expected fully deprotected
product 229 was recovered in 29 % yield, while the major less polar product 230, represented
48 % of the mixture. Mass spectrometry indicated a slightly higher molecular weight,
m/z = 522 [M+Na]+, which is 14 units more than expected, and a singlet at 3.25 ppm on the
1

H NMR spectrum was observed, suggesting the presence of the methoxy group. Comparison of

the NMR spectra of both fractions, which remain relatively similar with the exception of the
details mentioned above, it seems like the use of In(OTf)3 was affected by the reactivity of the
benzylic position. Although, the mechanism involved in installing the methoxy group remains
unclear and the methyl group might result from a reaction with the solvent (CH3CN). Identifying
the mechanism for the formation of the O-methyl side product requires more experiments, which
were not undertaken as this unexpected product does not take part in the focus of the study.

Figure 4.7. Reaction of 210 with In(OTf)3 leading to a mixture of partially and fully deprotected triazoles
229 and 230.
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4.2.2. Cleavage of the acetate protection
The unsuccesful attempts to cleave the acetonide protection of compounds 205 and 210,
encourage us to explore a different approach. Consequently, the deprotection of acetate groups
proceeded in mild conditions by treating a solution of the protected triazole derivative in methanol
with concentrated ammonia. The mixture was stirred at room temperature until disappearance of
the starting material and provided the expected target in excellent yields (> 90 %).
Table 4.5. Cleavage of the acetyl protection.

Compound

Ar

Yield (%)

Coumpound

Ar

Yield (%)

232

94

234

85

230

92

235

89

233

90

236

91

229

93

237

94

The acetyl group attached to the position mimicking the anomeric center of derivatives 212218 was cleaved efficiently (table 4.5). In contrast, the methyl ester of 219 and 220 remained
protected under these conditions, so as the Boc group attached to the N1-position of the indole
fragment (fig. 4.8). The corresponding triazole derivatives 238 and 239 were isolated in 83 %
and 79 % yields respectively.
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Figure 4.8. Preparation of the indole-based derivatives 238 and 239.

For both 218 and 219, the Boc group at the 1-position of the indole ring was inert to
ammonia’s nucleophilicity. This was deducted from the mass spectrum and confirmed by
large peaks in the 1H NMR spectrum, appearing at 1.62 ppm and integrating for 9 protons.
These compounds will be tested in the current form in which the Boc group takes part in the
hypothetical interaction with a hydrophobic pocket in the active site, consistently with the
phenoxy (as in 229) and cyclopentoxy groups (as in 230) used for this purpose in the rest of
the series. The hydrophobic groups provide three different steric and electrostatic features
from the flat aromatic phenyl group to the envelope-shaped cyclopenyl and the wider tertbutoxy group. In addition, the three moieties align consistently when the structures of
compounds 229, 230 and 238 are overlayed (fig. 4.9).

Figure 4.9. Superimposed structures of the phenoxy 229 (green sticks), cyclopentoxy 230 (orange sticks)
and indolic compounds 238 (purple sticks).

The deprotection of the isatin derivative 221 using ammonia in methanol provided the
expected product 240 in 88 % yield (fig. 4.10). This additional example illustrates the
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practicality of the deprotection method. Under such mild conditions, the deprotected product
240 is recovered in high yield and no side reaction was observed.

Figure 4.10. Preparation of the isatin-based derivative 240.

The cleavage of the acetyl protections of compound 222 using concentrated ammonia gave
the fluorinated ST inhibitor 241 in 86 %. The trifluoromethyl group attached to the benzylic
position did not promote any noticeable sterical hinderance and had no effect on the reactivity
of the benzylic acetate group.

Figure 4.11. Synthesis of the fluorinated triazole derivative 241.

Using this last procedure with the coupled products bearing exclusively acetate groups as a
protecting system also led to excellent results. The expected final cytidine-based compound
242 was attained in 87 % yield (fig. 4.12).

Figure 4.12. Deprotection of the cytidine derivative 242.
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The synthetic strategy employed to prepare the 5’-azidonucleoside derivatives provided
building block protected with acetyl groups. These were cleaved following the optimised
method described in chapter 3, by reaction of the ester protected compounds with
concentrated ammonia in methanol at room temperature. This procedure provided the
expected 5’-triazolenucleoside derivatives 242-246 in excellent yields (fig. 13). As expected
the aliphatic fluoro group at the 2’-position of compound 244 was inert to nucleophilic
substitution with ammonia.

Figure 4.13. Deprotection of the ST inhibitors modified on the nucleoside fragment.

There is a lack of evidence in the literature for acetonide protected nucleosides to be an
appropriate moiety for a prodrug strategy. Enzymes responsible for the in vivo cleavage of
acetal groups attached to the ribose fragment of nucleoside derivatives, if they exist, may not
have been identified to our knowledge. Although, the presence of this type of functional
group on such molecular edifice promotes other features such as increasing the
hydrophobicity, and thus elevate the log P, of the compound by masking the diol present on
the sugar and creating sterical hindrance, which might affect the affinity of the compound
with the active binding site to the enzyme. This second aspect endorses potential for achieving
selectivity towards the different ST subtypes as the cytidine binding pocket in ST6Gal-I is
geometrically tight, as indicated by the X-ray crystal structure,188-189 opposed to the porcine
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ST3Gal-I183 and human ST8Sia-III.190 This last point is confirmed by the docking of 248 and
249 into the porcine ST3Gal-I (fig. 4.14).

Figure 4.14. Cytidine derivative 248 (A) and uridine derivative 249 (B) overlayed with CMP 3 (in orange
sticks) in the active site of porcine ST3Gal I (PDB: 2WNB).

4.2.3. Separation of the diastereomers
Since the CuAAC reaction was set up using racemic propargyl esters, the corresponding
triazole derivatives were isolated as a mixture of diastereoisomers. In theory, the separation of
diastereoisomers should be attainable by using chromatographic methods but in our
experience, both steroisomers had similar retention times. As stereoisomers are expected to
exhibited significantly different activity,414-416 their separation was attempted by using HPLC.
The indolic 239 and the 5-FU derivative 247 were subjects to the preliminary trials. All
experiments were performed using a 0.1 % TFA solution in MilliQ H2O for elution in a C18
column. Various flow rates were examined and the optimal conditions only lead to a
resolution of a few seconds, which was not satisfying for translating the experiment into
preparative HPLC. As a result, the compounds were tested as a mixture of diastereoisomers.
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4.3. Computational data
4.3.1. Docking in sialyltransferases
All docking experiments were performed using Autodock Vina and the binding poses used for
this study were selected according to their ability to match alignment with the nucleoside
fragment which was co-crystalised with the protein. The docking results mostly highlighted
differences between the different ST subtypes used.
Cytidine binding region: The differences between ST3Gal and ST6Gal in the cytidine binding
pocket were consistently observed as suggested by Kuhn/Meng. Moreover, this applies to
ST8Sia as well which displays a binding mode comparable to ST6Gal. In ST3Gal, the cytosine
moiety binds exclusively through a hydrogen bond between the carbonyl group at the 2-position
and the amino group of the residue Gly293. When replaced with uracil, the nucleoside fragment
engages by forming an additional hydrogen bond between the NH group at the 3-position and
the carbonyl group of the same residue Gly293. In ST6Gal, C2=O forms a hydrogen bond with
Lys376. N4 gives a hydrogen bonds with C=O from Cys353 and OH from Thr365. Swapping
from cytidine to uridine induces the loss of the interaction with Cys353 but the C=O at the 4position is in theory still able to form a hydrogen bond with OH from Thr365 which is observed
during docking experiments. In ST8Sia, The carbonyl group at the 2-position of cytosine binds
to the amino group of Trp322. The amino group at the 4-position engages both hydrogen atoms
in hydrogen bonds with the carbonyl groups of Trp322 and Tyr336.
Ribose binding region: Endocyclic oxygen atom behaves like a hydrogen bond acceptor with
Asn150 in ST3Gal, Ser169 in ST6Gal and Asn167 in ST8Sia. Hydroxyl groups: 3’-OH is a
hydrogen bond acceptor with Gly273 in ST3Gal, Gly324 in ST6Gal and Gly302 in ST8Sia.
The type of bond is identical for the 3 subtypes. In ST3Gal, the crystal structure describes the
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2’-OH in CMP bridging with a water molecule. The docking results also showed the
possibility to form a hydrogen bond with Ser271 in ST6Gal-I or Ser300 in ST8Sia. In regards
to the hydroxyl groups at 2’ and 3’-positions, both OH do not necessarily bind
simultaneously. In some results, one of them forms a hydrogen bond while the second one
seems to be too far to interact with the neighbouring residues. The rigidity of the linker
appears to impose a different binding pose.
Triazole binding region: The triazole ring is composed of three nitrogen atoms and two of
them bear lone pairs of electrons, which do not participate in the aromaticity of the ring. As a
result, they are two hydrogen-bond acceptor sites. Accoring to the docking experiments, the
linker shows limited number of interactions with the amino-acid residues in the active site.
The rigidity of the triazole ring promotes the alignment of the two other fragments by
imposing dihedral angles.417 In addition, by being rigid, the triazole linker restricts the
freedom of rotations allowed by the phosphate counterpart. This, for example, results in a
fixed distance between the atoms attached to the 1- and the 4-position of the heterocycle
(fig. 4.15). In compounds bearing a phosphate linker, the distance between the carbon atoms
at the 5’-position of the nucleoside and the anomeric position of sialic acid is variable
because of the flexible nature of the linker. Measuring this distance amongst the docking
results showed a range of distances oscillating between 4.38 and 4.99 Å. Interestingly, the
range of distances determined is different depending of the ST subtype used for docking,
e.g. 3.925-4.949 Å in ST3Gal-I, 4.036-4.932 Å in ST6Gal-I and 4.380-4.892 Å, ST8Sia-III.
In the 5’-triazolonucleoside derivatives, the range of distances between the 5’position and the
benzylic position is narrower because of the rigidity of the heterocycle and is 4.81 Å. As a
result, using triazole as a linker constitutes a geometrical constrain.
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Figure 4.15. Distance between the pseudo-anomeric position of the sialyl mimic and the 5’-position.

Acceptor site: The acceptor site is the part of the active site in which the sequence between subtypes
differs the most. This is what contributes to the functional selectivity of each subtype of STs. For all
the derivatives bearing a phenoxy group or another bulky hydrophobic group at the 3-position of the
benzylic sialic mimic, similar binding poses were observed. The diaryl ether does not mimic the
sialic acid fragment as proposed in the first place but binds to the acceptor site. This was particularly
obvious in the porcine ST3Gal-I structure because the crystal structure included a dissacharide
acceptor. It is to note that for each subtype, the pocket is relatively hydrophobic, particularly for
ST8Sia. The interactions of the protein with the phenoxy group include possible stacking with
Tyr194 and Phe212 in ST3Gal-I. Hydrophobic interactions with Trp257, Tyr369, the backbone of
Gln235 and Pro259 were found in ST6Gal-I, as well as stacking or hydrophobic interactions with
Leu304, Trp244, Pro246, Phe249, Phe250 and the backbone of Asn211 in ST8Sia-III. The prefered
substituents for binding to this pocket are phenoxy, cyclopentoxy, 2-naphthyl and benzothienyl. In
ST8Sia, the hydrophobic pocket in the acceptor site is a lot wider than in the two other crystal
structures. As a result, bulky substituents on the phenoxy group might be tolerated and promote a
certain degree of selectivity. The diastereoisomers were docked separately in order to evaluated the
differences in their active conformation and in most cases, both isomers occupy the same pockets in
the ST active site (fig. 4.16).

118

Chapter 4

Figure 4.16. Docking of 229 into the porcine ST3Gal-I (PDB: 2WNB, A), the human ST6Gal-I (PDB:
4SJ2, B) and the human ST8Sia-III (PDB: 5CXY, C). Both diastereoisomers are shown (R in green sticks and
S in grey) along with CMP 3 (in orange sticks).

Docking the proposed ST inhibitors modified on the nucleoside fragment (242-247) into the
different subtypes highlights the major differences expected depending on the type of linkage.
For example, the thymidine derivative 234 and the 2’-O-methyluridine derivative 246 did not
provide any satisfying results when docking into the human ST6Gal-I and, as discussed in the
section 3.1.3, the methyl group promotes enough steric hinderance to restrict the affinity of
such compound in the enzyme’s active site. Conversly, both 234 and 246 fitted in the donor
binding pocket of ST3Gal-I and ST8Sia-III (fig. 4.17-A).
The indole derivative 239 bears a carboxylic ester moiety, which aims at mimicking the acid
group in the natural donor CMP-Neu5Ac 2. When docking 239 into the STs crystal structures,
the carboxylic function was found to engage in hydrogen bonds with Thr272 in ST3Gal-I,
Ser323 in ST6Gal-I and Thr301 in ST8Sia-III in a similar fashion to CMP-Neu5Ac. In
addition, the ester also interacted with the catalytic residues, as shown in fig. 4.17-B, where
the carbonyl group forms a hydrogen bond with the catalytic residue His354 of ST8Sia-III.
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Figure 4.17. Docking of 243 into the porcine ST3Gal-I (PDB: 2WNB, A, both diastereisomers are shown,
R in green sticks and S in grey) and 239 docking into the human ST8Sia-III (PDB: 5CXY, B) along with
CMP 3 (in orange sticks).

4.3.2. Docking into other glycosyltransferases
A number of GT crystal structures has been reported and are available on the RCSB Protein
Data Bank website (www.rcsb.org). All these enzymes use a sugar-nucleotide derivative as
the donor to perform the glycosylation reaction (Cf section 3.1.4).392 In addition, other 5’triazolonucleoside derivatives (not shown) have been proposed as GT inhibitors,418 including
galactosyltransferases,419-420 as well as chitin synthase.421
Amongst these GTs, two examples using a uridine-sugar conjugate as a natural donor were
chosen for docking our triazole-linked nucleosides into their crystal structures. Thus, several
compounds of our series of triazolonucleosides were docked into α3GT (PDB: 1GX4). This
galactosyltransferase uses (fig. 4.18-A).422 This GT enzyme uses UDP-α-D-galactose as a
glycosyl donor to catalyse the transfer onto N-acetyllactosamine.423 The second enzyme was
the O-linked N-acetylglucosamine transferase (EC.2.4.1.255), responsible for the posttranslational modification of protein serines/threonines with N-acetylglucosamine and
regulating many cellular processes by interfering with protein phosphorylation. Its natural
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donor is UDP-N-acetyl-D-glucosamine and the docking experiments were conducted using
the PDB: 4N3B (fig. 4.18-B).424

Figure 4.18. Docking of 229 into galactosyltransferase (PDB: 1GX4, A) and 230 into N-acetylglucosamine
transferase (PDB: 4N3B, B).

The docking results indicate that the 5’-triazolonucleosides proposed in this thesis have a
potential in inhibiting GT enzymes other than STs. As expected, attention must be paid to the
activity of the nucleoside derivatives attained using click chemistry towards other GTs.

4.4. Biological evaluation
4.4.1. Cytotoxicity
The cytotoxicity of the whole series of 5’-triazolonucleoside derivatives were tested using the
MTS assay, previously described in section 2.2.1.3. The compounds were incubated for 24 to
48 h with different cancer cell lines, MiaPaCa2, MCF-7, SKOV3, as well as macrophages
RAW264.7. These cell lines were selected because they were previously used in other studies
and have been found to express various types of STs. The pancreatic Mia-Paca-2 cells
overexpress ST6GalNAc-IV, down-regulates ST3Gal-I.425 The breast MCF-7 cells express
ST3Gal-III and ST6Gal-I,426 ST3Gal-I, III, IV and ST6Gal-I,427 as well as ST8Sia I.428 The
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ovarian SKOV3 cells are known for expressing ST6Gal-I,85,429 ST3Gal-IV,430 ST3Gal-V,431
and ST3Gal-VI.432 Finally, the murine macrophages RAW264.7 express ST6Gal-I,433
ST6Gal-II434 along with various ST subtypes.435
No apparent influence on cell viability for all the cell lines tested at concentrations up to 300 µM
was observed. The lack of toxicity of our triazolonucleoside derivatives will enable further cellbased biological assays in the aim of exploring the antimetastatic activity of these compounds.

4.4.2. Antibacterial activity
In addition to upregulation of STs (and other GTs) in cancer, sialic acid derivatives also play
important roles in a number of other diseases including viruses436 such as influenza229,437 and
Chagas disease.231 STs have also been identified in marine bacteria. 438 Cabral et al. observed
that α-2,6-ST deficiency improves phagocytosis.

439

However, decreased sialylation was

shown in other cases to enhance bacterial virulence. 440 STs are often referred to as potential
targets for antibacterial purposes, however, the rationale for considering STs as a target for
the design of a new antibacterial drug is not well established. In addition, the literature is
devoid of examples demonstrating the benefits of ST inhibition against bacteria. To explore
whether our compounds did show any potential antibacterial activity, they were screened
against a number of Gram-negative bacteria. These include Escherichia coli, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus.
Amongst our series of compounds, the six triazole derivatives 228, 240-243 and 248 were
tested and none of these displayed any activity at concentrations of up to 32 µg/mL. The lack
of antibiotic activity of this group of compounds does not exclude the possible inhibition of
bacterias invasiveness, which is yet to be evaluated.
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4.4.3. ST inhibition assay
For this study, 19 of our triazole derivatives were evaluated against ST8Sia-II using a
fluorimetric assay developed in the Gerardy-Schahn group, from the Hannover Medical
School in Germany.

441

The experiments were carried out by our collaborators on our library

of available compounds, however, the fluorinated compound 236 and sati derivative 240 were
not tested because they were synthesised at a later date.
Overall, the series of triazole-linked inhibitors tested exhibited varying degrees of inhibition
(19-98 %) towards ST8Sia-II at 100 µM (fig. 4.19). DMSO and water were used as negative
controls for this assay.
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Figure 4.19. Activity of the triazole-based ST inhibitors towards ST8Sia-II at 100 µM expressed in
inhibition rates after 1 h (green bars), 2 h (blue bars) and 4 h (orange bars) of incubation.
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Structure-activity relationship: Based on the present series of compounds which have been
evaluated, a SAR study can be established to compare and predict the activity of the
inhibitors. Herein, the SAR is presented in the form of two tables, the first one focuses on
comparing the influence of the nucleoside fragment on the activity (table 4.6) and the second
one deals with the sialic acid mimic (table 4.7).
First of all, the cytidine moiety led to the most potent inhibition with 91 % at 100 µM compared
to the rest of the series (table 4.6, entry 1). This was closely followed by the 5-FU derivative
246 in accordance with the results previously reported in this respect.389 Conversly, the addition
of a methyl group at the 5-position of the base was not tolerated by ST8Sia-II and resulted in a
decrease in the activity (table 4.6, entry 8). This reduction of the activity is independent to the
lack of hydroxyl group at the 2’-position because the 2’-deoxyuridine counterpart retained
stronger potency with 80 % inhibition at 100 µM (table 4.6, entry 3). Further modifications at
the 2’-position resulted in moderate activity. The 2’-fluoro derivative 244 gave slightly more
potent inhibition than the uridine counterpart with 53 % inhibition (table 4.6, entry 7) compared
to 45 % inhibition for 228 (table 4.6, entry 9). Sterically hindered groups were tolerated when
attached to the ribose fragment, as showed by the 2’-O-methyl derivative 245 with 68 %
inhibition (table 4.6, entry 5). Similar conclusions can be made for the acetonide protected
compounds 247 and 248 (table 4.6, entry 4 and 6) with 62 % and 80 % inhibition respectively.
Interestingly, the disarylether side chain tethered to the 5’-position of the nucleoside fragment
via a tetrazole ring seem to play a significant role in the binding affinity of the inhibitors
described here. In comparison to CMP derivatives previously reported by Al-Saraireh381 and
Miyazaki,385 5-methylCMP and 2’-O-methylCMP were found to be more potent than CMP
itself while in the present series, the cytidine-based inhibitor remains the most potent.
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241

246

243

248

245

247

244

242

228

91

86

80

80

68

62

53

52

45

-0.41

0.61

0.47

1.36

0.94

1.37

0.91

0.97

0.13

cLog P

Structure

% inhib Compound Entry

Table 4.6. Structure-Activity Relationship study based on the nucleoside fragment.

Table 4.7 reports the activity of the uridine-based inhibitors that differ by the sialic acid
mimic. Several trends can be concluded from this set of data, based on the type of
aromatic ring used and how it was substituted. First, the 3,4-disubstituted motifs promoted
greater potency as shown by the 4-fluoro-3-phenoxy derivative 234 (98 % inhibition,
table 4.7, entry 1), the 4-methoxy-3-phenoxy compound 233 (87 % inhibition, table 4.7,
entry 3) and its 4-methoxy-3-pentoxy analogue 232 (65 % inhibition, table 4.7, entry 6).
Of note, the incorporation of a fluorine atom contributed to the potency of the inhibitor, as
described for the nucleoside fragment (table 4.6, entry 2). The short and flexible group 3propoxy in 231 only led to weak activity (24 % inhibition, table 4.7, entry 9).
The use of heterocyclic scaffold to mimic the sialic acid fragment proved to be beneficial as
shown by the benzothienyl derivative 236 (87 % inhibition, table 4.7, entry 4) and the
indolic analogues 237 and 238 (87 % and 96 % inhibition respectively, table 4.7, entry 3
and 5). The t-butoxycarbonyl group attached to the 1-position of the indole ring could play a
role in the binding, similar to the 3-phenoxy group of 228, as suggested the modelling data
125

Chapter 4

(Cf section 4.2.2). The ester group present in 238 fulfilled its role in mimicking the
carboxylic acid group of the natural donor CMP-Neu5Ac 2 (Cf fig. 4.17-B) and contributed
to increase the potency of 238 by about 10 % compared to 237, which is lacking the
functional group.
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87

87
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51
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-1.11

-0.86

-0.94

-1.49

0.41

0.13

-0.57

0.23

cLog P

Structure

% inhib

Compound Entry

Table 4.7. Structure-Activity Relationship study based on the sialic acid mimic.

Of note, the Log P did not correlate with the potency of the triazolonucleoside derivatives.
Nevertheless, the molecular diversity of the library of compounds presented above
promoted a range of Log P values (as calcluated using chemdraw15, 0.23 < Log P < 2.66
and -1.49 < cLog P < 1.55) allowing to balance the high polarity and hydrophilicity of the
nucleoside fragment. In addition, these values are close to those of commonly used
anticancer agents in the clinic such as gemcitabine (Log P = -0.9 and cLog P = -0.73).
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This chapter presented the preparation of triazolonucleoside derivatives, which was achieved in
excellent yields by using the click chemistry approach. The convergent synthetic pathway
demonstrated its versatility and the advantage of preparing the building blocks separately. The
deprotection step was more challenging than expected and the acetyl protection strategy proved
to be the most appropriate for both the coupling step and the cleavage of the ester groups.
The computational study, mostly based on docking experiments highlighted some key
features in the possible mode of binding of the proposed inhibitors and these results correlate
accurately with the biological evaluation.
In addition to the low toxicity of our series of triazole-linked nucleosides, some compounds
exhibited promising inhibition towards ST8Sia-III, up to 98 % inhibition at 100 µM. The most
potent compounds of this series 239,243,245 and 248 confirmed the SAR aspects identified
earlier, in the design process. This last result gives promise to achieve selective inhibition of STs
in the nanomolar level by drugs prepared via cost effective and high yielding synthetic routes.
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Chapter 5 – Conclusion and Future Directions
5.1. General conclusion
Our ever-expanding knowledge of the intricate role of sialylation in cancer, inflammation,
immunology, and central nervous system disorders has highlighted the therapeutic potential of
this important family of enzymes. Today, a large body of evidence has established the merits
of inhibiting specific STs such as ST3Gal I, ST6Gal I and ST8Sia-II as a powerful new
antimetastatic strategy, with the potential to be effective on drug-resistant tumors. A small
number of pan-ST inhibitors are commercially available; however, for ST inhibitors to
proceed to the clinical stage, it is essential that selective inhibitors for the different ST
subtypes are developed to specifically target those STs overexpressed in cancers and to reduce
off-target effects. A wide variety of inhibitors have been developed over the last two decades
by rational design and from natural product and HTS efforts. The recent reports of
mammalian crystal structures for pST3Gal I, rST6Gal I and hST6Gal I, and hST8Sia III have
enabled the use of structure-based design to drive ST inhibitor design in the future to improve
inhibitor selectivity and pharmacokinetic profiles. Increased availability of subtype selective,
cell-permeable and synthetically accessible, small-molecule ST inhibitors in the future will
enable further exploration and therapeutic exploitation of the role of sialylation in a range of
diseases, in particular metastatic cancers.

5.2. Chapter 2
Chapter 2 featured the synthesis of building blocks suitable for mimicking the sialic acid
fragment in the natural ST donor CMP-Neu5Ac. Different synthetic approaches were
explored depending on the type of connectivity required for the carbamate and triazole linker.
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For the carbamate-based inhibitors, a series of nineteen diethyl α-hydroxyphosphonate esters
were prepared in excellent yields including 5 novel compounds. Twelve of these derivatives
were tested using a well known cell proliferation assay, which revealed no toxicity up to
100 µM. Three of these twelve compounds were also assessed for anti-inflammatory activity
and found to reduce nitric oxide production in lipopolysaccharide-activated murine
macrophages (>80 % inhibition at 10 µM). The full series of phosphonate esters were also
tested against five strains of Gram-negative bacteria, but were found to not inhibit growth.
Due to a change in focus to the triazole-based compounds, the α-hydroxyphosphonates were
not pursued further in this project.
For the triazole-based inhibitors, the preparation of propargylphosphonate esters from the
corresponding propargyl acetates was attempted using a copper catalyst. However, rather than
the expected alkyne products, the corresponding allene derivatives were isolated in good
yields (47-79 %) in accordance with results reported at the same time as this work by Shen et
al. and Hu et al. To synthesise the original propargylic targets via this route, other catalysts
and conditions would need to be investigated. In the end, a series of fifteen α-arylpropargyl
acetates, which included nine novel compounds, was achieved in good to excellent yields, as
the key building blocks for the final targets. Due to their significant lipophilicity, their
inherent bioactivity was not assessed.

5.3. Chapter 3
Chapter 3 explored the various aspects of the nucleoside fragment including an overview of the
nucleoside-based ST inhibitors and the hypothesis that functionalising this fragment constitutes
an avenue for achieving the preparation of selective ST inhibitors. The reported biological data
for these types of inhibitors was compared to computational analysis including sequence
alignments, to investigate major differences between the different ST subtypes. Docking
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experiments provided further insight on the mode of binding of the cytidine fragment in the
active site of STs leading to uridine being examined as a replacement for the natural cytidine
fragment with the potential to have greater affinity for the ST3Gal family over the other STs.
Seven commercially available nucleosides were selected as starting material for the preparation
of new potential ST inhibitors, including cytidine and uridine other nucleosides modified at
either the 2’- or 5-position. These included the naturally occurring 2’-deoxyuridine and
thymidine as well as synthetic analogues such as 2’-methyluridine, 5-fluorouridine and 2’deoxy-2’-fluorouridine. Several synthetic routes were optimised to give eleven clickable 5’azidonucleoside derivatives including three novel compounds. In addition, two different
protecting systems were implemented, one acid sensitive and the other one base sensitive.

5.4. Chapter 4
Chapter 4 detailed the preparation of the target triazole-based ST inhibitors by achieving the
coupling step between the sialic acid mimic (the α-arylpropargyl acetates from chapter 2) and the
nucleoside fragment (5-azidonucleosides from chapter 3). High yielding conditions were obtained
using the azidocytidine and azidouridine starting material bearing acetonide, Boc or acetyl
protecting groups. However, the best results were attained when using 1.2 equiv. of alkyne and
the reaction was catalysed with 25 mol% of copper acetate and 50 mol% of sodium ascorbate in a
mixture of acetonitrile and water [4:1]. The expected products were isolated in excellent yields
(90 %) and the protection system had little impact on the reaction outcome, expect for the cytidine
series for which the N4-Boc group gave the most soluble reagent. In total, 27 novel highly
functionalised compounds were synthesised.
The deprotection of the acetonide group attached to the nucleoside fragment was more
challenging than expected and inconsistent results were observed. Conversely, the cleavage of
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the acetyl groups proceeded successfully and an acetyl protection strategy proved to be the most
appropriate for both the coupling step and the cleavage of the ester groups. The series of
triazolonucleoside prepared using click chemistry was deprotected to give a further 20 novel
compounds in excellent yields (83-98 %).
Molecular docking methodologies were developed and standardised by examination of reported
phosphate-based inhibitor CMP. These docking studies indicated that compounds containing
triazole as a linker could potentially bind to various ST subtypes. Interestingly, the inhibitors
bearing a diarylether moiety, originally designed as a sialic acid mimic, may interact with the
acceptor site. The binding mode of compounds prepared from a nucleoside different from
cytidine confirmed that this fragment may facilitate selective discrimination of ST subtypes.
The cytotoxicity of the triazolonucleoside derivatives was evaluated against breast, ovarian
and pancreatic cancer cell lines (MCF-7, SKOV3 and MiaPaCa-2 repsectively) as well as the
murine macrophages RAW264.7 and none was detected at concentration of up to 300 µM.
The series of triazole derivatives was also subject to antibacterial activity evaluation against
five bacteria strains with no observed effect. The evaluation of ST3Gal-I inhibition is
currently in progress and the testing of our library of triazole-based derivatives towards
ST8Sia-II gave some promising results with inhibition ranging from 14 to 98 % when tested
at a concentration of 100 µM. Heterocyclic sialic acid mimics showed high affinity for
ST8Sia-II, in particular the indole derivative 239 with 96 % inhibition at 100 µM. The
nucleoside fragment also influenced the inhibitory activity, and a bulky group attached to the
ribose fragment was tolerated with only a slight decrease in the potency. 5-Fluorouridine is a
good candidate for the nucleoside fragment as demonstrated by the inhibitor 247 with 86 %
inhibition and far easier synthetic access than the cytidine counterpart.
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5.5. Future directions
Although the complete biological evaluation of our library of ST inhibitors is in progress,
some promising results already suggest directions for further development.
Synthesis: Further optimisation of our triazole-linked inhibitors should start with the
incorporation of the phosphonate group at the benzylic position of the sialic acid mimic, in
order to validate the SAR model previously described. This requires the preparation of
propargylphosphonate esters and which could be achieved via two different approaches. First,
the unsuccessful trials for the propargylic substitution described in chapter 2 need to be
addressed by screening a number of metal-based catalysts such as Fe, Bi or Ru, in accordance
with reported procedures. Another approach, inspired by the reactions achieved in this project
involving α-ketoesters, could utilise the addition of ethynylmagnesium bromide to
benzoylphosphonate

derivatives

to

synthesise

the

corresponding

α-ethynyl-α-

hydroxyphosphonate esters (fig. 5.1). This type of intermediate would be suitable for the
CuAAC reaction strategy described in chapter 4.

Figure 5.G. Retrosynthetic scheme for the preparation of triazole-based sialyltransferase inhibitors
bearing a phosphonate group (PG: protecting group).
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Amongst the most encouraging results presented in this thesis, the activity of the indole-based
inhibitor 239 gives promise to enable the scalable preparation of potent selective ST inhibitors.
The relatively complex structure of this sialic acid mimic actually has a straight-forward
retrosynthetic scheme, starting with inexpensive and readily building blocks (fig. 5.2). The
method should involve a protecting system that favours the fragments’ solubility and that is
cleavable in mild conditions and high yields, such as the benzyl group. The convergent approach
presented in fig 5.2 enables the versatile functionalisation of the targets via cost effective routes.

Figure 5.2. Retrosynthetic scheme for the preparation of highly functionalised indole-based
sialyltransferase inhibitors.

Within the indolic series, the issue of isolating the product as a diastereoisomeric mixture
remains. To address this challenge, the carboxylic acid function on the indolic fragment could
be protected with a chiral auxiliary in order to increase the physicochemical differences
between the diastereoisomers. The readily available natural product menthol has proven to
fulfil this role efficiently and could be easily incorporated into our synthetic sequence
(fig. 5.3). At this stage, the experiment should confirm the possibility to separate the
stereoisomers before or after the coupling step.
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Figure 5.3. Assymetric synthesis of indole-based sialyltransferase inhibitors.

In addition, the development of carbamate-based inhibitors using α-hydroxyphosphonate
esters is currently under optimisation in our group.
Computational studies: The use of molecular dynamics employing one crystal structure of each
ST subtype should bring some insights about the mode of binding of our inhibitors and facilitate
the elaboration of new compounds with improved selectivity. The ST subtypes that have not
been crystalised yet could be the object of homology modelling in order to expand the study.

136

CHAPTER 6

Experimental data

Chapter 6

Chapter 6: Experimental data
6.1. Chemical procedures
6.1.1. General
All chemicals were purchased from Sigma Aldrich Chemical Co. and used as received. All
solvents were either AR or HPLC grade for synthesis and purification respectively. Solvents were
purified by short path distillation, while solvents for HPLC were filtered through nylon membrane
filters (#7404-009, Whatman®) and degassed by sonication using a Soniclean ultrasonic bath
(Soniclean 250HT, Thebarton, Australia). Evaporation of solvents was performed using a Büchi
R-114 or R200 rotary evaporator, under vaccum and below 40 °C to avoid decomposition of the
samples. Melting points were determined using a Reichert melting points apparatus and are
uncorrected. The reaction yields were attained after drying under high vacuum.
Chromatography: Thin layer chromatography (TLC) was performed on Merck thin layer
aluminium sheets. Most reactions were monitored under an ultra-violet lamp at 254 nm as the
compounds prepared were visible under this wave length. Column chromatography was
performed on silica gel 60 (230-400 mesh) under “flash” conditions.442 The solvent used in
individual chromatographic experiments is indicated and all solvent proportions are given as
vol/vol ratios.
Analytical HPLC was performed using a Shimadzu system Prominence-i LC-2030C with a
PDA detector. The column used was a Phenomenex Kinetex C18 with a size of 2.10 x 100 mm.
Nuclear Magnetic Resonance (NMR) spectroscopy: NMR spectra were attained for all
samples either on a Varian Unity 500 MHz Inova, where 1H and 13C spectra were attained at
500 MHz and 125 MHz respectively, or on a Varian Unity 300 MHz spectrometer, where 1H
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and

13

C spectra were attained at 300 MHz and 75 MHz respectively, or on a Bruker Ascend

400, where 1H and 13C spectra were attained at 400 MHz and 125 MHz respectively.
The samples were dissolved in deuterated solvents as indicated in brackets. Chemical shifts
are reported in parts per million (ppm) downfield from tetramethylsilane (TMS), which was
used as an internal standard. Coupling constants (J) are given in Hertz. Hydrogen and carbon
assignments were performed using gradient correlation spectroscopy (gCOSY), gradient
heteronuclear single quantum correlation (gHSQC), gradient heteronuclear multiple bond
correlation (gHMBC) and nuclear Overhauser effect spectroscopy (NOESY) techniques.
Siganls are reported as singlet (s), doublet (d), doublet of doublet (dd), doublet of triplets (dt),
triplet (t) and multiplet (m). Diastereomeric peaks are indicated with +. Samples were
subjected to high vacuum overnight before performing NMR spectroscopy.
Mass Spectrometry: Low resolution direct insertion electron impact mass spectrometry (EIMS) was performed on a Shimadzu QP-5050A system. The probe was heated from 40 °C to
200 °C. Electrospray ionisation low resolution mass spectrometry (LRMS-ESI) was
performed on Waters Platfrom LCZ spectrometer. High resolution electrospray ionisation
mass spectra HRESI-MS were attained using a Waters Q-Tof Ultima spectrometer using
leucine encephalin (LeuEnk) as the internal standard.
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6.1.2. General synthetic procedures
General Procedure A: Preparation of dialkyl α-hydroxyphosphonate esters: Substituted
benzaldehyde (1.0 equiv.), diethyl phosphite (1.1 equiv.) and Et3N (2.2 equiv.) were stirred at
room temperature until disappearance of the starting material as monitored by TLC (18 to 26 h).
At this time, the reaction mixture was concentrated under reduced pressure, poured into water
and extracted with CH2Cl2. The organic layers were pooled, washed with a saturated solution of
NaHCO3 and then brine, dried over MgSO4, filtered and evaporated under reduced pressure.
The oily residue was crystalised from Et2O or purified by flash chromatography if required.
General Procedure B: Preparation of the alkyne building block: The aldehyde (or ketone)
derivative (1.0 equiv.) was dissolved in dry THF (20 mL) and added at 0 °C to a solution of
ethynylmagnesium bromide in THF (0.5 N in THF, 1.1-1.5 equiv.). After 3 h the reaction
mixture was quenched in a mixture of saturated NH4Cl solution (50 mL) and ice (50 mL). After
the evaporation of THF, diethyl ether (50 mL) was added. The organic and water layers were
separated and the organic layer was washed with brine (50 mL). After separation of phases the
organic layer was dried over anhydrous MgSO4 and concentrated to dryness. The crude product
was used without further purification in the next step.
A solution of the propargylic alcohol derivative (max. 7.3 mmol, 1.0 equiv.), Ac2O
(1.2 equiv.) and Et3N (1.5 equiv.) in dry CH2Cl2 (20 mL) was stirred overnight at room
temperature. If necessary a catalytic amount of DMAP was added to achieve total conversion.
The CH2Cl2 fraction was evaporated with a laboratory evaporator. The resulting crude
mixture was purified by silica gel column chromatography.443
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General procedure C: Synthesis of 5’-azido-5’-deoxynucleosides: The 5’-mesyl or 5’tosylnucleoside derivative (1.0 equiv.) was dissolved in dry DMF and added NaN3
(1.5 equiv.) and benzyltriethylammonium chloride (0.1 equiv.) and the solution was stirred at
80 °C until disappearance of the stating material as monitored by TLC. The reaction mixture
was poured into crushed ice and extracted with CH2Cl2 or EtOAc. The organic layer was
washed several times with water and brine, dried over MgSO4, filtered and evaporated. The
residue was purified by flash chromatography.
General procedure D: Huisgen cycloaddition: The protected 5’-azidonucleoside (1 equiv.),
the alkyne derivative (1.2 equiv.), Cu(OAc)2 (0.25 equiv.) and sodium ascorbate (0.5 equiv.)
were suspended in a mixture of water and CH3CN (1:4) and stirred at room temperature. After
disappearance of the starting material, as indicated by TLC, the reaction mixture was
concentrated under reduced pressure and extracted with EtOAc. The organic layer was
washed with water and brine, dried over MgSO4, filtered and evaporated to dryness. The
residue was purified by flash chromatography and eluted with CH2Cl2/EtOAc (1:2) to
EtOAc/Me2CO (4:1). The expected compounds were attained as a 1:1 diastereomeric mixture
which could not be readily separated in these conditions and reported as such.
General procedure E: Deprotection of the acetate-protected triazolonucleosides: The
protected 5’-triazolonucleoside derivative was taken up in CH3OH (2-5 mL) and to this
solution was added concentrated ammonia (2-3 mL). Stirring was continued until
disappearance of the starting material as moniroted by TLC. The solvent was evaporated
under reduced pressure and coevaporated twice with CH3OH to ensure the complete removal
of water. The residue was purified by flash chromatograph.
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6.1.3. Experimental for chapter 2
6.1.3.1. Preparation of benzaldehyde derivatives
3-Propoxybenzaldehyde 57

To a solution of commercially available 3-hydroxybenzaldehyde 56 (3.00 g, 24.58
mmol, 1.0 equiv.) and K 2CO3 (8.68 g, 24.58 mmol, 2.5 equiv.) in CH 3CN (40 mL) was
added 1-iodopropane (2.4 mL, 24.58 mmol, 1.0 equiv.). The mixture was stirred for 50 h at
room temperature and poured on crushed ice, and was extracted with EtOAc. The organic
layers were pooled and washed with water several times and then dried over MgSO4 to be
evaporated under reduced pressure. The residue was purified by flash chromatography
column eluted with CH2Cl2/hexane [1:1]. 3-Propoxybenzaldehyde 56 was attained as a
colourless oil (2.50 g, 62 %). The spectral data matched those reported.281 CAS: 67698-61-7.
1

H NMR (300 MHz, CDCl3): δ 1.05 (t, J = 7.6 Hz, 3H, H-3’), 1.84 (m, 2H, H-2’), 3.99 (t,

J = 6.7 Hz, 2H, H-1’), 7.16-7.20 (m, 1H, ArH), 7.39 (m, 1H, ArH), 7.44-7.45 (m, 2H, ArH),
9.97 (s, 1H, CHO). LRMS-ESI: m/z = 187 [M+Na]+
5-Bromo-2-methoxybenzaldehyde 60

To a solution of commercially available 5-bromo-2-hydroxybenzaldehyde 58 (1.95 g,
9.68 mmol, 1.0 equiv.) and K2CO3 (2.68 g, 19.40 mmol, 2.0 equiv.) in DMF (50 mL) was
added CH3I (0.9 mL, 14.5 mmol, 1.5 equiv.). The mixture was stirred for 42 h at room
temperature and then poured on crushed ice. The white solid that formed was removed by
filtration, washed with water and air dried. Recrystalisation from Et2O gave pure 5-bromo-2143
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methoxybenzaldehyde 60 as a beige solid (2.04 g, 98 %). m.p. 111-112 °C (lit. 107109 °C).444 The spectral data matched those reported.444 CAS: 25016-01-7.

1

H NMR

(200 MHz, CDCl3): δ 3.39 (s, 3H, OCH3), 7.01 (d, J = 8.7 Hz, 1H, ArH), 7.63 (dd,
J = 2.3 Hz, J = 2.8 Hz, 1H, ArH), 7.91 (d, J = 2.8 Hz, 1H, ArH), 10.36 (s, 1H, CHO). LRMSESI: m/z = 213, 215 [M+H]+ 79Br; 81Br
2-Methoxynaphthaldehyde 61

CH3I (1.1 mL, 17.42 mmol, 1.0 equiv.) was added to a solution of commercially available 2hydroxy-1-naphthaldehyde 59 (3.00 g, 17.42 mmol, 1.0 equiv.) and K2CO3 (2.41 g,
17.42 mmol, 1.0 equiv.) in DMF (10 mL). Stirring was followed for 30 h at room temperature
and the mixture was poured on crushed ice. The dark green solid formed was removed by
filtration, washed with water and air dried (2.40 g, 74 %). m.p. 80 °C (lit. 82 °C).445 The
spectral data matched those reported.445 CAS: 5392-12-1. 1H NMR (400 MHz, CDCl3):
δ 4.05 (s, 3H, OCH3), 7.29 (d, J = 9.3 Hz, 1H, ArH), 7.39-7.43 (m, 1H, ArH), 7.59-7.64 (m,
1H, ArH), 7.76-7.78 (m, 1H, ArH), 8.05 (d, J = 9.3 Hz, 1H, ArH), 9.27 (dd, J = 8.8 Hz,
J = 1.0 Hz, 1H, ArH), 10.89 (s, 1H, CHO). LRMS-ESI: m/z = 209 [M+Na]+
4-Acetoxy-3-methoxybenzaldehyde 63

Commercially available vanillin 62 (2.00 g, 13.14 mmol, 1.0 equiv.) was suspended in CH2Cl2
(20 mL), and Ac2O (1.50 mL, 15.77 mmol, 1.2 equiv.) and pyridine (1.30 mL, 15.77 mmol,
1.2 equiv.) were added. The resulting solution was stirred at room temperature for 18 h. The
reaction mixture was evaporated and taken up in EtOAc. The organic layer was washed with
water, a saturated NaHCO3 solution, a CuSO4 solution and brine, and then dried over anhydrous
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MgSO4. The organic layer was filtered, and concentrated under reduced pressure to give pure 4acetoxy-3-methoxybenzaldehyde 63 as white crystals (2.45 g, 96 %). m.p. 75-76 °C (lit. 7778 °C).283 The spectral data matched those reported.282 CAS: 881-68-5. 1H NMR (300 MHz,
CDCl3): δ 2.35 (s, 3H, CH3), 3.91 (s, 3H, OCH3), 7.21-7.24 (m, 1H, ArH), 7.47-7.50 (m, 2H,
ArH), 9.95 (s, 1H, CHO). LRMS-ESI: m/z = 195 [M+H]+
3-Bromo-4-hydroxy-5-methoxybenzaldehyde 64

A solution of bromine (3.40 mL, 65.72 mmol, 1.0 equiv.) in glacial AcOH (10 mL) was added
dropwise to commercially available vanillin 62 (10.00 g, 65.72 mmol, 1.0 equiv.) dissolved in
glacial AcOH (60 mL). After stirring for 2.5 h, the reaction mixture was poured on crushed
ice and a creamy white solid 64 formed, which was removed by filtration, washed with water
and air dried. (14.12 g, 93 %). m.p. 162-164 °C (lit. 163-164 °C).283 The spectral data
matched those reported.283 CAS: 2973-76-4. 1H NMR (300 MHz, DMSO-d6): δ 3.91 (s, 3H,
OCH3), 7.42 (m, 1H, ArH), 7.72 (m, 1H, ArH), 9.77 (s, 1H, CHO), 10.74 (br s, 1H, OH).
LRMS-ESI: m/z = 229, 231 [M]- 79Br; 81Br
4-Acetoxy-3-bromo-5-methoxybenzaldehyde 65

5-Bromovanillin 64 (2.30 g, 9.95 mmol, 1.0 equiv.) was suspended in CH2Cl2 (15 mL), and
then Ac2O (1.1 mL, 11.95 mmol, 1.2 equiv.) and pyridine (1.0 mL, 11.95 mmol, 1.2 equiv.)
were added. The resultant solution was stirred at room temperature for 2 days. Water was added
to the reaction mixture, which was then extracted with EtOAc. The organic layer was washed
with a saturated NaHCO3 solution, a CuSO4 solution and brine, and was dried over MgSO4. The
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organic layer was filtered, and concentrated under reduced pressure to give a pale amber oil.
Crystallisation from ethanol gave pure 4-acetoxy-3-bromo-5-methoxybenzaldehyde 65 as clear
crystals (2.23 g, 82 %). m.p. 83-84 °C (lit. 84 °C).446 The spectral data matched those
reported.284 CAS: 308088-29-1. 1H NMR (500 MHz, CDCl3): δ 2.39 (s, 3H, CH3), 3.91 (s,
3H, OCH3), 7.42 (d, J = 1.9 Hz, 1H, ArH), 7.69 (d, J = 1.9 Hz, 1H, ArH), 9.89 (s, 1H, CHO).
LRMS-ESI: m/z = 271, 273 [M+H]+ 79Br; 81Br
3-Bromo-4-hydroxybenzaldehyde 67

To a solution of commercially available 4-hydroxybenzaldehyde 66 (10.00 g, 81.89 mmol,
1.0 equiv.) in a mixture of CHCl3 (100 mL) and CH3OH (10 mL) was added a solution of
bromine (4.61 mL, 90.07 mmol, 1.1 equiv.) in CHCl3 (10 mL) dropwise at room temperature.
The mixture was stirred for 2 h and washed with water until at neutral pH. The organic phase
was dried over MgSO4 and the solvent was evaporated. Recrystallization from CHCl3 afforded
3-bromo-4-hydroxybenzaldehyde 67 as a white solid (13.66 g, 83 %). m.p. 123 °C (lit. 118120 °C).447 The spectral data matched those reported.447 CAS: 2973-78-6. 1H NMR (300 MHz,
DMSO-d6): δ 6.31 (s, 1H, OH), 7.08 (d, J = 8.3 Hz, 1H, ArH), 7.70 (dd, J = 8.3 Hz,
J = 1.9 Hz, 1H, ArH), 7.97 (d, J = 1.9 Hz, 1H, ArH), 9.74 (s, 1H, CHO). LRMSESI: m/z = 199, 201 [M+H]+ 79Br; 81Br
4-Acetoxy-3-bromobenzaldehyde 68

3-Bromo-4-hydroxybenzaldehyde 67 (2.50 g, 12.43 mmol, 1.0 equiv.) was suspended in
CH2Cl2 (50 mL), and then Ac2O (1.4 mL, 14.92 mmol, 1.2 equiv.) and pyridine (1.2 mL,
14.92 mmol, 1.2 equiv.) were added. The resultant solution was stirred at room temperature
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for 3 days. Water was added to the reaction mixture, which was extracted with EtOAc. The
organic layer was washed with a saturated NaHCO3 aqueous solution, a CuSO4 solution and
brine, and was dried over MgSO4. The organic layer was filtered, and concentrated under
reduced pressure to give pure 4-acetoxy-3-bromobenzaldehyde 68 as amber crystals (2.69 g,
89 %). m.p. 57 °C (lit. 58-60 °C).448 The spectral data matched those reported.448
CAS: 74849-11-9. 1H NMR (300 MHz, CDCl3): δ 2.39 (s, 3H, CH3), 7.32 (d, J = 8.3 Hz, 1H,
ArH), 7.86 (dd, J = 8.3 Hz, J = 1.5 Hz, 1H, ArH), 8.14 (d, J = 1.5 Hz, 1H, ArH), 9.95 (s, 1H,
CHO). LRMS-ESI: m/z = 241, 243 [M+H]+ 79Br; 81Br
4-Methoxy-3-phenoxybenzaldehyde 99

A suspension of commercially available 3-hydroxy-4-methoxybenzaldehyde 98 (300 mg,
1.97 mmol, 1.0 equiv.), phenylboronic acid (265 mg, 2.17 mmol, 1.1 equiv.), Et3N (997 mg,
9.85 mmol, 5.0 equiv.), anhydrous Cu(OAc)2 (394 mg, 1.97 mmol, 1.0 equiv.) and 4 Å
molecular sieves in CH2Cl2 were stirred at room temperature until disappearance of the
starting material as monitored by TLC (14 h). At this time, the reaction mixture was
concentrated under reduced pressure, poured on water and extracted with EtOAc. The organic
layers were pooled, washed with brine, dried over MgSO4 and evaporated under reduced
pressure. The oily residue was purified using a chromatography column and eluted with
CH2Cl2 to give 4-methoxy-3-phenoxybenzaldehyde 99 as a beige solid (355 mg, 79 %).
m.p. 48 °C (lit. 49-51 °C).449 The spectral data matched those reported.449 CAS: 4664-64-6.
1

H NMR (300 MHz, CDCl3): δ 3.58 (s, 3H, OCH3), 6.60-6.62 (m, 2H, ArH), 6.73-6.76 (m,

2H, ArH), 6.94-6.99 (m, 2H, ArH), 7.07 (m, 1H, ArH), 7.27-7.30 (m, 1H, ArH), 10.62 (s, 1H,
CHO). LRMS-ESI: m/z = 251 [M+Na]+
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3-(4’-Fluorophenoxy)benzaldehyde 103

A slurry of commercially available 3-hydroxybenzaldehyde 57 (500 mg, 4.09 mmol,
1.0 equiv.), 4-fluorophenylboronic acid (687 mg, 4.91 mmol, 1.2 equiv.), anhydrous
Cu(OAc)2 (163 mg, 0.82 mmol, 0.2 equiv.), and Et3N (1.7 mL, 12.28 mmol, 3 equiv.) in
CH2Cl2 (15 mL) was stirred at room temperature for 22 h. At this time, the solution was
washed with water, 1 N aqueous HCl and brine before being dried over MgSO4, filtered and
evaporated under reduced pressure. The residue was purified by silica gel chromatography
column eluted with Hexane/CH2Cl2 [1:2] to give the title compound 103 as a clear oil
(690 mg, 78 %). The spectral data matched those reported.450 CAS: 65295-61-6. 1H NMR
(500 MHz, CDCl3): δ 7.00-7.09 (m, 4H, ArH), 7.26 (d, J = 8.1 Hz, 1H, ArH), 7.41 (s, 1H, ArH),
7.50 (t, J = 7.8 Hz, 1H, ArH), 7.59 (d, J = 7.3 Hz, 1H, ArH), 9.96 (s, 1H, CHO). LRMS-ESI:
m/z = 239 [M+Na]+
3-Cyclopentoxybenzaldehyde 104

A solution of commercially available 3-hydroxybenzaldehyde 56 (1.50 g, 12.28 mmol,
1.0 equiv.) in anhydrous DMF was aded K2CO3 (2.54 g, 18.42 mmol, 1.5 equiv.) and the
suspension was stirred at room temperature for 1 h before adding cyclopentyl bromide
(15 mL, 13.51 mmol, 1.1 equiv.). After 20 h, TLC indicated the disappearance of the starting
material and the reaction mixture was poured on crushed ice and the resulting solution was
extracted with CH2Cl2. The organic layer was then washed with saturated NaHCO3 and brine
and dried over MgSO4, filtered and evaporated. The residue was purified by flash
chromatography and eluted with CH2Cl2/Hexane [1:1] to give the title compound 104 as a
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pale yellow oil (1.82 g, 78 %). The compound is known but the spectral data has not been
reported to our knowledge. CAS: 273722-75-1. 1H NMR (500 MHz, CDCl3): δ 1.64-1.66 (m,
2H, H-3’a/H-4’a), 1.78-1.88 (m, 4H, H-2’a/H-3’b/H-4’b/H-5’a), 1.94-1.99 (m, 2H, H-2’b/H-5’b),
4.82-4.85 (m, 1H, H-1’), 6.96 (dd, J = 7.3 Hz, J = 2.9 Hz, 1H, ArH), 7.37 (d, J = 1.5 Hz, 1H,
ArH), 7.42-7.43 (m, 2H, ArH), 9.97 (s, 1H, CHO). LRMS-ESI: m/z = 191 [M+H]+
3-(Cyclopentoxy)-4-methoxybenzaldehyde - 105

To a solution of commercially available 3-hydroxy-4-methoxybenzaldehyde 98 (800 mg,
5.26 mmol, 1.0 equiv.) in anhydrous DMF was aded K2CO3 (1.45 g, 10.52 mmol, 2.0 equiv.)
and the suspension was stirred at room temperature for 1 h before adding cyclopentyl bromide
(0.68 mL, 6.31 mmol, 1.2 equiv.). After stirring for 20 h, TLC indicated the disappearance of
the starting material and the reaction mixture was poured on crushed ice and the resulting
solution was extracted with CH2Cl2. The organic layer was then washed with saturated NaHCO3
and brine and dried over MgSO4 and evaporated. The residue was purified by flash
chromatography eluted with CH2Cl2/Hexane [1:1] to give the title compound 105 as a pale
yellow oil (940 mg, 81 %). The spectral data matched those reported.451 CAS: 67387-76-2.
1

H NMR (500 MHz, CDCl3): δ 1.52-1.64 (m, 2H, H-3’a/H-4’a), 1.80-2.14 (m, 6H, H-2’/H-

3’b/H-4’b/H-5’), 3.90 (s, 3H, OCH3), 4.85-4.74 (m, 1H, H-1’), 6.96 (d, J = 8.1 Hz, 1H, ArH),
7.33 (d, J = 1.7 Hz, 1H, ArH), 7.39 (dd, J = 8.1 Hz, J = 1.7 Hz, 1H, ArH), 9.80 (s, 1H, CHO).
LRMS-ESI: m/z = 221 [M+H]+
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tert-Butyl 3-formyl-1H-indole-1-carboxylate 126

A solution of commercially available indole-3-carboxaldehyde 125 (500 mg, 3.44 mmol,
1.0 equiv.), di-tert-butyl dicarbonate (1.50 g, 6.89 mmol, 2.0 equiv.), and DMAP (84 mg,
0.69 mmol, 0.5 equiv.) in CH2Cl2 (50 mL) was stirred at room temperature for 16 h. A
saturated NH4Cl solution (5 mL) was added and the layers were separated. The organic phase
was washed with brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The
residue was purified by column chromatography eluted with EtOAc/Hexane [1:4] to give the
126 as a white powder (642 mg, 76 %); m.p. 120-121°C (lit. 124-126°C).364 The spectral data
matched those reported.364 CAS: 57476-50-3. 1H NMR (500 MHz, CDCl3): δ 1.72 (s, 9H,
3 x CH3), 7.35-7.45 (m, 2H, H-5/H-6), 8.14-8.17 (m, 1H, ArH), 8.24 (s, 1H, H-2), 8.28-8.31
(m, 1H, ArH), 10.11 (s, 1H, CHO). LRMS-ESI: m/z = 268 [M+Na]+
Methyl 2-(1H-indol-3-yl)-2-oxoacetate 128

Oxalyl chloride (0.86 mL, 10 mmol, 1.0 equiv.) was added dropwise to a solution of
commercially available 1H-indole 127 (1.17 g, 10 mmol, 1.0 equiv.) in Et2O (12 mL) cooled in
an ice bath. The reaction mixture was kept stirring under the same conditions for 30 min.
CH3OH (4.7 mL, 23 mmol, 2.3 equiv.) was added dropwise followed by Et3N (1.68 mL,
12 mmol, 1.2 equiv.). The reaction mixture was allowed to warm to room temperature, stirred
for an additional 30 min and quenched by adding water (18 mL). The product was isolated by
filtration, washed with CH2Cl2 and dried to give 128 as a yellow solid (1.73 g, 87 %). m.p. 232234 °C (lit. 228 °C).452 The spectral data matched those reported.453 CAS: 18372-22-0.
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1

H NMR (500 MHz, CDCl3): δ 3.97 (s, 3H, OCH3), 7.35-7.38 (m, 2H, ArH), 7.45-7.48 (m,

1H, ArH), 8.45-8.48 (m, 1H, ArH), 8.52 (d, J = 3.2 Hz, 1H, ArH), 8.84 (br s, 1H, NH).
LRMS-ESI: m/z = 226 [M+Na]+
Methyl 2-(1H-indol-3-yl)-2-oxoacetate – 129

To a solution of methyl 2-(indol-3-yl)-2-oxoacetate 128 (1.35 g, 6.64 mmol, 1.0 equiv.) in
THF (12 mL) was added Boc2O (2.90 g, 13.29 mmol, 2.0 equiv.) and DMAP (81 mg,
0.66 mmol, 0.1 equiv.) and stirred at room temperature for 18 h. The mixture was treated with
CH3OH (5 mL) and evaporated under reduced pressure. The residue was purified by flash
chromatography and eluted with CH2Cl2/Hexane [2:1] to give the title compound 129 as a
white solid (1.45 g, 72 %). m.p. 127-128°C (lit. 129-130°C).364 The spectral data matched
those reported.364 CAS: 473927-91-2. 1H NMR (500 MHz, CDCl3): δ 1.72 (s, 9H, 3 x CH3),
3.99 (s, 3H, CH3), 7.38-7.45 (m, 2H, H-5/H-6), 8.16-8.19 (m, 1H, ArH), 8.39-8.42 (m, 1H,
ArH), 8.82 (s, 1H, H-2). LRMS-ESI: m/z = 294 [M+H]+
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6.1.3.2. Preparation of a-hydroxyphosphonate esters
Diethyl (4-methyl-α-hydroxybenzyl)phosphonate 69

This compound was prepared following procedure A, described p. 142, using commercially
available 4-tolualdehyde (1.00 g, 8.32 mmol, 1.0 equiv.), diethyl phosphite (1.18 mL, 9.15 mmol,
1.1 equiv.) and Et3N (2.54 mL, 18.31 mmol, 2.2 equiv.) at room temperature for 18 h. After work
up, the title compound 69 was attained as colourless needles (1.36 g, 78 %). m.p. 100-102 °C
(lit. 98-100 °C).454 The spectral data matched those reported.454 CAS: 79158-40-0. 1H NMR
(300 MHz, CDCl3): δ 1.23 (t, J = 6.9 Hz, 3H, CH3), 1.29 (t, J = 6.9 Hz, 3H, CH3), 2.36 (s,
3H, CH3), 3.19 (br s, 1H, OH), 3.95-4.10 (m, 4H, 2 x CH2), 4.98 (d, J = 10.3 Hz, 1H, CHOH),
7.17-7.39 (m, 4H, ArH). LRMS-ESI: m/z = 281 [M+Na]+
Diethyl (4-ethyl--hydroxybenzyl)phosphonate 70

This compound was prepared following procedure A using commercially available 4ethylbenzaldehyde (500 g, 3.73 mmol, 1.0 equiv.), diethyl phosphite (4.80 mL, 4.10 mmol,
1.1 equiv.) and Et3N (1.15 mL, 8.20 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 70 was attained as white needles (964 mg, 95 %). m.p. 46-47 °C
(lit. oil).455 The spectral data matched those reported.455 CAS: 1397716-66-3. 1H NMR
(500 MHz, CDCl3): δ 1.22 (t, J = 7.5 Hz, 3H, CH3), 1.23 (t, J = 7.5 Hz, 3H, CH3), 1.29 (t,
J = 7.0 Hz, 3H, H-2’), 2.65 (q, J = 7.0 Hz, 2H, H-1’), 3.94-4.09 (m, 4H, 2 x CH2), 4.98 (d,
J = 10.0 Hz, 1H, CHOH), 7.19-7.40 (m, 4H, ArH). LRMS-ESI: m/z = 295 [M+Na]+
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Diethyl (α,3-dihydroxybenzyl)phosphonate 71

This compound was prepared following procedure A using commercially available 3hydroxybenzaldehyde 56 (0.50 g, 4.09 mmol, 1.0 equiv.), diethyl phosphite (1.05 mL,
8.18 mmol, 2.0 equiv.) and Et3N (2.27 mL, 16.4 mmol, 4.0 equiv.) at room temperature for
18 h. After work up, the title compound 71 was attained as white needles (0.97 g, 92 %).
m.p. 96-97 °C (lit. 96-97 °C).280 The spectral data matched those reported.280 CAS: 50652-89-6.
1

H NMR (500 MHz, CDCl3): δ 1.16 (t, J = 7.5 Hz, 3H, CH3), 1.26 (t, J = 7.5 Hz, 3H, CH3),

3.81-4.12 (m, 4H, 2 x CH2), 4.94 (d, J = 11.5 Hz, 1H, CHOH), 6.70-7.25 (m, 4H, ArH). LRMSESI: m/z = 283 [M+Na]+
Diethyl (3-methoxy-α-hydroxybenzyl)phosphonate 72

This compound was prepared following procedure A using commercially available 3methoxybenzaldehyde (500 mg, 3.67 mmol, 1.0 equiv.), diethyl phosphite (1.06 g, 4.04 mmol,
1.1 equiv.) and Et3N (1.14 mL, 8.08 mmol, 2.2 equiv.) at room temperature for 18 h. After work
up, the title compound 72 was attained as a white solid (967 mg, 96 %). m.p. 91-93-°C. The
spectral data matched those reported.456 CAS: 49640-97-3. 1H NMR (500 MHz, CDCl3):
δ 1.22 (t, J = 7.2 Hz, 3H, CH3); 1.26 (t, J = 7.2 Hz, 3H, CH3), 3.83 (s, 3H, OCH3), 4.12-3.93
(m, 5H, OH & 2 x CH2), 5.01 (d, J = 10.7 Hz, 1H, CHOH), 6.82-6.88 (m, 1H, ArH), 7.01-7.08
(m, 2H, ArH), 7.24-7.29 (m, 1H, ArH). LRMS-ESI: m/z = 297 [M+Na]+
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Diethyl (3-propoxy-α-hydroxybenzyl)phosphonate 73

This compound was prepared following procedure A using 3-propoxybenzaldehyde 57
(630 mg, 3.84 mmol, 1.0 equiv.), diethyl phosphite (0.54 mL, 4.22 mmol, 1.1 equiv.) and Et3N
(1.19 mL, 8.44 mmol, 2.2 equiv.) at room temperature for 18 h. After work up, the title
compound 73 was attained as a white solid (1.078 g, 93 %). m.p. 103-104 °C. 1H NMR
(400 MHz, DMSO-d6): δ 1.02 (t, J = 7.3 Hz, 3H, H-3’), 1.22 (t, J = 7.13 Hz, 3H, CH3), 1.27 (t,
J = 7.13 Hz, 3H, CH3), 1.79 (sxt, J = 6.6 Hz, 2H, H-2’), 3.91 (t, J = 6.6 Hz, 2H, H-1’), 3.964.11 (m, 4H, 2 x CH2), 4.99 (d, J = 11.0 Hz, 1H, CHOH), 5.15 (br s, 1H, OH), 6.81-6.85 (m,
1H, ArH), 7.00-7.03 (m, 1H, ArH), 705-7.06 (m, 1H, ArH), 7.23 (dt, J = 8.3 Hz, J = 0.7 Hz, 1H,
ArH).

13

C NMR (125 MHz, CDCl3): δ 10.2 (C-3’), 16.1 (2 x CH3), 22.3 (C-2’), 62.7 (d,

J = 7.7 Hz, CH2), 63.0 (d, J = 7.7 Hz, CH2), 69.2 (C-1’), 70.4 (d, J = 159.2 Hz, CHOH), 112.8
(C-2), 114.1 (C-4), 119.1 (C-6), 128.7 (C-5), 138.3 (C-1), 158.8 (C-3). LRMS-ESI:
m/z = 325 [M+Na]+. HRESI-MS: m/z calcd for C14H23O5PNa [M+Na]+: 325.1181; found
325.1203; Δ = 6.77 ppm
Diethyl (3-phenoxy-α-hydroxybenzyl)phosphonate 74

This compound was prepared following procedure A using commercially available 3phenoxybenzaldehyde (0.40 g, 2.20 mmol, 1.0 equiv.), diethyl phosphite (0.29 mL, 2.22 mmol,
1.1 equiv.) and Et3N (0.62 mL, 4.44 mmol, 2.2 equiv.) at room temperature for 18 h. After work
up, the title compound 74 was attained a thick oil (624 mg, 92 %). The compound is known but
the spectral data has not been reported to our knowledge. CAS: 85374-19-2. 1H NMR
(400 MHz, CDCl3): δ 1.22 (t, J = 7.1 Hz, 3H, CH3), 1.26 (t, J = 7.1 Hz, 3H, CH3), 3.98-4.11
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(m, 4H, 2 x CH2), 4.76 (br s, 1H, OH), 4.99 (d, J = 11.0 Hz, 1H, CHOH), 6.93-6.96 (m, 1H,
ArH), 6.98-7.02 (m, 2H, ArH), 7.07-7.11 (m, 1H, ArH), 7.16-7.17 (m, 1H, ArH), 7.21-7.24
(m, 1H, ArH), 7.29-7.35 (m, 3H, ArH). LRMS-ESI: m/z = 359 [M+Na]+
Diethyl (α-hydroxy-3-nitrobenzyl)phosphonate 75

This compound was prepared following procedure A using commercially available 3-nitrobenzaldehyde (500 mg, 3.31 mmol, 1.0 equiv.), diethyl phosphite (0.47 mL, 3.64 mmol,
1.1 equiv.) and Et3N (0.94 mL, 7.28 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 75 was attained as white needles (880 mg, 94 %). m.p. 89-90 °C
(lit. 94-95 °C).457 The spectral data matched those reported.457 CAS: 50652-91-0. 1H NMR
(500 MHz, CDCl3): δ= 1.27 (t, J = 7.5 Hz, 3H, CH3), 1.29 (t, J = 7.5 Hz, 3H, CH3), 4.09-4.15
(m, 4H, 2 x CH2), 5.15 (d, J = 11.5 Hz, 1H, CHOH), 7.53-8.38 (m, 4H, ArH). LRMS-ESI:
m/z = 312 [M+Na]+
Diethyl (2-fluoro-α-hydroxybenzyl)phosphonate 76

This compound was prepared following procedure A using commercially available 2-fluorobenzaldehyde (500 mg, 4.03 mmol, 1.0 equiv.), diethyl phosphite (0.57 mL, 4.43 mmol,
1.1 equiv.) and Et3N (1.24 mL, 8.86 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 76 was attained as white needles (972 mg, 92 %). m.p. 62-63 °C.
1

H NMR (500 MHz, CDCl3): δ 1.21 (t, J = 7.0 Hz, 3H, CH3), 1.31 (t, J = 7.0 Hz, 3H, CH3),

4.04-4.17 (m, 4H, 2 x CH2), 5.38 (d, J = 11.5 Hz, 1H, CHOH), 7.02-7.68 (m, 4H, ArH).
13

C NMR (125 MHz, CDCl3): δ 16.1 (CH3), 16.2 (CH3), 63.1 (d, J = 7.6 Hz, CH2), 63.4 (d,

J = 7.6 Hz, CH2), 64.1 (d, J = 164.4 Hz, CHOH), 114.9 (d, J = 22.0 Hz, ArCH), 124.1 (3 d,
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J = 2.5 Hz, ArCH), 128.9, 129.5, 124.6 (d, J = 13.4 Hz, C-1), 159.8 (d, J = 245.6 Hz, C-2).
LRMS-ESI: m/z = 285 [M+Na]+. HRESI-MS: m/z calcd for C11H18FO4P [M+H]+: 263.0849;
found 263.0847; Δ = 0.76 ppm
Diethyl (3-fluoro-α-hydroxybenzyl)phosphonate 77

This compound was prepared following procedure A using commercially available 4-fluorobenzaldehyde (500 mg, 4.03 mmol, 1.0 equiv.), diethyl phosphite (0.57 mL, 4.43 mmol,
1.1 equiv.) and Et3N (1.24 mL, 8.86 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 77 was attained as white needles (1.003 g, 95 %). m.p. 58-59 °C
(lit. oil).455 The spectral data matched those reported.455 CAS: 96258-60-5. 1H NMR
(500 MHz, CDCl3): δ 1.25 (t, J = 7.5 Hz, 3H, CH3), 1.28 (t, J = 7.5 Hz, 3H, CH3), 4.02-4.12 (m,
4H, 2 x CH2), 5.02 (d, J = 11 Hz, 1H, CHOH), 6.98-7.35 (m, 4H, ArH). LRMS-ESI:
m/z = 285 [M+Na]+
Diethyl (4-fluoro-α-hydroxybenzyl)phosphonate 78

This compound was prepared following procedure A using commercially available 4-fluorobenzaldehyde (500 mg, 4.03 mmol, 1.0 equiv.), diethyl phosphite (0.57 mL, 4.43 mmol,
1.1 equiv.) and Et3N (1.24 mL, 8.86 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 78 was attained as a white solid (993 mg, 94 %). m.p. 56-57 °C
(lit. 55-57 °C).455 The spectral data matched those reported.455 CAS: 21386-00-5. 1H NMR
(500 MHz, CDCl3): δ 1.24 (t, J = 7.5 Hz, 3H, CH3), 1.27 (t, J = 7.5 Hz, 3H, CH3), 4.02-4.07
(m, 4H, 2 x CH2), 5.02 (d, J = 10.5 Hz, 1H, CHOH), 7.05-7.48 (m, 4H, ArH). LRMS-ESI:
m/z = 285 [M+Na]+
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Diethyl (3-bromo-α-hydroxybenzyl)phosphonate 79

This compound was prepared following procedure A using commercially available 3-bromobenzaldehyde (800 mg, 4.32 mmol, 1.0 equiv.), diethyl phosphite (0.61 mL, 4.76 mmol,
1.1 equiv.) and Et3N (1.34 mL, 9.51 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 79 was attained as a colourless oil (1.271 g, 91 %). The spectral
data matched those reported.455 CAS: 73584-08-4. 1H NMR (300 MHz, CDCl3): δ 1.26 (t,
J = 7.0 Hz, 3H, CH3), 1.29 (t, J = 7.0 Hz, 3H, CH3), 3.93 (br s, 1H, OH), 4.03-4.11 (m, 4H,
2 x CH2), 5.00 (dd, J = 11.1 Hz, J = 5.0 Hz, 1H, CHOH), 7.24 (t, J = 7.7 Hz, 1H, ArH), 7.417.46 (m, 2H, ArH), 7.67 (s, 1H, ArH). LRMS-ESI: m/z = 321, 323 [M+Na]+ 79Br; 81Br
Diethyl (hydroxy(naphthalen-2-yl)methyl)phosphonate 80

This compound was prepared following procedure A using commercially available
naphthaldehyde (600 mg, 3.84 mmol, 1.0 equiv.), diethyl phosphite (0.54 mL, 4.22 mmol,
1.1 equiv.) and Et3N (1.17 mL, 8.45 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 80 was attained as white needles (972 mg, 86 %). m.p. 83-84 °C
(lit. 88-89 °C).456 The spectral data matched those reported.456 CAS: 1090-99-9. 1H NMR
(400 MHz, CDCl3): δ 1.21 (t, J = 7.1 Hz, 3H, CH3), 1.26 (t, J = 7.1 Hz, 3H, CH3), 3.97-4.11 (m,
4H, 2 x CH2), 5.21 (d, J = 13.9 Hz, 1H, CHOH), 7.46-7.50 (m, 2H, ArH), 7.61 (dt, J = 8.6 Hz,
J = 1.7 Hz, 1H, ArH), 7.82-7.85 (m, 3H, ArH), 7.96-7.97 (m, 1H, ArH). LRMS-ESI:
m/z = 317 [M+Na]+
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Diethyl (hydroxy(2-methoxynaphthalen-1-yl)methyl)phosphonate 81

This compound was prepared following procedure A using 2-methoxynaphthaldehyde 61
(1.00 g, 5.37 mmol, 1.0 equiv.), diethyl phosphite (0.76 mL, 5.91 mmol, 1.1 equiv.) and Et3N
(1.66 mL, 11.81 mmol, 2.2 equiv.) at room temperature for 18 h. After work up, the title
compound 81 was attained as a beige solid (975 mg, 56 %). m.p. 98-99 °C. 1H NMR
(300 MHz, DMSO-d6): δ 0.96 (t, J = 7.3 Hz, 3H, CH3), 1.22 (t, J = 7.3 Hz, 3H, CH3), 3.643.81 (m, 2H, CH2), 3.92 (s, 3H, OCH3), 4.00-4.06 (m, 2H, CH2), 5.99 (dd, J = 18.1 Hz,
J = 5.4 Hz, 1H, CHOH), 6.21 (dd, J = 17.1 Hz, J = 5.9 Hz, 1H, OH), 7.30-7.34 (m, 1H, ArH),
7.37-7.43 (m, 2H, ArH), 7.80 (d, J = 8.3 Hz, 1H, ArH), 7.89 (dd, J = 9.3 Hz, J = 1.9 Hz, 1H,
ArH), 8.72 (d, J = 8.8 Hz, 1H, ArH). 13C NMR (125 MHz, DMSO-d6): δ 16.0 (d, J = 5.8 Hz,
CH3), 16.3 (d, J = 0.9 Hz, CH3), 56.7 (OCH3), 61.5 (d, J = 6.6 Hz, CH2), 61.8 (d, J = 6.6 Hz,
CH2), 63.2 (d, J = 168.7 Hz, CHOH), 113.4 (d, J = 2.2 Hz, ArCH), 119.0 (ArC), 123.3
(ArCH), 125.0 (ArCH), 127.6 (ArCH), 127.8 (ArCH), 129.1 (d, J = 2.2 Hz, ArC), 129.9 (d,
J = 3.7 Hz, C-3), 132.5 (d, J = 2.9 Hz, ArC), 154.2 (d, J = 8.8 Hz, ArC). LRMS-ESI:
m/z = 325 [M+H]+. HRESI-MS: m/z calcd for C16H21O5PNa [M+Na]+: 347.1024; found
347.1033; Δ = 2.59 ppm
Diethyl (3,4-dimethoxy-α-hydroxybenzyl)phosphonate 82

This compound was prepared following procedure A using commercially available 3,4dimethoxybenzaldehyde (300 mg, 1.80 mmol, 1.0 equiv.), diethyl phosphite (0.26 mL,
1.98 mmol, 1.1 equiv.) and Et3N (0.56 mL, 3.97 mmol, 2.2 equiv.) at room temperature for
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18 h. After work up, the title compound 82 was attained as white needles (505 mg, 86 %).
m.p. 100 °C (lit. 101-103 °C).458 The spectral data matched those reported.458 CAS: 62002-64-6.
1

H NMR (500 MHz, DMSO-d6): δ 1. 14 (t, J = 7.2 Hz, 3H, CH3); 1.18 (t, J = 7.2 Hz, 3H,

CH3), 3.73 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 3.81-4.02 (m, 4H, 2 x CH2), 4.84 (dd,
J = 12.4 Hz, J = 5.5 Hz, 1H, OH), 6.09 (d, J = 5.8 Hz, 1H, CHOH), 6.89-6.96 (m, 2H, ArH),
7.03 (m, 1H, ArH). LRMS-ESI: m/z = 327 [M+Na]+
Diethyl (3,5-dimethoxy-α-hydroxybenzyl)phosphonate 83

This compound was prepared following procedure A using commercially available 3,5dimethoxybenzaldehyde (600 mg, 3.61 mmol, 1.0 equiv.), diethyl phosphite (0.51 mL,
3.96 mmol, 1.1 equiv.) and Et3N (1.12 mL, 7.94 mmol, 2.2 equiv.) at room temperature for
18 h. After work up, the title compound 83 was attained as a white solid (923 mg, 84 %).
m.p. 99-100 °C (lit. 101-103 °C).459 The spectral data matched those reported.459
CAS: 266000-71-9. 1H NMR (500 MHz, CDCl3): δ 1.24 (t, J = 6.9 Hz, 3H, CH3), 1.28 (t,
J = 6.9 Hz, 3H, CH3), 3.78 (s, 6H, 2 x OCH3), 4.00 (q, J = 7.6 Hz, 2H, CH2), 4.08 (q,
J = 7.6 Hz, 2H, CH2), 4.95 (d, J = 11.2 Hz, 1H, CHOH), 6.40-6.67 (m, 3H, ArH). LRMSESI: m/z = 327 [M+Na]+
Diethyl (2,5-dimethoxy-α-hydroxybenzyl)phosphonate 84

This compound was prepared following procedure A using commercially available 2,5dimethoxybenzaldehyde (800 mg, 4.71 mmol, 1.0 equiv.), diethyl phosphite (0.68 mL,
5.29 mmol, 1.1 equiv.) and Et3N (1.49 mL, 10.60 mmol, 2.2 equiv.) at room temperature for
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18 h. After work up, the title compound 84 was attained as white needles (1.392 g, 95 %).
m.p. 74-75 °C. The compound is commercially available but the spectral data has not been
reported to our knowledge. CAS: 430471-09-3. 1H NMR (500 MHz, CDCl3): δ 1.20 (t,
J = 6.9 Hz, 3H, CH3), 1.32 (t, J = 6.9 Hz, 3H, CH3), 3.59 (br s, 1H, OH), 3.78 (s, 3H, OCH3), 3.82
(s, 3H, OCH3), 3.91-4.07 (m, 2H, CH2), 4.12-4.17 (m, 2H, CH2), 5.37 (d, J = 12.1 Hz, 1H,
CHOH), 6.83 (m, 2H, ArH), 7.11 (m, 1H, ArH), LRMS-ESI: m/z = 327 [M+Na]+
Diethyl (4-acetoxy-3-methoxy-α-hydroxybenzyl)phosphonate 85

This compound was prepared following procedure A using 4-acetoxy-3-methoxybenzaldehyde 63 (400 mg, 2.06 mmol, 1.0 equiv.), diethyl phosphite (0.3 mL, 2.26 mmol,
1.1 equiv.) and Et3N (0.6 mL, 4.53 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 85 was attained as a beige solid (685 mg, 66 %). m.p. 84 °C.
1

H NMR (300 MHz, CDCl3): δ 1.23 (t, J = 7.1 Hz, 3H, CH3), 1.30 (t, J = 7.1 Hz, 3H, CH3),

2.31 (s, 3H, Ac), 3.50 (br s, 1H, OH), 3.90 (s, 3H, OCH3), 3.93-4.12 (m, 4H, 2 x CH2), 4.92
(d, J = 9.9 Hz, 1H, CHOH), 6.88-6.90 (m, 1H, ArH), 6.93-6.96 (m, 1H, ArH), 7.09 (t,
J = 2.0 Hz, 1H, ArH). 13C NMR (75 MHz, CDCl3): δ 16.4 (2 x CH3), 56.0 (OCH3), 63.1 (d,
J = 7.4 Hz, CH2), 63.2 (d, J = 7.4 Hz, CH2), 70.7 (d, J = 160.2 Hz, CHOH), 109.8 (d,
J = 5.4 Hz, C-2), 114.2 (C-5), 120.4 (d, J = 7.4 Hz, C-6), 128.1 (C-1), 145.8 (C-4), 146.6 (C3), 169.8 (C=O). LRMS-ESI: m/z = 355 [M+Na]+. HRESI-MS: m/z calcd for C14H21O7PNa
[M+Na]+: 355.0923; found 355.0935; Δ = 3.38 ppm
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Diethyl 4-acetoxy-3-bromo-5-methoxy-α-hydroxybenzylphosphonate 86

This compound was prepared following procedure A using 4-acetoxy-3-bromo-5-methoxybenzaldehyde 65 (500 mg, 1.83 mmol, 1.0 equiv.), diethyl phosphite (0.26 mL, 2.01 mmol,
1.1 equiv.) and Et3N (0.57 mL, 4.03 mmol, 2.2 equiv.) at room temperature for 18 h. After
work up, the title compound 86 was attained as a white solid (708 mg, 94 %). m.p. 141 °C.
1

H NMR (300 MHz, CDCl3): δ 1.27 (t, J = 6.9 Hz, 3H, CH3), 1.30 (t, J = 6.9 Hz, 3H, CH3),

2.36 (s, 3H, Ac), 3.84 (s, 3H, OCH3), 4.05-4.12 (m, 4H, 2 x CH2), 4.96 (d, J = 11.0 Hz, 1H,
CHOH), 7.11 (s, 1H, H-2), 7.30 (s, 1H, H-6).

13

C NMR (75 MHz, CDCl3): δ 16.3 (CH3),

16.4 (CH3), 20.4 (Ac-CH3), 56.3 (OCH3), 63.3 (d, J = 6.9 Hz, CH2), 63.6 (d, J = 6.9 Hz, CH2),
69.9 (d, J = 160.1 Hz, CHOH), 110.1 (d, J = 4.6 Hz, C-2), 116.8 (d, J = 3.4 Hz, C-5), 122.7
(d, J = 6.9 Hz, C-6), 136.3 (C-1), 146.0 (C-4), 152.2 (d, J = 2.3 Hz, C-3), 167.9 (C=O).
LRMS-ESI: m/z = 433, 435 [M+Na]+ 79Br; 81Br, HRESI-MS: m/z calcd for C14H20BrO7PNa
[M+H]+: 433.0028; found 433.0026; Δ = 0.46 ppm
Diethyl (2,5-dimethoxy-α-hydroxybenzyl)phosphonate 87

This compound was prepared following procedure A using 5-bromo-2-methoxybenzaldehyde
60 (600 mg, 2.79 mmol, 1.0 equiv.), diethyl phosphite (0.4 mL, 3.07 mmol, 1.1 equiv.) and
Et3N (0.86 mL, 6.14 mmol, 2.2 equiv.) at room temperature for 18 h. After work up, the title
compound 87 was attained as white needles (670 mg, 68 %). m.p. 94-95 °C. 1H NMR
(500 MHz, CDCl3): δ 1.23 (t, J = 7.0 Hz, 3H, CH3), 1.29 (t, J = 7.0 Hz, 3H, CH3), 3.83 (s,
3H, OCH3), 3.98-4.15 (m, 4H, 2 x CH2), 5.14 (br s., 1H, OH), 5.39 (J = 11.7 Hz, 1H, CHOH),
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6.75 (d, J = 8.8 Hz, 1H, H-3), 7.37 (dt, J = 8.8 Hz, J = 2.2 Hz, 1H, H-6), 7.66 (t,
J = 2.2 Hz, 1H, H-4).

13

C NMR (125 MHz, CDCl3): δ 16.2 (d, J = 5.9 Hz, CH3), 16.3 (d,

J = 5.9 Hz, CH3), 55.8 (OCH3), 63.0 (d, J = 7.3 Hz, CH2), 63.3 (d, J = 7.3 Hz, CH2), 64.8 (d,
J = 160.7 Hz, CHOH), 112.2 (C-3), 113.1 (d, J = 3.7 Hz, C-5), 127.6 (d, J = 1.5 Hz, C-1),
131.3 (d, J = 4.4 Hz, C-4), 131.7 (d, J = 3.7 Hz, C-6), 155.7 (d, J = 5.9 Hz, C-2). LRMS-ESI:
m/z = 375, 377 [M+Na]+

79

Br;

81

Br. HRESI-MS: m/z calcd for C12H18BrO5PNa [M+Na]+:

374.9973; found 374.9991; Δ = 4.80 ppm

6.1.3.3. Preparation of alkyne derivatives
1-(4-Methylphenyl)prop-2-yn-1-yl acetate 95

This compound was prepared following procedure B, described p. 142, using commercially
available 4-methylbenzaldehyde (250 mg, 2.08 mmol, 1.0 equiv.) and ethynylmagnesium
bromide (5.00 mL of a 0.5 M solution in THF, 2.50 mmol, 1.2 equiv.) at room temperature for
2 h. After extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (0.44 mL,
3.12 mmol, 1.5 equiv.) and Ac2O (0.24 mL, 2.50 mmol, 1.2 equiv.) at room temperature
overnight. After work up, the title compound 95 was attained as an amber oil (352 mg, 90 %).
The spectral data matched those reported.346 CAS: 179248-90-9. 1H NMR (300 MHz,
CDCl3): δ 2.10 (s, 3H, Ac), 2.36 (s, 3H, CH3), 2.68 (s, 1H, H-3), 6.42 (s, 1H, H-1), 7.21-7.24
(m, 4H, ArH).
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Diethyl (3-(4’-methylphenyl)-propa-1,2-dien-1-yl)phosphonate 97

To a solution of 1-(4-methylphenyl)propargyl acetate 95 (60 mg, 319 µmol, 1.0 equiv.),
diethyl phosphite (48 mg, 350 µmol, 1.1 equiv.) and Et3N (50 µL, 382 µmol, 1.2 equiv.) in
CH2Cl2 (5 mL) was added CuI (6.1 mg, 32 µmol, 10 mol%) and the mixture was stirred at
room temperature for 2.5 h. The reaction mixture was diluted with CH2Cl2 (20 mL) and
washed with water, saturated NaHCO3 and brine before being dried over MgSO4 and
evaporated under reduced pressure. The residue was purified by flash chromatography and
eluted with CH2Cl2/Hexane [1:2] to give the title compound 97 as a pale yellow oil (66 mg,
78 %). The spectral data matched those reported.350 CAS: 201932-99-2. 1H NMR (400 MHz,
CDCl3): δ 1.28 (t, J = 7.1 Hz, 3H, CH3), 1.31 (t, J = 7.1 Hz, 3H, CH3), 2.30 (s, 3H, CH3),
4.07-4.16 (m, 4H, CH2), 5.77 (d, J = 6.8 Hz, 1H, H-3), 6.42 (dd, J = 13.6 Hz, J = 6.8 Hz, 1H,
H-1), 7.11-7.17 (m, 4H, ArH).

13

C NMR (125 MHz, CDCl3): δ 16.2 (d, J = 5.8 Hz, CH3).

21.2 (CH3), 62.3 (d, J = 4.6 Hz, CH2), 62.5 (d, J = 4.1 Hz, CH2), 84.1 (d, J = 192.4 Hz, C-1),
95.3 (d, J = 16.3 Hz, C-3), 127.0 (d, J = 2.3 Hz, C-2’/C-6’), 128.2 (d, J = 8.6 Hz, C-3’/C-5’),
129.2 (d, J = 1.3 Hz, C-1’), 136.9 (d, J = 2.4 Hz, C-4’), 212.6 (d, J = 1.2 Hz, C-2). LRMSESI: m/z = 266 [M+H]+
1-(3’-Methoxyphenyl)prop-2-yn-1-ol 106

This compound was prepared following procedure B using commercially available 3methoxybenzaldehyde (450 mg, 3.30 mmol, 1.0 equiv.) and ethynylmagnesium bromide
(7.93 mL of a 0.5 M solution in THF, 3.97 mmol, 1.2 equiv.) at room temperature for 2 h.
After extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (0.70 mL,
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496 mmol, 1.5 equiv.) and Ac2O (0.37 mL, 3.97 mmol, 1.2 equiv.) at room temperature
overnight. After work up, the title compound 106 was attained as an amber oil (628 mg,
93 %). The spectral data matched those reported.346 CAS: 179249-08-2. 1H NMR (500 MHz,
CDCl3): δ 2.11 (s, 3H, Ac), 2.66 (s, 1H, H-3), 3.81 (s, 3H, OCH3), 6.42 (s, 1H, H-1), 6.89 (d,
J = 8.3 Hz, 1H, ArH), 7.06-7.13 (m, 2H, ArH), 7.30 (t, J = 7.9 Hz, 1H, ArH).
1-(2’,5’-Dimethoxyphenyl)prop-2-yn-1-ol 107

This compound was prepared following procedure B using commercially available 2,5dimethoxybenzaldehyde (580 mg, 3.49 mmol, 1.0 equiv.) and ethynylmagnesium bromide
(8.4 mL of a 0.5 M solution in THF, 4.19 mmol, 1.2 equiv.) at room temperature for 2 h. After
extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (0.7 mL, 5.23 mmol,
1.5 equiv.) and Ac2O (0.4 mL, 4.19 mmol, 1.2 equiv.) at room temperature overnight. After
work up, the title compound 107 was attained as an amber oil (728 mg, 89 %). 1H NMR
(500 MHz, CDCl3): δ 2.23 (s, 3H, Ac), 2.60 (d, J = 2.0 Hz, 1H, H-3), 3.81 (s, 3H, OCH3),
3.81 (s, 3H, OCH3), 6.76 (d, J = 2.0 Hz, 1H, H-1), 6.83-6.85 (m, 1H, ArH), 6.88-6.90 (m, 1H,
ArH), 7.25 (d, J = 3.2 Hz, 1H, ArH).

13

C NMR (125 MHz, CDCl3): δ 22.1 (CH3), 55.8

(OCH3), 56.3 (OCH3), 63.5 (C-1), 74.6 (C-3), 80.3 (C-2), 112.2 (C-3’), 114.6 (C-4’),
115.1 (C-6’), 125.7 (C-1’), 150.9 (C-2’), 153.7 (C-5’), 169.5 (C=O). IR (Neat) vmax
3286, 2948, 1739, 1499, 1214, 967, 711 cm-1
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1-(3’-Propoxyphenyl)prop-2-yn-1-ol 108

This compound was prepared following procedure B using 3-propoxybenzaldehyde 56
(400 mg, 2.43 mmol, 1.0 equiv.) and ethynylmagnesium bromide (5.8 mL of a 0.5 M solution
in THF, 2.92 mmol, 1.2 equiv.) at room temperature for 2 h. After extraction, the residue was
resuspended in CH2Cl2 and treated with Et3N (0.5 mL, 3.65 mmol, 1.5 equiv.) and Ac2O
(0.3 mL, 2.92 mmol, 1.2 equiv.) at room temperature overnight. After work up, the title
compound 108 was attained as an amber oil (520 mg, 92 %). 1H NMR (500 MHz, CDCl3):
δ 1.23 (t, J = 7.3 Hz, 3H, H-3”), 2.00 (sxt, J = 7.3 Hz, 2H, H-2”), 2.30 (s, 3H, Ac), 2.85 (s, 1H,
H-3), 4.12 (t, J = 6.8 Hz, 2H, H-1”), 6.61 (s, 1H, H-1), 7.08 (d, J = 7.8 Hz, 1H, H-2’), 7.27-7.29
(m, 2H, H-4’/H-6’), 7.47 (t, J = 7.8 Hz, 1H, H-5’). 13C NMR (125 MHz, CDCl3): δ 10.4 (C3”), 20.9 (C-2”), 22.4 (CH3), 65.1 (C-1”), 69.4 (C-1), 75.3 (C-3), 80.1 (C-2), 113.7 (C-2’),
115.0 (C-4’), 119.6 (C-6’), 129.6 (C-5’), 137.7 (C-1’), 159.2 (C-3’), 169.6 (C=O).
1-(3’-Cyclopentoxyphenyl)prop-2-yn-1-ol 109

This compound was prepared following procedure B using 3-cyclopentoxybenzaldehyde 102
(600 mg, 3.15 mmol, 1.0 equiv.) and ethynylmagnesium bromide (7.6 mL of a 0.5 M solution
in THF, 3.78 mmol, 1.2 equiv.) at room temperature for 2 h. After extraction, the residue was
resuspended in CH2Cl2 and treated with Et3N (0.7 mL, 4.73 mmol, 1.5 equiv.) and Ac2O
(0.4 mL, 3.78 mmol, 1.2 equiv.) at room temperature overnight. After work up, the title
compound 109 was attained as a clear oil (730 mg, 89 %). 1H NMR (500 MHz, CDCl3):
δ 1.61-1.64 (m, 2H, H-3”a/H-4”a), 1.78-1.94 (m, 6H, H-2”/H-3”b/H-4”b/H-5”), 2.12 (s, 3H,
Ac), 2.64 (d, J = 1.9 Hz, 1H, H-3), 4.76-4.79 (m, 1H, H-1”), 6.40 (d, J = 1.9 Hz, 1H, H-1),
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6.86 (dd, J = 8.3 Hz, J = 2.4 Hz, 1H, ArH), 7.05-7.07 (m, 2H, ArH), 7.26-7.29 (m, 1H, ArH).
13

C NMR (125 MHz, CDCl3): δ 21.0 (CH3), 24.0 (C-3”/C-4”), 32.8 (C-2”/C-5”), 65.2 (C-1),

75.2 (C-3), 79.3 (C-1”), 80.2 (C-2), 114.9 (C-2’), 116.0 (C-4’), 119.4 (C-6’), 129.6 (C-5’),
137.7 (C-1’), 158.3 (C-3’), 169.7 (C=O). IR (Neat) vmax 3287, 2962, 1739, 1601, 1449, 1369,
1221, 1167, 1014, 962, 790, 696 cm-1
1-(3’-Cyclopentoxy-4’-methoxyphenyl)prop-2-yn-1-ol 110

This compound was prepared following procedure B using 3-cyclopentoxy-4-methoxybenzaldehyde 103 (500 mg, 2.27 mmol, 1.0 equiv.) and ethynylmagnesium bromide (5.5 mL of
a 0.5 M solution in THF, 2.72 mmol, 1.2 equiv.) at room temperature for 2 h. After extraction,
the residue was resuspended in CH2Cl2 and treated with Et3N (0.5 mL, 3.40 mmol, 1.5 equiv.)
and Ac2O (0.26 mL, 2.72 mmol, 1.2 equiv.) at room temperature overnight. After work up, the
title compound 110 was attained as an orange oil (595 mg, 91 %). 1H NMR (400 MHz,
CDCl3): δ 1.77-1.97 (m, 8H, H-2”/H-3”/H-4”/H-5”), 2.10 (s, 3H, Ac), 2.65 (d, J = 2.3 Hz, 1H,
H-3), 3.85 (s, 3H, OCH3), 4.78-4.81 (m, 1H, CH-1”), 6.38 (d, J = 2.3 Hz, 1H, H-1), 6.85-6.87
(m, 1H, ArH), 7.06-7.08 (m, 2H, ArH). 13C NMR (125 MHz, CDCl3): δ 21.0 (Ac-CH3), 24.0
(C-3”/C-4”), 32.8 (C-2”/C-5”), 56.1 (OCH3), 63.4 (C-1), 65.3 (C-1”), 75.0 (C-3), 80.5 (C-1’),
80.6 (C-2), 111.7 (C-2’), 114.6 (C-5’), 120.4 (C-6’), 128.9 (C-1’), 147.8 (C-3’), 150.7 (C-4’),
169.7 (C=O). IR (Neat) vmax 3280, 2964, 1734, 1594, 1512, 1367, 1226, 1136, 1014, 808 cm-1
1-(3’-Phenoxyphenyl)prop-2-yn-1-yl acetate 111

This compound was prepared following procedure B using commercially available 3phenoxybenzaldehyde (500 mg, 2.52 mmol, 1.0 equiv.) and ethynylmagnesium bromide
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(6.05 mL of a 0.5 M solution in THF, 3.03 mmol, 1.2 equiv.) at room temperature for 4 h.
After extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (0.53 mL,
3.78 mmol, 1.5 equiv.) and Ac2O (0.29 mL, 3.03 mmol, 1.2 equiv.) at room temperature
overnight. After work up, the title compound 111 was attained as an amber oil (598 mg,
89 %). The spectral data matched those reported.346 CAS: 83807-99-2. 1H NMR (500 MHz,
CDCl3): δ 2.11 (s, 3H, Ac), 2.63 (d, J = 2.2 Hz, 1H, H-3), 6.41 (d, J = 2.2 Hz, 1H, H-1), 6.97
(dd, J = 11.3 Hz, J = 5.7 Hz, 1H, ArH), 7.02 (d, J = 7.7 Hz, 2H, ArH), 7.12 (t, J = 7.4 Hz, 1H,
ArH), 7.21-7.20 (m, 1H, ArH), 7.25 (d, J = 8.2 Hz, 1H, ArH), 7.34 (dd, J = 15.4 Hz,
J = 7.6 Hz, 3H, ArH).
1-(4’-Methoxy-3’-phenoxyphenyl)prop-2-yn-1-yl acetate 112

This compound was prepared following procedure B using 4-methoxy-3-phenoxybenzaldehyde
99 (500 mg, 2.19 mmol, 1.0 equiv.) and ethynylmagnesium bromide (5.3 mL of a 0.5 M
solution in THF, 2.63 mmol, 1.2 equiv.) at room temperature for 2 h. After extraction, the
residue was resuspended in CH2Cl2 and treated with Et3N (0.35 mL, 2.66 mmol, 1.5 equiv.) and
Ac2O (0.25 mL, 2.63 mmol, 1.2 equiv.) at room temperature overnight. After work up, the title
compound 112 was attained as an amber oil (539 g, 83%). 1H NMR (500 MHz, CDCl3):
δ 2.09 (s, 3H, Ac), 2.63 (d, J = 2.4 Hz, 1H, H-3), 3.86 (s, 3H, OCH3), 6.35 (d, J = 2.4 Hz, 1H,
H-1), 6.95-6.97 (m, 2H, ArH), 7.00 (d, J = 8.4 Hz, 1H, ArH), 7.07 (m, 1H, ArH), 7.18 (d,
J = 8.4 Hz, 1H, ArH), 7.30-7.33 (m, 3H, ArH). 13C NMR (125 MHz, CDCl3): δ 21.0 (CH3),
56.1 (OCH3), 64.7 (C-1), 75.3 (C-3), 80.1 (C-2), 112.5 (C-5), 117.2 (C-2” & C-6”), 120.5 (C6’), 122.7 (C-4”), 124.3 (ArCH), 129.3 (C-1’), 129.6 (C3” & C-5”), 144.9 (C-4’), 152.0 (C3’), 157.5 (C-1”), 169.7 (C=O).
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1-(4’-Fluoro-3’-phenoxyphenyl)prop-2-yn-1-yl acetate 113

This compound was prepared following procedure B using commercially available 4-fluoro3-phenoxybenzaldehyde (400 mg, 1.75 mmol, 1.0 equiv.) and ethynylmagnesium bromide
(4.2 mL of a 0.5 M solution in THF, 5.25 mmol, 1.2 equiv.) at room temperature for 2 h. After
extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (1.2 mL, 8.75 mmol,
1.5 equiv.) and Ac2O (0.5 mL, 5.25 mmol, 1.2 equiv.) at room temperature overnight. After
work up, the title compound 113 was attained as an amber oil (494 mg, 94 %). 1H NMR
(300 MHz, CDCl3): δ 2.09 (s, 3H, Ac), 2.63 (d, J = 2.2 Hz, 1H, H-3), 6.36 (d, J = 2.2 Hz, 1H,
H-1), 6.98-7.00 (m, 2H, ArH), 7.09-7.24 (m, 3H, ArH), 7.27-7.37 (m, 3H, ArH).

13

C NMR

(125 MHz, CDCl3): δ 20.9 (CH3), 64.7 (C-1), 75.3 (C-3), 80.1 (C-2), 112.6 (C-2’), 117.2 (C-3” &
C-5”), 120.6 (C-6’), 122.7 (C-4”), 124.3 (ArCH), 129.4 (ArCH), 129.6 (C-2” & C-6”), 137.4 (C1’), 146.4 (d, J = 278.7 Hz, C-4’), 152.1 (C-3’), 157.6 (C-1”), 169.6 (C=O).
1-(3’-(4”-Fluorophenoxy)phenyl)prop-2-yn-1-yl acetate 114

This compound was prepared following procedure B using 4-fluoro-3-phenoxybenzaldehyde
103 (400 mg, 1.75 mmol, 1.0 equiv.) and ethynylmagnesium bromide (4.2 mL of a 0.5 M
solution in THF, 5.25 mmol, 1.2 equiv.) at room temperature for 2 h. After extraction, the
residue was resuspended in CH2Cl2 and treated with Et3N (1.2 mL, 8.75 mmol, 1.5 equiv.)
and Ac2O (0.5 mL, 5.25 mmol, 1.2 equiv.) at room temperature overnight. After work up, the
title compound 114 was attained as an amber oil (484 mg, 92 %). 1H NMR (500 MHz,
CDCl3): δ 2.07 (s, 3H, Ac), 2.65 (d, J = 2.4 Hz, 1H, H-3), 6.41 (d, J = 2.4 Hz, 1H, H-1), 6.94
(dd, J = 8.3 Hz, J = 1.9 Hz, 1H, ArH), 6.99-7.02 (m, 2H, ArH), 7.04-7.08 (m, 2H, ArH), 7.17
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(m, 1H, ArH), 7.24-7.25 (m, 1H, ArH), 7.32-7.36 (m, 1H, ArH). 13C NMR (125 MHz, CDCl3):
δ 20.9 (CH3), 63.5 (C-1), 64.8 (C-3), 75.5 (C-2), 116.3 (C-3” & C-5”), 116.5 (C-2’), 117.4 (C4’), 118.4 (C-6’), 120.7 (C-2” & C-6”), 122.7 (ArCH), 124.3 (ArCH), 130.0 (ArCH), 138.4
(C-1’), 152.4 (d, J = 2.7 Hz, ArC-O), 158.0 (ArC-O), 169.6 (C=O).
Benzothien-2-ylpropargyl acetate 116

This compound was prepared following procedure B using commercially available 2benzothiophenecarboxaldehyde 115 (400 mg, 2.47 mmol, 1.0 equiv.) and ethynylmagnesium
bromide (5.9 mL of a 0.5 M solution in THF, 2.96 mmol, 1.2 equiv.) at room temperature for
2 h. After extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (5.2 mL,
3.70 mmol, 1.5 equiv.) and Ac2O (0.28 mL, 2.96 mmol, 1.2 equiv.) at room temperature
overnight. After work up, the title compound 116 was attained as a dark amber oil (488 mg,
86 %). 1H NMR (300 MHz, CDCl3): δ 2.14 (s, 3H, Ac), 2.73 (d, J = 2.3 Hz, 1H, H-3), 6.75
(d, J = 2.3 Hz, 1H, H-1), 7.34-7.37 (m, 2H, H-5’/H-6’), 7.50 (s, 1H, H-3’), 7.75-7.83 (m, 2H,
H-4’/H-7’).

13

C NMR (75 MHz, CDCl3): δ 22.1 (CH3), 61.1 (C-1), 75.6 (C-3), 79.1 (C-2),

122.4 (C-3’), 124.2 (C-7’), 124.5 (C-4’), 125.6 (C-5’), 125.1 (C-6’), 138.8 (ArC), 139.6
(ArC), 140.3 (C-2’), 166.4 (C=O). IR (Neat) vmax 3283, 3063, 2119, 1739, 1458, 1370, 1218,
1207, 1014, 945, 843, 755, 730, 720 cm-1
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tert-Butyl 3-(1-acetoxyprop-2-yn-1-yl)-1H-indole-1-carboxylate 130

This compound was prepared following procedure B using 1-tert-butoxycarbonylindole-3carboxaldehyde 126 (400 mg, 1.63 mmol, 1.0 equiv.) and ethynylmagnesium bromide (4 mL
of a 0.5 M solution in THF, 2.00 mmol, 1.2 equiv.) at room temperature for 2 h. After
extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (3.4 mL, 2.45 mmol,
1.5 equiv.) and Ac2O (0.2 mL, 1.96 mmol, 1.2 equiv.) at room temperature overnight. After
work up, the title compound was 130 attained as an amber oil (306 mg, 73 %). The spectral
data matched those reported.460 CAS: 1378870-85-9. 1H NMR (300 MHz, CDCl3): δ 1.67 (s,
9H, Boc), 2.11 (s, 3H, Ac), 2.65 (d, J = 1.9 Hz, 1H, H-3), 6.72 (d, J = 2.4 Hz, 1H, H-1), 7.267.29 (m, 1H, ArH), 7.34-7.37 (m, 1H, ArH), 7.71-7.72 (m, 1H, ArH), 7.80 (s, 1H, ArH), 8.158.17 (m, 1H, ArH).
tert-Butyl 3-(2-hydroxy-1-methoxy-1-oxobut-3-yn-2-yl)-1H-indole-1-carboxylate 131

This compound was prepared following procedure B using tert-butyl 3-(2-methoxy-2oxoacetyl)-1H-indole-1-carboxylate

129

(700 mg,

2.31 mmol,

1.0 equiv.)

and

ethynylmagnesium bromide (5.5 mL of a 0.5 M solution in THF, 2.77 mmol, 1.2 equiv.) at
room temperature for 2 h. After work up, the title compound 131 was attained as an amber oil
(388 mg, 51 %). 1H NMR (400 MHz, CDCl3): δ 1.68 (s, 9H, 3 x CH3), 2.86 (s, 1H, H-4),
3.82 (s, 3H, OCH3), 5.62 (br s, 1H, OH), 7.29-7.32 (m, 1H, ArH), 7.61-7.65 (m, 1H, ArH),
7.57-762 (m, 2H, ArH), 8.12-8.14 (m, 1H, ArH).
170
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C NMR (125 MHz, CDCl3): δ 28.1

Chapter 6

(3 x CH3), 53.8 (OCH3), 76.3 (C-4), 83.4 (C-3), 84.2 (Boc-C(CH3)3), 88.1 (C-2), 114.6
(ArC), 115.3 (ArCH), 118.9 (ArCH), 119.4 (ArCH), 122.7 (ArCH), 125.1 (ArCH), 125.6
(ArCH), 125.7 (ArC), 135.9 (ArC), 149.5 (C=O), 169.9 (C=O).
3-Ethynyl-3-hydroxyindolin-2-one 133

This compound was prepared following procedure B using commercially available isatin 132
(580 mg, 3.49 mmol, 1.0 equiv.) and ethynylmagnesium bromide (8.4 mL of a 0.5 M solution
in THF, 4.19 mmol, 1.2 equiv.) at room temperature for 8 h. After extraction, the residue was
purified by flas chromatography and the title compound 133 was attained as an orange solid
(728 mg, 58 %). m.p. 176 °C (lit. 185-190 °C).367 The spectral data matched those reported.367
CAS: 1403336-39-9. 1H NMR (300 MHz, DMSO-d6): δ 2.57 (br s, 1H, OH), 6.49 (s, 1H, H4), 6.81 (d, J = 7.7 Hz, ArH), 6.94 (td, J = 7.6 Hz, J = 0.8 Hz, 1H, ArH), 7.14 (td, J = 7.7 Hz,
J = 1.2 Hz, 1H, ArH), 7.39 (d, J = 7.3 Hz, 1H, ArH), 10.12 (br s, 1H, NH).
1,1,1-Trifluoro-2-phenylbut-3-yn-2-yl acetate 136

This compound was prepared following procedure B using commercially available 1’,1’,1’trifluoroacetophenone 135 (500 mg, 2.87 mmol, 1.0 equiv.) and ethynylmagnesium bromide
(6.9 mL of a 0.5 M solution in THF, 3.44 mmol, 1.2 equiv.) at room temperature for 2 h. After
extraction, the residue was resuspended in CH2Cl2 and treated with Et3N (0.7 mL, 5.23 mmol,
1.5 equiv.) and Ac2O (0.4 mL, 4.19 mmol, 1.2 equiv.) at room temperature overnight. After
work up, the title compound 136 was attained as an amber oil (728 mg, 89 %). The spectral
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data matched those reported.368 CAS: 141946-97-6. 1H NMR (400, MHz, CDCl3): δ 2.21
(Ac), 2.94 (s, 1H, H-4), 7.41-7.43 (m, 3H, ArH), 7.63-7.65 (m, 2H, ArH).

6.1.4. Experimental for chapter 3
6.1.4.1. Cytidine
5’-(tert-Butyldimethylsilyl)cytidine 163

t-Butyldimethylsilyl chloride (1.00 g, 6.63 mmol, 1.1 eq.), Et3N (0.9 mL, 6.63 mmol, 1.1 eq.)
and DMAP (75.0 mg, 603 µmol, 0.1 eq.) were added to a solution of commercially available
cytidine 137 (1.47 g, 6.03 mmol, 1.0 eq.) in anhydrous DMF (15 mL). The mixture was
stirred at room temperature until disappearance of the starting material as monitored by TLC
(about 24 h). At this time, the reaction mixture was poured into cold water. A white
precipitate was formed and filtered, washed with water and air dried to give the title
compound 163 as a white solid (985 mg, 67 %). m.p. 160-161 °C (lit. 162-164 °C). The
spectral data matched those reported.461 CAS: 72409-16-6. 1H NMR (300 MHz, CD3OD):
δ 0.08 (s, 6H, 2 x CH3), 0.88 (s, 9H, Boc), 3.79 (dd, J = 10.5 Hz, J = 4.5 Hz, 1H, H-5’a), 3.92
( dd, J = 10.5 Hz, J = 4.5 Hz, 1H, H-5’b), 4.14-4.27 (m, 3H, H-2’/H-3’/H-4’), 5.85 (d,
J = 7.5 Hz, 1H, H-5), 5.95 (d, J = 3.7 Hz, 1H, H-1’), 8.01 (d, J = 7.5 Hz, 1H, H-6). LRMSESI: m/z = 358 [M+H]+

172

Chapter 6

5’-(tert-Butyldimethylsilyl)-N4,O2’,O3’-triacetylcytidine 164

Ac2O (4.00 mL, 41.96 mmol, 10.0 eq.) was added dropwise to a solution of 163 (1.50 g,
4.19 mmol, 1.0 eq.) in anhydrous pyridine (12.0 mL) cooled to 0 °C. The mixture was stirred
at room temperature until disappearance of the starting material as monitored by TLC (18 h).
At this time, the reaction mixture was neutralised with saturated NaHCO3 and extracted with
CH2Cl2, then EtOAc. The organic layers were pooled, washed with saturated CuSO4, water
and then brine and dried over MgSO4 to be finally concentrated under reduced pressure to
give 164 as a beige solid (1.84 g, 91 %). m.p. 230-231 °C (lit. 229-231 °C). The spectral data
matched those reported.461 CAS: 1257796-15-8. 1H NMR (300 MHz, CD3OD): δ 0.13 (s,
6H, 2 x CH3), 0.93 (s, 9H, Boc), 2.06 (s, 3H, Ac), 2.09 (s, 3H, Ac), 2.27 (s, 3H, Ac), 3.82 (dd,
J = 10.5 Hz, J = 4.5 Hz, 1H, H-5’a), 3.98 (dd, J = 10.5 Hz, J = 4.5 Hz, 1H, H-5’b), 4.27 (m,
1H, H-4’), 5.35-5.38 (m, 2H, H-2’/H-3’), 6.35 (d, J = 4.5 Hz, 1H, H-1’), 7.38 (d, J = 7.5 Hz,
1H, H-5), 8.31 (d, J = 7.5 Hz, 1H, H-6). LRMS-ESI: m/z = 506 [M+Na]+
N4,O2’,O3’-Triacetylcytidine 165

A 1.0 M solution of tetrabutylammonium fluoride in THF (1.5 mL, 1.478 mmol, 1.1 eq.) was
added to a solution of 163 (650 mg, 1.344 mmol, 1.0 eq.) in anhydrous THF (5 mL). The
mixture was stirred at room temperature until disappearance of the starting material as
monitored by TLC (1 h). At this time, the reaction mixture was concentrated under reduced
pressure. The oily residue was taken up in EtOAc, washed with water then brine, dried over
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MgSO4 and filtered to be evaporated under reduced pressure and purified by flash
chromatography and eluted with CH2Cl2/CH3CN [6/4] to give the title compound 165 as a
beige solid (382 mg, 77 %). m.p. 172-173 °C (lit. 173-175 °C). The spectral data matched
those reported.461 CAS: 40632-06-2. 1H NMR (500 MHz, CDCl3): δ 2.07 (s, 3H, Ac), 2.11
(s, 3H, Ac), 2.27 (s, 3H, Ac), 3.84 (dd, J = 10.5 Hz, J = 2.9 Hz, 1H, H-5’a), 4.00 (dd,
J = 10.5 Hz, J = 4.5 Hz, 1H, H-5’b), 4.26 (m, 1H, H-4’), 5.50 (dd, J = 5.7 Hz, J = 5.5 Hz, 1H,
H-3’), 5.59 (dd, J = 5.7 Hz, J = 4.5 Hz, 1H, H-2’), 6.03 (d, J = 4.5 Hz, 1H, H-1’), 7.47 (d,
J = 7.5 Hz, 1H, H-5), 8.26 (d, J = 7.5 Hz, 1H, H-6). LRMS-ESI: m/z = 392 [M+Na]+
5’-Deoxy-5’-tosyl-2’,3’,4-triacetylcytidine 166

A solution of N4,O2’,O3’-triacetylcytidine 165 (105 mg, 284 mmol, 1.0 equiv.) and
dimethylaminopyridine (35 mg, 427 mmol) in dichloromethane (4 mL) was added 4toluenesulfonyl chloride (139 mg, 427 mmol) and stirred at room temperature for 16 h.
Triethylamine (200 mL) was added before the solution was concentrated. The residue was
purified over silica gel (toluene/acetone 3:1) to give the title compound 166 as a colourless
syrup (114 mg, 77%). The spectral data matched those reported.200
1

CAS: 34245-75-5.

H NMR (400 MHz, DMSO-d6): δ 2.03 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.24 (s, 3H, NHAc),

2.43 (s, 3H, Ts-CH3), 4.26 (dd, J = 10.9 Hz, J = 3.3 Hz, 1H, H-5’a), 4.32-4.35 (m, 1H, H-4’),
4.41 (m, 1H, H-5’b), 4.17-4.22 (m, 1H, H-4’), 4.24 (dd, J = 6.3 Hz, J = 5.1 Hz, 1H, H-3’),
4.36 (dd, J = 6.3 Hz, J = 3.9 Hz, 1H, H-2’), 6.07 (d, J = 3.9 Hz, 1H, H-1’), 7.32 (d,
J = 7.6 Hz, 1H, H-5), 7.35 (d, 2H, H-2”/H-6”), 7.68 (d, J = 7.6 Hz, 1H, H-6), 7.79 (d, 2H, H3”/H-5”), 9.98 (br s, 1H, NH). LRMS-ESI: m/z = 269 [M+H]+
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5’-Azido-5’-deoxy- N4,O2’,O3’-triacetylcytidine 167

This compound was prepared following procedure C, described p. 143, using 5’-Deoxy-5’tosyl-2’,3’,4-triacetylcytidine 166 (680 mg, 1.30 mmol, 1.0 equiv.), NaN3 (170 mg,
2.60 mmol, 2.0 equiv.) and benzyltriethylammonium chloride (60 mg, 260 µmol, 0.2 equiv.)
in dry DMF (15 mL). The suspension was stirred overnight and after work up, the title
compound 167 was attained as a pale yellow syrup (484 mg, 94 %). [α]20
D = 68.62
(c = 5 mg.mL-1, CH3OH). 1H NMR (500 MHz, CDCl3): δ 2.09 (s, 3H, Ac), 2.10 (s, 3H, Ac),
2.27 (s, 3H, Ac), 3.71 (dd, J = 13.4 Hz, J = 3.8 Hz, 1H, H-5’a), 3.80 (dd, J = 13.4 Hz,
J = 2.9 Hz, 1H, H-5’b), 4.27-4.30 (m, 1H, H-4’), 5.33-5.36 (dd, J = 5.7 Hz, J = 5.5 Hz, 1H, H3’), 5.40-5.42 (dd, J = 5.9 Hz, J = 4.8 Hz, 1H, H-2’), 6.11 (d, J = 4.8 Hz, 1H, H-1’), 7.51 (d,
J = 7.6 Hz, 1H, H-5), 7.95 (d, J = 7.6 Hz, 1H, H-6), 9.90 (br s, 1H, NH).

13

C NMR (125

MHz, CDCl3): δ 20.4 (CH3), 20.5 (CH3), 24.9 (CH3), 51.6 (C-5’), 70.5 (C-3’), 73.6 (C-2’),
80.6 (C-4’), 89.0 (C-5), 97.5 (C-1’), 144.6 (C-6), 154.8 (C-2), 163.1 (C-4), 169.5 (C=O),
169.7 (C=O), 170.8 (C=O). LRMS-ESI: m/z = 395 [M+H]+, HRESI-MS: m/z calcd for
C15H20N6O7 [M+H]+: 395.3520; found 395.3523; Δ = 0.76 ppm
N4-Acetyl-2’,3’-O-isopropylidenylcytidine 170

Commercially available N4-acetylcytidine 169 (6.70 g, 23.50 mmol) was dissolved in dry
Me2CO (300 mL). To this suspension was added HClO4 drop-wise until the reaction mixture
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just turned clear. Excess 2,2-dimethoxypropane (75 mL) was added, and the solution was
stirred for 4 h at room temperature. After concentration under reduced pressure to about one
third of the original reaction volume, the product solidified. Et2O was added to induce further
precipitation, and the resulting solid was collected by filtration, washed with ether and dried
to give the title compound 170 as a white solid (6.30 g, 83 %). m.p. 166 °C (lit. 167-169 °C).
The spectral data matched those reported.462 CAS: 16667-80-4. 1H NMR (300 MHz,
CD3OD): δ 1.29 (s, 3H, CH3), 1.49 (s, 3H, CH3), 2.10 (s, 3H, Ac), 3.54–3.59 (m, 1H, H-5’a),
3.62–3.67 (m, 1H, H-5’b), 4.20 (dt, J = 7.8 Hz, J = 3.8 Hz, 1H, H-4’), 4.76 (dd, J = 6.2 Hz,
J = 3.8 Hz, 1H, H-3’), 4.87 (dd, J = 6.2 Hz, J = 2.1 Hz, 1H, H-2’), 5.09 (t, J = 5.1 Hz, 1H,
OH-5’), 5.85 (d, J = 2.1 Hz, 1H, H-1’), 7.19 (d, J = 7.5 Hz, 1H, H-5), 8.22 (d, J = 7.5 Hz, 1H,
H-6), 10.89 (s, 1H, NH). LRMS-ESI: m/z = 348 [M+Na]+
N4-Acetyl-2’,3’-O-isopropylidenyl-5’-methanesulfonylcytidine 171

MsCl (0.14 mL, 1.84 mmol, 1.2 equiv.) was added dropwise to a solution of 170 (500 mg,
1.54 mmol, 1 equiv.), Et3N (0.32 mL, 2.30 mmol, 1.5 equiv.) in CH2Cl2 (10 mL) at 0 °C. The
mixture was stirred at 0 °C for 1 h. The mixture was diluted with CH2Cl2 (25 mL), washed
with saturated aqueous NaHCO3 and brine, dried over MgSO4 and filtered. The solvent was
evaporated under reduced pressure to give the crude mesylate 171 as a white solid (508 mg,
82 %). m.p. 168-171 °C. The compound is known but the spectral data has not been reported
to our knowledge. CAS: 16667-81-5. 1H NMR (500 MHz, CDCl3): δ 1.29 (s, 3H, CH3), 1.50
(s, 3H, CH3), 2.21 (s, 3H, Ac), 2.68 (m, 2H, H-5’), 3.01 (s, 3H, Ms), 4.40-4.45 (m, 1H, H-4’),
4.88 (m, 1H, H-3’), 5.06 (m, 1H, H-2’), 5.62 (s, 1H, H-1’), 7.40 (d, J = 7.3 Hz, 1H, H-5), 7.69
176

Chapter 6

(d, J = 7.3 Hz, 1H, H-6), 10.16 (s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 25.1 (Ac-CH3),
25.2 (CH3), 27.0 (CH3), 37.6 (Ms-CH3), 69.2 (C-5’), 81.7 (C-3’), 84.7 (C-2’), 86.9 (C-4’),
96.7 (C-5), 98.3 (C-1’), 114.4 (C), 147.5 (C-6), 154.7 (C-2), 163.1 (C-4), 170.1 (C-8).
LRMS-ESI: m/z = 426 [M+Na]+, HRESI-MS: m/z calcd for C15H21N3O8SNa [M+Na]+:
426.0947; found 426.0961; Δ = 3.28 ppm
N4-Acetyl-5’-azido-5’-deoxy-2’,3’-O-isopropylidenylcytidine 172

This compound was prepared following procedure C, described p. 143, using N4-acetyl-2’,3’O-isopropylidenyl-5’-mesylcytidine 171 (500 mg, 1.240 mmol, 1.0 equiv.) and NaN3
(161 mg, 2.479 mmol, 2.0 equiv.) in DMF (5 mL). The suspension was stirred overnight and
after work up, the title compound 172 was attained as a white solid (308 mg, 71 %).
m.p. 188.5-191.5 °C. The spectral data matched those reported.197 CAS: 1452840-34-4.
1

H NMR (300 MHz, CDCl3): δ 1.30 (s, 3H, CH3), 1.57 (s, 3H, CH3), 2.25 (s, 3H, Ac), 3.59

(dd, 1H, J = 13.0 Hz, J = 6.7 Hz, H-5’a), 3.70 (dd, 1H, J = 13.0 Hz, J = 4.4 Hz, H-5’b), 4.31 (dt,
J = 6.7 Hz, J = 4.1 Hz, 1H, H-4’), 4.85 (dd, J = 6.4 Hz, J = 4.1 Hz 1H, H-3’), 5.07
(dd, J = 6.4 Hz, J = 1.5 Hz, 1H, H-2’), 5.66 (d, J = 1.0 Hz, 1H, H-1’), 7.46 (d, J = 7.3 Hz, 1H,
H-5), 7.72 (d, J = 7.3 Hz, 1H, H-6), 9.82 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 25.0
(Ac-CH3), 25.2 (CH3), 27.1 (CH3), 52.5 (C-5’), 82.0 (C-3’), 84.9 (C-2’), 87.2 (C-4’), 96.8 (C5), 97.2 (C-1’), 114.4 (Cq), 147.1 (C-6), 154.7 (C-2), 163.3 (C-4), 170.4 (C=O). LRMS-ESI :
m/z = 351 [M+H]+, 373 [M+Na]+
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5’-Azido-N4-tert-butoxycarbonyl-5’-deoxy-2’,3’-O-isopropylidenylcytidine 174

A solution of 172 (600 mg, 1.94 mmol) and Boc2O (850 mg, 3.89 mmol) in dry THF was
heated at 60 °C overnight. To the mixture was added CH3OH (5 mL), then stirred for 20 min
and evaporated to dryness. The residue was purified by flash chromatography eluting with
CH2Cl2/EtOAc [2:1] to give the title compound 174 as a white solid (750 mg, 94 %).
m.p. 109-111 °C. The spectral data matched those reported.197 CAS: 1452840-35-5. 1H NMR
(300 MHz, CDCl3): δ 1.35 (s, 3H, CH3), 1.52 (s, 9H, Boc), 1.57 (s, 3H, CH3), 3.60 (dd,
J = 12.7 Hz, J = 4.4 Hz, 1H, H-5’a), 3.74 (dd, J = 12.7 Hz, J = 7.3 Hz, 1H, H-5’b), 4.28-4.34
(m, 1H, H-4’), 4.90 (dd, J = 6.1 Hz, J = 4.1 Hz, 1H, H-3’), 5.13-5.14 (m, 1H, H-2’), 5.62 (s,
1H, H-1’), 7.23 (d, J = 7.6 Hz, 1H, H-5), 7.41 (br s, 1H, NH), 7.63 (d, J = 7.6 Hz, 1H, H-6).
13

C NMR (75 MHz, CDCl3): δ 25.2 (CH3), 27.1 (CH3), 28.0 (Boc-C(CH3)3), 52.6 (C-5’),

82.2 (C-3’), 83.1 (Boc-C(CH3)3), 84.8 (C-2’), 87.5 (C4’), 95.1 (C-5), 97.6 (C-1’), 114.2 (C),
146.7 (C-6), 151.0 (Boc-C=O), 154.6 (C-2), 163.3 (C-4). LRMS-ESI: m/z = 431 [M+Na]+

178

Chapter 6

6.1.4.2. Uridine
2’,3’-O-Isopropylidenyluridine 176

To a suspension of commercially available uridine 175 (3.00 g, 12.28 mmol) in dry Me2CO
(120 mL) was added concentrated sulfuric acid (12 drops) dropwise and the resulting mixture
was stirred for 6 h. The solution was neutralised with Et3N (1 mL) and the solvent evaporated
under vacuum. The residue was resuspended in a minimum amount of Me2CO and added to
Et2O (100 mL). The supernatant was discarded and the residue was dried under vaccum to
give the title product 176 as a white solid (3.00 g, 86 %), which was used in the following
step without further purification. m.p. 162-164 °C (lit. 165-168 °C). The spectral data
matched those reported.463 CAS: 362-43-6. 1H NMR (300 MHz, DMSO-d6): δ 1.28 (s, 3H,
CH3), 1.48 (s, 3H, CH3), 3.54-3.59 (m, 2H, H-5’), 4.06 (dt, J = 8.2 Hz, J = 4.3 Hz, 1H, H-4’),
4.73 (dd, J = 6.3 Hz, J = 3.6 Hz, 1H, H-3’), 4.89 (dd, J = 6.3 Hz, J = 2.5 Hz, 1H, H-2’), 5.09
(t, J = 5.2 Hz, 1H, OH), 5.63 (d, J = 8.2 Hz, 1H, H-5), 5.82 (d, J = 2.5 Hz, 1H, H-1’), 7.79 (d,
J = 8.2 Hz, 1H, H-6), 11.38 (br s, 1H, NH). LRMS-ESI: m/z = 285 [M+H]+
2’,3’-O-Isopropylidenyl-5’-mesyluridine 177

A solution of 2’,3’-O-isopropylidenyluridine 176 (2.00 g, 7.03 mmol) and pyridine (1.7 mL,
21.11 mmol) in 50 mL dry DCM was cooled with an external ice bath and added dropwise a
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solution of MsCl (0.8 mL, 10.55 mmol) in 5 mL CH2Cl2. The mixture was stirred at 0 °C for 2 h
and purified by silica gel chromatography and eluted with CH2Cl2/MeOH [95:5] to give the title
compound 177 as a beige solid (2.32 g, 91 %). Beige solid. m.p. 107 °C (lit. 108-110 °C).464
The spectral data matched those reported.464 CAS: 15083-09-7. 1H NMR (300 MHz, CD3OD):
δ 1.36 (s, 3H, CH3), 1.57 (s, 3H, CH3), 3.09 (s, 3H, Ms), 4.39 (dt, J = 9.3 Hz, J = 4.9 Hz, 1H, H4’), 4.45-4.47 (m, 2H, H-5’), 4.88 (dd, J = 6.4 Hz, J = 3.9 Hz, 1H, H-2’), 5.05 (dd, J = 6.4 Hz,
J = 1.9 Hz, 1H, H-3’), 5.62 (m, 1H, H-1’), 5.75 (d, J = 7.5 Hz, 1H, H-5), 7.26 (d, J = 7.5 Hz,
1H, H-6), 8.85 (br s, 1H, NH). LRMS-ESI: m/z = 385 [M+Na]+
5’-Azido-5’-deoxy-2’,3’-O-isopropylidenyluridine 178

This compound was prepared following procedure C using 2’,3’-O-isopropylidenyl-5’mesyluridine 177 (2.00 g, 5.52 mmol, 1.0 equiv.), NaN3 (717 mg, 11.04 mmol, 2.0 equiv.)
and benzyltriethylammonium chloride (250 mg, 1.10 mmol, 0.2 equiv.) in dry DMF (15 mL).
The suspension was stirred at 80 °C overnight and after work up, the title compound 178 was
attained as a white solid (1.47 g, 86 %). m.p. 127-129 °C (lit. 129-132 °C).465 The spectral
data matched those reported.466 CAS: 15083-05-3. 1H NMR (300 MHz, CDCl3): δ 1.28 (s,
3H, CH3), 1.48 (s, 3H, CH3), 3.57-3.59 (m, 2H, H-5’), 4.13 (dt, J = 5.6 Hz, J = 4.4 Hz, 1H, H4’), 4.75 (dd, J = 6.2 Hz, J = 4.4 Hz, 1H, H-3’), 5.07 (dd, J = 6.2 Hz, J = 2.0 Hz, 1H, H-2’),
5.65 (d, J = 7.9 Hz, 1H, H-5), 5.80 (d, J = 1.8 Hz, 1H, H-1’), 7.73 (d, J = 7.9 Hz, 1H, H-6),
11.46 (br s, 1H, NH). LRMS-ESI: m/z = 310 [M+H]+
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5’-Azido-5’-deoxyuridine 179

5’-Azido-2’,3’-O-isopropylidenyluridine 178 (2.50 g, 8.08 mmol, 1.0 equiv.) was dissolved in
a mixture of CH3CN/H2O [9:1] (15 mL) and to this was added In(OTf)3 (227 mg, 404 µmol,
5 mol%)and the solution was refluxed for 6 h. The solvents were then evaporated under
reduced pressure and the residue was purified by silica gel chromatography eluted with
CH2Cl2/CH3OH [9:1] to afford the title product 179 as a white foam (2.07 g, 95 %). The
spectral data matched those reported.284 CAS: 39483-48-2. 1H NMR (300 MHz, CDCl3):
δ 3.68 (dd, J = 13.7 Hz, J = 4.9 Hz, 1H, H-5’a), 3.81 (dd, J = 13.7 Hz, J = 3.1 Hz, 1H, H-5’b),
4.21 (dt, J = 8.6 Hz, J = 5.0 Hz, 1H, H-4’), 4.27 (m, 1H, H-3’), 4.43 (m, 1H, H-2’), 5.93-5.89
(m, 2H, H-5, H-1’), 7.81 (d, J = 8.1 Hz, 1H, H-6). LRMS-ESI: m/z = 292 [M+Na]+
5’-Azido-5’-deoxy-2’,3’-O-diacetyluridine 180

A solution of 5’-azidouridine 179 (1.50 g, 5.57 mmol, 1 equiv.) in pyridine (6 mL) was
treated with Ac2O (1.3 mL, 13.93 mmol, 2.5 equiv.) and the mixture was stirred at room
tempature overnight. The reaction mixture was then poured on crushed ice and extrated with
EtOAc. The organic layers were pooled together and washed with water, NaHCO3 and brine
before being dried over MgSO4, filtered and evaporated. The residue was purified by silica
gel chromatography eluted with CH2Cl2/MeOH [9:1] to afford the title compound 180 as a
white foam (1.91 g, 97 %). The spectral data matched those reported.467 CAS: 96535-66-9.
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H NMR (300 MHz, CDCl3): δ 2.10 (s, 3H, Ac), 2.13 (s, 3H, Ac), 3.70 (dd, J = 13.5 Hz,

J = 3.7 Hz, 1H, H-5’a), 3.78 (dd, J = 13.5 Hz, J = 2.9 Hz, 1H, H-5’b), 4.22-4.23 (m, 1H, H-2’),
5.31-5.35 (m, 2H, H-3’/H-4’), 5.84 (d, J = 8.1 Hz, 1H, H-5), 6.08-6.09 (m, 1H, H-1’), 7.49
(d, J = 8.1 Hz, 1H, H-6), 9.39 (br s, 1H, NH). LRMS-ESI: m/z = 376 [M+Na]+

6.1.3.6. 5-Fluorouridine
5-Fluoro-2’,3’-O-isopropylidenyluridine 182

To a suspension of commercially available 5-fluorouridine 181 (1.50 g, 5.72 mmol,
1.0 equiv.) and 2,2-dimethoxypropane (1.4 mL, 11.44 mmol, 2.0 equiv.) in Me2CO (60 mL)
was added 4 drops of concentrated sulphuric acid. After stirring for 1 h at room temperature,
the starting material was no longer detectable by TLC (CH2Cl2/CH3OH [9:1]) and 1.0 mL was
added to the mixture concentrated ammonia and stirred for an additional hour. The solvent
was evaporated under reduced pressure and the residue was washed with Et2O to give the title
compound 182 as a white powder (1.38 g, 80 %). m.p. 197-198 °C (lit. 196-197 °C). The
spectral data matched those reported.468 CAS: 2797-17-3. 1H NMR (300 MHz, CDCl3):
δ 1.37 (s, 3H, CH3), 1.60 (s, 3H, CH3), 3.86 (dt, J = 12.0 Hz, J = 2.6 Hz, 1H, H-4’), 3.97 (dd,
J = 12.0 Hz, J = 2.3 Hz, 1H, H-3’), 4.34-4.36 (m, 1H, H-2’), 4.91-4.93 (m, 2H, H-5’), 5.72 (m,
1H, H-1’), 7.69 (d, J = 6.2 Hz, 1H, H-6).LRMS-ESI: m/z = 325 [M+Na]+
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5-Fluoro-2’,3’-O-isopropylidenyl-5’-methanesulfonyluridine 183

Methanesulfonyl chloride (0.37 mL, 4.73 mmol, 1.1 equiv.) was added dropwise to a solution
of 182 (1.30 g, 4.30 mmol, 1.0 equiv.), Et3N (0.90 mL, 6.45 mmol, 1.5 equiv.) in CH2Cl2
(30 mL) at 0 °C. The mixture was stirred at 0 °C during 1 h. The mixture was diluted with
CH2Cl2 (25 mL), washed with saturated aqueous NaHCO3 and brine, dried over MgSO4 and
filtered. The solvent was evaporated in vacuo to give the crude mesylate 183 as a pale amber
syrup (1.41 g, 86 %). The spectral data matched those reported.401 CAS: 82207-42-9.
1

H NMR (300 MHz, CDCl3): δ 1.35 (s, 3H, CH3), 1.56 (s, 3H, CH3), 3.06 (s, 3H, Ms-CH3),

4.38-441 (m, 1H, H-4’), 4.46 (m, 1H, H-5’), 4.86 (dd, J = 6.3 Hz, J = 3.9 Hz, 1H, H-3’), 5.02
(m, 1H, H-2’), 5.66 (m, 1H, H-1’), 7.44 (d, J = 5.9 Hz, 1H, H-6), 9.80 (br s, 1H, NH). LRMSESI: m/z = 403 [M+Na]+
5’-Azido-5’-deoxy-5-fluoro-2’,3’-O-isopropylidenyluridine 184

This compound was prepared following procedure C using 5-Fluoro-2’,3’-O-isopropylidenyl5’-methanesulfonyluridine 183 (1.00 g, 2.63 mmol, 1.0 equiv.), NaN3 (341 mg, 5.26 mmol,
2.0 equiv) and benzyltriethylammonium chloride (120 mg, 526 µmol, 0.2 equiv.) in dry
10 mL DMF. The suspension was stirred at 80 °C overnight and after work up, the title
compound 184 was attained as a white solid (793 mg, 94 %). m.p. 158-160 °C (lit. 160163 °C).469 The spectral data matched those reported.401 CAS: 82207-45-2.
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1

H NMR (300 MHz, DMSO-d6): δ 1.28 (s, 3H, CH3), 1.48 (s, 3H, CH3), 3.59-3.61 (m, 2H,

H-5’), 4.13 (dt, J = 10.4 Hz, J = 5.4 Hz, 1H, H-4’), 4.75 (dd, J = 6.5 Hz, J = 4.2 Hz, 1H, H3’), 5.06 (dd, J = 6.5 Hz, J = 2.3 Hz, 1H, H-2’), 5.77 (d, J = 2.3 Hz, 1H, H-1’), 8.12 (d,
J = 6.9 Hz, 1H, H-6), 11.98 (br s, 1H, NH). LRMS-ESI: m/z = 326 [M+H]+
5’-Azido-5’-deoxy-5-fluorouridine 185

5’-Azido-5’-deoxy-5-fluoro-2’,3’-O-isopropylidenyluridine 184 (600 mg, 1.83 mmol,
1.0 equiv.) was dissolved in CH3CN/H2O [8:2] (20 mL) and to this was added In(OTf)3
(51 mg, 92 µmol, 5 mol%). The solution was refluxed for 6 h and, after cooling,
evaporated to dryness. The residue was purified by flash chromatography column eluted
with CH2Cl2/CH3OH [9:1] to give the title compound 185 as a thick colourless syrup
(505 mg, 96 %). The spectral data matched those reported.401 CAS: 82207-46-3.
1

H NMR (500 MHz, DMSO-d6): δ 3.58 (dd, J = 13.7 Hz, J = 2.9 Hz, 1H, H-5’a), 3.65

(dd, J = 13.2 Hz, J = 6.4 Hz, 1H, H-5’b), 3.90-3.93 (m, 2H, H-3’ & H-4’), 4.14 (dd,
J = 10,9 Hz, J = 4.9 Hz, H-2’), 5.30 (d, J = 4.9 Hz, 1H, OH-2’), 5.49 (d, J = 5.4 Hz,
1H, OH-3’), 5.75-5.76 (m, 1H, H-1’), 8.02 (d, J = 7.3 Hz, 1H, H-6), 11.92 (br s, 1H,
NH). LRMS-ESI: m/z = 310 [M+Na]+
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5’-Azido-5’-deoxy-2’,3’-diacetyl-5-fluorouridine 186

5’-Azido-5’-deoxy-5-fluorouridine 185 (450 mg, 1.57 mmol, 1.0 equiv) was dissolved in
pyridine (8 mL) and the solution was cooled with an external ice bath. Ac2O (0.37 mL,
3.92 mmol, 2.5 equiv) was added dropwise and the mixture stirred while returning to room
temperature. After 4 h, the starting material was no longer detectable by TLC and the
mixture was taken up in EtOAc, washed with water, saturated NaHCO3 and brine before
being dried over MgSO4, filtered and evaporated under reduced pressure. The resulting
syrup 186 (535 mg, 92 %) displayed satisfying purity for using immediately in the
following step and the spectral data matched those reported.470 CAS: 1266253-85-3.
1

H NMR (500 MHz, CDCl3): δ 2.11 (s, 3H, Ac), 2.15 (s, 3H, Ac), 3.74 (dd, J = 13.4 Hz,

J = 3.0 Hz, 1H, H-5’a), 3.84 (dd, J = 13.4 Hz, J = 2.7 Hz, 1H, H-5’b), 4.24-4.26 (m, 1H, H4’), 5.28-5.33 (m, 2H, H-2’ & H-3’), 6.11 (d, J = 5.7 Hz, 1H, H-1’), 7.66 (d, J = 6.0 Hz,
1H, H-6), 9.03 (br s, 1H, NH). LRMS-ESI: m/z = 394 [M+Na]+

6.1.4.3. Thymidine
3’-O-Acetyl-5’-tosylthymidine 188

Thymidine 152 (0.484 g, 2.00 mmol, 1.0 equiv.) was dissolved in pyridine (5.0 mL) and the
solution was cooled to 0 °C. Tosyl chloride (0.42 g, 2.2 mmol, 1.1 equiv.) was added to the
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cold solution with stirring. Stirring was continued for 3 h and Ac2O (1.0 mL, 10.59 mmol,
10.6 equiv.) was added to the reaction mixture. The solution was stirred for an additional 16 h
and the solution was diluted with CH2Cl2 (30 mL). The solution of the O-tosyl derivative, was
washed with 1 M HCl and then with brine (30 mL). The product was purified by silica gel
column chromatography eluting with CH2Cl2/CH3OH [1:9]. Colourless syrup. The title
compound 188 is known but the spectral data has not been reported to our knowledge.
CAS: 75145-86-7. 1H NMR (300 MHz, CDCl3): δ 1.98 (s, 3H, CH3-5), 2.20-2.29 (m, 1H, H2’a), 2.41-2.48 (m, 1H, H-2’b), 2.51 (s, 3H, CH3), 3.75-3.82 (m, 2H, H-5’), 4.17-4.21 (m, 1H,
H-3’), 5.20-5.22 (m, Hz, 1H, H-4’), 6.35 (dd, J = 8.7 Hz, J = 5.2 Hz, 1H, H-1’), 7.40 (s, 1H,
H-6), 8.15 (br s, 1H, NH). LRMS-ESI: m/z = 461 [M+Na]+
3’-O-Acetyl-5’-azido-5’-deoxythymidine 189

This compound was prepared following procedure C using 3’-O-Acetyl-5’-tosylthymidine 188
(400 mg, 912 µmol, 1.0 equiv.), NaN3 (297 mg, 1.82 mmol, 2.0 equiv.) and
benzyltriethylammonium chloride (43 mg, 182 µmol, 0.2 equiv.) in dry 6 mL DMF. The
suspension was stirred at 80 °C overnight and after work up, the title compound 189 was
attained as a colourless syrup (262 mg, 93 %). The spectral data matched those reported.409
CAS: 27766-92-3. 1H NMR (300 MHz, CDCl3): δ 1.96 (s, 3H, CH3-5), 2.11 (s, 3H, Ac),
2.21-2.27 (m, 1H, H-2’a), 2.39-2.44 (m, 1H, H-2’b), 3.71-3.79 (m, 2H, H-5’), 4.11 (dt,
J = 5.4 Hz, J = 2.4 Hz, 1H, H-3’), 5.19 (dt, J = 7.3 Hz, J = 2.4 Hz, 1H, H-4’), 6.34 (dd,
J = 8.8 Hz, J = 5.4 Hz, 1H, H-1’), 7.38 (s, 1H, H-6), 8.02 (br s, 1H, NH). LRMS-ESI:
m/z = 332 [M+Na]+
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6.1.4.3. 2’-Deoxyuridine
3’-O-Acetyl-5’-deoxy-5’-tosyluridine 190

A solution of comercially available 2’-deoxyuridine 187 (600 mg, 2.63 mmol, 1.0 equiv.) in
dry pyridine (5 mL) was cooled with an external ice bath and treated with tosyl chloride
(551 mg, 2.89 mmol, 1.1 equiv.) and stirred at room temperature for 1 h. Ac2O (1.25 mL) was
added to the reaction mixture and stirred for another 3h. The solution was then taken up in
CH2Cl2 and washed with 0.5 M hydrochloric acid, water and brine. The organic layer was
dried on MgSO4, filtered and evaporated under reduced pressure and the residue was purified
using silica gel chromatography eluted with (CH2Cl2/EtOAc [2:1]) to give the title compound
-1
1
190 as a pale yellow syrup (692 mg, 62%). [α]20
D = 27.82 (c = 5 mg.mL , CH3OH). H NMR

(300 MHz, CDCl3): δ 2.10 (s, 3H, Ac), 2.13-2.19 (m, 1H, H-2’a), 2.43-2.47 (m, 1H, H-2’b),
2.48 (s, 3H, Ts-CH3), 4.18-4.19 (m, 1H, H-3’), 4.33 (m, 2H, H5’), 5.19-5.21 (m, 1H, H-4’),
5.76 (d, J = 8.3 Hz, 1H, H-5), 6.33 (dd, J = 8.8 Hz, J = 5.4 Hz, 1H, H-1’), 7.40 (d, J = 8.3 Hz,
2H, H-3”/H-5”), 7.53 (d, J = 7.8 Hz, 1H, H-6), 7.80 (d, J = 8.3 Hz, 2H, H-2”/H-6”), 8.14 (br
s, 1H, NH). 13C NMR (75 MHz, CDCl3): δ 20.7 (Ac-CH3), 21.5 (Ts-CH3), 37.0 (C-2’), 68.9
(C-5’), 74.2 (C-3’), 81.9 (C-4’), 84.7 (C-1’), 103.0 (C-5), 127.7 (C-3”/C-5”), 130.0 (C-2”/C6”), 131.9 (C-4”), 139.1 (C-6), 145.5 (C-1”), 150.4 (C-2), 163.3 (C-4), 170.4 (C=O). LRMSESI: m/z = 447 [M+Na]+, HRESI-MS: m/z calcd for C18H20N2O8SNa [M+Na]+: 447.0838;
found 447.0839; Δ = 0.22 ppm
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3’-O-Acetyl-5’-azido-2’,5’-dideoxyuridine 191

This compound was prepared following procedure C using 3’-O-Acetyl-5’-deoxy-5’tosyluridine 190 (400 mg, 942 µmol, 1.0 equiv.), NaN3 (122 mg, 1.88 mmol, 2.0 equiv.) and
benzyltriethylammonium chloride (43 mg, 188 µmol, 0.2 equiv.) in dry 6 mL DMF. The
suspension was stirred at 80 °C overnight and after work up, the title compound 191 was
attained as a colourless syrup (259 mg, 93 %). The spectral data matched those reported.411
CAS: 85144-91-8. 1H NMR (300 MHz, CDCl3): δ 2.02-2.26 (m, 1H, H-2’a), 2.09 (s, 3H, Ac),
2.39-2.47 (m, 1H, H-2’b), 3.73-3.75 (m, 2H, H-5’), 4.09-4.11 (m, 1H, H-4’), 5.16-5.18 (m,
1H, H-3’), 5.81 (d, J = 8.2 Hz, 1H, H-5), 6.31 (dd, J = 8.3 Hz, J = 5.7 Hz, 1H, H-1’), 7.58 (d,
J = 8.2 Hz, 1H, H-6), 10.01 (br s, 1H, NH). 13C NMR (75 MHz, CDCl3): δ 20.8 (CH3), 37.2
(C-2’), 52.4 (C-5’), 74.6 (C-3’), 82.6 (C-4’), 84.6 (C-1’), 103.3 (C-5), 139.2 (C-6), 150.5 (C2), 163.3 (C-4), 170.6 (C=O). LRMS-ESI: m/z = 318 [M+Na]+

6.1.4.5. 2’-Deoxy-2’-fluorouridine
3’-O-Acetyl-2’-deoxy-2’-fluoro-5’-tosyluridine 193

Commercially available 2’-deoxy-2’-fluorouridine 192 (600 mg, 2.44 mmol, 1.0 equiv.) was
dissolved in pyridine (6 mL) and the solution was cooled to 0 °C. Tosyl chloride (511 mg,
2.69 mmol, 1.1 equiv.) was added to the cold solution with stirring. Stirring was continued for
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3 h and Ac2O (1.15 mL, 12.19 mmol, 5.0 equiv.) was added to the reaction mixture. The
solution was stirred for additional 16 h and the solution was diluted with CH2Cl2. The solution
of the O-tosyl derivative, was washed with 1 M HCl and brine before being dried over
MgSO4, filtered and evaporated under reduced pressure. The residue was purified by silica gel
column chromatography eluted with CH2Cl2/EtOAc [2:1] to give the title compound 193 as a
foam (507 mg, 47 %). The spectral data matched those reported.471 CAS: 1668560-67-5.
1

H NMR (500 MHz, CDCl3): δ 2.01 (s, 3H, Ac), 2.46 (s, 3H, Ts-CH3), 4.04 (dt, J = 12.5 Hz,

J = 4.8 Hz, 1H, H-4’), 4.28-4.34 (m, 2H, H-5’), 5.15-5.23 (m, 1H, H-3’), 5.30 (dd, J = 5.5 Hz,
J = 4.9 Hz, 1H, H-2’), 5.57 (d, J = 21.8 Hz, H-5), 5.76 (d, J = 8.0 Hz, 1H, H-1’), 7.33 (d,
J = 8.1 Hz, 1H, H-6), 7.38 (d, J = 8.2 Hz, 2H, ArH), 7.85 (d, J = 7.9 Hz, 2H, ArH), 9.92 (s,
1H, NH). LRESI-MS: m/z = 465 [M+Na]+
3’-O-Acetyl-5’-azido-2’,5’-dideoxy-2’-fluoro-5’-tosyluridine 194

This compound was prepared following procedure C using 3’-O-Acetyl-2’-deoxy-2’-fluoro-5’tosyluridine 193 (450 mg, 1.02 mmol, 1.0 equiv.), NaN3 (132 mg, 2.03 mmol, 2.0 equiv.) and
benzyltriethylammonium chloride (46 mg, 203 µmol, 0.2 equiv.) in dry DMF (40 mL). The
suspension was stirred at 80 °C overnight and after work up, the title compound 194 was
-1
attained as a white solid (283 mg, 89 %). m.p. 172-174 °C. [α]20
D = 32.57 (c = 5 mg.mL ,

CH3OH). 1H NMR (300 MHz, CDCl3): δ 2.17 (s, 3H, Ac), 3.60 (dd, J = 13.5 Hz, J = 4.4 Hz,
1H, H-5’a), 3.80 (dd, J = 13.5 Hz, J = 2.4 Hz, 1H, H-5’b), 4.29-4.32 (m, 1H, H-4’), 5.19-5.25
(m, 1H, H-3’), 5.32-5.44 (m, 1H, H-2’), 5.82 (d, J = 7.9 Hz, 1H, H-5), 5.86 (dd, J = 19.8 Hz,
J = 2.0 Hz, 1H, H-1’), 7.42 (d, J = 7.9 Hz, 1H, H-6), 9.25 (br s, 1H, NH).

13

C NMR

(75 MHz, CDCl3): δ 20.4 (CH3), 51.0 (C-5’), 70.2 (d, J = 15.3 Hz, C-3’), 79.4 (C-4’), 90.4
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(d, J = 126.6 Hz, C-2’), 90.6 (C-4’), 91.5 (C-1’), 103.3 (C-5), 140.8 (C-6), 149.8 (C-2), 162.8
(C-4), 169.8 (C=O). LRMS-ESI: m/z = 336 [M+Na]+. HRESI-MS: m/z calcd for
C11H12FN5O5Na [M+Na]+: 336.0720; found 336.0734; Δ = 4.16 ppm

6.1.3.5. 2’-O-Methyluridine
3’-Acetyl-5’-tert-butyldimethylsilyl-2’-methyluridine 198

A solution of 2’-methyluridine 195 (600 mg, 2.32 mmol, 1.0 equiv.) and imidazole (395 mg,
5.81 mmol, 2.5 equiv.) in dry DMF (5 mL) was treated with t-butyldimethylsilyl chloride
(385 mg, 2.55 mmol, 1.1 equiv.) and stirred at room temperature for 20 h. The reaction
mixture was poured on crushed ice and the white precipitate 197 was collected by filtration,
air dried and used in the following step without further purification. The solid was suspended
in CH2Cl2 (12 mL) and added successively trimethylamine (0.5 mL, 3.48 mmol, 1.5 equiv.)
and Ac2O (0.26 mL, 2.79 mmol, 1.2 equiv.) and the resulting solution was stirred at room
temperature. After 3 h, the starting material was no longer detectable by TLC and the solution
was diluted with CH2Cl2 and washed with water, NaHCO3 and brine and finally dried over
MgSO4, filtered and evaporated under reduced pressure. The residue was purified by silica gel
chromatography eluted with CH2Cl2 to CH2Cl2/EtOAc [4:1] to give the title compound 198 as
-1
1
a colourless syrup (810 mg, 74 %). [α]20
D = 25.3 (c = 5.0 mg.mL , CH3OH). H NMR

(300 MHz, CDCl3): δ 0.10 (s, 6H, 2 x SiCH3), 0.92 (s, 9H, 3 x CH3), 2.14 (s, 3H, Ac), 3.43
(s, 3H, OCH3), 3.77-3.79 (m, 1H, H-2’), 3.97-4.00 (m, 2H, H-5’), 4.20-4.22 (m, 1H, H-4’),
5.12-5.14 (m, 1H, H-3’), 5.70 (d, J = 7.9 Hz, 1H, H-5), 6.06 (d, J = 2.7 Hz, 1H, C-1’), 7.92 (d,
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J = 7.9 Hz, 1H, H-6), 9.60 (br s, H, NH).

13

C NMR (75 MHz, CDCl3): δ -5.7 (SiCH3), -5.6

(SiCH3), 18.3 (SiCq), 20.7 (Ac-CH3), 25.8 (3 x CH3), 58.9 (OCH3), 62.0 (C-5’) 69.9 (C-4’)
82.5 (C-2’) 86.8 (C-1’) 102.5 (C-5) 139.6 (C-6) 150.3 (C-2) 163.2 (C-4) 170.2 (C=O).
LRMS-ESI: m/z = 437 [M+Na]+, HRESI-MS: m/z calcd for C18H30N2O7SiNa [M+Na]+:
437.5198; found 437.5199, Δ = 0.23 ppm
3’-Acetyl-2’-methyluridine 199

To a solution of 3’-acetyl-5’-tert-butyldimethylsilyl-2’-methyluridine 198 (650 mg,
1.57 mmol, 1.0 equiv.) and AcOH (0.13 mL, 2.35 mmol, 1.5 equiv.) in dry THF (15 mL) was
added a 1.0 M solution of TBAF in THF (2.00 mL, 2.04 mmol, 1.3 equiv.) dropwise at 0 °C.
Stirring was continued for 6 h and the reaction mixture was evaporated to dryness. The
reisdue was purified by silica gel chromatography column eluted with CH2Cl2/EtOAc [1:1] to
give the title compound 199 as a white solid (358 mg, 76 %). The spectral data matched those
reported.472 CAS: 287101-01-3. 1H NMR (300 MHz, CDCl3): δ 2.16 (s, 3H, CH3), 3.44 (s,
3H, CH3), 3.79 (m, 1H, H-2’), 3.96 (m, 1H, H-3’), 4.20-4.23 (m, 2H, H-5’), 5.30 (m, 1H, H4’), 5.77 (d, J = 6.8 Hz, 1H, H-5), 5.83 (d, J = 4.4 Hz, 1H, H-1’), 7.78 (d, J = 7.8 Hz, 1H, H6), 9.64 (br s, 1H, NH). LRMS-ESI: m/z = 323 [M+Na]+
3’-Acetyl-2’-methyl-5’-methylsulfonyluridine 200

A solution of 3’-acetyl-2’-methyluridine 199 (300 mg, 1.00 mmol, 1.0 equiv.) in dry CH2Cl2
(10 mL) was treated with Et3N (0.1 mL, 1.50 mmol, 1.5 equiv.) and MsCl (0.09 mL,
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1.20 mmol, 1.2 equiv.) at 0 °C. Stirring was continued for 16 h and the reaction mixture was
washed with water, NaHCO3 sat and brine before being dried over MgSO4 and evaporated
under reduced pressure. The residue was purified by silica gel chromatography and eluted
with CH2Cl2/CH3OH, [9:1] to give the title compound 200 as a colourless syrup (272 mg,
72 %). m.p. 156-157°C. The spectral data matched those reported.473 CAS: 1352173-41-1.
1

H NMR (300 MHz, CDCl3): δ 2.14 (s, 3H, Ac), 3.10 (s, 3H, Ms-CH3), 3.42 (s, 3H, OCH3),

4.06-4.08 (m, 1H, H-2’), 4.32-4.43 (m, 1H, H-3’), 4.42 (dd, J = 11.2 Hz, J = 3.4 Hz, 1H, H5’a), 4.54 (dd, J = 11.2 Hz, J = 3.4 Hz, 1H, H-5’b), 5.13-5.15 (m, 1H, H-4’), 5.77 (d,
J = 8.3 Hz, 1H, H-5), 5.90-5.91 (m, 1H, H-1’), 7.50 (d, J = 8.3 Hz, 1H, H-6), 10.23 (br s, 1H,
NH). LRMS-ESI: m/z = 401 [M+Na]+
3’-Acetyl-5’-azido-5’-deoxy-2’-methyluridine 201

This compound was prepared following procedure C using 3’-Acetyl-2’-methyl-5’methylsulfonyluridine 200 (250 mg, 660 µmol, 1.0 equiv.), NaN3 (86.0 mg, 1.32 mmol,
2.0 equiv.) and benzyltriethylammonium chloride (30 mg, 132 µmol, 0.2 equiv.) in dry 6 mL
DMF. The suspension was stirred at 80 °C overnight and after work up, the title compound 201
-1
was attained as a white foam (195 mg, 91 %). [α]20
D = 37.86 (c = 5 mg.mL , CH3OH).
1

H NMR (500 MHz, CDCl3): δ 2.17 (s, 3H, Ac), 3.44 (s, 3H, OCH3), 3.66 (d, J = 13.2 Hz,

1H, H-5’a), 3.81 (d, J = 13.7 Hz, 1H, H-5’b), 4.03-4.04 (m, 1H, H-4’), 4.24 (m, 1H, H3’), 5.07-5.09 (m, 1H, H-2’), 5.83 (d, J = 7.8 Hz, 1H, H-5), 5.98 (d, J = 3.4 Hz, 1H, H1’), 7.56 (d, J = 7.8 Hz, 1H, H-6).

13

C NMR (125 MHz, CDCl3): δ 20.6 (Ac-CH3), 51.6

(C-5’), 59.1 (OCH3), 70.6 (C-3’), 80.0 (C-2’), 81.3 (C-4’), 88.0 (C-1’), 103.3 (C-5),
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139.5 (C-6), 150.1 (C-2), 162.7 (C-4), 170.1 (C=O). LRMS-ESI: m/z = 348 [M+Na]+,
HRESI-MS: m/z calcd for C12H15N5O6Na [M+Na]+: 348.0920; found 348.0917; Δ = 0.86 ppm

6.1.5. Experimental for chapter 4
6.1.5.1. CuAAC reactions
5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-N4-Acetyl-5’-deoxy-2’,3’-O-isopropylidenylcytidine 202

This compound was prepared following procedure D, described p. 143, using 172 (250 mg,
714 µmol, 1.0 equiv.), 111 (228 mg, 856 µmol, 1.2 equiv.), Cu(OAc)2 (32 mg, 178 µmol,
0.25 equiv.) and sodium ascorbate (71 mg, 357 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The
suspension was stirred at r. t. for 24 h and after work up, the title compound 202 was attained
-1
1
as a dark yellow oil (282 mg, 64 %). [α]20
D = 19.68 (c = 5 mg.mL , CH3OH). H NMR

(300 MHz, CDCl3): δ 1.32 (s, 3H, CH3), 1.51 (s, 3H, CH3), 2.10 (s, 3H, Ac), 2.26 (s, 3H, Ac),
4.54 (m, 1H, H-4’), 4.75-4.77 (m, 2H, H-5’), 5.00-5.02 (m, 1H, H-3’), 5.14-5.17 (m, 1H, H2’), 5.56 (m, 1H, H-1’), 6.87-6.90 (m, 1H, ArH), 6.96-6.99 (m, 3H, ArH), 7.07-7.17 (m, 3H,
ArH), 7.25-7.34 (m, 4H, ArH), 7.44-7.47 (m, 1H, H-6), 7.54 + 7.60 (2 s, 1H, H-5”), 10.04 (br
s, 1H, NH).

13

C NMR (300 MHz, CDCl3): δ 21.0 (CH3), 24.8 (Ac-CH3), 25.0 (CH3), 26.8

(Ac-CH3), 52.1 (C-5’), 69.4 + 69.5 (C-1”), 82.4 (C-3’), 84.4 (C-2’), 87.3 + 87.3 (C-4’), 97.1
(C-1’), 98.2 + 98.3 (C-5), 114.3 (C), 117.3 (ArCH), 118.1 + 118.2 (ArCH), 118.8 + 118.9
(ArCH), 121.6 + 121.7 (ArCH), 123.4 (ArCH), 123.4 + 123.5 (C-5”), 129.7 (ArH), 129.8
193

Chapter 6

(ArCH), 140.1 + 140.2 (C-4”), 146.7 + 146.7 (C-6), 147.8 + 147.9 (C), 154.7 (C-4),
156.6 + 156.6 (ArC-O), 157.3 (ArC-O), 163.6 + 163.7 (C-2), 169.8 (C=O), 170.8 (C=O).
LRMS-ESI: m/z = 639 [M+Na]+. HRESI-MS: m/z calcd for C31H33N6O8 [M+H]+: 617.2360;
found 617.2375; Δ = 2.43 ppm
5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-N4-tert-butoxycarbonyl-5’-deoxy-2’,3’-Oisopropylidenylcytidine 203

This compound was prepared following procedure D using 174 (460 mg, 1.13 mmol,
1.0 equiv.), 111 (360 mg, 1.35 mmol, 1.2 equiv.), Cu(OAc)2 (51 mg, 281 µmol, 0.25 equiv.)
and sodium ascorbate (111 mg, 563 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension
was stirred at r. t. for 24 h and after work up, the title compound 203 was attained as a dark
-1
1
amber oil (653 mg, 86 %). [α]20
D = 23.17 (c = 5 mg.mL , CH3OH). H NMR (500 MHz,

CDCl3): δ 1.34 (s, 3H, CH3), 1.52 (s, 12H, Boc/CH3), 2.10 + 2.11 (2 s, 3H, Ac), 4.58 (m, 1H,
H-4’),4.76-4.77 (m, 2H, H-5’), 5.03-5.05 (m, 1H, H-3’), 5.22-5.23 (m, 1H, H-2’), 5.48-5.49
(m, 1H, H-5), 6.89-6.90 (m, 1H, ArH), 6.94 + 6.95 (s, 1H, CHOAc), 6.99-7.00 (m, 2H, ArH),
7.08-7.11 (m, 2H, ArH/H-5”), 7.14-7.17 (m, 1H, ArH), 7.26-7.36 (m, 4H, ArH), 7.47 + 7.52
(d, J = 7.3 Hz, 1H, H-6), 7.68 (br s, 1H, NH).

13

C NMR (125 MHz, CDCl3): δ 21.0 (CH3),

25.1 (CH3), 26.9 (Ac-CH3), 27.9 (Boc-C(CH3)3), 52.3 (C-5’), 69.6 (CHOAc), 82.8 (C-4’),
83.2 (C-3’), 84.5 (C-2’), 87.6 (C-1’), 99.2 (C-5), 114.2 (C), 117.4 (ArCH), 118.2 (ArCH),
118.9 (2 x ArCH), 121.7 (ArCH), 123.4 (C-5”), 123.7 (ArCH), 129.7 (2 x ArCH), 129.8
(ArCH), 140.3 (C-4”), 147.5 (C-6), 150.9 (C-2), 156.7 (ArC-O), 157.3 (ArC-O), 163.6 (C-4),
169.7

(Ac-C=O).

LRMS-ESI:

m/z

=

697

[M+Na]+.

HRESI-MS: m/z calcd

C34H38N6O9Na [M+Na]+: 697.2598; found 697.2606. Δ = 1.15 ppm
194

for

Chapter 6

5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-N4,2’,3’-triacetylcytidine 204

This compound was prepared following procedure D using 167 (120 mg, 304 µmol,
1.0 equiv.), 111 (97 mg, 365 µmol, 1.2 equiv.), Cu(OAc)2 (14 mg, 76 µmol, 0.25 equiv.) and
sodium ascorbate (30 mg, 152 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was
stirred at r. t. for 24 h and after work up, the title compound 204 was attained as an amber film
-1
1
(183 mg, 91 %). [α]20
D = 17.53 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3):

δ 2.06 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.11 + 2.12 (2 s, 3H, Ac), 2.25 (s, 3H, Ac), 4.53 (m, 1H,
H-4’), 4.72-4.82 (m, 2H, H-5’), 5.52-5.54 (m, 2H, H-2’/H-3’), 5.67 (m, 1H, H-1’), 6.89 + 6.91
(m, 1H, ArH), 6.95-6.99 (m, 3H, ArH/CHOAc), 7.08-7.12 (m, 2H, ArH/H-5”), 7.16-7.19 (m,
1H, ArH), 7.27-7.33 (m, 3H, ArH), 7.47-7.51 (m, 2H, ArH/H-6), 9.82 (br s, 1H, NH).
13

C NMR (125 MHz, CDCl3): δ 20.3 (2 x Ac-CH3), 20.4 + 20.4 (Ac-CH3), 21.0 + 21.1 (Ac-

CH3), 24.8 + 24.9 (CH3), 51.4 + 51.4 (C-5’), 69.5 + 69.5 (CHOAc), 71.0 + 71.0 (C-3’), 73.4
(C-2’), 80.5 + 80.6 (C-4’), 93.7 + 93.7 (C-1’), 97.3 + 97.4 (C-5), 117.3 + 117.3 (ArCH),
118.2 + 118.3 (ArCH), 118.9 + 119.0 (2 x ArCH), 121.7 + 121.7 (ArCH), 123.4 (C-5”),
124.0 + 124.1 (ArCH), 129.7 + 129.8 (2 x ArCH), 129.9 (ArCH), 140.1 + 140.2 (C-4”),
146.4 + 146.5 (C-6), 147.0 + 147.1 (ArC), 154.5 + 154.5 (C-2), 156.6 (ArC-O), 157.4 + 159.4
(ArC-O), 163.3 + 163.4 (C-4), 169.5 + 169.6 (2 x Ac-C=O), 169.8 + 169.8 (Ac-C=O),
170.8 + 170.8 (Ac-C=O). LRMS-ESI: m/z = 683 [M+Na]+. HRESI-MS: m/z calcd for
C32H32N6O10Na [M+Na]+: 683.2078; found 683.2094; Δ = 2.34 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenyluridine 205

This compound was prepared following procedure D using 178 (350 mg, 1.13 mmol,
1.0 equiv.), 111 (362 mg, 1.36 mmol, 1.2 equiv.), Cu(OAc)2 (51 mg, 283 µmol, 0.25 equiv.)
and sodium ascorbate (112 mg, 566 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension
was stirred at r. t. for 24 h and after work up, the title compound 205 was attained as a dark
-1
1
yellow oil (573 mg, 88 %). [α]20
D = 91.88 (c = 5 mg.mL , CH3OH). H NMR (500 MHz,

CDCl3): δ 1.32 (s, 3H, CH3), 1.52 (s, 3H, CH3), 2.10 (s, 3H, Ac), 4.40-4.50 (m, 1H, H-4’), 4.594.77 (m, 2H, H-5’), 4.89-4.99 (m, 1H, H-3’), 5.00-5.08 (m, 1H, H-2’), 5.53 (s, 1H, H-1’), 5.655.74 (m, 1H, H-5), 6.90 (dd, J = 8.1 Hz, J = 1.4 Hz, 1H, ArH), 6.95-7.02 (m, 3H, ArH), 7.037.21 (m, 4H, ArH), 7.24-7.36 (m, 4H, ArH), 7.44 + 7.47 (2 s, 1H, H-5”), 7.50 (d, J = 3.4 Hz,
1H, ArH), 10.23 (br s, 1H, NH).

13

C NMR (125 MHz, CDCl3): δ 21.0 (CH3), 25.1 (CH3),

26.8 + 26.9 (Ac-CH3), 51.7 (C-5’), 69.5 + 69.5 (CHOAc), 81.6 + 81.7 (C-3’), 84.1 (C-2’), 86.0
(C-4’), 95.9 + 95.9 (C-1’), 102.8 + 102.8 (C-5), 114.7 (Cq), 117.3 (ArCH), 118.2 + 118.2
(ArCH), 118.8 (ArCH), 118.9 (2 x ArCH), 121.7 (ArCH), 123.4 (ArCH), 123.6 + 123.7 (C-5”),
129.7 (2 x ArCH), 129.8 (ArCH), 140.1 + 140.2 (ArC), 143.2 + 143.2 (C-6), 146.7 + 146.8 (C4”), 150.2 (C-2), 156.6 (ArC-O), 157.3 (ArC-O), 163.5 (C-4), 169.7 + 169.8 (Ac-C=O).
LRMS-ESI: m/z = 598 [M+Na]+. HRESI-MS: m/z calcd for C27H27N5O7Na [M+Na]+:
598.1914; found 598.1931; Δ = 2.84 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 206

This compound was prepared following procedure D using 180 (250 mg, 708 µmol,
1.0 equiv.), 111 (226 mg, 849 µmol, 1.2 equiv.), Cu(OAc)2 (32 mg, 177 µmol, 0.25 equiv.)
and sodium ascorbate (70 mg, 354 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension
was stirred at r. t. for 24 h and after work up, the title compound 206 was attained as a pale
-1
1
yellow oil (631 mg, 90 %). [α]20
D = 11.64 (c = 5 mg.mL , CH3OH). H NMR (500 MHz,

CDCl3): δ 2.08 + 2.08 (2 s, 6H, 2 x Ac), 2.13 + 2.14 (s, 3H, Ac), 4.42-4.47 (m, 1H, H-4’),
4.67-4.76 (m, 2H, H-5’), 4.75-4.77 (m, 1H, H-2’), 5.26-5.30 (m, 1H, H-3’), 5.30-5.37 (m, 1H,
H-1’), 5.62-5.64 (m, 1H, H-5), 5.69-5.72 (m, 1H, CHOAc), 6.90 (m, 1H, ArH), 6.95-7.02 (m,
3H, ArH), 7.03-7.21 (m, 3H, ArH), 7.24-7.36 (m, 2H, ArH), 7.44-7.47 (m, 1H, H-6),
7.49 + 7.50 (2 s, 1H, H-5”), 9.63 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 20.5 (AcCH3), 20.6 (Ac-CH3), 21.1/21.2 (Ac-CH3), 51.0 (C-5’), 69.8 (CHOAc), 70.5 (C-3’), 72.8 (C2’), 79.9 (C-4’), 91.2/91.3 (C-1’), 102.9/103.0 (C-5), 117.3 (ArCH), 118.2 (ArCH), 118.8
(CH, ArCH), 118.9 (2 x ArCH), 121.7 (ArCH), 123.4 (C-5”), 129.6 (2 x ArCH), 129.7
(ArCH), 139.0 (ArC), 141.2 (C-6), 146.6/146.7 (C-4”), 150.0 (C-2), 157.4 (ArC-O), 158.2
(ArC-O), 162.7 (C-4), 169.5 (Ac-C=O), 169.7 (Ac-C=O), 169.8 (Ac-C=O). LRMS-ESI:
m/z = 642 [M+Na]+. HRESI-MS: m/z calcd for C30H29N5O10Na [M+Na]+: 642.1812; found
642.1837. Δ = 3.89 ppm
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5’-(4-(α-Acetoxy-3-methoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenyluridine 207

This compound was prepared following procedure D using 178 (310 mg, 1.00 mmol,
1.0 equiv.), 1-(3-methoxyphenyl)propargyl acetate 106 (246 mg, 1.20 mmol, 1.2 equiv.),
Cu(OAc)2 (45 mg, 250 µmol, 0.25 equiv.) and sodium ascorbate (99 mg, 501 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 207 was attained as a dark yellow syrup (479 mg, 93 %).
-1
1
[α]25
D = 10.46 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3): δ 1.33 (s, 3H, CH3),

1.53 (s, 3H, CH3), 2.13 (s, 3H, Ac), 3.79 (s, 3H, OCH3) 4.42-4.47 (m, 1H, H-4’), 4.62-4.71
(m, 2H, H-5’), 4.93 (dd, J = 16.9 Hz, J = 5.1 Hz, 1H, H-3’), 5.00-5.02 (m, 1H, H-2’), 5.51
(m, 1H, H-5), 5.70 (t, J = 7.1 Hz, 1H, H-1’), 6.85 (d, J = 8.1 Hz, 1H, H-6), 6.96 (d,
J = 2.7 Hz, 1H, ArH), 7.00-7.05 (m, 3H, ArH), 7.25-7.29 (m, 1H, ArH), 7.41 + 7.43 (2 s,
1H, H-5”), 9.57 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 20.9 (Ac-CH3), 25.2 (CH3),
27.0 (CH3), 51.6 (C-5’), 55.2 (OCH3), 69.8 (CHOAc), 81.5 (C-3’), 84.0 (C-2’), 85.7 (C-4’),
95.8 (C-1’), 102.9 (C-5), 113.1 (ArCH), 113.6 (ArCH), 114.9 (Cq), 119.4 (ArCH), 123.7 (C5”), 129.7 (ArCH), 139.8 (ArC), 143.0 (C-6), 147.1 (C-4”), 150.0 (C-2), 159.7 (ArC-O),
163.2 (C-4), 169.8 (Ac-C=O). LRESI-MS: m/z = 536 [M+Na]+. HRESI-MS: m/z calcd for
C24H27N5O8Na [M+Na]+: 536.1757; found 536.1783; Δ = 4.85 ppm
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5’-(4-(α-Acetoxy-2,5-dimethoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenyluridine 208

This compound was prepared following procedure D using 178 (310 mg, 1.00 mmol,
1.0 equiv.), 1-(2,5-dimethoxyphenyl)propargyl acetate 107 (280 mg, 1.20 mmol, 1.2 equiv.),
Cu(OAc)2 (45 mg, 250 µmol, 0.25 equiv.) and sodium ascorbate (99 mg, 501 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 208 was attained as an amber syrup (480 mg, 88 %). [α]20
D = 16.91
(c = 5 mg.mL-1, CH3OH). 1H NMR (500 MHz, CDCl3): δ 1.32 (s, 3H, CH3), 1.53 (s, 3H,
CH3), 2.12 (s, 3H, Ac), 3.74 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 4.41-4.45 (m, 1H, H4’), 4.65-4.66 (m, 2H, H-5’), 4.91-5.00 (m, 2H, H-2’/H-3’), 5.55 (m, 1H, H-5), 5.675.79 (m, 1H, H-1’), 6.81 (s, 1H, CHOAc), 6.99-7.05 (m, 1H, H-6), 7.13 (m, 1H, ArH),
7.30 (d, J = 4.9 Hz, 1H, ArH), 7.43 (d, J = 4.4 Hz, 1H, ArH), 9.83 (br s, 1H, NH).
13

C NMR (125 MHz, CDCl3): δ 21.1 (Ac-CH3), 25.1 (CH3), 27.0 (CH3), 51.4 (C-5’),

55.6 (OCH3), 56.3 (OCH3), 64.4 (CHOAc), 81.3 (C-3’), 83.9 (C-2’), 85.4 (C-4’), 95.3
(C-1’), 102.9 (C-5), 112.1 (ArCH), 113.6 (Cq), 114.0 (ArCH), 114.9 (ArC), 123.9 (C5”), 127.8 (ArCH), 142.9 (C-6), 146.6 (C-4”), 150.0 (ArC-O), 150.4 (C-2), 153.6
(ArC-O), 163.4 (C-4), 169.8 (Ac-C=O). LRESI-MS: m/z = 566 [M+Na]+. HRESI-MS:
m/z calcd for C29H29N5O9Na [M+Na]+: 592.1863; found 592.1868; Δ = 0.84 ppm
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5’-(4-(α-Acetoxy-3-propoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenyluridine 209

This compound was prepared following procedure D using 178 (130 mg, 420 µmol,
1.0 equiv.), 1-(3-propoxyphenyl)propargyl acetate 108 (117 mg, 504 µmol, 1.2 equiv.),
Cu(OAc)2 (19 mg, 105 µmol, 0.25 equiv.) and sodium ascorbate (42 mg, 210 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 209 was attained as a pale yellow syrup (205 mg, 90 %).
[α]25
D

= 30.14 (c = 5 mg.mL-1, CH3OH).

1

H NMR (500 MHz, CDCl3): δ 1.02 (t,

J = 7.8 Hz, 3H, H-3””), 1.33 (s, 3H, CH3), 1.53 (s, 3H, CH3), 1.78 (q, J = 6.8 Hz, 2H,
H-2””), 2.12 (s, 3H, Ac), 3.90 (t, J = 6.4 Hz, 2H, H-1””), 4.43-4.46 (m, 1H, H-4’),
4.62-4.71 (m, 2H, H-5’), 4.93 (dt, J = 17.1 Hz, J = 4.9 Hz, 1H, H-3’), 5.00-5.02 (m,
1H, H-2’), 5.52 (m, 1H, CHOAc), 5.69-5.71 (m, 1H, H-5), 6.84 (d, J = 7.8 Hz, 1H, H1’), 6.95 (d, J = 4.4 Hz, 1H, ArH), 7.00-7.07 (m, 3H, ArH/H-6), 7.23-7.26 (m, 1H,
ArH), 7.43 (d, J = 7.8 Hz, 1H, ArH), 9.83 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3):
δ 10.4 (C-3””), 21.1 (Ac-CH3), 22.5 (C-2””), 25.2 (CH3), 27.0 (CH3), 51.6 + 51.7 (C5’), 69.5 (C-1””), 69.8 + 69.9 (CHOAc), 81.5 + 81.6 (C-3’), 84.0 + 84.1 (C-2’),
85.8 + 85.7 (C-4’), 95.7 + 95.8 (C-1’), 102.9 (C-5), 109.9 (ArCH), 113.5 + 113.5 (C),
114.1 + 114.8

(ArCH),

119.0 + 119.1

(ArCH),

123.7

(C-5”), 129.6

(ArCH),

139.7 + 139.7 (ArC), 143.0 + 143.1 (C-6), 147.1 (C-4”), 150.1 (C-2), 159.2 (ArC-O),
163.4 (C-4), 169.8 (Ac-C=O). LRESI-MS: m/z = 564 [M+Na]+. HRESI-MS: m/z calcd for
C26H31N5O8Na [M+Na]+: 564.2070; found 564.2088; Δ = 3.19 ppm
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5’-(4-(α-Acetoxy-3-cyclopentoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenyluridine 210

This compound was prepared following procedure D using 178 (350 mg, 1.13 mmol,
1.0 equiv.), 1-(3-cyclopentoxyphenyl)propargyl acetate 109 (351 mg, 1.36 mmol, 1.2 equiv.),
Cu(OAc)2 (51 mg, 283 µmol, 0.25 equiv.) and sodium ascorbate (112 mg, 566 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 210 was attained as a dark yellow oil (584 mg, 91 %). [α]25
D = 18.58
(c = 5 mg.mL-1, CH3OH). 1H NMR (300 MHz, CDCl3): δ 1.33 (s, 3H, CH3), 1.53 (s, 3H,
CH3), 1.77-1.88 (m, 8H, H-2””/H-3””/H-4””/H-5””), 2.12 + 2.12 (s, 3H, Ac), 4.45 (m, 1H, H4’), 4.62-4.67 (m, 1H, H-5’a), 4.69-4.74 (m, 1H, H-1””/H-5’b), 4.92-4.97 (m, 1H, H-3’), 5.025.03 (m, 1H, H-2’), 5.55 (m, 1H, H-1’), 5.69-5.71 (m, 1H, H-5), 6.80 (d, J = 7.8 Hz,
J = 1.4 Hz, 1H, ArH), 6.95-6.98 (m, 3H, CHOAc/ArH), 7.09 (d, J = 7.8 Hz, 1H, H-6), 7.23 (t,
J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 6.3 Hz, 1H, H-5”), 10.16 (br s, 1H, NH).

13

C NMR

(75 MHz, CDCl3): δ 21.0 (Ac-CH3), 23.9 (C-3””/C-4””), 25.1 (CH3), 26.9 (CH3), 32.6 (C2””/C-5””), 51.6 (C-5’), 69.7 (CHOAc), 79.1 (C-1””), 81.6 (C-3’), 84.0 (C-2’), 85.8 (C-4’),
95.6 (C-1’), 102.7 (C-5), 114.4 (ArCH), 114.6 (C), 114.9 (ArCH), 118.6 (ArCH), 123.6 (C5”), 129.4 (ArCH), 139.6 (ArC), 143.1 (C-6), 147.0 (C-4”), 150.1 (C-2), 158.1 (ArC-O),
163.5 (C-4), 169.7 (Ac-C=O). LRMS-ESI: m/z = 590 [M+Na]+. HRESI-MS: m/z calcd for
C28H33N5O8Na [M+H]+: 590.2227; found 590.2249; Δ = 3.73 ppm
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5’-(4-(N-tert-butoxycarbonylindol-3-yl)-α-hydroxy-α-methoxycarbonylmethyl)triazolo)-5’deoxy-2’,3’-O-isopropylidenyluridine 211

This compound was prepared following procedure D using 178 (250 mg, 808 µmol,
1.0 equiv.), 1-(N-tert-butoxycarbonyl-3-indolyl)propargyl acetate 131 (319 mg, 970 µmol,
1.2 equiv.), Cu(OAc)2 (38 mg, 202 µmol, 0.25 equiv.) and sodium ascorbate (80 mg,
404 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and
after work up, the title compound 211 was attained as a dark yellow oil (418 mg, 81 %).
-1
1
[α]25
D = 16.05 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3): δ 1.32 (s, 3H, CH3),

1.53 (s, 3H, CH3), 1.65 (s, 9H, Boc), 3.82 (s, 3H, OCH3), 4.43 (m, 1H, H-4’), 4.69 (m,
2H, H-5’), 4.91 (m, 1H, H-3’), 4.99-5.02 (m, 1H, H-2’), 5.46 (m, 1H, H-1’), 5.69 (m,
1H, OH), 6.99-7.13 (m, 2H, H-6/ArH), 7.27 (m, 1H, ArH), 7.47-7.73 (m, 3H, H5”/ArH), 8.12 (m, 1H, ArH), 9.71 (br s, 1H, NH).

13

C NMR (75 MHz, CDCl3):

δ 25.3 + 25.3 (CH3), 27.1 + 27.1 (CH3), 28.1 (Boc-C(CH3)3), 51.6 + 51.9 (C-5’), 53.8 + 53.8
(OCH3), 81.2 + 81.5 (C-3’), 84.0 + 84.1 (C-2’), 84.3 (Boc-C(CH3)3), 85.5 + 85.9 (C-4’), 95.8
(C-1’), 96.2 (C-2”), 102.9 + 103.0 (C-5), 114.9 (C), 115.3 (ArCH), 121.1 + 121.2 (ArCH),
122.6 + 122.7 (C-5”), 124.5 + 124.6 (ArCH), 125.3 (ArCH), 125.5 (ArCH), 127.9 + 127.9
(ArC), 134.0 (ArC), 136.0 + 136.1 (ArC), 143.2 (C-6), 143.4 (C-4”), 149.6 + 149.6 (Boc-C=O),
150.0 + 150.1 (C-2), 163.2 + 163.3 (C-4), 171.2 (C=O). LRMS-ESI: m/z = 661 [M+Na]+.
HRESI-MS: m/z calcd for C30H34N6O10Na [M+Na]+: 661.2234; found 661.2251; Δ = 2.57 ppm
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5’-(4-(α-Acetoxy-3-propoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 212

This compound was prepared following procedure D using 180 (220 mg, 623 µmol,
1.0 equiv.), 1-(3-propoxyphenyl)propargyl acetate 108 (173 mg, 747 µmol, 1.2 equiv.),
Cu(OAc)2 (28 mg, 156 µmol, 0.25 equiv.) and sodium ascorbate (62 mg, 311 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 212 was attained as a dark amber syrup (328 mg, 90 %).
-1
1
[α]20
D = 12.56 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3): δ 1.02 + 1.02 (2 t,

J = 7.5Hz, 3H, H-3””), 1.76-1.81 (m, 2H, H-2””), 2.08 + 2.09 (2 s, 6H, 2 x Ac), 2.14 + 2.14
(2 s, 3H, Ac), 3.92 + 3.92 (2 t, J = 6.4 Hz, 2H, H-1””), 4.41-4.46 (m, 1H, H-4’), 4.66-475 (m,
2H, H-5’), 5.27-5.32 (m, 1H, H-2’), 5.35-5.38 + 5.40-5.43 (m, 1H, H-3’), 5.62-5.63 (m, 1H,
H-5), 5.69-5.72 (m, 1H, H-1’), 6.84-6.86 (m, 1H, ArH), 6.94-7.03 (m, 4H, ArH, H6/CHOAc), 7.25-7.28 (m, 1H, ArH), 7.50 + 7.53 (2 s, 1H, H-5”), 8.95 (br s, 1H, NH).
13

C NMR (125 MHz, CDCl3): δ 10.5 (C-3””), 20.4 (Ac-CH3), 20.4 (Ac-CH3), 21.1 (Ac-

CH3), 22.5 (C-2””), 50.9 (C-5’), 69.6 (C-1””), 69.9 (CHOAc), 70.5 (C-3’), 72.7 (C-2’),
79.9 (C-4’), 91.4 (C-1’), 103.4 (C-5), 113.6 (ArCH), 114.3 (ArC), 119.1 (ArCH), 124.1
(C-5”), 129.7 (ArCH), 139.7 (ArC), 141.3 (C-6), 147.5 (C-4”), 149.5 (C-2), 159.3
(ArC-O), 162.6 (C-4), 169.5 (Ac-C=O), 169.6 (Ac-C=O), 169.8 (Ac-C=O). LRESIMS: m/z = 708 [M+Na]+. HRESI-MS: m/z calcd for C27H31N5O10Na [M+Na]+: 608.1969;
found 608.2043; Δ = 12.17 ppm
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5’-(4-(α-Acetoxy-3-cyclopentoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 213

This compound was prepared following procedure D using 180 (250 mg, 708 µmol,
1.0 equiv.), 1-(3-cyclopentoxyphenyl)propargyl acetate 109 (220 mg, 849 µmol, 1.2 equiv.),
Cu(OAc)2 (32 mg, 177 µmol, 0.25 equiv.) and sodium ascorbate (70 mg, 354 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 213 was attained as a dark yellow oil (385 mg, 89 %). [α]20
D = 37.44
(c = 5 mg.mL-1, CH3OH). 1H NMR (500 MHz, CDCl3): δ 1.75-1.89 (m, 8H, H-2””/H-3””/H4””/H-5””), 2.09 (m, 6H, 2 x Ac), 2.15 (s, 3H, Ac), 4.41-4.45 (m, 1H, H-4’), 4.65-4.72 (m,
2H, H-5’), 4.74-4.78 (m, 1H, H-2’), 5.25-5.29 (m, 1H, H-3’), 5.33-5.41 (m, 1H, H-1’), 5.615.63 (m, 1H, H-5), 5.69-5.72 (m, 1H, CHOAc), 6.82-6.84 (m, 1H, H-1’), 6.93 (d, J = 8.0 Hz,
1H, H-6), 6.95-7.00 (m, 3H, ArH), 7.24-7.27 (m, 1H, ArH), 7.46 + 7.50 (2 s, 1H, H-5”), 8.56
(br s, 1H, NH).

13

C NMR (125 MHz, CDCl3): δ 20.4 (Ac-CH3), 20.4 (Ac-CH3), 21.2 (Ac-

CH3), 24.0 (2 x CH2), 32.8 (2 x CH2), 50.9 (C-5’), 69.9 + 70.6 (CHOAc), 72.7 (C-3’), 79.3
(C-2’), 80.0 (C-4’), 91.3 (C-1’), 103.4 (C-5), 114.7 (ArCH), 115.2 (ArCH), 118.8 (ArCH),
124.1 (C-5”), 129.7 (ArCH), 139.6 (ArCH), 141.3 (C-6), 147.6 (C-4”), 149.6 (C-2), 158.3
(ArC-O),

161.8

(C-4),

169.6

(2 x Ac-C=O),

169.8

(Ac-C=O).

LRMS-ESI:

m/z = 634 [M+Na]+. HRESI-MS: m/z calcd for C29H33N5O10Na [M+H]+: 634.2125; found
634.2142; Δ = 2.68 ppm
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5’-(4-(α-Acetoxy-3-cyclopentoxy-4-methoxybenzyl)triazolo)-5’-deoxy-2’,3’-Odiacetyluridine 214

This compound was prepared following procedure D using 180 (250 mg, 708 µmol,
1.0 equiv.), 1-(3-cyclopentoxy-4-methoxyphenyl)propargyl acetate 110 (250 mg, 849 µmol,
1.2 equiv.), Cu(OAc)2 (32 mg, 177 µmol, 0.25 equiv.) and sodium ascorbate (70 mg,
354 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and
after work up, the title compound 214 was attained as a dark yellow oil (381 mg, 84 %).
-1
1
[α]20
D = 15.37 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3): δ 1.56-1.59 (m, 2H,

H-3””a/H-4””a), 1.77-1.90(m, 6H, H-2””/H-3””b/H-4””b/H-5””), 2.06 (m, 3H, Ac), 2.07 (m,
3H, Ac), 2.11 (s, 3H, Ac), 3.81 (s, 3H, OCH3), 4.41-4.46 (m, 1H, H-4’), 4.66-4.72 (m, 2H, H5’), 4.74-4.78 (m, 1H, H-2’), 5.27-5.31 (m, 1H, H-3’), 5.35-5.42 (m, 1H, H-1’), 5.63 (m, 1H,
H-5), 5.68-5.74 (m, 1H, CHOAc), 6.81-6.83 (m, 1H, ArH), 6.89-6.92 (m, 1H, H-6), 6.95-7.03
(m, 2H, ArH), 7.04-7.06 (m, 1H, ArH), 7.50 + 7.52 (2 s, 1H, H-5”), 9.67 (br s, 1H, NH).
13

C NMR (125 MHz, CDCl3): δ 20.2 (Ac-CH3), 20.3 (Ac-CH3), 21.1 (Ac-CH3), 23.9 (C-

3””/C-4””), 32.6 (C-2””/C-5””), 50.9 (C-5’), 56.0 (OCH3), 69.8 (CHOAc), 70.4 (C-3’), 72.7
(C-2’), 79.9 + 80.5 (C-4’), 91.3 (C-1’), 103.2 (C-5), 111.7 (ArCH), 114.3 (ArCH), 119.7
(ArCH), 123.9 (C-5”), 130.5 (ArC), 141.1 (C-6), 147.6 (C-4”), 149.6 (ArC-O), 150.1 (C-2),
157.1 (ArC-O), 162.9 (C-4), 169.6 (Ac-C=O), 169.9 (Ac-C=O), 170.0 (Ac-C=O). LRMSESI: m/z = 663 [M+Na]+. HRESI-MS: m/z calcd for C30H35N5O11Na [M+Na]+: 666.2231;
found 666.2246; Δ = 2.25 ppm
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5’-(4-(α-Acetoxy-(4-methoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 215

This compound was prepared following procedure D using 180 (200 mg, 566 µmol,
1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate 112 (178 mg, 679 µmol, 1.2 equiv.),
Cu(OAc)2 (26 mg, 141 µmol, 0.25 equiv.) and sodium ascorbate (56 mg, 283 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 215 was attained as a dark yellow oil (310 mg, 89 %).
-1
1
[α]20
D = 9.22 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3): δ 2.07 (Ac), 2.08 (Ac),

2.23 (Ac), 3.81 (s, 3H, OCH3), 4.43-4.47 (m, 1H, H-4’), 4.66-4.76 (m, 2H, H-5’), 4.91-4.97
(m, 2H, H-3’), 5.01-5.05 (m, 1H, H-2’), 5.56-5.59 (m, 1H, H-1’), 5.71 + 5.72 (d, J = 8.1 Hz,
1H, H-5), 6.65-6.68 (m, 1H, CHOAc), 6.95-6.97 (m, 2H, ArH), 7.01-7.09 (m, 3H, ArH), 7.137.21 (m, 2H, ArH), 7.28-7.31 (m, 2H, ArH/H-6), 7.62 + 7.63 (m, 1H, H-5”), 9.87 (br s, 1H,
NH).

13

C NMR (75 MHz, CDCl3): δ 20.7 (Ac-CH3), 20.8 (Ac-CH3), 21.0 (Ac-CH3),

51.7 + 51.8 (C-5’), 56.0 + 56.1 (OCH3), 69.5 + 69.6 (CHOAc), 81.7 + 81.8 (C-3’),
84.1 + 84.2 (C-2’), 85.9 + 86.0 (C-4’), 95.9 +96.0 (C-1’), 102.9 +103.0 (C-5), 112.8 (ArCH, ),
114.9 + 115.0 (ArCH), 116.9 + 117.0 (2 x ArCH), 122.5 (ArCH), 123.5 + 123.6 (C-5”), 124.1
(ArCH), 129.5 (2 x ArCH), 131.2 + 131.3 (ArC), 141.5 + 141.6 (C-6), 147.1 + 147.2 (C-4”),
150.1 + 150.2 (C-2), 151.6 (ArC-O), 157.0 (ArC-O), 158.0 (ArC-O), 163.4 (C-4), 169.6 (AcC=O), 169.8 (Ac-C=O), 169.9 (Ac-C=O). LRMS-ESI: m/z = 672 [M+Na]+. HRESI-MS: m/z
calcd for C31H31N5O11Na [M+Na]+: 672.1918; found 672.1913; Δ = 0.74 ppm
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5’-(4-(α-Acetoxy-3-(4-fluorophenoxy)benzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 216

This compound was prepared following procedure D using 180 (160 mg, 453 µmol,
1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate 113 (154 mg, 543 µmol, 1.2 equiv.),
Cu(OAc)2 (20 mg, 113 µmol, 0.25 equiv.) and sodium ascorbate (45 mg, 226 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 216 was attained as a dark yellow oil (251 mg, 87 %).
-1
1
[α]20
D = 14.86 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3): δ 2.08 (s, 3H, Ac),

2.09 (s, 3H, Ac), 2.24 (s, 3H, Ac), 4.43-4.47 (m, 1H, H-4’), 4.66-4.76 (m, 2H, H-5’), 5.355.44 (m, 2H, H-3’/H-2’), 5.59 (m, 1H, H-1’), 5.71-5.75 (m, 1H, H-5), 6.90-6.92 (m, 1H,
CHOAc), 6.94-6.96 (m, 2H, ArH), 7.04-7.10 (m, 2H, H-6/ArH), 7.14-7.24 (m, 3H, ArH),
7.29-7.32 (m, 2H, ArH), 7.59 + 7.61 (2 s, 1H, H-5’’), 9.87 (br s, 1H, NH).

13

C NMR

(75 MHz, CDCl3): δ 20.3 (Ac-CH3), 20.3 (Ac-CH3), 21.0 (Ac-CH3), 51.1 (C-5’), 68.9
(CHOAc), 70.5 (C-3’), 72.8 (C-2’), 79.9 (C-4’), 91.9 (C-1’), 103.2 (C-5), 117.0 (2 x ArCH),
117.2 (ArCH), 120.9 (d, J = 6.0 Hz, ArCH), 123.2 (C-5”), 123.7 (d, J = 7.4 Hz, ArCH), 124.1
(d, J = 11.6 Hz, ArCH), 129.7 (2 x ArCH), 135.0 (d, J = 3.7 Hz, ArC-F), 141.8 (C-6), 143.4
(d, J = 11.6 Hz, ArCH), 146.7 (C-4”), 150.1 (C-2), 154.0 (d, J = 250.3 Hz, ArC-F), 157.0
(2 x ArC-O), 163.1 (C-4), 169.6 (Ac-C=O), 169.7 (Ac-C=O), 169.8 (Ac-C=O). LRMS-ESI:
m/z = 660 [M+Na]+. HRESI-MS: m/z calcd for C30H28FN5O10Na [M+Na]+: 660.1718; found
660.1713; Δ = 0.76 ppm
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5’-(4-(α-Acetoxy-3-(4-fluorophenoxy)benzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 217

This compound was prepared following procedure D using 180 (140 mg, 397 µmol, 1.0 equiv.),
1-(3-phenoxyphenyl)propargyl acetate 114 (135 mg, 475 µmol, 1.2 equiv.), Cu(OAc)2 (18 mg,
99 µmol, 0.25 equiv.) and sodium ascorbate (39 mg, 198 µmol, 0.5 equiv.) in CH3CN/H2O
[4:1]. The suspension was stirred at r. t. for 24 h and after work up, the title compound 217 was
-1
1
attained as a yellow oil (240 mg, 95 %). [α]20
D = 25.24 (c = 5 mg.mL , CH3OH). H NMR

(400 MHz, CDCl3): δ 2.08 + 2.08 (2 s, 3H, Ac), 2.09 (s, 3H, Ac), 2.13 + 2.13 (2 s, 3H, Ac), 4.444.49 (m, 1H, H-4’), 4.68-4.79 (m, 2H, H-5’), 5.34-5.38 (m, 1H, H-3’), 5.40-5.47 (m, 1H, H-2’),
5.65 (d, J = 3.9 Hz, 1H, H-5), 5.70-5.73 (m, 1H, H-1’), 6.86-6.88 (m, 1H, ArH), 6.97-7.08 (m,
6H, H-6, CHOAc/ArH), 7.09-7.12 (m, 1H, ArH), 7.17-7.20 (m, 1H, ArH), 7.28-7.32 (m, 1H,
ArH), 7.59 + 7.61 (2 s, 1H, H-5”), 9.83 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 20.2
(Ac-CH3), 20.3 (Ac-CH3), 20.9 + 21.0 (Ac-CH3), 51.0 + 51.0 (C-5’), 69.4 + 69.5 (CHOAc),
70.4 + 70.5 (C-3’), 72.7 + 7.2.7 (C-2’), 79.9 + 80.0 (C-4’), 91.4 + 91.5 (C-1’), 103.2 + 103.2 (C5), 116.3 (d, J = 23.5 Hz, 2 x ArCH), 116.8 + 116.8 (ArCH), 117.6 + 117.6 (ArCH),
120.6 + 120.7 (2 x ArCH), 121.6 + 121.6 (ArCH), 124.0 + 124.1 (C-5”), 129.9 (ArCH),
140.1 + 140.2 (C-6), 141.5 (ArC), 146.9 (C-4”), 150.1 + 150.1 (C-2), 152.3 + 152.3 (ArC-O),
157.6 + 157.8 (ArC-O), 158.9 (d, J = 225.9 Hz, C-F), 163.0 (C-4), 169.6 (Ac-C=O), 169.6 (AcC=O), 169.8 (Ac-C=O). LRMS-ESI: m/z = 660 [M+Na]+. HRESI-MS: m/z calcd for
C30H28FN5O10Na [M+Na]+: 660.1718; found 660.1733; Δ = 2.27 ppm
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5’-(4-(α-Acetoxy-benzothien-2-ylmethyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 218

This compound was prepared following procedure D using 180 (300 mg, 849 µmol,
1.0 equiv.), 1-benzothienylpropargyl acetate 116 (235 mg, 1.02 mmol, 1.2 equiv.),
Cu(OAc)2 (38 mg, 212 µmol, 0.25 equiv.) and sodium ascorbate (84 mg, 424 µmol,
0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work
up, the title compound 218 was attained as a dark yellow oil (456 mg, 92 %). [α]20
D = 32.08
(c = 5 mg.mL-1, CH3OH). 1H NMR (500 MHz, CDCl3): δ 2.09 (s, 6H, 2 x Ac), 2.16 (s, 3H,
Ac), 4.45-4.49 (m, 1H, H-4’), 4.70-4.80 (m, 2H, H-5’), 5.31-5.33 (m, 1H, H-2’), 5.38-5.45 (m,
1H, H-3’), 5.60-5.63 (m, 1H, H-1’), 5.70 + 5.70 (2 d, J = 8.0 Hz, 1H, H-5), 7.01 + 7.04 (2 d,
J = 8.0 Hz, 1H, H-6), 7.31-7.38 (m, 4H, CHOAc/ArCH), 7.72-7.74 (m, 2H, ArCH), 7.78 + 7.80
(2 s, 1H, H-5”), 9.23-9.25 (m, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 20.3 (Ac-CH3), 20.4
(Ac-CH3), 21.0 + 21.1 (Ac-CH3), 51.1 + 51.2 (C-5’), 66.2 + 66.3 (CHOAc), 70.5 + 70.6 (C-3’),
72.7 + 72.7 (C-2’), 80.0 + 80.1 (C-4’), 91.6 (C-1’), 103.3 + 103.4 (C-5), 122.3 (C-3’’’),
123.8 + 123.8 (C-5”), 124.0 (CHOAc), 124.3 + 124.3 (C-4’’’), 124.6 (C-5’’’), 124.9 (C-6’’’),
138.9 (ArC), 139.8 + 139.9 (ArC), 141.2 + 141.2 (C-6), 141.5 + 141.5 (ArC), 146.3 + 146.3 (C4”), 149.9 + 150.0 (C-2), 162.7 + 162.7 (C-4), 169.6 (Ac-C=O), 169.7 + 169.8 (Ac-C=O), 169.8
(Ac-C=O). LRMS-ESI: m/z = 606 [M+Na]+. HRESI-MS: m/z calcd for C26H25N5O9SNa
[M+Na]+: 606.1271; found 606.1276; Δ = 0.82 ppm
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5’-(4-(α-Acetoxy-(N-tert-butoxycarbonylindol-3-yl)methyl)triazolo)-5’-deoxy-2’,3’-Oisopropylidenyluridine 219

This compound was prepared following procedure D using 180 (350 mg, 991 µmol,
1.0 equiv.), 1-(N-tert-butoxycarbonyl-3-indolyl)propargyl acetate 130 (372 mg, 1.19 mmol,
1.2 equiv.), Cu(OAc)2 (45 mg, 248 µmol, 0.25 equiv.) and sodium ascorbate (98 mg,
495 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and
after work up, the title compound 219 was attained as a pale yellow oil (594 mg, 90 %).
-1
1
[α]20
D = 23.81 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3): δ 1.67 (s, 9H, Boc), 2.10

(s, 3H, Ac), 2.11 (s, 3H, Ac), 2.14 (s, 3H, Ac), 4.42-4.46 (m, 1H, H-4’), 4.64-4.70 (m, 1H, H-5’a),
4.76-4.79 (m, 1H, H-5’b), 5.30-5.44 (m, 2H, H-2’/H-3’), 5.57-5.58 (m, 1H, H-5), 5.69-5.73 (m,
1H, H-1’), 6.99-7.03 (m, 1H, CHOH), 7.21 (t, J = 7.3 Hz, 1H, ArH), 7.30-7.34 (m, 2H, ArH),
7.53-7.56 (m, 1H, ArH), 7.65-7.66 (m, 1H, H-6), 7.74 + 7.76 (2 s, 1H, H-5”), 8.12-8.13 (m, 1H,
ArH), 8.92 (br s, 1H, NH). 13C NMR (125 MHz, CDCl3): δ 20.3 (Ac-CH3), 20.4 (Ac-CH3), 21.1
(Ac-CH3), 28.1 (Boc-C(CH3)3), 50.8 + 51.0 (C-5’), 63.8 + 63.9 (CHOAc), 70.2 + 70.5 (C-3’),
72.8 + 72.9 (C-2’), 79.9 + 80.0 (C-4’), 84.3 (Boc-C(CH3)3), 91.9 (C-1’), 103.3 + 103.3 (C-5),
115.5 (ArCH), 119.8 (ArCH), 122.8 (ArCH), 124.1 + 124.3 (C-5”), 124.8 (ArCH), 125.2 (ArCH),
128.2 (ArC), 136.5 (ArC), 141.6 (C-6), 146.3 (C-4”), 146.4 (C), 149.7 + 149.7 (C-2), 162.5 (C-4),
169.6 (Ac-C=O), 170.0 (Ac-C=O), 170.2 (Ac-C=O). LRMS-ESI: m/z = 645 [M+Na]+. HRESIMS: m/z calcd for C31H34N6O11Na [M+Na]+: 689.2183; found 689.2198; Δ = 2.18 ppm
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5’-(4-(N-tert-butoxycarbonylindol-3-yl)-α-hydroxy-α-methoxycarbonylmethyl)triazolo)-5’deoxy-2’,3’-O-diacetyluridine 220

This compound was prepared following procedure D using 180 (250 mg, 707 µmol,
1.0 equiv.), 1-(N-tert-butoxycarbonyl-3-indolyl)propargyl acetate 131 (280 mg, 849 µmol,
1.2 equiv.), Cu(OAc)2 (32 mg, 177 µmol, 0.25 equiv.) and sodium ascorbate (64 mg,
354 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and
after work up, the title compound 220 was attained as a dark yellow oil (391 mg, 81 %).
-1
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[α]20
D = 33.40 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3): δ 1.67 (s, 9H, Boc),

2.10 (s, 3H, Ac), 2.12 (s, 3H, Ac), 3.85 (s, 3H, OCH3), 4.43 (m, 1H, H-4’), 4.58-4.80 (m, 3H,
OH, H-5’), 5.25-5.32 (m, 1H, H-2’), 5.39-5.40 (m, 1H, H-3’), 5.55-5.60 (m, 1H, H-1’), 5.695.75 (m, 1H, H-5), 6.92-7.01 (m, 1H, H-6), 7.13-7.19 (m, 1H, ArH), 7.29-7.33 (m, 2H, ArH),
7.47-7.52 (m, 1H, ArH), 7.65-7.77 (m, 2H, ArH/H-5”), 8.13-8.15 (m, 1H, ArH), 8.72 (br s,
1H, NH).
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C NMR (75 MHz, CDCl3): δ 20.4 (Ac-CH3), 20.4 (Ac-CH3), 28.1 (Boc-

C(CH3)3), 50.8 (C-5’), 53.9 (OCH3), 70.4 (C-3’), 72.8 (C-2’), 79.9 (C-4’), 84.4 (BocC(CH3)3), 91.6 (C-1’) 103.4 (C-5), 115.3 (ArCH), 121.1 (ArCH), 122.7 (ArCH), 124.6 (C5”), 136.0 (ArC), 143.9 (C-4”), 149.6 (Boc-C=O), 149.8 (C-2), 162.3 (C-4), 169.6 (Ac-C=O),
169.6 (Ac-C=O), 169.6 (Ac-C=O). LRMS-ESI: m/z = 705 [M+Na]+. HRESI-MS: m/z calcd
for C31H34N6O12Na [M+Na]+: 705.2132; found 705.2140; Δ = 1.13 ppm
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5’-(4-(3-Acetoxyindan-3-yl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 221

This compound was prepared following procedure D using 180 (300 mg, 849 µmol,
1.0 equiv.), 3-Acetoxy-3-ethynylindanone 133 (176 mg, 1.02 mmol, 1.2 equiv.), Cu(OAc)2
(38 mg, 212 µmol, 0.25 equiv.) and sodium ascorbate (84 mg, 424 µmol, 0.5 equiv.) in
CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work up, the title
compound 221 was attained as a dark yellow syrup (375 mg, 84 %).[α]20
D = 49.20
(c = 5 mg.mL-1, CH3OH). 1H NMR (400 MHz, DMSO-d6): δ 2.00 + 2.02 (s, 3H, Ac),
2.04 + 2.04 (s, 3H, Ac), 4.42-4.48 (m, 1H, H-4’), 4.77-4.80 (m, 2H, H-5’), 5.37-5.46 (m, 2H,
H-2’/H-3’), 5.67-5.70 (m, 1H, H-5), 5.86-5.89 (m, 1H, H-1’), 6.69 (m, 1H, OH), 6.84-6.86
(m, 1H, ArH), 6.93-6.97 (m, 1H, ArH), 7.20-7.25 (m, 2H, ArH), 7.59 + 7.68 (d, J = 8.3 Hz,
1H, H-6), 8.12 + 8.13 (s, 1H, H-5”), 10.42 + 10.43 (s, 1H, NH), 11.47 (br s, 1H, NH).
13

C NMR (125 MHz, DMSO-d6): δ 20.1 (Ac-CH3), 20.2 (Ac-CH3), 50.6 + 50.7 (C-5’),

71.5 + 71.6 (C-3’), 72.9 + 73.0 (C-2’), 78.6 + 78.9 (C), 79.2 + 79.3 (C-4’), 88.0 + 88.6 (C-1’),
102.4 + 102.5 (C-5), 109.8 (ArCH), 121.8 + 121.8 (ArCH), 123.9 + 124.0 (C-5”),
125.2 + 125.2 (ArCH), 129.3 (ArCH), 132.0 (ArC), 141.6 + 141.8 (ArC), 141.8 (C-6), 148.1
(C-4”), 150.3 + 150.3 (C-2), 162.9 + 163.0 (C-4), 169.2 (C=O), 169.3 (C=O), 177.2 (C=O).
LRMS-ESI: m/z = 549 [M+Na]+. HRESI-MS: m/z calcd for C23H22N6O9Na [M+Na]+:
549.1346; found 549.1351; Δ = 0.91 ppm
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5’-(4-(α-Acetoxy-α-trifluoromethylbenzyl)triazolo)-5’-deoxy-2’,3’-O-diacetyluridine 222

This compound was prepared following procedure D using 180 (250 mg, 707 µmol,
1.0 equiv.), 2-(pheny)propargyl acetate 136 (206 mg, 849 µmol, 1.2 equiv.), Cu(OAc)2
(32 mg, 177 µmol, 0.25 equiv.) and sodium ascorbate (64 mg, 354 µmol, 0.5 equiv.) in
CH3CN/H2O [4:1]. The suspension was stirred at r. t. for 24 h and after work up, the title
compound

222

was

attained

as

a

pale

yellow

oil

(409 mg,

97 %).

-1
1
[α]20
D = 29.53 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3): δ 2.07 (Ac), 2.10

(Ac), 2.23 (Ac), 4.43-4.50 (m, 1H, H-4’), 4.72-4.88 (m, 2H, H-5’), 5.09-5.11 + 5.22-5.26.42
(m, 1H, H-3’), 5.22-5.26 + 5.39-5.42 (m, 1H, H-2’), 5.44-5.45 + 5.66-5.67 (m, 1H, H-5),
5.72-5.73 + 5.80-5.81 (m, 1H, H-1’), 6.95-6.97 + 7.03-7.04 (m, 1H, H-6), 7.39-7.43 (m, 3H,
ArH), 7.46-7.50 (m, 2H, ArH), 7.82-7.84 (m, 1H, H-5”), 9.34-9.39 (m, 1H, NH).

13

C NMR

(125 MHz, CDCl3): δ 20.3 (Ac-CH3), 21.7 (Ac-CH3), 50.6 + 50.9 (C-5’), 70.0 + 70.5 (C3’), 72.0 + 72.4 (C-2’), 79.7 + 80.0 (C-4’), 89.3 + 90.4 (C-1’), 103.4 + 103.5 (C-5),
127.3 + 127.4 (C-2’’’/C-6’’’), 127.3-127.5 (m, CF3), 128.2 + 128.3 (C-3’’’/C-5’’’),
129.3 + 129.5 (C-4’’’), 132.7 + 133.1 (ArC), 140.8 + 141.2 (C-6), 142.6 + 142.9 (C-4”),
150.2 + 150.2 (C-2), 162.7 + 162.8 (C-4), 167.7 + 168.0 (C=O), 169.4 + 169.6 (C=O),
169.6 + 169.7 (C=O). LRMS-ESI: m/z = 618 [M+Na]+. HRESI-MS: m/z calcd for
C25H24N5O9Na [M+Na]+: 618.1424; found 618.1437; Δ = 2.10 ppm

213

Chapter 6

5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-3’-acetyl-5’-deoxythymidine 223

This compound was prepared following procedure D using 5’-Azido-3’-acetyl-5’-deoxythymidine 189 (200 mg, 647 µmol, 1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate 111
(207 mg, 776 µmol, 1.2 equiv.), Cu(OAc)2 (29 mg, 162 µmol, 0.25 equiv.) and sodium
ascorbate (64 mg, 323 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at
r. t. for 24 h and after work up, the title compound 223 was attained as a colourless syrup
-1
1
(350 mg, 94 %). [α]20
D = 48.27 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3):

δ 1.89 (d, J = 0.9 Hz, 3H, CH3), 2.10 (s, 3H, Ac), 2.12 (s, 3H, Ac), 2.13-2.17 (m, 1H, H-2’a),
2.32-2.36 (m, 1H, H-2’b), 4.27-4.30 (m, 1H, H-4’), 4.72-4.73 (m, 2H, H-5’), 5.21-5.29 (m,
1H, H-3’), 6.14-6.18 (m, 1H, H-1’), 6.87 (m, 1H, CHOAc), 6.92-6.94 (m, 1H, ArH), 6.967.01 (m, 3H, ArH), 7.10-7.12 (m, 2H, ArH), 7.17-7.18 (m, 1H, ArH), 7.30-7.35 (m, 3H, ArH),
7.51 (d, J = 9.8 Hz, 1H, ArH), 8.38. (br s, 1H, NH).

13

C NMR (125 MHz, CDCl3): δ 12.4

(CH3), 20.8 (Ac-CH3), 21.1 + 21.1 (Ac-CH3), 36.1 (C-2’), 51.3 + 51.4 (C-5’), 69.6
(CHOAc), 74.2 + 74.4 (C-3’), 82.1 (C-4’), 85.4 (C-1’), 111.9 (C-5), 117.3 + 117.4
(ArCH), 118.4 (ArCH), 119.0 (2 x ArCH), 121.7 (ArCH), 123.6 (C-5”), 124.0 + 124.1
(ArCH), 129.8 (2 x ArCH), 130.0 (ArCH), 135.4 + 135.5 (C-6), 140.0 + 140.1 (C-6),
147.2 (C-4”), 150.0 (C-2), 156.7 (ArC-O), 157.6 (ArC-O), 163.0 (C-4), 169.7 (Ac-C=O),
170.7 (Ac-C=O). LRMS-ESI: m/z = 598 [M+Na]+. HRESI-MS: m/z calcd for
C29H29N5O8Na [M+Na]+: 598.1914; found 598.1917; Δ = 0.50 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-3’-acetyl-2’,5’-dideoxyuridine 224

This compound was prepared following procedure D using 5’-Azido-3’-acetyl-2’,5’dideoxyuridine 191 (245 mg, 830 µmol, 1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate
111 (265 mg, 995 µmol, 1.2 equiv.), Cu(OAc)2 (38 mg, 207 µmol, 0.25 equiv.) and sodium
ascorbate (82 mg, 415 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at
r. t. for 24 h and after work up, the title compound 224 was attained as a pale yellow oil
-1
1
(394 mg, 84%). [α]20
D = 43.61 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3):

δ 2.02-2.06 (m, 1H, H-2’a), 2.09 (s, 3H, Ac), 2.12 (s, 3H, Ac), 2.30-2.36 (m, 1H, H-2’b), 4.28
(m, 1H, H-4’), 4.66-4.70 (m, 1H, H-5’a), 4.75-4.80 (m, 1H, H-5’b), 5.25-5.31 (m, 1H, H-3’),
5.67-5.70 (m, 1H, H-5), 6.16 (t, J = 6.7 Hz, 1H, H-1’), 6.91-7.00 (m, 4H, ArH), 7.04-7.06 (m,
1H, ArH), 7.08-7.12 (m, 2H, ArH), 7.16-7.19 (m, 1H, H-6), 7.29-7.33 (m, 3H, ArH), 7.527.56 (m, 1H, ArH), 9.88 (br s, 1H, NH).

13

C NMR (125 MHz, CDCl3): δ 20.6 (Ac-CH3),

21.0 (Ac-CH3), 36.1 (C-2’), 51.1 (C-5’), 69.5 (CHOAc), 74.2 (C-3’), 82.1 (C-4’), 85.2 (C-1’),
103.2 (C-5), 117.2 (ArCH), 118.3 (ArCH), 119.0 (2 x ArCH), 121.6 (ArCH), 123.5 (C-5”),
125.8 (ArCH), 127.7 (ArCH), 128.0 (ArCH), 128.8 (ArCH), 129.4 (ArCH), 129.7
(2 x ArCH), 129.9 (ArCH), 134.5 (ArCH), 136.4 (ArCH), 140.0 (C-6), 147.0 (C-4”), 150.3
(C-2), 156.5 (ArC-O), 157.5 (ArC-O), 163.1 (C-4), 169.6 (Ac-C=O), 170.5 (Ac-C=O).
LRMS-ESI: m/z = 584 [M+Na]+. HRESI-MS: m/z calcd for C28H27N5O8Na [M+Na]+:
584.1757; found 584.1749; Δ = 1.37 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-3’-acetyl-2’,5’-dideoxy-2’-fluorouridine 225

This compound was prepared following procedure D using 5’-Azido-2’,5’-dideoxy-2’-fluoro2’,3’-diacetyluridine 194 (220 mg, 702 µmol, 1.0 equiv.), 1-(3-phenoxy-phenyl)propargyl
acetate 111 (224 mg, 843 µmol, 1.2 equiv.), Cu(OAc)2 (32 mg, 176 µmol, 0.25 equiv.) and
sodium ascorbate (69 mg, 351 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was
stirred at r. t. for 24 h and after work up, the title compound 225 was attained as an off-white
-1
powder (382 mg, 94 %). [α]20
D = 69.28 (c = 5 mg.mL , CH3OH).

1

H NMR (400 MHz,

CDCl3): δ 2.09 (s, 3H, Ac), 2.11 (s, 3H, Ac), 4.46-4.52 (m, 1H, H-4’), 4.62-4.67 (m, 1H, H5’a), 4.71-4.77 (m, 1H, H-5’b), 5.22-5.33 (m, 1H, H-3’), 5.37-5.40 (m, 1H, H-2’), 5.69-5.72
(m, 1H, H-3’), 5.89-5.92 (m, 1H, H-5), 6.89-6.92 (m, 1H, ArH), 6.97 (m, 1H, CHOAc), 6.986.99 (m, 1H, H-1’), 7.00-7.01 (m, 1H, ArH), 7.02-7.06 (m, 1H, ArH), 7.08-7.10 (m, 1H, H-6),
7.12-7.14 (m, 1H, ArH), 7.17-7.20 (m, 1H, ArH), 7.28-7.34 (m, 3H, ArH/H-5”), 7.55 (m, 1H,
H-6), 9.68 (br s, 1H, NH).

13

C NMR (400 MHz, CDCl3): δ 20.2 (Ac-CH3), 21.0 (Ac-CH3),

50.8 (C-5’), 69.6 (CHOAc), 71.0 (d, J = 15.5 Hz, C-3’), 79.0 (C-4’), 90.7 (d, J = 190.5 Hz, C2’), 93.8 (d, J = 37.7 Hz, C-3’), 94.0 (C-1’), 103.3 (C-5), 117.4 (ArCH), 118.3 (ArCH), 119.0
(2 x ArCH), 121.8 (ArCH), 123.5 (C-5”), 124.0 (ArCH), 129.8 (2 x ArCH), 129.9 (ArCH),
140.2 (C-6), 142.4 (ArCH), 147.1 (C-4”), 149.8 (C-2), 156.7 (ArC-O), 157.4 (ArC-O), 162.9
(C-4), 169.7 (Ac-C=O), 169.8 (Ac-C=O). LRMS-ESI: m/z = 602 [M+Na]+. HRESI-MS:
m/z calcd for C28H26FN5O8Na [M+Na]+: 602.1663; found 602.1669. Δ = 0.99 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-3’-acetyl-5’-deoxy-2’-methyluridine 226

This compound was prepared following procedure D using 5’-Azido-3’-acetyl-5’-deoxyuridine
201 (160 mg, 492 µmol, 1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate 111 (130 mg,
590 µmol, 1.2 equiv.), Cu(OAc)2 (22 mg, 123 µmol, 0.25 equiv.) and sodium ascorbate
(49 mg, 246 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at r. t. for
24 h and after work up, the title compound 226 was attained as a dark yellow thick oil
-1
1
(241 mg, 83%). [α]20
D = 54.72 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3):

δ 2.13 (s, 3H, Ac), 2.14, (s, 3H, Ac), 3.36 + 3.37 (s, 3H, OCH3), 3.93-3.95 + 3.96-3.98
(m, 1H, H-4’), 4.41-4.45 (m, 1H, H-3’), 4.69-4.70 (m, 2H, H-5’), 5.08-5.11 + 5.12-5.14
(m, 1H, H-2’), 5.67 + 5.69 (d, J = 8.8 Hz, 1H, H-5), 5.72-5.74 (m, 1H, H-1’),
6.77 + 6.88 (d, J = 8.3 Hz, 1H, CHOAc), 6.92-6.94 (m, 1H, H-6), 6.97-7.02 (m, 2H,
ArH), 7.10-7.13 (m, 2H, ArH), 7.18 (t, J = 7.3 Hz, 1H, ArH), 7.30-7.35 (m, 2H, ArH),
7.49 + 7.53 (m, 1H, 5”), 9.21 (br s, 1H, NH).

13

C NMR (75 MHz, CDCl3): δ 20.5 (Ac-

CH3), 21.1 (Ac-CH3), 50.7 (C-5’), 59.1 (OCH3), 69.6 (C-7’’’), 71.0 (C-2’), 79.5 (C-3’),
80.1 (C-4’), 90.3 (C-1’), 103.4 (C-5), 117.3 (ArCH), 118.4 (ArCH), 119.1 (2 x ArCH),
121.7 (ArCH), 123.6 (C-5”), 124.3, 129.8 (2 x ArCH), 130.0 (ArCH), 140.0 + 140.0
(C-6), 140.3 + 140.5 (ArC), 147.2 + 147.2 (C-4”), 149.9 + 149.9 (C-2), 156.6 + 156.6
(ArC-O), 157.5 + 157.6 (ArC-O), 162.6 + 162.7 (C-4), 169.8 (Ac-C=O), 170.0 (AcC=O). LRMS-ESI: m/z = 614 [M+Na]+. HRESI-MS: m/z calcd for C29H29N5O9Na
[M+Na]+: 614.1863; found 614.1858; Δ = 0.81 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-5-fluoro-2’,3’-O-diacetyluridine 227

This compound was prepared following procedure D using 5’-Azido-5’-deoxy-5-fluoro-2’,3’diacetyluridine 186 (220 mg, 592 µmol, 1.0 equiv.), 1-(3-phenoxyphenyl)propargyl acetate
111 (189 mg, 711 µmol, 1.2 equiv.), Cu(OAc)2 (27 mg, 148 µmol, 0.25 equiv.) and sodium
ascorbate (57 mg, 296 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was stirred at
r. t. for 24 h and after work up, the title compound 227 was attained as a dark yellow oil
-1
1
(363 mg, 96 %). [α]20
D = 38.52 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, CDCl3):

δ 2.07 (Ac), 2.08 (Ac), 2.11 (Ac), 4.44-4.48 (m, 1H, H-4’), 4.67-4.78 (m, 2H, H-5’), 5.295.35 (m, 1H, H-3’), 5.37-5.41 (m, 1H, H-2’), 5.62-5.66 (m, 1H, H-5), 6.89-6.91 (m, 1H, H1’), 6.97-7.00 (m, 3H, ArH), 7.08-7.14 (m, 2H, ArH), 7.17-7.20 (m, 1H, ArH), 7.22-7.23 (m,
1H, ArH), 7.27-7.32 (m, 3H, ArH/H-6), 7.58 + 7.60 (s, 1H, H-5”), 9.89 (br s, 1H, NH).
13

C NMR (125 MHz, CDCl3): δ 20.3 (Ac-CH3), 20.3 (Ac-CH3), 21.0 + 21.0 (Ac-CH3), 50.9

(C-5’), 69.4 + 69.5 (CHOAc), 70.3 + 70.4 (C-3’), 72.6 + 72.7 (C-2’), 79.9 (C-4’), 90.9 + 91.2
(C-1’), 117.3 + 117.4 (ArCH), 118.2 + 118.3 (ArCH), 118.9 (2 x ArCH), 121.7 (ArCH),
123.5 (C-5”), 124.1 + 124.2 (ArCH), 125.5 + 125.8 (2 d, J = 34.5 Hz, C-6), 129.7 (2 x ArCH),
129.9 + 129.9 (ArCH), 140.1 + 140.1 (ArC), 140.6 (d, J = 239.4 Hz, C-5), 147.1 + 147.2 (C4”), 148.8 + 148.8 (C-2), 156.6 (ArC-O), 156.6 + 156.7 (2 d, J = 26.8 Hz, C-4), 157.4 + 157.4
(ArC-O), 169.7 (Ac-C=O), 169.8 + 169.8 (Ac-C=O), 169.9 + 169.9 (Ac-C=O). LRMS-ESI:
m/z = 660 [M+Na]+. HRESI-MS: m/z calcd for C30H28FN5O10Na [M+Na]+: 660.1718; found
660.1733. Δ = 2.43 ppm
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5’-(4-(α-Acetoxy-3-phenoxybenzyl)triazolo)-5’-deoxy-5-fluoro-2’,3’-Oisopropylidenuridine 228

This compound was prepared following procedure D using 5’-Azido-5’-deoxy-5-fluoro-2’,3’isopropylidenuridine 184 (250 mg, 763 µmol, 1.0 equiv.), 1-(3-phenoxy-phenyl)propargyl
acetate 111 (244 mg, 917 µmol, 1.2 equiv.), Cu(OAc)2 (35 mg, 191 µmol, 0.25 equiv.) and
sodium ascorbate (76 mg, 382 µmol, 0.5 equiv.) in CH3CN/H2O [4:1]. The suspension was
stirred at r. t. for 24 h and after work up, the title compound 228 was attained as a dark yellow
-1
1
oil (413 mg, 91 %). [α]20
D = 61.85 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, CDCl3):

δ 1.32 (s, 3H, CH3), 1.53 + 1.53 (2 s, 3H,CH3), 2.11 (s, 3H, Ac), 4.44-4.47 (m, 1H, H-4’), 4.624.72 (m, 2H, H-5’), 4.90-4.94 (m, 1H, H-3’), 5.00-5.04 (m, 1H, H-2’), 5.47-5.48 + 5.50-5.51
(m, 1H, H-1’), 6.88-6.91 (m, 1H, ArH), 6.97-7.00 (m, 3H, ArH/CHOAc), 7.27-7.33 (m, 3H,
ArH/H-6), 7.49 + 7.50 (2 s, 1H, H-5”), 10.50 (br s, 1H, NH).

13

C NMR (75 MHz, CDCl3):

δ 21.0 (Ac-CH3), 25.1 (CH3), 26.9 (CH3), 51.9 (C-5’), 69.5 (CHOAc), 81.4 (C-3’), 83.9 (C2’), 85.6 (C-4’), 95.5 (C-1’), 115.0 (Cq), 117.4 (ArCH), 118.3 (ArCH), 118.9 (2 x ArCH),
121.7 (ArCH), 123.5 (C-5”), 123.8 (ArCH), 127.1 (d, J = 33.4 Hz, C-6), 129.7 (2 x ArCH),
129.9 (ArCH), 140.1 (ArC), 141.9 (d, J = 238.4 Hz, C-5), 146.9 (C-4”), 148.8 (C-2), 156.6
(ArC-O), 157.1 (d, J = 26.5 Hz, C-4), 157.3 (ArC-O), 169.9 (Ac-C=O). LRMS-ESI:
m/z = 616 [M+Na]+. HRESI-MS: m/z calcd for C29H28FN5O8Na [M+Na]+: 616.1834; found
616.1833; Δ = 0.16 ppm
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6.1.5.2. Deprotection
5’-Deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)uridine 229

This compound was prepared according to general procedure E, described p. 143, using 206
(130 mg, 0.21 mmol, 1.0 equiv.). After work up, the title compound 229 was attained as a
-1
white powder (96 mg, 93 %). m.p. 173-174 °C. [α]20
D = 27.63 (c = 5 mg.mL , CH3OH).
1

H NMR (300 MHz, DMSO-d6): δ 3.97-4.00 (m, 1H, H-3’), 4.03-4.06 (m, 1H, H-2’), 4.14-

4.16 (m, 1H, H-4’), 4.59-4.64 (m, 1H, H-5’a), 4.66-4.71 (m, 1H, H-5’b), 5.42-5.43 (s, 1H, OH2’), 5.54-5.56 (m, 1H, OH-3’), 5.58-5.61 (m, 1H, H-5), 5.75-5.76 (m, 1H, H-1’), 5.81-5.82
(m, 1H, CHOH), 6.09 (m, 1H, OH), 6.86-6.88 (m, 1H, ArH), 6.99-7.01 (m, 2H, ArH), 7.097.11 (m, 1H, ArH), 7.13-7.16 (m, 2H, ArH), 7.31-7.34 (m, 1H, ArH), 7.36-7.39 (m, 2H, ArH),
7.43-7.44 + 7.48-7.50 (m, 1H, H-6), 7.85 + 7.85 (2 s, 1H, H-5”), 11.40 (br s, 1H, NH).
13

C NMR (75 MHz, DMSO-d6): δ 51.2 + 51.2 (C-5’), 67.5 (CHOH), 70.6 (C-3’), 72.1 + 72.2

(C-2’), 81.8 + 81.9 (C-4’), 88.5 + 88.6 (C-1’), 102.2 (C-5), 116.3 + 116.4 (ArCH),
117.2 + 117.2 (ArCH), 118.8 (2 x ArCH), 121.5 + 121.5 (ArCH), 123.0 + 123.1 (C-5”),
123.6 (ArCH), 129.8 (ArCH), 130.1 (2 x ArCH), 138.3 (ArC), 140.9 + 141.0 (C-6),
146.3 + 146.4 (C-4”), 150.7 + 150.7 (C-2), 151.2 + 151.3 (ArC-O), 156.6 + 156.7 (ArC-O),
163.1 + 163.1 (C-4). LRMS-ESI: m/z = [M+Na]+. HRESI-MS: m/z calcd for C27H27N5O7Na
[M+Na]+: 598.1914; found 598.1931; Δ = 2.84 ppm
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5’-Deoxy-5’-(4-(3-cyclopentoxy-α-hydroxybenzyl)triazolo)uridine 230

This compound was prepared according to general procedure E using 210 (280 mg,
0.458 mmol, 1.0 equiv.). After work up, the title compound 230 was attained as a colourless
-1
1
syrup (204 mg, 92 %). [α]20
D = 21.36 (c = 5 mg.mL , CH3OH). H NMR (400 MHz, DMSO-

d6): δ 1.53-1.59 (m, 2H, H-3””a/H-4””a), 1.63-1.72 (m, 4H, H-2””a/H-3””b/H-4””b/H-5””a),
1.84-1.92 (m, 2H, H-2””b/H-5””b), 3.93-3.98 (m, 2H, H-2’/H-3’), 4.11-4.16 (m, 1H, H-4’),
4.57-4.70 (m, 2H, H-5’), 4.72-4.78 (m, 1H, H-1””), 5.37-5.39 (m, 1H, OH-2’), 5.49-5.51 (m,
1H, OH-3’), 5.55-5.61 (m, 1H, H-5), 5.73-5.77 (m, 2H, H-1’/CHOH), 5.95-5.96 (m, 1H, OH),
6.74-6.77 (m, 1H, ArH), 6.90-6.92 (m, 2H, ArH), 7.17-7.21 (m, 1H, ArH), 7.42 + 7.47
(2 d, J = 8.1 Hz, 1H, H-6), 7.82 + 7.82 (2 s, 1H, H-5”), 11.36 (br s, 1H, NH). 13C NMR
(125 MHz, DMSO-d6): δ 23.6 (C-3””/C-4””), 32.3 (C-2””/C-5””), 51.1 + 51.1 (C-5’), 67.8
(CHOH), 70.5 + 70.5 (C-3’), 72.1 + 72.1 (C-2’), 79.2 (C-1””), 81.7 + 81.8 (C-4’), 88.4 + 88.5
(C-1’), 102.1 + 102.1 (C-5), 113.4 + 113.4 (ArCH), 113.7 + 133.8 (ArCH), 118.3 + 118.3
(ArCH), 122.8 + 122.9 (ArCH), 129.1 (ArCH), 140.8 + 140.9 (C-6), 145.6 + 145.6 (C-4”),
150.6 (C-2), 151.5 (ArC), 157.5 (ArC-O), 163.0 (C-4). LRESI-MS: m/z = 508 [M+Na]+.
HRESI-MS: m/z calcd for C23H27N5O7Na [M+Na]+: 508.1808; found 508.1804;
Δ = 0.79 ppm
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5’-Deoxy-5’-(4-(3-cyclopentoxy-α-methoxybenzyl)triazolo)uridine 231

5’-(4-(α-Acetoxy-3-cyclopentoxybenzyl)triazolo)-5’-deoxy-2’,3’-O-isopropylidenuridine

210

(400 mg, 0.705 mmol, 1.0 equiv.) and In(OTf)3 (20 mg, 0.035 mmol, 5 mol%) were dissolved in
CH3CN/H2O [9:1] (20 mL) and the solution was stirred at r. t. overnight. At this stage, no reaction
was occurring judging by TLC and the mixture was brought to reflux. After 6 h, the solvent was
evaporated under reduced pressure and the remaining water was co-evaporated with methanol.
The residue was purified by silica gel chromatography eluted with CH2Cl2/CH3OH [9:1] to afford
the title compound 231 was attained as a colourless syrup (169 mg, 48 %) along with 230
-1
1
(99 mg, 29 %). [𝛂]𝟐𝟎
𝐃 = 19.46 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6): δ 1.56

(m, 2H, H-3””a/H-4””a), 1.68 (m, 4H, H-2””a/H-3””b/H-4””b/H-5””a), 1.88 (m, 2H, H-2””b/H5””b), 3.24 + 3.25 (2 s, 3H, OCH3), 3.95-4.03 (m, 2H, H-2’/H-3’), 4.13 (m, 1H, H-4’), 4.58-4.64
(m, 1H, H-5’a), 4.67-4.68 (m, 1H, H-5’b), 5.35-5.36 (d, J = 5.1 Hz, 1H, OH-2’), 5.41 (m, 1H, H1””), 5.48-5.49 (d, J = 5.5 Hz, 1H, OH-3’), 5.55-5.57 (m, 1H, H-5), 5.72-5.73 (m, 1H, H-1’),
6.80-6.81 (m, 1H, ArH), 6.90-6.92 (m, 2H, ArH), 7.21-7.25 (m, 1H, ArH), 7.40 + 7.46 (2 d,
J = 8.1 Hz, 1H, H-6), 7.90 + 7.91 (2 s, 1H, H-5”), 11.32 (br s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 23.5 (C-3””/C-4””), 32.2 + 32.2 (C-2””/C-5””), 56.2 + 56.2 (C-5’),
70.5 + 70.5 (C-3’), 72.0 + 72.1 (C-2’), 77.4 + 77.4 (CH), 78.5 + 78.5 (C-1””), 81.6 + 81.7 (C4’), 88.5 + 88.6 (C-1’), 102.0 (C-5), 113.8 + 113.8 (ArCH), 114.4 + 114.5 (ArCH), 118.8
(ArCH), 123.5 (C-5”’), 129.4 (ArCH), 140.8 + 140.8 (C-6), 141.9 (ArC), 148.2 + 148.2 (C4”), 150.6 (C-2), 157.6 (ArC-O), 162.9 (C-4). LRESI-MS: m/z = 522 [M+Na]+. HRESI-MS:
m/z calcd for C24H29N5O7Na [M+Na]+: 522.1965; found 522.1953; Δ = 2.30 ppm
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Chapter 6

5’-Deoxy-5’-(4-(α-hydroxy-3-propoxybenzyl)triazolo)uridine 232

This compound was prepared according to general procedure E using 212 (250 mg,
0.427 mmol, 1.0 equiv.). After work up, the title compound 232 was attained as a colourless
-1
1
syrup (184 mg, 94 %). [α]20
D = 17.86 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-

d6): δ 0.96 + 0.96 (2 t, J = 7.3 Hz, 3H, H-3””), 1.68-1.73 (m, 2H, H-2””), 3.86-3.90 (m, 2H,
H-1””), 3.94-3.97 (m, 2H, H-2’/H-3’), 4.08-4.15 (m, 1H, H-4’), 4.57-4.63 (m, 1H, H-5’a),
4.65-4.69 (m, 1H, H-5’b), 5.37-5.38 (m, 1H, OH-2’), 5.49-5.51 (m, 1H, OH-3’), 5.56 + 5.60
(2 d, J = 8.1 Hz, 1H, H-5), 5.73-5.74 (m, 1H, H-1’), 5.76-5.77 (m, 1H, CHOH), 5.96-5.97
(m, 1H, OH), 6.78-6.80 (m, 1H, ArH), 6.93-6.94 (m, 1H, ArH), 6.96 (m, 1H, ArH), 7.18-7.22
(m, 1H, ArH), 7.42 + 7.47 (2 d, J = 8.1 Hz, 1H, H-6), 7.83 + 7.83 (2 s, 1H, H-5”), 11.36
(br s, 1H, NH).

13

C NMR (125 MHz, DMSO-d6): δ 10.3 + 10.5 (C-3””), 22.0 (C-2””),

51.0 + 51.2 (C-5’), 67.7 + 67.8 (CHOH), 70.4 + 70.6 (C-3’), 71.9 + 72.0 (C-1””), 72.1 + 72.2
(C-2’), 81.7 + 81.8 (C-4’), 88.3 + 88.5 (C-1’), 102.1 + 102.1 (C-5), 112.3 + 112.4 (ArCH),
112.9 + 113.0 (ArCH), 118.4 + 118.5 (ArCH), 123.0 + 123.0 (C-5”), 129.0 (ArC), 129.2
(ArCH), 140.7 + 141.0 (C-6), 145.6 + 145.6 (C-4”), 150.6 (C-2), 158.5 (ArC-O),
162.9 + 162.9 (C-4). LRESI-MS: m/z = 459 [M+Na]+. HRESI-MS: m/z calcd for
C21H25N5O7Na [M+Na]+: 482.1652; found 482.1667. Δ = 3.11 ppm

223

Chapter 6

5’-Deoxy-5’-(4-(3-cyclopentoxy-4-methoxy-α-hydroxybenzyl)triazolo)uridine 233

This compound was prepared according to general procedure E using 214 (230 mg, 0.358 mmol,
1.0 equiv.). After work up, the title compound 233 was attained as a white powder (166 mg,
-1
1
90 %). m.p. 236-238 °C. [α]20
D = 15.07 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-

d6): δ 1.55 (m, 2H, H-3””/H-4””a), 1.69 (m, 4H, H-2””/H-3””/H-4””/H-5””a), 1.81-1.82 (m, 2H,
H-2””/H-5””b), 3.72 (s, 3H, OCH3), 4.43 (m, 1H, H-3’), 4.73-4.75 (m, 3H, H-5’/H-1””), 5.35-5.36
(m, 1H, H-2’), 5.40-5.47 (m, 1H, H-4’), 5.63-5.66 (m, 1H, H-5), 5.84-5.85 (m, 1H, H-1’), 6.876.91 (m, 2H, H-2’’’/H-5’’’), 6.93-6.94 (m, 1H, H-6’’’), 7.60-7.65 (m, 1H, H-6), 7.90 + 7.92 (2 s,
1H, H-5”), 11.49 (br s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 23.5 (C-3””/C-4””), 32.1
(C-2””/C-5””), 50.5 (C-5’), 55.5 (OCH3), 70.3 (C-3’), 71.6 (C-2’), 77.2 (C-1””), 79.4 (C-4’),
88.4 (C-1’), 102.3 (C-5), 112.0 + 112.0 (C-2’’’), 113.5 (C-6’’’), 119.4 (C-5’’’), 123.3 + 123.4
(C-5”), 132.6 (C-1’’’), 141.8 (C-6), 146.9 (C-4”), 148.7 (C-3’’’), 149.2 (C-4’’’), 150.2 (C-2),
162.9 (C-4). LRESI-MS: m/z = 538 [M+Na]+. HRESI-MS: m/z calcd for C29H27FN5O8Na
[M+Na]+: 538.1914; found 538.1921. Δ = 1.30 ppm
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Chapter 6

5’-Deoxy-5’-(4-(α-hydroxy-4-methoxy-3-phenoxybenzyl)triazolo)uridine 234

This compound was prepared according to general procedure E using 215 (240 mg, 0.370 mmol,
1.0 equiv.). After work up, the title compound 234 was attained as a white powder (164 mg, 85 %).
-1
1
m.p. 293-295 °C. [α]25
D = 1.02 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6):

δ 2.88 (s, 3H, OCH3), 3.08-3.21 (m, 2H, H-2’/H-3’), 3.26-3.34 (m, 1H, H-4’), 3.73-3.87 (m,
2H, H-5’), 4.48-4.56 (m, 1H, OH-3’), 4.65 (m, 1H, OH-2’), 4.74 (t, J = 8.2 Hz, 1H, H-1’),
4.88-4.93 (m, 2H, H-5, CHOH), 5.10 (m, 1H, OH), 5.98 (d, J = 7.8 Hz, 2H, ArH), 6.18 (t,
J = 7.2 Hz, 1H, ArH), 6.31-6.22 (m, 2H, ArH), 6.35 (d, J = 8.2 Hz, 1H, ArH), 6.45 (t,
J = 7.5 Hz, 2H, ArH), 6.59 (dd, J = 24.8, 8.0 Hz, 1H, H-6), 10.51 (s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 51.0 + 51.1 (C-5’), 55.7 + 55.7 (OCH3), 67.1 + 67.1 (CHOH), 70.5
(C-3’), 72.1 + 72.1 (C-2’), 81.6 + 81.7 (C-4’), 88.5 + 88.7 (C-1’), 102.0 (C-5), 113.0 (ArCH),
116.0 (ArCH), 119.6 (ArCH), 119.6 (ArCH), 122.0 (ArCH), 122.8 (ArCH), 123.2 (ArCH),
123.3 (C-5”), 1296 (ArCH), 1371 + 137.1 (C), 140.8 + 140.9 (C-6), 143.2 (C-4”),
150.3 + 150.6 (C-2), 151.4 + 151.4 (ArC-O), 157.7 (ArC-O), 162.9 (C-4). LRESI-MS:
m/z = 628 [M+Na]+. HRESI-MS: m/z calcd for C30H31N5O9Na [M+Na]+: 628.2019; found
628.2047; Δ = 4.46 ppm
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5’-Deoxy-5’-(4-(4-fluoro-α-hydroxy-3-phenoxybenzyl)triazolo)uridine 235

This compound was prepared according to general procedure E using 216 (180 mg,
0.282 mmol, 1.0 equiv.). After work up, the title compound 235 was attained as a white
-1
1
powder (128 mg, 89 %). m.p. 221-223°C. [α]20
D = 12.64 (c = 5 mg.mL , CH3OH). H NMR

(500 MHz, DMSO-d6): δ 3.24-3.10 (m, 2H, H-2’, H-3’), 3.34-3.26 (m, 1H, H-4’), 3.89-3.74
(m, 2H, H-5’), 4.56 (d, J = 4.7 Hz, 1H, OH-3’), 4.69-4.66 (m, 1H, OH-2’), 4.78-4.74 (m, 1H,
H-5), 4.91 (d, J = 5.2 Hz, 1H, H-1’), 4.98 (d, J = 3.3 Hz, 1H, CHOH), 5.29-5.24 (m, 1H, OH),
6.14 (d, J = 7.5 Hz, 2H, ArH), 6.32-6.26 (m, 1H, ArH), 6.42-6.35 (m, 2H, ArH), 6.57-6.47
(m, 3H, ArH), 6.63 (dd, J = 29.0 Hz, J = 8.0 Hz, 1H, H-6), 10.52 (s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 52.2 + 52.0 (C-5'), 67.7 + 67.8 (CHOH), 71.4 + 71.5 (C-3’),
72.9 + 72.9 (C-2’), 82.5 + 82.6 (C-4’), 89.4 + 89.6 (C-1’), 103.0 (C-5), 117.8 (2 x ArCH),
117.9 (ArCH), 120.7 (d, J = 6.1 Hz, ArCH), 123.8 + 124.0 (C-5”), 124.2 (d, J = 11.6 Hz,
ArCH), 130.8 (2 x ArCH), 131.1 (ArC), 141.6 + 141.7 (C-6), 143.3 (d, J = 11.7 Hz, ArCH),
151.6 + 151.9 (C-2), 153.5 (d, J = 249.7 Hz, C-F), 157.7 (2 x ArC-O), 163.9 (C-4). LRESIMS: m/z = 534 [M+Na]+. HRESI-MS: m/z calcd for C24H22FN5O7Na [M+Na]+: 534.1401;
found 534.1427; Δ = 4.87 ppm
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5’-Deoxy-5’-(4-(α-hydroxy-3-(4-fluorophenoxy)benzyl)triazolo)uridine 236

This compound was prepared according to general procedure E using 217 (180 mg, 0.282 mmol,
1.0 equiv.). After work up, the title compound 236 was attained as a white powder (131 mg,
-1
1
91 %). m.p. -°C. [α]20
D = 41.19 (c = 5 mg.mL , CH3OH). H NMR (400 MHz, DMSO-d6):

δ 3.94-3.98 (m, 1H, H-3’), 4.00-4.07 (m, 1H, H-2’), 4.11-4.15 (m, 1H, H-4’), 4.57-4.71 (m, 2H,
H-5’), 5.39 (br s, 1H, OH-3’), 5.51 (br s, 1H, OH-2’), 5.56 + 5.59 (2 d. J = 8.3 Hz, 1H, H-5),
5.73-5.75 (m, 1H, H-1’), 5.80 (m, 1H, CHOH), 6.04 (br s, 1H, OH), 6.82-6.90 (m, 1H, ArH),
7.03-7.07 (m, 3H, ArH), 7.12-7.14 (m, 1H, ArH), 7.19-7.25 (m, 2H, ArH), 7.20-7.33 (m, 1H,
ArH), 7.41-7.48 (m, 1H, H-6), 7.83 + 7.84 (2 s, 1H, H-5”), 10.96 (br s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 51.1 (C-5’), 67.4 (CHOH), 70.5 (C-3’), 72.0 + 72.1 (C-2’), 81.7 + 81.8
(C-4’), 88.4 + 88.5 (C-1’), 102.0 + 102.1 (C-5), 115.7 + 115.8 (ArCH), 116.5 (ArCH), 116.6 (d,
J = 24.2 Hz, 2 x ArCH), 120.7 + 120.8 (2 d, J = 8.1 Hz, 2 x ArCH), 121.3 (ArCH), 122.9 + 123.0
(C-5”), 129.7 (ArCH), 140.1 + 140.2 (ArC), 141.5 (C-6), 150.6 + 150.6 (C-2), 151.1 + 151.2 (C4”), 152.4 + 152.4 (ArC-O), 157.0 (ArC-O), 158.2 (d, J = 240.6 Hz, ArC-F), 162.9 (C-4).
LRMS-ESI: m/z = 534 [M+Na]+. HRESI-MS: m/z calcd for C24H22FN5O7Na [M+Na]+:
534.1401; found 534.1422. Δ = 3.93 ppm
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5’-(4-(α-Hydroxy-benzothien-2-ylmethyl)triazolo)-5’-deoxyuridine 237

This compound was prepared according to general procedure E using 218 (135 mg, 0.23 mmol,
1.0 equiv.). After work up, the title compound 237 was attained as a off white powder (99 mg,
-1
1
94 %). m.p. 202-204°C. [α]25
D = 29.08 (c = 1 mg.mL , CH3OH). H NMR (500 MHz, DMSO-

d6): δ 3.97 (m, 1H, H-3’), 4.10 (m, 1H, H-2’), 4.13-4.17 (m, 1H, H-4’), 4.61-4.67 (m, 1H, H5’a), 4.69-4.71 + 4.72-4.73 (m, 1H, H-5’b), 5.41 (br s, 1H, OH-3’), 5.53 (br s, 1H, OH-2’),
5.58 + 5.62 (2 d, J = 8.1 Hz, 1H, H-5), 5.74 + 5.75 (m, 1H, H-1’), 6.16 (m, 1H, CHOH), 6.55
(m, 1H, OH), 7.26-7.35 (m, 3H, H-3’’’/H-5’’’/H-6’’’), 7.48-7.50 + 7.53-7.55 (m, 1H, H-6),
7.75-7.77 (m, 1H, H-4’’’), 7.88-7.90 (m, 1H, H-7’’’), 7.99 + 8.01 (2 s, 1H, H-5”), 11.37 (br s,
1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 51.2 + 51.2 (C-5’), 64.6 + 64.7 (CHOH), 70.5
(C-3’), 72.0 + 72.0 (C-2’), 81.7 + 81.8 (C-4’), 88.4 + 88.5 (C-1’), 102.1 + 102.2 (C-5),
120.4 + 120.5 (C-3’’’), 122.4 (C-7’’’), 123.2 + 123.2 (C-5”), 123.5 (C-4’’’), 124.1 (C-5’’’),
124.2 (C-6’’’), 138.9 + 138.9 (ArC), 139.2 + 139.2 (ArC), 141.0 + 141.0 (C-6), 149.2 + 149.2
(C-4”), 150.2 + 150.3 (C-2), 150.7 + 150.7 (C-2’’’), 163.0 (C-4). LRMS-ESI: m/z = 480
[M+Na]+. HRESI-MS: m/z calcd for C20H19N5O6SNa [M+Na]+: 480.0954; found 480.0972;
Δ = 3.75 ppm
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5’-(4-(N-tert-Butoxycarbonylindol-3-yl)hydroxymethyltriazolo)-5’-deoxyuridine 238

This compound was prepared according to general procedure E using 219 (300 mg,
0.450 mmol, 1.0 equiv.). After work up, the title compound 238 was attained as a white
-1
1
powder (202 mg, 83 %). m.p. 215-216 °C. [α]20
D = 38.30 (c = 5 mg.mL , CH3OH). H NMR

(500 MHz, DMSO-d6): δ 1.62 (s, 9H, Boc), 3.95-3.96 (m, 1H, H-3’), 4.00-4.03 (m, 1H, H2’), 4.09-4.15 (m, 1H, H-4’), 4.58-4.64 (m, 1H, H-5’a), 4.66-4.71 (m, 1H, H-5’b), 5.38 (br s,
1H, OH-2’), 5.50 (br s, 1H, OH-3’), 5.55-5.59 (m, 1H, H-5), 5.72-5.78 (m, 1H, H-1’), 6.016.03 (m, 1H, OH), 6.07 (m 1H, CHOH), 7.12-7.17 (m, 1H, ArH), 7.27-7.30 (m, 2H, H5”/ArH), 7.44-7.46 (m, 1H, H-6), 7.49-7.52 (m, 1H, ArH), 7.57-7.58 (m, 1H, ArH), 8.03-8.05
(m, 1H, ArH), 11.34 (br s, 1H, NH).

13

C NMR (125 MHz, DMSO-d6): δ 27.7 (Boc-

C(CH3)3), 51.2 (C-5’), 61.8 (CHOH), 70.5 (C-3’), 72.0 (C-2’), 81.8 (C-4’), 83.7 (BocC(CH3)3), 88.4 (C-1’), 102.1 (C-5), 114.7 (ArCH), 120.5 (ArCH), 122.5 (ArCH), 123.3
(ArC), 123.7 (ArCH), 124.3 (C-5”), 128.3 (ArCH), 135.1 (ArC), 140.9 (C-6), 149.1 (C-4”),
150.3 (Boc-C=O), 150.6 (C-2), 162.9 (C-4). LRMS-ESI: m/z = 563 [M+Na]+. HRESI-MS:
m/z calcd for C25H28N6O8Na [M+Na]+: 563.1866; found 563.1891; Δ = 4.40 ppm
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5’-(4-(N-tert-Butoxycarbonylindol-3-yl)-α-carboxamido-α-hydroxymethyltriazolo)-5’deoxyuridine 239

This compound was prepared according to general procedure E using 220 (250 mg,
0.366 mmol). After work up, the title compound 239 was attained as an off white powder
-1
(173 mg, 79 %). m.p. > 280 °C, decomposed. [α]20
D = 36.28 (c = 5 mg.mL , CH3OH).
1

H NMR (500 MHz, DMSO-d6): δ 1.62 (s, 9H, Boc), 3.67 + 3.67 (2 s, 3H, OCH3), 3.96-4.01

(m, 2H, H-2’/H-3’), 4.14-4.18 (m, 1H, H-4’), 4.63-4.67 (m, 1H, H-5’a), 4.71-4.74 (m, 1H, H5’b), 5.38-5.39 (m, 1H, OH-2’), 5.50-5.51 (m, 1H, OH-3’), 5.56-5.58 (m, 1H, H-5), 5.57-5.76
(m, 1H, H-1’), 6.85 (s, 1H, OH-2”), 7.10-7.15 (m, 1H, ArH), 7.26-7.31 (m, 1H, ArH), 7.397.47 (m, 2H, ArH), 7.55 (d, J = 9.1 Hz, 1H, H-6), 7.97-8.01 (m, 1H, H-5”), 8.04-8.06 (m, 1H,
ArH).
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C NMR (125 MHz, DMSO-d6): δ 27.6 (Boc-C(CH3)3), 51.2 (C-5’), 52.6 (OCH3),

70.5 + 70.5

(C-3’),

72.0 + 72.1

84.0 + 84.0 (Boc-C(CH3)3),

(COH),

88.3 + 88.3

72.5 + 72.6
(C-1’),

102.1

(C-2’),
(C-5),

81.7 + 81.8
114.5

(C-4’),
(ArCH),

122.0 + 122.1 (ArCH), 122.4 (ArC), 124.1 (ArCH) 124.3 (C-5”), 128.0 (ArCH) 133.2 (ArC)
135.1 (ArCH), 137.7 + 137.8 (ArC), 140.8 (C-6), 148.6 (C-4”), 148.9 (Boc-C=O),
150.6 + 150.7 (C-2), 162.9 (C-4), 172.0 (C=O). LRMS-ESI: m/z = 621 [M+Na]+. HRESIMS: m/z calcd for C27H30N6O10Na [M+Na]+: 621.1921; found 621.1930; Δ = 1.45 ppm
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Chapter 6

5’-(4-(3’’’-Hydroxyindan-2-on-3-yl)triazolo)-5’-deoxyuridine 240

This compound was prepared according to general procedure E using 221 (250 mg, 0.475 mmol,
1.0 equiv.). After work up, the title compound 240 was attained as a white powder (185 mg,
-1
1
88 %). m.p. 241-243°C. [α]20
D = 62.54 (c = 5 mg.mL , CH3OH). H NMR (400 MHz, DMSO-

d6): δ 3.91-4.03 (m, 2H, H-2’/H-3’), 4.14-4.18 (m, 1H, H-4’), 4.62-4.74 (m, 2H, H-5’), 5.41
(br s, 1H OH-2’), 5.51 (br s, 1H, OH-3’), 5.62 + 5.63 (2 d, J = 8.1 Hz, H-5), 5.75-5.77 (m,
1H, H-1’), 6.70 (br s, 1H, OH-3’’’), 6.85-6.87 (m, 1H, ArH), 6.94-6.98 (m, 1H, ArH), 7.217.26 (m, 2H, ArH), 7.40 + 7.49 (2 d, J = 8.3 Hz, 1H, H-6), 8.09 + 8.10 (2 s, 1H, H-5”), 10.43
(br s, 1H, NH-1’’’), 11.33 (br s, 1H, NH-3). 13C NMR (125 MHz, DMSO-d6): δ 51.1 + 51.2
(C-5’), 70.4 + 70.5 (C-3’), 72.0 + 72.1 (C-2’), 73.0 + 73.0 (C), 81.7 + 81.8 (C-4’), 88.2 + 88.4
(C-1’), 102.2 + 102.2 (C-5), 109.8 (ArCH), 121.8 (ArCH), 124.0 + 124.2 (C-5”),
125.2 + 125.3 (ArC), 129.4 (ArCH), 132.1 (ArCH), 140.8 + 140.9 (ArC), 141.8 + 141.9 (C6), 148.0 + 148.0 (C-4”), 150.6 + 150.7 (C-2), 163.0 (C-4), 177.2 (C=O). LRMS-ESI:
m/z = 465 [M+Na]+. HRESI-MS: m/z calcd for C19H18N6O7Na [M+Na]+: 465.1135; found
465.1135; Δ = 0 ppm
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5’-(4-(α-Hydroxy-α-trifluoromethylbenzyl)triazolo)-5’-deoxyuridine 241

This compound was prepared according to general procedure E using 222 (300 mg, 0.504 mmol,
1.0 equiv.). After work up, the title compound 241 was attained as a white powder (203 mg, 86 %).
-1
1
m.p. 122-123 °C. [α]25
D = 18.67 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6):

δ 3.96-4.00 (m, 1H, H-3’), 4.03-4.09 (m, 1H, H-2’), 4.14-4.21 (m, 1H, H-4’), 4.66-4.79 (m,
2H, H-5’), 5.36-5.38 (m, 1H, OH-2’), 5.45-5.61 (m, 3H, H-5/OH/OH-3’), 5.74-5.76 (m, 1H,
H-1’), 7.37-7.42 (m, 2H, ArH), 7.44-7.47 (m, 1H, ArH), 7.47 + 7.55 (2 d, J = 8.3 Hz, 1H, H6), 7.59-7.62 (m, 2H, ArH), 8.12 + 8.13 (2 s, 1H, H-5”), 11.29 (br s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 51.3 + 51.3 (C-5’), 70.5 + 70.6 (C-3’), 72.0 + 72.0 (C-2’),
81.6 + 81.7 (C-4’), 88.6 + 88.7 (C-1’), 102.0 + 102.1 (C-5), 125.0 + 125.0 (C-5”), 125.1
(ArCH), 127.4 (d, J = 4.4 Hz, 2 x ArCH), 127.8 (2 x ArCH), 128.0 (d, J = 286.8 Hz, CF3),
128.3 (d, J = 28.6 Hz, C), 137.8 + 137.9 (ArC), 140.9 + 141.0 (C-6), 146.6 (C-4”), 150.7 (C2), 162.9 (C-4). LRMS-ESI: m/z = 492 [M+Na]+. HRESI-MS: m/z calcd for C19H18FN5O6Na
[M+Na]+: 492.1107; found 492.1123. Δ = 3.25 ppm
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5’-Deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)cytidine 242

This compound was prepared according to general procedure E using 204 (90 mg, 136 µmol,
1.0 equiv.). After work up, the title compound 242 was attained as a white powder (58 mg, 87 %).
-1
1
m.p. 231-233 °C. [α]20
D = 23.19 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, DMSO-d6):

δ 3.93 (m, 1H, H-3’), 3.98 (m, 1H, H-2’), 4.11-4.12 (m, 1H, H-4’), 4.57-4.63 (m, 1H, H-5’a),
4.65-4.71 (m, 1H, H-5’b), 5.34 (br s, 1H, OH-2’), 5.44 (br s, 1H, OH-3’), 5.72 (m, 1H,
CHOH), 5.74-5.76 (m, 1H, H-5), 5.80-5.81 (m, 1H, H-1’), 6.05-6.07 (m, 1H, OH), 6.85-6.87
+ 6.88-6.89 (m, 1H, ArH), 6.98-7.01 (m, 2H, ArH), 7.08-7.15 (m, 3H, ArH), 7.21 (br s, 1H,
NH), 7.26 (br s, 1H, NH), 7.30-7.33 (m, 1H, ArH), 7.34-7.43 (m, 3H, ArH/H-6), 7.83 + 7.83
(2 s, 1H, H-5”). 13C NMR (75 MHz, DMSO-d6): δ 51.3 + 51.4 (C-5’), 67.5 + 67.5 (CHOH),
70.7 + 70.8 (C-3’), 72.8 + 72.8 (C-2’), 81.2 + 81.3 (C-4’), 90.1 + 90.3 (C-1’), 94.5 + 94.5 (C5), 116.3 + 116.4 (ArCH), 117.1 (ArCH), 118.7 (2 x ArCH), 121.4 + 121.5 (ArCH), 122.9
(ArCH), 123.5 (C-5”), 129.7 (ArCH), 130.0 (2 x ArCH), 141.6 + 141.7 (C-4”),
146.3 + 146.3 (C-6), 151.2 + 151.2 (C-2), 155.2 + 155.3 (ArC-O), 156.6 (ArC-O), 165.6 (C4). LRMS-ESI: m/z = 515 [M+Na]+. HRESI-MS: m/z calcd for C24H24N6O6Na [M+Na]+:
555.1655; found 555.1669; Δ = 2.52 ppm
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5’-Deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)thymidine 243

This compound was prepared according to general procedure E using 223 (280 mg, 0.486 mmol,
1.0 equiv.). After work up, the title compound 243 was attained as a white powder (232 mg,
-1
1
97 %). m.p. 218-220 °C. [α]20
D = 46.96 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-

d6): δ 1.77 (s, 3H, CH3). 2.07-2.13 (m, 2H, H-2’), 4.07 (m, 1H, H-4’), 4.26 (m, 1H, H3’), 4.54-4.60 (m, 1H, H-5’a), 4.65-4.68 (m, 1H, H-5’b), 5.48 (m, 1H, OH-3’), 5.80 (m,
1H, CHOH), 6.03 (m, 1H, OH), 6.16 (m, 1H, CH-1’), 6.86 (d, J = 7.8 Hz, 1H, ArH),
6.98 (m, 2H, ArH), 7.06 (m, 1H, ArH), 7.11-7.24 (m, 2H, C-6, ArH), 7.30-7.32 (m,
2H, ArH), 7.36-7.39 (m, 2H, ArH), 7.85 (d, J = 8.8 Hz, 1H, ArH), 11.27 (br s, 1H,
NH).

13

C NMR (125 MHz, DMSO-d6): δ 11.9 (CH3), 37.9 (C-2’), 51.1 + 51.2 (C-5’),

67.4 + 67.5 (CHOH), 70.8 + 70.8 (C-3’), 83.9 + 83.9 (C-4’), 84.0 (C-1’), 109.8 (C-5),
116.3 + 116.3

(ArCH),

117.0 + 117.1

121.4 (ArCH),

122.7 + 122.7

(C-5”),

(ArCH),
123.4 + 123.4

188.5 + 118.6
(ArCH),

(2 x ArCH),

129.6

(ArCH),

129.9 (2 x ArCH), 135.8 + 135.9 (C-6), 146.3 + 146.3 (C-4”), 150.3 (C-2),
151.1 + 151.2 (ArC-O), 156.5 (ArC-O), 156.5 + 156.5 (C), 163.6 + 163.6 (C-4).
LRMS-ESI: m/z = 514 [M+Na]+. HRESI-MS: m/z calcd for C25H25N5O6Na [M+Na]+:
514.1703; found 514.1722; Δ = 3.69 ppm
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2’,5’-Dideoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)uridine 244

This compound was prepared according to general procedure E using 224 (250 mg, 0.445 mmol,
1.0 equiv.). After work up, the title compound 244 was attained as a white powder (195 mg,
-1
1
92 %). m.p. 232-233-°C. [α]20
D = 51.16 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-

d6): δ 2.08 (m, 2H, H-2’), 4.04-4.08 (m, 1H, H-4’), 4.23-4.24 (m, 1H, H-3’), 4.53-4.58 (m,
1H, H-5’a), 4.63-4.67 (m, 1H, H-5’b), 5.49-5.50 (m, 1H, H-3’), 5.57-5.59 (m, 1H, H-5), 5.795.80 (m, 1H, CHOH), 6.03-6.04 (m, 1H, OH), 6.13-6.15 (m, 1H, H-1’), 6.86-6.88 (m, 1H,
ArH), 6.99-7.00 (m, 2H, ArH), 7.07 (m, 1H, ArH), 7.12-7.15 (m, 2H, ArH), 7.31-7.32 (m, 1H,
ArH), 7.36-7.39 (m, 2H, ArH), 7.47-7.53 (m, 1H, H-6), 7.84 (m, 1H, H-5”), 11.33 (br s, 1H,
NH).

13

C NMR (125 MHz, DMSO-d6): δ 38.1 (C-2’), 51.2 + 51.2 (C-5’), 67.4 (CHOH),

70.7 + 70.8 (C-3’), 84.1 + 84.2 (C-4’), 84.3 + 84.4 (C-1’), 102.0 (C-5), 116.3 + 116.3 (ArCH),
117.1 + 117.1 (ArCH), 118.6 (ArC), 118.7 (2 x ArCH), 121.4 + 121.4 (ArCH), 122.8 (C-5”),
123.4 + 123.4 (ArCH), 129.6 (ArCH), 130.0 (2 x ArCH), 140.6 + 140.7 (C-6), 146.3 (C-4”),
150.4 (C-2), 151.1 + 151.2 (ArC-O), 156.5 + 156.5 (ArC-O), 163.0 (C-4). LRMS-ESI:
m/z = 500 [M+Na]+. HRESI-MS: m/z calcd for C24H23N5O6Na [M+Na]+: 500.1546; found
500.1583 Δ = 7.40 ppm
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2’,5’-Dideoxy-2’-fluoro-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)uridine 245

This compound was prepared according to general procedure E using 225 (250 mg, 0.431 mmol,
1.0 equiv.). After work up, the title compound 245 was attained as a white powder (205 mg, 96 %).
-1
1
m.p. 164-166 °C. [α]20
D = 73.04 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6):

δ 4.15-4.17 (m, 2H, H-5’), 4.61-4.66 (m, 1H, H-4’), 4.73-4.76 (m, 1H, H-3’), 5.08-5.21 (m,
1H, H-2’), 5.53-5.57 (m, 1H, H-5), 5.80-5.81 (m, 1H, CHOH), 5.86 (m, 1H, OH-3’), 5.90 (br
s, 1H, OH), 6.04 (m, 1H, H-1’), 6.86 (m, 1H, ArH), 6.99-7.01 (m, 2H, ArH), 7.09 (m, 1H, H6), 7.11-7.16 (m, 2H, ArH), 7.31-7.39 (m, 4H, ArH), 7.87-7.89 (m, 1H, H-5”), 11.39 (br s,
1H, NH).

13

C NMR (125 MHz, DMSO-d6): δ 50.6 (C-5’), 67.4 (CHOH), 69.6 (d,

J = 16.3 Hz, C-3’), 80.1 (C-4’), 90.7 (d, J = 190.5 Hz, C-2’), 93.8 (d, J = 37.7 Hz, C-3’), 93.4
+ 93.4 (C-1’), 101.9 + 102.0 (C-5), 116.3 + 116.4 (ArCH), 117.1 (ArCH), 118.6 (2 x ArCH),
121.5 (ArCH), 122.9 + 123.0 (ArCH), 123.4 (C-5”), 129.6 (ArCH), 130.0 (2 x ArCH),
141.2 + 141.3 (C-6), 146.3 (C-4”), 150.1 (C-2), 151.2 (ArC-O), 156.5 + 156.5 (ArC-O), 163.1
(C-4). LRMS-ESI: m/z = 496 [M+H]+. HRESI-MS: m/z calcd for C24H22FN5O6Na [M+Na]+:
518.1452; found 518.1459, Δ = 1.35 ppm
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5’-Deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)-2’-O-methyluridine 246

This compound was prepared according to general procedure E using 226 (180 mg, 0.304 mmol,
1.0 equiv.). After work up, the title compound 246 was attained as a white powder (147 mg, 95 %).
-1
1
m.p. 205-207 °C. [α]20
D = 56.23 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6):

δ 3.35 (s, 3H, OCH3). 3.77-3.79 + 3.81-3.83 (m, 1H, H-2’), 4.08-4.16 (m, 3H, H, H3’), 4.60-4.65 (m, 1H, H-5’a), 4.68-4.69 + 4.71-4.72 (m, 1H, H-5’b), 5.53-5.55 (m, 1H,
H-4’), 5.57 + 5.59 (2 d, J = 8.2 Hz, 1H, H-5), 5.80 (m, 2H, H-1’/CHOH), 6.07-6.08 (m,
1H, OH), 6.85-6.87 (m, 1H, ArH), 6.98-7.00 (m, 2H, ArH), 7.08 (m, 1H, ArH), 7.117.15 (m, 2H, ArH), 7.30-7.33 (m, 1H, ArH), 7.36-7.39 (m, 2H, ArH), 7.43 + 7.48 (2 d,
J = 8.2 Hz, 1H, H-6), 7.87 + 7.88 (2 s, 1H, H-5”), 11.39 (br s, 1H, NH).

13

C NMR

(125 MHz, DMSO-d6): δ 50.9 + 50.9 (C-5’), 57.6 + 57.7 (OCH3), 67.4 (CHOH),
69.3 + 69.3 (C-1’), 81.1 + 81.1 (C-2’), 81.9 + 81.9 (C-3’), 86.9 + 87.0 (C-4’),
102.1 + 102.2 (C-5), 116.3 + 116.3 (ArCH), 117 (ArCH), 118.6 (2 x ArCH),
121.4 (ArCH),

122.9

(ArCH),

123.4

(C-5”),

128.9

(ArC),

129.6

(ArCH),

130.0 (2 x ArCH), 140.5 + 140.6 (C-6), 146.3 (C-4”), 150.3 (C-2), 151.2 (ArC-O),
156.5 (ArC-O), 162.9 (C-4). LRMS-ESI: m/z = 530 [M+Na]+. HRESI-MS: m/z calcd for
C25H25N5O7Na [M+Na]+: 530.1652; found 530.1674; Δ = 4.15 ppm
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5’-Deoxy-5-fluoro-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)uridine 247

This compound was prepared according to general procedure E using 227 (260 mg, 0.408 mmol,
1.0 equiv.). After work up, the title compound 247 was attained as a white powder (204 mg, 98 %).
-1
1
m.p. 193-195 °C. [α]25
D = 25.47 (c = 5 mg.mL , CH3OH). H NMR (500 MHz, DMSO-d6):

δ 3.96 (m, 1H, H-3’), 4.08-4.11 (m, 1H, H-2’), 4.12-4.15 (m, 1H, H-4’), 4.62-4.71 (m, 2H, H5’), 5.39 (br s, 1H, OH-2’), 5.53 (br s, 1H, OH-3’), 5.75 + 5.76 (m, 1H, H-1’), 5.80 (m, 1H,
CHOH), 6.03-6.06 (m, 1H, OH), 6.86-6.88 (m, 1H, ArH), 6.99-7.01 (m, 2H, ArH ),
7.07 + 7.08 (m, 1H, ArH), 7.12-7.15 (m, 2H, ArH), 7.30-7.33 + 7.31-7.34 (m, 1H, ArH), 7.377.40 (m, 2H, ArH), 7.86 + 7.86 (s, 1, H-5”), 7.94-7.95 + 7.98-8.00 (m, 1H, H-6), 11.80 (br s,
1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 51.2 + 51.2 (C-5’), 67.4 + 67.5 (CHOH), 70.5
(C-3’), 72.0 + 72.0 (C-2’), 81.9 + 82.0 (C-4’), 88.6 + 88.6 (C-1’), 116.3 + 116.4 (ArCH),
117.1 (ArCH), 118.7 + 118.7 (2 x ArCH), 121.4 + 121.4 (ArCH), 122.7 + 122.8 (C-5”),
123.4 + 123.5 (ArCH), 125.2 + 125.5 (2 d, J = 34.5 Hz, C-6), 129.6 + 129.7 (ArCH),
130.0 (2 x ArCH), 140.2 + 140.8 (d, J = 231.9 Hz, C-5), 146.3 + 146.3 (C-4”), 149.4 (C-2),
151.2 + 151.3 (ArC-O), 156.5 + 156.6 (ArC-O), 157.0 + 157.0 (2 d, J = 26.2 Hz, C-4).
LRMS-ESI: m/z = 512 [M+Na]+. HRESI-MS: m/z calcd for C24H22FN5O7Na [M+Na]+:
534.1401; found 534.1412; Δ = 2.06 ppm
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5’-Deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)-2’,3’-O-isopropylidenylcytidine 248

This compound was prepared according to general procedure E using 202 (160 mg, 259 µmol,
1.0 equiv.). After work up, the title compound 248 was attained as a white powder (134 mg,
-1
1
97 %). m.p. 179-181 °C. [α]20
D = 13.42 (c = 5 mg.mL , CH3OH). H NMR (300 MHz, DMSO-

d6): δ 1.25 (s, 3H, CH3), 1.45 (s, 3H, CH3), 4.30-4.38 (m, 1H, H-4’), 4.53-4.70 (m, 2H, H-5’),
4.79-4.85 (m, 1H, H-3’), 5.03 (dd, J = 14.2 Hz, J = 6.8 Hz, 1H, H-2’), 5.36 (m, 1H, OH), 5.75
(dd, J = 11.2 Hz, J = 7.3 Hz, 1H, H-1’), 5.93 (m, 1H, H-5), 6.80-6.81 (m, 1H, CHOH), 6.90-7.03
(m, 4H, ArH), 7.11 (m, 2H, ArH), 7.18-7.26 (m, 3H, ArH), 7.43 + 7.44 (s, 1H, H-5”), 7.69 (br s,
1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 25.0 (CH3), 26.9 (CH3), 51.5 (C-5’), 67.4 + 67.4
(CHOH), 82.1 (C-3’), 84.2 (C-4’), 85.9 + 86.0 (C-2’), 94.3 (C-5), 95.2 + 95.3 (C-1’), 112.9
(Cq), 116.4 (ArCH), 117.1 (ArCH), 118.7 (2 x ArCH), 121.5 (ArCH), 122.5 (ArCH), 123.4
(C-5”), 129.6 (ArCH), 130.0 (2 x ArCH), 144.7 (C-4”), 146.3 (C-6), 151.2 + 151.2 (C-2),
154.8 (ArC-O), 156.5 (ArC-O), 166.2 (C-4). LRMS-ESI: m/z = 555 [M+Na]+. HRESI-MS:
m/z calcd for C27H28N6O6Na [M+Na]+: 555.1968; found 555.1965; Δ = 0.54 ppm
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5’-deoxy-5’-(4-(α-hydroxy-3-phenoxybenzyl)triazolo)-2’,3’-O-isopropylidenyluridine 249

This compound was prepared according to general procedure E using 205 (110 mg, 0.19 mmol,
1.0 equiv.). After work up, the title compound 249 was attained as a white powder (96 mg,
-1
1
94 %). m.p. 143-144 °C. [α]25
D = 7.68 (c = 1 mg.mL , CH3OH). H NMR (400 MHz, DMSO-

d6): δ 1.28 (s, 3H, CH3), 1.46 (s, 3H, CH3), 4.33-4.39 (m, 1H, H-4’), 4.57-4.63 (m, 1H, H-5’a),
4.67-4.72 (m, 1H, H-5’b), 4.85-4.88 (m, 1H, H-3’), 5.08-5.11 (m, 1H, H-2’), 5.60-5.63 (m, 1H,
H-5), 5.77-5.80 (m, 2H, H-1’/CHOH), 6.01-6.03 (m, 1H, OH), 6.85 + 6.87 (d, J = 2.4 Hz, 1H,
ArH), 6.99 + 7.00 (m, 2H, ArH), 7.07 (m, 1H, ArH), 7.13-7.15 (m, 2H, ArH), 7.30-7.33 (m, 1H,
ArH), 7.37-7.40 (m, 2H, ArH), 7.62-7.65 (m, 1H, H-6), 7.90 + 7.90 (2 s, 1H, H-5”), 11.46 (br s,
1H, NH).

13

C NMR (125 MHz, DMSO-d6): δ 25.0 + 25.0 (CH3), 26.8 (CH3), 51.1 (C-5’),

67.4 + 67.4 (CHOH), 81.4 + 81.4 (C-3’), 83.5 (C-2’), 85.0 + 85.2 (C-4’), 93.0 + 93.1 (C-1’),
101.9 + 101.9 (C-5), 113.4 (C), 116.3 + 116.4 (ArCH), 117.0 (ArCH), 118.6 + 118.6
(2 x ArCH), 119.0 (ArCH), 121.4 (ArCH), 122.5 + 122.5 (ArCH), 123.4 (C-5”), 129.5 (ArCH),
129.9 (2 x ArCH), 130.2 (ArCH), 143.3 (C-6), 146.3 (C-4”), 150.3 (C-2), 151.2 (ArC-O), 156.5
(ArC-O), 163.4 (C-4). LRMS-ESI: m/z = 556 [M+Na]+. HRESI-MS: m/z calcd for
C27H27N5O7Na [M+Na]+: 534.1989; found 534.2000; Δ = 2.06 ppm
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6.2. Biological procedures
6.2.1. ST inhibition assay
19 triazoles derivatives were evaluated by the Gerardy-Schahn group at the university of
Hannover against ST8Sia-II using a fluorimetric assay as follows.441 Sodium cacodylate
(100 mM, pH 6.7), Glycerol (50 %), MgCl2 (1 M), MnCl2 (100 mM), CMP-Neu5Ac
(10 mM), ST8Sia-II (250 ng), and the acceptor DMB-DP3 250 (25 µM, used as a labelled
acceptor, fig. 6.1) along with the inhibitor sample (final concentration of 100 µM) were
incubated at 25° C for the indicated times. The reactions were terminated by 10-fold dilution
in Tris–HCl (100 mM, pH 8.0) / ethylenediamine-tetraacetic acid (EDTA, 20 mM) followed
by 10 min incubation at 50 °C. Finally, the samples were centrifuged and analysed on a
DNAPAC PA 100 analytical anion exchange column (Ex. 373 nm/Em. 448 nm). The elution
system used was a mixture of H2O and 5.0 M ammonium acetate buffer (pH 7.4). HPLC was
carried out using a Waters 2695 Separations Module connected to an RF-10A
spectrofluorometric detector at a flow rate of 1 mL/min.

Figure 6.1. Structure of the fluorescent reagent DMB-DP3 250.
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6.2.2. Cell lines and cell culture conditions
The cancer cell lines MiaPaCa-2, SKOV3 and MCF-7 were cultured in DMEM medium
containing 2 mM L-glutamine and 10 % fœtal bovine serum.
RAW264.7 cells were regularly cultured in vitro in culture medium consisting of RPMI-1640
medium, along with 2 mM L-glutamine, 5.6 % (2 g/L) NaHCO3 and 5 % fetal calf serum.
Determination of cell number: Cell counts were performed by mixing 20 µL of media
containing cells with 20 µL of Trypan blue and dispensing 20 µL of this mixture under a
cover-slip on the haemocytometer. Count the number of cells using the following equation:

𝑁𝑜. 𝑜𝑓 𝐶𝑒𝑙𝑙𝑠 =

(# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 4 𝑔𝑟𝑖𝑑𝑠)
× 2 × 10000
4

6.2.3. MTS Cell proliferation assay
The MTS assay described here utilises Promega’s MTS CellTiter 96® AQueous One Solution
Cell Proliferation assay and is performed according to the manufacturer’s instructions. 474-475
Day 1: The chosen cells were suspended in DMEM medium containing 10% fetal bovine serum
and seeded in 96-well tissue culture plates at cells per well. The plates were incubated at 37 °C
for 24 h. Three raws were kept on the plate for controls and blank which include cells alone,
cells treated with 10 % DMSO and samples in media.
Sample preparation: The samples are prepared from a stock solution in DMSO at a
concentration of 1 mM. The stock solution is diluted with media in a separate plate before
being added to the cells in order to minimise the DMSO concentration to a maximum of 1 %.
Day 2: The samples were tranfered from the dilution plate to the cells and incubated at 37 °C
for 24 to 48 h.
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Day 3: The MTS reagent 86 is added to the plate (10 µL in each well) and incubated for 3 h at
37 °C. The MTS reagent is light sensitive so this step has to be performed with the lights off
in the cytotoxic cabinet and it is preferable to cover the plate with foil during the final
incubation. The absorbance of the final mixture is read at 490 nm.
The cell viability when exposed to the samples is deducted from the absorbance read by
comparing with those of the cells in media alone (which correspond to the 100 % viability)
and those treated with 10 % DMSO (which correspond to the 0 % viability). The blank (media
containing the sample only) was substracted before proceeding in order to eliminate the false
positive due to the absorbance of the compound added itself.

6.2.4. Griess reagent assay
The assay was performed by following reported procedures.302 The assay requires three sets
of plates: one for the sample preparation, one for seeding the cells and a reading plate.
Day 1: RAW264.7 cells were suspended in RPMI-1640 medium containing 10 % fetal bovine
serum and 1 % Glutamax and seeded in 96-well tissue culture plates at 5000 cells per well.
The plates were incubated at 37 °C for 24 h. Three raws were kept on the plate for controls and
blank which include cells alone, cells treated with 10 % DMSO and samples in media.
Sample preparation: The samples are prepared from a stock solution in DMSO at a
concentration of 1 mM. The stock solution is diluted with media in a separate plate before
being added to the cells in order to minimise the DMSO concentration to a maximum of 1 %.
Day 2: The samples were tranfered from the dilution plate to the cells, added 25 µM of a
1 mg.mL-1 solution of LPS and incubated at 37 °C for 24 h.
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Calibration curve: A solution is prepared with 69 mg of NaNO2 in 1 mL MilliQ H2O. 1 µL of
this solution was diluted in 10 mL MilliQ H2O from which 11 dilutions were prepared as
described in table 6.1. 10 µL of these solutions were transferred to the reading plate in
duplicate.
Table 6.1. Concentration of the NaNO2 solutions used for the calibration curve in the Griess reagent assay.
Standard (µM)

0

10

20

30

40

50

60

70

80

90

100

NaNO2 solution

0

100

200

300

400

500

600

700

800

900

1000

1000

900

800

700

600

500

400

300

200

100

0

MilliQ water

Griess Reagent: Two solutions prepared from 1.0 g sulphanilamide 88 in 100 mL 5 % HCl
and 0.1 g N-(1-Naphthyl)ethylenediamine dihydrochloride 89 in 100 mL MilliQ H2O were
stored separately at 4 °C in dark glass bottles.
Day 3: 50 µL of the cell supernant and standard were transferred to the reading plate. Each
well was added 20 µL of 1 % sulphanilamide and 25 µL of 0.1 % of N-(1-naphthyl)ethylenediamine dihydrochloride and incubated for 10 min at room temperature. The
absorbance of each well was read at 540 nm using a microplate reader.
Calculate nitrite concentration of samples from the absorbances using interpolation from the
standard curve (0-100 µM of sodium nitrite in a 10 µM stepwise increment).

6.2.5. Antibacterial activity evaluation
This assay was performed by WADI (Worldwide Antibiotic Discovery Initiative).
23 compounds

were

tested,

including

18

α-hydroxyphosphonate

derivatives

and

5 triazolonucleosides, on 5 Gram negative bacteria strains (Escherichia coli (ATCC 25922),
Klebsiella

pneumoniae

(ATCC700603),

Acinetobacter

baumannii

(ATCC

19606),

Pseudomonas aeruginosa (ATCC 27853) and Staphylococcus aureus (ATCC 43300)). The
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results were compared to those of control compounds (Colistin, Polymyxin B, Vancomycin
and Daptomycin) tested at 10 mg/mL in water.
Single point bacterial inhibition assay: Bacteria were cultured in Muller Hinton broth
(MHB) at 37 °C overnight. A sample of each culture was then diluted 40-fold in fresh MHB
broth and incubated at 37 °C for 1.5-3 h. The compounds were plated at a single concentration
of 64 μg/mL in non-binding surface 96-well plates (Corning; Cat. No 3641, NBS). For
bacterial inhibitor controls, Colistin, Polymyxin B, Vancomycin and Daptomycin were
serially diluted two-fold across the wells, with compound concentrations ranging from
0.03 to 4 μg/mL for Colistin and Polymyxin B, and from 0.125 to 16 μg/mL for Vancomycin
and Daptomycin. The resultant mid-log phase cultures were diluted to the final concentration
of 5 x 105 CFU/mL, then 50 μL was added to each well of the plates, giving a final compound
concentration of 32 μg/mL and a concentration range for the controls of 0.015 to 2 μg/mL for
Colistin and Polymyxin B, 0.06 to 8 μg/mL for Vancomycin and Daptomycin. All the plates
were covered and incubated at 37 °C for 24 h.
Inhibition of bacterial growth was determined visually, classifying wells into either with or
without any bacterial growth.
MIC (Minimum Inhibitory Concentration) assay: Bacteria were cultured in Muller Hinton
broth (MHB) at 37 °C overnight. A sample of each culture was then diluted 40-fold in fresh
MHB broth and incubated at 37 °C for 1.5-3 h. The compounds were serially diluted two-fold
across the wells of non-binding surface 96-well plates (Corning; Cat. No 3641, NBS), with
compound concentrations ranging from 0.03 μg/mL to 64 μg/mL, plated in duplicate. The
resultant mid-log phase cultures were diluted to the final concentration of 5 x 105 CFU/mL,
then 50 μL was added to each well of the compound-containing 96-well plates, giving a final
compound concentration range of 0.015 μg/mL to 32 μg/mL. All the plates were covered and
incubated at 37 °C for 24 h.
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The inhibition of bacterial growth was determined visually after 24 h, where the MIC is
recorded as the lowest compound concentration with no visible growth.

6.3. Computational procedures
6.3.1. Protein and Ligand
For docking purposes, the crystallographic coordinates of the porcine ST3Gal-I, the
human ST6Gal-I and the human ST3Sia-III complexed with CMP were attained from
the RCSB Protein Data Bank (PDB code 2WNB,183 4JS2189 and 5BO6, 5BO7190 and
5CXY respectively). The ligand was then removed to leave the receptor complex using
Discovery Studio 4, which was used for the subsequent docking studies. The threedimensional structures of the inhibitors were prepared utilising ChemDraw 14.0 and
Discovery Studion 4. The PDBQT files for the STs and the inhibitors were generated using
Autodock Tools 1.5.6 and used as the input for AutoDock Vina 1.1.2.476 When docking, the
grid scale was set as 30 Å x 30 Å x 30 Å based on grid module, cantered at the active site.
The dimension was chosen to ensure it was big enough to cover all of the flexible residues.
The docking procedure was validated by re-docking to replicate the crystallographically
determined ST-CMP complex. Gasteiger charges477 were set for both substrates and protein.
The protein was kept rigid, all torsional bonds of the ligands were kept free and water
molecules have been removed from the PDB file.

6.3.2. Docking
In the context of this study, docking into the crystal structures was performed by using
AutodockVina.476 It is the lastest member of the AutoDock suite introduced in 2010 which
has been developed at The Scripps Research Institute. The enzymes and ligands structures
were prepared using AutoDock Tools as well as the docking parameters, such as the size of
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the grid box which defines the search area.478 A series of comparisons were made for models
generated for different exhaustiveness values. The exhaustiveness is a function that controls
how “exhaustive” a search the program performs to find a global minimum. Default settings
had an exhaustiveness value of 12.

6.3.3. Protein alignment
The protein sequence alignments were performed using the online platform T-coffee.479 The
acronym ‘T-coffee’ stands for ‘Tree-based Consistency Objective Function For alignment
Evaluation’ and allows multiple alignments. The protein sequences were collected from the
Universal Protein Ressource (Uniprot)480 and used in the FASTA format.
Structures were superimposed using Discovery Studio 4 (Copyright 2005-2013, Accelrys
Software Inc.).
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Figure A.1. 1H NMR of compound 228 in CDCl3

Figure A.2. APT NMR of compound 228 in CDCl3
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Figure A.3. COSY NMR of compound 228 in CDCl3

Figure A.4. HMBC NMR of compound 228 in CDCl3

Figure A.5. HSQC NMR of compound 228 in CDCl3
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Table B.1. Percentage inhibition of the triazole derivatives at 100 µM against ST8Sia-II.
Compound

cLog P
Log P

1h

% Inhibition at
2h

4h

228

0.13
1.07

45

46

51

229

-0.57
0.54

42

45

42

230

-0.30
0.90

26

27

35

231

1.55
0.23

25

23

24

232

-1.40
0.41

35

50

65

233

-0.86
0.95

80

81

87

234

0.07
1.23

93

97

98

236

-0.94
0.57.

69

77

87

237

-1.49
0.78

238

-1.11
0.54

Structure

66

92
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68

96

87

96
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240

-1.19
0.39

30

29

66

241

-0.41
1.31

91

98

97

242

0.97
2.23

52

55

56

243

0.47
1.88

80

87

88

244

0.91
1.78

53

56

91

245

0.94
1.43

68

74

76

246

0.61
0.71

86

91

94

247

1.37
2.66

62

66

75

248

1.36
2.43

80

79

78
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This appendix contains the front pages of selected published journal articles:
Montgomery, A.; Szabo, R.; Skropeta, D.; Yu, H., Computational characterisation of the
interactions between hST6Gal I and transition state analogues: Insights for inhibitor design.
J. Mol. Recognit. 2016, 29, 210-222.
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Szabo, R.; Skropeta, D., Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges
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